---
document_datetime: 2026-01-17 13:12:34.451366
document_pages: 187
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/rinvoq-h-c-004760-ii-0004-epar-assessment-report-variation_en.pdf
document_name: rinvoq-h-c-004760-ii-0004-epar-assessment-report-variation_en.pdf
version: success
processing_time: 255.7858453
conversion_datetime: 2026-01-17 23:24:27.033253
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
10 December 2020 EMA/708066/2020

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Rinvoq

International non-proprietary name: upadacitinib

Procedure No. EMEA/H/C/004760/II/0004

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product............................................................................................13      |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......14                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................14                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................15          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................15                                             |
| 2.2.2. Conclusion on the non-clinical aspects................................................................15             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................16    |
| 2.3.1. Introduction....................................................................................................16   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................19      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................27         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................28      |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................51             |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................53              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................53    |
| 2.4.1. Dose response study........................................................................................53        |                                                                                                         |
| 2.4.2. Main studies                                                                                                         | ...................................................................................................53   |
| 2.4.3. Discussion on clinical efficacy..........................................................................            | 130                                                                                                     |
| 2.4.4. Conclusions on the clinical efficacy...................................................................              | 136                                                                                                     |
| 2.5. Clinical safety ..................................................................................................     | 136                                                                                                     |
| 2.5.1. Discussion on clinical safety ............................................................................           | 176                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 180                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 181 |
| 2.6. Risk management plan......................................................................................             | 181                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 188                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 188                                                                                                     |
| 3. Benefit-Risk Balance............................................................................188                      |                                                                                                         |
| 3.1. Therapeutic Context .........................................................................................          | 188                                                                                                     |
| 3.1.1. Disease or condition.......................................................................................          | 188                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 189                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 189             |
| 3.2. Favourable effects ............................................................................................        | 189                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 191                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 192                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 192                                                             |
| 3.6. Effects Table....................................................................................................      | 192                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 194                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 194                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.7.2. Balance of benefits and risks  ...........................................................................  195

3.8. Conclusions .....................................................................................................  195

4. Recommendations ...............................................................................  196

5. EPAR changes  ......................................................................................  199

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACR

American College of Rheumatology

ACR20/50/70   American College of Rheumatology 20%, 50%, 70% response

ADA

adalimumab

AE(s)

adverse event(s)

AESI

adverse events of special interest

ALT

alanine aminotransferase

ANCOVA

analysis of covariance

Anti-CCP

anti-cyclic citrullinated peptide

AO

As Observed

ASDAS

Ankylosing Spondylitis Disease Activity Score

AST

aspartate aminotransferase

BASDAI

Bath Ankylosing Spondylitis Disease Activity Index

bDMARD

biologic disease-modifying antirheumatic drug

BID

twice a day

BMI

body mass index

BSA

body surface area

CAC

Cardiovascular Adjudication Committee

CASPAR

Classification Criteria for Psoriatic Arthritis

cDMARDs

conventional disease-modifying anti-rheumatic drugs

CI

confidence interval

CMH

Cochran-Mantel-Haenszel test

CMQ

company MedDRA query

CNS

central nervous system

COPD

chronic obstructive pulmonary disease

CPK

creatine phosphokinase

CRO

contract research organization

CRP

C-reactive protein

csDMARD

conventional synthetic disease-modifying anti-rheumatic drug

CSR

clinical study report

CTCAE

Common Terminology Criteria for Adverse Events

CV

cardiovascular

DAPSA

Disease Activity in Psoriatic Arthritis

DAS

disease activity score

DAS28

disease activity score (28 joints)

Diff

difference

DMARD

disease-modifying anti-rheumatic drug

DMARD-IR

disease-modifying anti-rheumatic drug-intolerant or inadequate responder

DMC

Data Monitoring Committee

DNA

deoxyribonucleic acid

DVT

deep vein thrombosis

E

events

E/100 PY

events per 100 patient-year

EAER

exposure-adjusted event rate

EAIR

exposure-adjusted incidence rate

ECG

electrocardiogram

eCRF

electronic case report form

EOW

every other week

EQ-5D-5L

EuroQoL-5 Dimensions - 5 Levels

ESR

erythrocyte sedimentation rate

EULAR

European League Against Rheumatism

F

female

FACIT-F

Functional Assessment of Chronic Illness Therapy-Fatigue

FAS

Full Analysis Set

GCP

Good Clinical Practice

GI

gastrointestinal

GRAPPA

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis

HAQ-DI

Health Assessment Questionnaire - Disability Index

Hb

Haemoglobin

HBV

hepatitis B virus

HCQ

hydroxychloroquine

HDL

high-density lipoprotein

HDL-C

high-density lipoprotein-cholesterol

HRU

Health Resource Utilization

hsCRP

high-sensitivity C-reactive protein

ICF

informed consent form

ICH

International Council for Harmonisation

IEC

Independent Ethics Committee

IL

interleukin

INH

isoniazid

IR

inadequate response

IRB

institutional review board

JAK

Janus kinase

JSN

joint space narrowing

LDI

Leeds Dactylitis Index

LDL

low-density lipoprotein

LDL-C

low-density lipoprotein-cholesterol

LEI

Leeds Enthesitis Index

LS

least square

M

male

MACE

major adverse cardiac event

Max

maximum

MCS

Mental Component Summary of the SF-36™ Health Status Survey

MDA

minimal disease activity

MedDRA

Medical Dictionary for Regulatory Activities

MI

Multiple Imputation

Min

minimum

MMRM

Mixed-Effects Model Repeated Measures

mTSS

modified Total Sharp Score

MTX

methotrexate

NAPF

National Psoriasis Foundation

NI

non-inferiority

NMSC

non-melanoma skin cancer

NRI

Non-Responder Imputation

NRS

numerical rating scale

NSAID

nonsteroidal anti-inflammatory drug

PASDAS

Psoriatic Arthritis Disease Activity Score

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| PASI                                                                                | Psoriasis Area Severity Index                                                       |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| PASI 75/90/100 75, 90, 100 percent improvement in Psoriasis Area and Severity Index | PASI 75/90/100 75, 90, 100 percent improvement in Psoriasis Area and Severity Index |
| PCS                                                                                 | Physical Component Summary                                                          |
| PE                                                                                  | pulmonary embolism                                                                  |
| PGA                                                                                 | physician's global assessment                                                       |
| PPD                                                                                 | packs per day                                                                       |
| Ps                                                                                  | psoriasis                                                                           |
| PsA                                                                                 | psoriatic arthritis                                                                 |
| PsARC                                                                               | Psoriatic Arthritis Response Criteria                                               |
| PT                                                                                  | preferred term                                                                      |
| PtGA                                                                                | Patient's Global Assessment                                                         |
| PY                                                                                  | patient-year                                                                        |
| QD                                                                                  | once daily                                                                          |
| RA                                                                                  | rheumatoid arthritis                                                                |
| RF                                                                                  | rheumatoid factor                                                                   |
| Rx                                                                                  | study drug                                                                          |
| SAE                                                                                 | serious adverse event                                                               |
| SAP                                                                                 | statistical analysis plan                                                           |
| SAPS                                                                                | Self-Assessment of Psoriasis Symptoms                                               |
| SD                                                                                  | standard deviation                                                                  |
| SF-36                                                                               | 36-Item Short Form Health Survey                                                    |
| SF-36 PCS                                                                           | 36-Item Short Form Health Survey Physical Component Score                           |
| SF-36 MCS                                                                           | 36-Item Short Form Health Survey Mental Component Score                             |
| SIR                                                                                 | standard incidence ratios                                                           |
| SHS                                                                                 | Sharp/van der Heijde Score                                                          |
| sIGA                                                                                | static Investigator Global Assessment                                               |
| sIGA 0/1                                                                            | sIGA of psoriasis of 0 or 1 and at least a 2-point improvement from baseline        |
| SJC                                                                                 | swollen joint count                                                                 |
| SMQ                                                                                 | standardized MedDRA query                                                           |
| SOC                                                                                 | system organ class                                                                  |
| SpA                                                                                 | spondyloarthritis                                                                   |
| SPARCC                                                                              | Spondyloarthritis Research Consortium of Canada                                     |
| SSZ                                                                                 | sulfasalazine                                                                       |
| STAT                                                                                | signal transducer and activator of transcription                                    |
| TB                                                                                  | tuberculosis                                                                        |
| TEAE                                                                                | treatment-emergent adverse event                                                    |
| TJC                                                                                 | tender joint count                                                                  |
| TNF                                                                                 | tumour necrosis factor                                                              |
| ULN                                                                                 | upper limit of normal                                                               |
| UNK                                                                                 | unknown                                                                             |
| US                                                                                  | United States                                                                       |
| vs.                                                                                 | versus                                                                              |
| VTE                                                                                 | venous thromboembolic event                                                         |
| WPAI                                                                                | Work Productivity and Activity Impairment                                           |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AbbVie Deutschland GmbH &amp; Co. KG submitted to the European Medicines Agency on 1 June 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

## C.I.6 (Extension of indication)

Extension of indication to include the treatment of active psoriatic arthritis in adult patients for Rinvoq; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates were made to the Annex II. Version 2.0 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0322/2019 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0322/2019 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 26 January 2017 (EMEA/H/SA/3190/3/2016/II)15 June 2017 (EMEA/H/SA/3190/3/2016/II)13 February 2017 (EMEA/H/SA/3190/3/2016/II). The Scientific Advice pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP were:

Co-Rapporteur:

Outi Mäki-Ikola

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 1 June 2020       |
| Start of procedure:                                  | 20 June 2020      |
| CHMP Rapporteur Assessment Report                    | 14 August 2020    |
| CHMP Co-Rapporteur Assessment Report                 | 14 August 2020    |
| PRAC Rapporteur Assessment Report                    | 20 August 2020    |
| PRAC Outcome                                         | 4 September 2020  |
| CHMP members comments                                | 07 September 2020 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 10 September 2020 |
| Request for supplementary information (RSI)          | 17 September 2020 |
| CHMP Rapporteur Assessment Report                    | 10 November 2020  |
| PRAC Rapporteur Assessment Report                    | 13 November 2020  |
| PRAC members comments                                | 18 November 2020  |
| Updated PRAC Rapporteur Assessment Report            | 19 November 2020  |
| PRAC Outcome                                         | 26 November 2020  |
| CHMP members comments                                | 30 November 2020  |
| Updated CHMP Rapporteur Assessment Report            | 03 December 2020  |
| Opinion                                              | 10 December 2020  |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease classified as a sub type of spondyloarthritis (SpA) and characterized by the association of arthritis and psoriasis. It comprises both musculoskeletal as well as non-musculoskeletal manifestations; the latter particularly include the skin and the nails, but also potentially the gut (inflammatory bowel disease) or the eyes (uveitis). Active chronic PsA also associates with cardiovascular, psychological and metabolic comorbidities, which add a significant impact on quality of life (QoL) and increased mortality. About 40%-60% of patients develop erosive and deforming joint complications (Liu JT et al., 2014 1 ). Joint damaging

1  Liu, Jung-Tai, et al. \"Psoriatic arthritis: epidemiology, diagnosis, and treatment.\" World journal of orthopedics 5.4 (2014): 537.

<div style=\"page-break-after: always\"></div>

complications cause reduced articular function, affecting also the patients' ability to work and their social relationships. The major clinical features of PsA are spondylitis (18%-46%), inflammatory neck pain (23%-39%), thoracic inflammatory pain (13%-21%), and axial symptoms (25%-50%).

## State the claimed the therapeutic indication

The MAH proposed the following indication:

## Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with non-biologic DMARDs.

The proposed posology is the same as currently approved for rheumatoid arthritis: 15 mg once daily.

## Epidemiology

The incidence and prevalence of PsA vary markedly between different geographical areas. The reasons for the observed difference of PsA morbidity between countries and continents are unclear. In a recent systematic review, the prevalence of psoriasis varied from 0.14 % (95 % uncertainty interval 0.05 % to 0.40 %) in East Asia to 1.99 % (0.64 % to 6.60 %) in Australasia. The prevalence of psoriasis was also high in Western Europe (1.92 %, 1.07 % to 3.46 %), central Europe (1.83 %, 0.62 % to 5.32 %), North America (1.50 %, 0.63 % to 3.60 %), and high income southern Latin America (1.10 %, 0.36 % to 2.96 %). Since psoriasis is usually a lifetime disease, the prevalence increases with age.

The epidemiology of PsA depends on that of psoriasis and is therefore also variable across geographical areas. The exact prevalence of PsA is not known, but estimates vary from 0.3 % to 1 % of the population. Around 20% of patients with psoriasis develop psoriatic arthritis, however, in patients with moderate-to-severe disease the proportion of patients with psoriatic arthritis is higher, about 25 %. In a recent meta-analysis, the prevalence of PsA in European patients with psoriasis was 22.7 %.

Diagnosis of PsA is symptomatic. Clinical features associated with PsA as compared with uncomplicated skin psoriasis are higher extent of psoriasis; psoriasis involvement of the scalp and inter-gluteal area; and nail lesions.

The Classification Criteria for PsA (CASPAR) criteria, used in the Phase 3 studies of upadacitinib, is a diagnostic tool for specialists of rheumatology, since the criteria are based on the stem of inflammatory musculoskeletal disease. However, multiple other questionnaire-based screening tools have also been used in the literature. These tools have moderate accuracy to identify PsA among psoriasis patients.

## Aetiology and pathogenesis

PsA is a highly heritable polygenic disease. Hereditary factors include certain HLA-classes and their subtypes as well as polymorphism of genes encoding interleukin-23 receptor,(IL23R), variants in nuclear factor κB (NF κB) gene expression, (TNIP1) and signaling (TNFAIP3), TNF expression, as well as risk alleles in interleukin 12A (IL12A), interleukin-12B (IL12B), IL23R, and genes that regulate NFκB. Environmental factors increasing risk for PsA include obesity, trauma or deep lesions at sites of trauma, and severe psoriasis. The interaction between genetic and environmental factors triggers an inflammatory response at multiple sites.

<div style=\"page-break-after: always\"></div>

Key cytokines involved in PsA pathogenesis, such as interleukin (IL)-6, IL-7, IL-22, IL-23 and interferon, signal through the Janus kinase (JAK) pathway. Some of these cytokines activate Th1 and Th17 cells, which in turn release further pro-inflammatory cytokines, including IL-1, IL-17, IL-21, IL-22 and tumour necrosis factor.

As JAK inhibitors mediate signals of multiple pro-inflammatory cytokines in various immune cell types, targeting these intra-cellular kinases can be an effective approach to reduce inflammatory responses by directly and indirectly inhibiting key cytokines involved in the pathogenesis of PsA (See Section Clinical aspects, subsection Pharmacodynamics of this assessment report).

## Clinical presentation, diagnosis

Patients with PsA are usually affected with psoriasis before signs of joint disease have developed. The mean time to onset of PsA is 10 years after the first signs of psoriasis appear. PsA affects men and women equally. PsA can be distinguished from other inflammatory arthritic diseases by its clinical and radiographic features; especially by the presence of other manifestations of psoriasis. Skin involvement occurs most often the scalp, nails, trunk, elbows, and knees. In general, PsA affects fewer joints than rheumatoid arthritis (RA), and it often has an asymmetrical distribution of the affected joints rather than the symmetrical pattern seen in RA. Spinal involvement (sacroiliac joints, lumbar, thoracic or cervical spine) occurs in more than 40% or patients with PsA but is uncommon in rheumatoid arthritis. Enthesitis is common, affecting 30% to 50 % of patients with PsA. Reumafactor is usually negative. One in four patients with PsA are HLA-B27-positive.

Untreated PsA may lead to progressive joint damage and disability, causing absenteeism from work. The life expectancy of PsA patients has been reported to be decreased due to cardiovascular diseases.

## Management

The management of patients with PsA includes non-pharmacological as well as pharmacological interventions. The latest European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of PsA   state that the primary goal of treating patients with psoriatic arthritis is to maximise health-related quality of life, through control of symptoms, prevention of structural damage, normalisation of function and social participation; abrogation of inflammation is an important component to achieve these goals. Furthermore, the EULAR recommendation states that nonmusculoskeletal manifestations (skin, eye and gastrointestinal tract) should be taken into account; comorbidities such as metabolic syndrome, cardiovascular disease or depression should also be considered when managing patients with psoriatic arthritis.

The updated recommendation puts forward the treat-to-target approach in the treatment of PsA: remission or low disease activity should be targeted, with the deletion of the previously stated term of minimal disease activity (which refers to a score allowing the assessment of low disease activity rather than to a target).  Remission in PsA is difficult to define. Remission should be seen as abrogation of inflammation.

Figure 1 shows the summary of EULAR recommendations for the management of PsA at each phase. As the figure shows, after initial treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and local glucocorticoid injections, systemic pharmacological treatment is recommended to be started in non-responders. Systemic corticosteroids should be used with caution at the lowest effective dose for a short time. Treatment algorithm has been revised to contain a different path for patients with oligoarticular and polyarticular disease, the latter having five or more active swollen joints, as demonstrated in Figure below.

<div style=\"page-break-after: always\"></div>

Systemic medications for PsA include corticosteroids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate (MTX) , sulfasalazine (SSZ), leflunomide (LEF), or cyclosporine; targeted synthetic DMARDs, such as phosphodiesterase-4 inhibitors like apremilast; and biologic DMARDs, such as tumour necrosis factor (TNF) inhibitors, interleukin-12/23 inhibitors, and interleukin-17 inhibitors. Tofacitinib was the first JAK inhibitor (JAKi) approved for use in PsA.

The current recommendation is to consider starting a JAKi in patients with peripheral arthritis and an inadequate response to at least one csDMARD and at least one bDMARD, or when a bDMARD is not appropriate. Of the currently marketed JAKi's (tofacitinib, baricitinib, and upadacitinib), only tofacitinib has been approved for treatment of PsA, only in combination with MTX.

<div style=\"page-break-after: always\"></div>

<!-- image -->

bDMARDs, biological disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; IL12/23i, interleukin-12/23 inhibitor; IL-17i, interleukin-17 inhibitor; JAKi, Janus kinase inhibitor; NSAIDs, nonsteroidal anti- inflammatory drugs; PDE4i, phosphodiesterase-4 inhibitor; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.

Figure 1 The EULAR 2019 algorithm for treatment of PsA with pharmacological non-topical treatments.

## Unmet medical need

Despite the beneficial results achieved with the available biologic agents, a marked proportion of PsA patients do not achieve clinical remission after 1 year of treatment or sustained remission for at least 1

<div style=\"page-break-after: always\"></div>

year. Polyarticular disease, increased inflammatory marker levels, progressive radiographical changes and concomitant diabetes and cardiovascular diseases indicate poor prognosis. In a recent study, based on clinical practice (Lubrano E, Perrotta FM, Scriffignano S, Coates LC, Helliwell P. Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatol Ther. 2019 Dec;6(4):521-528. doi: 10.1007/s40744-019-00171-w. Epub 2019 Aug 19. PMID: 31428989; PMCID: PMC6858418.), a sustained very low disease activity (VLDA) was achieved in only 17.5% and a sustained remission according to the Disease Activity index for Psoriatic Arthritis (DAPSA) criteria in only 30% of patients with PsA.

Since a substantial proportion of patients with PsA do not have a sustained response to current treatment regimens, there remains a medical need for additional therapeutic options in PsA for patients with inadequate response to or intolerance to currently available therapies.

## 2.1.2. About the product

The mechanism of action of upadacitinib is inhibition of JAKs, intracellular enzymes that transmit cytokine or growth factor signals involved in a broad range of cellular processes including inflammatory responses, haematopoiesis and immune surveillance. The JAK family of enzymes contains four members, JAK1, JAK2, JAK3 and TYK2 which work in pairs to phosphorylate and activate signal transducers and activators of transcription (STATs). This phosphorylation, in turn, modulates gene expression and cellular function. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function. Upadacitinib is a selective and reversible JAK inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.

Upadacitinib (Rinvoq) has been approved in the EU on 18 December 2019 for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate.

The initial approval was based primarily on the efficacy, safety, and immunogenicity data from five pivotal Phase 3 studies and clinical pharmacology data from 22 Phase 1 studies, 2 supportive dose ranging Phase 2 studies, 1 supportive Phase 2b/3 dose ranging study in Japanese subjects.

The current submission presents data to support the use of upadacitinib in adult patients with active PsA. The submission includes one bioavailability study and two controlled pivotal randomized, doubleblind, Phase 3 studies: one study in subjects with inadequate response (IR) to non biologic diseasemodifying anti-rheumatic drugs (DMARDs), 'DMARD-IR' subjects (Study M15-572) and one study in subjects with IR to biologic DMARDs, 'bDMARD-IR' subjects (Study M15-554).

The clinical development programme of upadacitinib in PsA was designed to demonstrate the efficacy of upadacitinib in reducing the musculoskeletal and cutaneous signs and symptoms of PsA, inhibiting the progression of structural joint damage, and improving physical function and health-related quality of life (QoL) outcomes. The global Phase 3 development programme for PsA evaluated the efficacy and safety of 2 doses of upadacitinib, 15 mg QD and 30 mg QD extended-release formulation, in combination with non biologic DMARDs or as monotherapy in adults with moderately to severely active PsA, including those who are non-biologic DMARD-IR or bDMARD-IR.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

In addition to rheumatoid arthritis and PsA, upadacitinib is being developed for the treatment of other immune-mediated inflammatory diseases such as Crohn's disease, ulcerative colitis, atopic dermatitis, ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (SpA), polyarticular course juvenile idiopathic arthritis, Takayasu arteritis, and giant cell arteritis.

Upadacitinib is also being developed for paediatric population from 1 to less than 18 years of age for the treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis). A waiver has been granted for paediatric population from birth to less than 1 year of age.

Scientific advice (SA) was given by the CHMP on 26 January 2017 (EMEA/H/SA/3190/3/2016/II) and clarifications on the same SA procedure on 13 February 2017 and 15 June 2017. The SA concerned the Phase 3 trials in PsA. The advice pertained to the inclusion criteria, endpoints, the planned duration of placebo treatment, and rescue medication.

- The MAH was advised to foresee and detail the handling of missing data detailed in the final protocols.
- The CHMP commented that placebo subjects will be randomized at baseline to either 15 mg QD or 30 mg QD and switched blindly to one of the doses of upadacitinib after Week 24 regardless of clinical response. The reason for this was not obvious to the CHMP and the CHMP commented that it is expected that the switched treatment groups after Week 24 will not be of similar size. In the final protocol, subjects who were assigned to placebo at baseline are preassigned to receive either upadacitinib 15 mg QD or upadacitinib 30 mg QD starting at Week 24 in a 1:1 ratio.
- The CHMP advised on determination of the non-inferiority (NI) margin for the comparison with adalimumab in study M15-572 based on all data available on the effect size of adalimumab in PsA for determination of the NI margin.
- The CHMP was asked if all primary and ranked secondary endpoints of the studies could be included in section 5.1 of the SmPC, if statistically significant. The CHMP stated that inclusion of the end-points will be based on results. Further, since this section should only include limited information relevant to the prescriber, only main results, statistically compelling and clinically relevant results are foreseen to be included in accordance with SmPC guideline.
- The CHMP stated that the Phase 3 programme is overall comprehensive and in line with the EMA PsA guideline.

## 2.1.4. General comments on compliance with GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH, and the sponsor has provided audit reports for the audits performed by the sponsor.

No regulatory inspections on the Phase 3 studies are reported in the submission. Since no problems concerning GCP have been identified during assessment, this is not considered an issue by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The MAH submitted an Environmental Risk Assessment (ERA) to evaluate the risks associated with patient use of upadacitinib in support of the Marketing Authorisation Application (MAA) for treatment of rheumatoid arthritis (RA) by upadacitinib (15 mg/day). The experimentally determined n-octanolbuffer distribution coefficient (log Kow) of 2.5 for upadacitinib does not indicate the potential for bioaccumulation, therefore a persistence, bioaccumulation and toxicity (PBT) screening was not required. The ERA Phase I and II studies were conducted in accordance with the European Medicines Agency's (EMA) 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' and supporting questions and answers on the EMA Guidance, as well as Organization for Economic Cooperation and Development (OECD) and European Chemicals Agency (ECHA) guidance documents. In the original ERA submitted for the MAA for RA approval, a Phase I assessment was completed and the PECSURFACEWATER RA was calculated with a dose of 15 mg/day and the default Fpen value of 0.01. The resulting PECSURFACEWATER RA was 0.075 µg/L.

To support the MAA seeking approval of upadacitinib for the treatment of psoriatic arthritis (PsA) the original ERA was completed. Therefore, as part of the Phase I assessment, the PECSURFACEWATER PsA was calculated using a dose of 15 mg/day and the default Fpen value of 0.01, resulting in a PECSURFACEWATER value of 0.075 µg/L for PsA. To support the request to extend the indications for upadacitinib to include both RA and PsA and to assess the potential impact of patient use of upadacitinib for both indications the PECSURFACEWATER value was recalculated involving both RA and PSA PECSURFACEWATER values, both being 0.075 µg/L. The PEC value that includes both RA and PsA is the PECSW-TOTAL of 0.15 µg/L. Phase I and Phase II Tier A assessment studies have already been completed and no additional studies were needed for the updated ERA. The PECSW-TOTAL value of 0.15 µg/L was used to recalculate the PEC/Predicted No Effect Concentration (PNEC) ratios for the Phase II Tier A risk assessments. All of the PEC/PNEC risk assessment ratios remained less than one, indicating that patient use of upadacitinib for both RA and PsA is unlikely to represent a risk to the aquatic environment.

## 2.2.2. Conclusion on the non-clinical aspects

The updated data submitted in this application lead to a significant increase in environmental exposure further to the use of upadacitinib.

Considering the above data, upadacitinib is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

| Type of Study   | Study ID   | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                         | Study Design and Type of Control                                                  | Test Product(s); Dosage Regimen; Route of Administration (if not PO)                                                                                                                  |   Number of Subjects | Healthy Subjects or Diagnosis of Patients   | Duration of Treatment                                                                                                 |
|-----------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| BA              | M20-017    | Part 1: Assess BA of UPA market- image formulation (15 mg) relative to reference 15 mg strength Phase 3 formulation after a high- fat/high- calorie meal and under fasting conditions. Part 2: Assess BA of UPA market- image formulation (30 mg) relative to the reference 30 mg strength Phase 3 formulation after a high- fat/high- calorie meal and under fasting conditions. | Single-dose, open-label, randomized, 4-period, 4-sequence, 2-part crossover study | Part 1: UPA Phase 3 15 mg tablet (ER17Y) and upadacitinib market-image 15 mg tablet (ER17) Part 2: UPA Phase 3 30 mg tablet (ER18Y) and upadacitinib market-image 30 mg tablet (ER18) |                   80 | Healthy adult subjects                      | Part 1: Four single-doses of UPA 15 mg separated by 4 days Part 2: Four single-doses of UPA 30 mg separated by 4 days |

<div style=\"page-break-after: always\"></div>

| Type of Study       | Study ID   | Objective(s) of the Study                                                                                                                                                                                                             | Study Design and Type of Control                                                         | Test Product(s); Dosage Regimen; Route of Administration (if not PO)   |   Number of Subjects | Healthy Subjects or Diagnosis of Patients                                                                                   | Duration of Treatment                                                                                                                                                               |
|---------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy and Safety | M15-554    | Period 1: Compare the efficacy, safety, and tolerability of UPA 15 mg QD and 30 mg QD vs PBO Period 2: Evaluate the long-term safety, tolerability, and efficacy of UPA 15 mg QD and 30 mg QD in subjects who have completed Period 1 | Period 1: Randomized, DB, parallel- group, PBO- controlled Period 2: Long-term extension | UPA 15 mg and 30 mg QD Matching PBO                                    |                  642 | Adult subjects with moderately to severely active PsA who have had an inadequate response or intolerance to biologic DMARDs | Period 1: 56 weeks; Period 2: Up to 3 years (or until local regulatory approval and/or applicable local reimbursement approval of the study drug if approval occurs after Week 152) |

<div style=\"page-break-after: always\"></div>

| Type of Study       | Study ID   | Objective(s) of the Study                                                                                                                                                                                                                                                                                                                                                    | Study Design and Type of Control                                                                                       | Test Product(s); Dosage Regimen; Route of Administration (if not PO)   |   Number of Subjects | Healthy Subjects or Diagnosis of Patients                                                                                      | Duration of Treatment                       |
|---------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Efficacy and Safety | M15-572    | Period 1: Compare the efficacy (signs and symptoms), safety, and tolerability of UPA 15 mg QD and 30 mg QD vs PBO and ADA and compare the efficacy of UPA 15 mg QD and 30 mg QD vs PBO for the prevention of structural progression Period 2: Evaluate the long-term safety, tolerability, and efficacy of UPA 15 mg QD and 30 mg QD in subjects who have completed Period 1 | Period 1: Randomized, DB, parallel- group, PBO- and active comparator- controlled study Period 2: Long-term extension. | UPA 15 mg and 30 mg QD ADA 40 mg eow SC Matching PBO                   |                 1705 | Adult subjects with moderately to severely active PsA who have had an inadequate response or intolerance to nonbiologic DMARDs | Period 1: 56 weeks; Period 2: Up to 5 years |

## 2.3.2. Pharmacokinetics

## Analytical methods

For the applied indication extension, the same prolonged-release formulations of upadacitinib marketed for treatment of patients with RA is proposed for the treatment of adult patients with active PsA. The formulation of the product used for clinical studies in the application is manufactured at another site and shows some differences in its outfit compared to the commercial one. Bioanalytical methods were used for the bioequivalence study and two efficacy and safety studies of the formulations. The bioequivalence of the extended-release (ER) formulation used in PsA Phase 3 studies and the commercial formulation was tested in study M20-017.

<div style=\"page-break-after: always\"></div>

The same bioanalytical methods that were used in the regulatory application for the use of upadacitinib in the treatment of RA were used for the analysis of plasma samples in the current submission. The validation of the method, including stability at various stages of the analysis, has been assessed as part of the application for RA. Assuming that the different patient groups do not affect the analytical performance of the method, this validation can be considered valid also for determinations of plasma samples obtained from PsA patients.

The performance of the method in the bioanalytical phase of the bioequivalence study was followed by quality criteria for calibrations, use of quality control samples in the analytical batches and incurred sample reanalysis (more than 10% of the total number of samples that fulfils the EMA recommendation given in the Guideline on bioanalytical method validation ). Some quality indicating data are listed in Table below.

Table 1 Performance indicating parameters for bioanalysis of upadacitinib in human plasma in study M20-017

|                                                                                                | Results                                                                                                         |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Mean bias (RE %) and CV% of calibration samples                                                | -1.7 - 2.3 %(RE), CV% ≤ 5.3%                                                                                    |
| Quality control samples, mean bias (RE %) and CV% 0.136 ng/mL 3.16 ng/mL 39.9 ng/mL 79.0 ng/mL | 0,7% (RE), 6.9% (CV) -0.6% (RE), 3.8% (CV) 3.0% (RE), 3.2% (CV) 3.2% (RE), 4.1% (CV) Difference -23.8% - 18.2%, |
| Incurred sample reanalysis                                                                     | 635 of 637 met the acceptance criteria                                                                          |

A total of 5088 samples were assayed in 57 analytical batches (including batches for ISR) for the clinical study. The back-calculated concentrations of calibration samples, the reproducible slope and high r2 values for the calibration curves, the results obtained for quality control samples and incurred sample reanalysis reported do not raise immediate concerns concerning the sufficient quality of the bioanalytical results.

The bioanalytical method was also used for determination of upadacitinib in plasma samples from the efficacy and safety studies M15-554 and M15-572. The performance of the method in the laboratories performing the determinations in these studies have been reported in interim reports.

For study M15-572, the bioanalyses were performed in two laboratories. The performance of the methods have been controlled by quality criteria for the calibrations and quality control samples. Incurred sample reanalysis from these studies were not used to assess the reproducibility of the method, except for the determinations done by WuXi AppTec. Some quality indicating data for Study M15-554 are summarized in Table below.

<div style=\"page-break-after: always\"></div>

Table 2 Performance indicating parameters for bioanalysis of upadacitinib in human plasma in study M15-554

|                                                                                                                    | Results                                                         |
|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Mean bias (RE %) and CV% of calibration samples, calibrations March 2018 - October 2018                            | -5.0 - 4.0 %(RE), CV% ≤ 5.4%                                    |
| Mean bias (RE %) and CV% of calibration samples, calibrations December 2018 - April 2019                           | -2.7 - 3.1 %(RE) CV% ≤ 4.3%                                     |
| Mean bias (RE %) and CV% of calibration samples, calibrations October 2019 - December 2019                         | -2.2 - 2.9 %(RE) CV% ≤ 4.5%                                     |
| Quality control samples, mean bias (RE %) and CV% , March 2018 - October 2018 0.12 ng/mL 3.76 ng/mL 79.0 ng/mL     | 5.0% (RE), 7.8% (CV) 4.5% (RE), 4.8% (CV) -2.5% (RE), 7.0% (CV) |
| Quality control samples, mean bias (RE %) and CV% , December 2018 - April 2019 0.136 ng/mL 3.16 ng/mL 79.0 ng/mL   | 1.5% (RE), 5.7% (CV) 0.6% (RE), 3.9%(CV) 1.0% (RE), 5.4% (CV)   |
| Quality control samples, mean bias (RE %) and CV% , October 2019 - December 2019 0.136 ng/mL 3.16 ng/mL 79.0 ng/mL | 2.2% (RE), 5.1% (CV) 0.3% (RE), 2.7% (CV) 2.8% (RE), 1.8% (CV)  |

The slope of the calibration curves between December 2018 and April 2019 varied between 0.122 and 0.331.

In studies M15-554 and M15-572, the CHMP noted a big variability in the slope of the calibration curves. According to the MAH responses, instrument responses can be varied from mass spectrometer to mass spectrometer and from day to day.  Therefore, the slope may vary depending on mass spectrometers used and time of injection. The variability observed is obviously caused by the use of different mass spectrometers and times of injection. The explanation was considered acceptable to the CHMP.

In the interim report from AbbVie, the calibration data shows a low bias and intra-day precision for the back-calculated standards. Quality control samples of three concentrations were analysed in the analytical batches; the maximum bias of the mean for all quality controls was 3.5%, indicating good enough intra-day accuracy and precision.

In the interim report from VuXi AppTec, the calibration data for back-calculated concentrations of calibration samples show a low bias and inter-day variability. The slope of the calibration curve from 24.12.2019 (0.17) differs significantly from the general trend (abut 0.26). VuXi AppTech used 5 QC samples of 5 concentrations. The highest value for bias of these QC runs was 1.4% and the maximum CV% of the QC samples was 8.7%, n=20 (at 0.15 ng/mL), indicating good enough accuracy and interday precision in using the method. Incurred sample reanalysis was done on 60 selected samples 100% of these met the acceptance criteria.

In the BE-study M20-017, QC samples of four concentrations were analyzed. In the WuXi AppTec laboratory, five different concentrations were used for QC samples in study M15-572. During the review, the CHMP asked the MAH to clarify why the concentration was in the middle range of the concentration range not included in the analyses of samples from study M15-554. The MAH clarified that three levels: low, mid (geometric mean) and high QCs are the three levels used. The low QC concentration must be within three times the lower limit of quantitation (LLOQ) concentration. The mid QC concentration must be close to the geometric mean of the low and high QCs. The high QC concentration must be within 75% of the upper limit of quantitation (ULOQ) concentration. Three concentration levels are considered enough by the CHMP and the response was considered acceptable.

<div style=\"page-break-after: always\"></div>

## Bioequivalence

## Study M20-017

Study M20-017 was a Phase 1 single-dose, open-label, randomized, four-period, four-sequence, twopart crossover design to assess the bioavailability of upadacitinib 15 and 30 mg market-image formulations relative to the reference 15 and 30 mg Phase 3 formulations used in Phase 3 studies M15-554 and M15-572 after high-fat/high-calorie meal and under fasting conditions.

## Part 1

In Part 1, the bioavailability of upadacitinib market-image formulation (15 mg) relative to the reference 15 mg strength Phase 3 formulation after a high-fat/high-calorie meal and under fasting conditions was evaluated in 39 healthy subjects.  The schematic of study M20-017 Part 1 (15 mg dose) is shown in Figure below.

<!-- image -->

Allowwashoutofatleast4DaysbetweenDoses

Figure 2 Study M20-017 Part 1: Design Schematic

A washout interval of 4 days separated the doses between the four study periods. Blood samples for assay of upadacitinib were collected for 72 hours after dosing in each period.

Subjects were confined to the study site and supervised for approximately 17 days. Confinement in each period began on Day -1 of Period 1 and ended after the collection of the 72-hour blood samples and completion of scheduled procedures on Day 4 of Period 4.

In all periods, each dose of study drug was taken orally with ~240 mL of water on Day 1 (Table 3). For Regimens C and D, study drug was taken ~30 minutes after starting a high-fat/high-calorie breakfast (Table 4). For Regimens A and B, each dose of study drug was taken after a minimum 10-hour fast and ~4 hours before lunch. Subjects within each regimen received standardized meals during confinement. The upadacitinib formulations used in study M20-017 Part 1 are presented in Table 5.

<div style=\"page-break-after: always\"></div>

Table 3 Study M20-017 Part 1: Summary of dosing regimens.

| Regimen A   | Single 15 mg dose of upadacitinib Phase 3 formulation (ER17Y) administered under fasting conditions (Reference for B).         |
|-------------|--------------------------------------------------------------------------------------------------------------------------------|
| Regimen B   | Single 15 mg dose of upadacitinib market-image formulation (ER17) administered under fasting conditions (Test for A).          |
| Regimen C   | Single 15 mg dose of upadacitinib Phase 3 formulation (ER17Y) administered after high-fat/high-calorie meal (Reference for D). |
| Regimen D   | Single 15 mg dose of upadacitinib market-image formulation (ER17) administered after high-fat/high-calorie meal (Test for C).  |

Table 4 Study M20-017 Part 1: Content and composition of the high-fat/high-calorie breakfast.

| Menu                                                                                                                                        | Meal composition                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| breakfast croissant (3 oz), sliced cheddar cheese (0.5 oz), hard fried egg, sliced ham (1 oz), Swiss cheese (0.75 oz), peanut butter, apple | 826 Kcal; 51.5% calories from fat, 33.6% calories from carbohydrates, and 15% calories from protein |

Table 5 Study M20-017 Part 1: Identity of Investigational Products

|                      | Upadacitinib Formulations (l5mg)   | Upadacitinib Formulations (l5mg)   |
|----------------------|------------------------------------|------------------------------------|
|                      | Phase3 Formulation (Reference)     | Market-Image Formulation (Test)    |
| Dosage Form          | Tablet                             | Tablet                             |
| Formulation          | ER17Y                              | ER17                               |
| Strength (mg)        | 15                                 | 15                                 |
| MMID                 | 20014313                           | 20015270                           |
| BulkProductLot       | 1000298099                         | 1000186478                         |
| Finishing Lot Number | 19-003629                          | 19-003630                          |
| Retest Date          | 31-December-2022                   | 31-March-2021                      |

MMID=Material MasterIdentification

PK parameters: Blood samples for assay of upadacitinib were collected prior to dosing (0 hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after dosing in each period. Values for the pharmacokinetic parameters of upadacitinib were estimated using noncompartmental methods. PK parameters were defined in the protocol as follows:

1. The Cmax and Tmax were determined directly from the plasma concentration-time data.
2. The value of the apparent terminal phase elimination rate constant (β) was obtained from the slope of the least squares linear regression of the logarithms of the plasma concentration versus time data from the terminal log-linear phase of the profile. The range of concentrationtime data points selected for the calculation of β was identified by the maximum adjusted R 2 value from the regressions of all the possible ranges of data points, beginning with the last three data points with non-zero concentrations, and then testing additional data points up to but not including Tmax. In addition, the data points that were selected by the algorithm were evaluated by visual inspection; when appropriate, data points were removed or added and the regression rerun. The actual times used for each subject are listed in the tables of the

<div style=\"page-break-after: always\"></div>

calculated pharmacokinetic parameters. The terminal phase elimination half-life (t½) was calculated as ln(2)/β.

3. The area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt), AUC from time 0 to 12 hours after dosing (AUC0-12), and AUC from 12 hours after dosing to time of last measurable concentration (AUC12-t) were calculated by the linear trapezoidal rule. The AUC was extrapolated to infinite time by dividing the last measurable plasma concentration (Ct ) by β. Denoting the extrapolated portion of the AUC by AUCext, the AUC from time 0 to infinite time (AUCinf) was calculated as follows:

AUCinf = AUCt + AUCext

4. The percentage of the contribution of AUCext to the overall AUCinf was calculated by dividing the AUCext by the AUCinf and multiplying this quotient by 100.

Statistical Methods: For each part, a linear mixed effects analysis was performed for the natural logarithms of Cmax, AUCt, AUCinf, AUC0-12 and AUC12-t using SAS PROC MIXED. The model included effects for sequence, period, and regimen. Within the mixed modeling framework, each test regimen was compared to the corresponding reference regimen.

The bioavailability of a test regimen relative to that of the corresponding reference regimens (marketimage versus Phase 3 formulation and high-fat/high calorie meal versus fasting condition) was assessed by point estimates of the central values and corresponding 90% confidence intervals (CI) obtained from the analyses of the natural logarithms of Cmax, AUCt, AUCinf, AUC0-12 and AUC12-t. These CIs were obtained by taking the antilogarithm of the upper and lower limits of CIs for the difference of the least squares (LS) means on the logarithmic scale within the framework of mixed effects models.

Conduct of the study: In Part 1, all PK samples collected 5 hours or less after dosing were obtained within 10% of the protocol-scheduled times; all samples collected more than 5 hours after dosing were obtained within 30 minutes of the protocol-scheduled times. The scheduled times were used in the calculations of the PK parameters. No protocol deviations were reported in study M20-017.

Data set analysed: 40 subjects were randomised in Part 1. One subject discontinued study drug due to an adverse event (cholelithiasis) after receiving Regimen D in Period 3 and did not receive Regimen B in Period 4. Therefore, only data for Regimens A, C, and D from this subject were included in the linear mixed effects analyses of PK parameters. In addition, one subject was lost to follow up after completing all 4 periods of the study. Prior to enrolment in the study, each subject was judged to be in good health based on review of his/her medical history, a physical examination, vital signs, 12-lead ECG and laboratory tests. A summary of the demographic data is presented in Table below.

Table 6 Study M20-017 Part 1: Demographic Summary (N=40)

|                                                                 | Mean ± SD (Minimum to Maximum)                                  |
|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Age (years)                                                     | 38.0 ± 9.65 (19 to 56)                                          |
| Weight (kg)                                                     | 81.4 ± 11.5 (55.1 to 101)                                       |
| Height (cm)                                                     | 176 ± 9.33 (152 to 193)                                         |
| BMI (kg/m 2 )                                                   | 26.2 ± 2.59 (19.5 to 29.4)                                      |
| Sex                                                             | 35 Males (88%), 5 Females (13%) a                               |
| Race a                                                          | 13 White (33%), 20 Black (50%), 1 Asian (3%), 6 Multiple (15%)  |
| BMI = Body Mass Index a. Due to rounding over 100% is reported. | BMI = Body Mass Index a. Due to rounding over 100% is reported. |

<div style=\"page-break-after: always\"></div>

## PK results:

## Part 1

The mean upadacitinib plasma concentration-time profiles by study drug regimens are presented in Figure 3 and Figure 4. The point estimates for relative bioavailability and the corresponding 90% confidence intervals from the linear mixed effects analysis are presented in Table 7. The results demonstrated that the 15 mg upadacitinib commercial formulation is bioequivalent to the 15 mg formulation used in PsA Phase 3 studies under fasting conditions and after a high-fat/high-calorie meal.

<!-- image -->

Regimen A:

Regimen B:

Single15mgdose of upadacitinibPhase3formulation(ER17Y)administeredunderfastingconditions

(N = 40).

Single 15 mg dose ofupadacitinib market-image formulation(ER17) administered under fasting conditions (N =39).

Figure 3 Study  M20-017  Part  1:  Mean  Upadacitinib  Plasma  Concentrations  vs  Time  Profiles Following  Administration  of  Upadacitinib  15  mg  Market-Image  Formulation  (ER17)  and  Phase  3 Formulation (ER17Y) Under Fasting Conditions.

<div style=\"page-break-after: always\"></div>

<!-- image -->

calorie meal(N=40).

Figure 4 Study M20-017 Part 1: Mean Upadacitinib Plasma Concentrations vs Time Profiles Following Administration of Upadacitinib 15 mg Market-Image Formulation (ER17) and Phase 3 Formulation (ER17Y) After a High-Fat/High-Calorie Meal.

<div style=\"page-break-after: always\"></div>

Table 7 Study M20-017 Part 1: Point Estimates and 90% Confidence Intervals for the Bioavailability of Upadacitinib 15 mg Commercial Formulation Relative to the Upadacitinib Phase 3 Formulation under Fasting Conditions and after High Fat/High Calorie Meal.

| Regimens        |                    |                |                | Relative Bioavailability   | Relative Bioavailability   |
|-----------------|--------------------|----------------|----------------|----------------------------|----------------------------|
| Test vs.        | Pharmacokinetic    | Central Value* | Central Value* | Point                      | 90% Confidence             |
| Reference       | Parameter (units)  | Test           | Reference      | Estimate                   | Interval                   |
| Regimen B vs. A | C max (ng/mL)      | 29.1           | 28.1           | 1.038                      | 0.936 - 1.150              |
|                 | AUC t (ng•h/mL)    | 250            | 256            | 0.973                      | 0.919 - 1.031              |
|                 | AUC inf (ng•h/mL)  | 254            | 265            | 0.960                      | 0.907 - 1.015              |
|                 | AUC 0-12 (ng•h/mL) | 184            | 184            | 1.003                      | 0.938 - 1.072              |
|                 | AUC 12-t (ng•h/mL) | 62.7           | 70.3           | 0.892                      | 0.823 - 0.968              |
| Regimen D vs. C | C max (ng/mL)      | 47.4           | 48.4           | 0.980                      | 0.915 - 1.049              |
|                 | AUC t (ng•h/mL)    | 318            | 335            | 0.949                      | 0.906 - 0.994              |
|                 | AUC inf (ng•h/mL)  | 323            | 339            | 0.952                      | 0.910 - 0.997              |
|                 | AUC 0-12 (ng•h/mL) | 267            | 281            | 0.949                      | 0.897 - 1.004              |
|                 | AUC 12-t (ng•h/mL) | 49.1           | 51.4           | 0.956                      | 0.882 - 1.036              |

- Regimen A : Single 15 mg dose of Phase 3 formulation (ER17Y) administered under fasting conditions (reference for B).
- Regimen B : Single 15 mg dose of market-image formulation (ER17) administered under fasting conditions (test for A).
- Regimen C : Single 15 mg dose of Phase 3 formulation (ER17Y) administered after a high fat/high calorie meal (reference for D).
- Regimen D :  Single 15 mg dose of market-image formulation (ER17) administered after a high fat/high calorie meal (test for C).

Part 2

In Part 2, the bioavailability of upadacitinib market-image formulation (30 mg) relative to the reference 30 mg strength Phase 3 formulation after a high-fat/high-calorie meal and under fasting conditions was evaluated in 40 healthy subjects.

Results for Part 2 indicated bioequivalence between upadacitinib 30 mg ER tablet market-image formulation and 30 mg ER tablet Phase 3 formulation under fasting conditions and after a highfat/high-calorie meal. An application to extend the marketing authorisation for the 30 mg strength was not applied. Therefore, details of study M20-017 Part 2 are not presented.

## 2.3.3. Pharmacodynamics

## Mechanism of action and primary pharmacology

No new studies on pharmacodynamics of upadacitinib are presented within this application. The mode of action of upadacitinib is described below based on published literature.

JAKs are intracellular enzymes that transmit cytokine or growth factor signals involved in a broad range of cellular processes including inflammatory responses, haematopoiesis and immune surveillance. The JAK family is composed of 4 members: JAK 1, 2, 3, and tyrosine kinase 2 (Tyk2). These cytoplasmic tyrosine kinases act in tandem to activate the Signal Transducer and Activator of

<div style=\"page-break-after: always\"></div>

Transcription (STAT) that transduces cytokine-mediated signals, and are associated with multiple membrane cytokine receptors such as common gamma-chain (CGC) receptors and the glycoprotein 130 (gp130) trans-membrane proteins. Interleukin-6 (IL-6), a pro-inflammatory cytokine, propagates its signalling through the IL-6 receptor and gp130 which in turn results in activation of JAK1, JAK2 and Tyk2 with possible preferential usage of JAK1. JAK3 and JAK1 are components of the CGC cytokine receptor complexes that are responsible for the signalling of the inflammatory cytokines interleukin (IL)-2, -4, -7, -9, -15 and -21; whereas IL-12 and IL-23 signal through JAK2 and Tyk2. Propagation of these signals is important in the amplification of inflammatory responses.

The phosphorylated STATs (pSTATs) form either homo- or heterodimers, which translocate into the nucleus where they bind their cognate promoter elements to regulate transcription of target genes and modulate, in turn, gene expression and cellular function. As the antigen presenting cell engages with the T cell receptor, several cytokines are released to promote the differentiation of various T cell subtypes. Each cytokine involved in T cell differentiation and function have particular JAKs that mediate the signalling. Differentiated T cells produce cytokines that contribute to various immune responses and are implicated in inflammatory and autoimmune diseases.

The exact pathophysiology of psoriasis and PsA has not been fully elucidated. Dysregulated functions of immune cells, mainly dendritic cells and Th17 and Th1, and keratinocyte proliferation/differentiation are involved. In PsA, immune cells, such as activated T cells, dendritic cells, macrophages, and innate lymphoid cells, infiltrate peripheral or axial joints, entheses, and tenosynovial sheaths. The inflammatory cytokines driving the infiltration include IL1β, IL -2, IL-10, interferon gamma (IFNγ), and tumour necrosis factor alpha (TNFα). These mediators can further recruit and stimulate the proliferation of immune cells contributing to synovial hypertrophy and bone destruction. Many of these cytokines and immune cell responses are regulated by JAK/STAT signalling pathways.

Upadacitinib is a selective and reversible JAK inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Upadacitinib induces a dose-, and concentration-dependent inhibition of IL-6 (JAK1/JAK2) - induced STAT3 and IL-7 (JAK1/JAK3)-induced STAT5 phosphorylation, oncostatin M, IL2 and IFNγ. The exact mode of action at involved sites is not fully clear. However, alleviation of the inflammatory JAK/STAT signalling pathways is the overall mode of action of upadacitinib in the treatment of PsA.

## 2.3.4. PK/PD modelling

## Population pharmacokinetic analysis

Population pharmacokinetic (PPK) analysis in patients with PsA was performed using data from Study M15-554 Period 1 and Study M15-572 Period 1 (up to 24 Weeks). The objective of PPK analysis was to characterize the population PK of upadacitinib in subjects with moderate to severe PsA. Individual predicted upadacitinib exposures based on the PPK model were subsequently used in exposure-response analyses.

Results from prior PPK analyses in healthy subjects and patients with RA were leveraged to inform upadacitinib PK parameters in subjects with PsA. The observed binned plasma concentration versus time profiles of upadacitinib between subjects with RA and subjects with PsA were comparable (Figure 5). Therefore, a Bayesian PK modeling approach was implemented using prior information from the previous upadacitinib PPK model (hereafter ' PPK model 1 ' based on 4170 subjects; 96% subjects with RA and 4% healthy subjects), which was assessed within the Rinvoq marketing authorisation application. Specifically, the structural, statistical (inter- and intra-individual variability) and covariate components of the previous model were maintained. Population parameter estimates, the variance-

<div style=\"page-break-after: always\"></div>

covariance matrix of the fixed effects and estimates for the random effects (inter- and intra-individual variability) from the PPK model 1 were used as priors via the $PRIOR TNPRI function in NONMEM. All model parameters were re-estimated using the data in subjects with PsA from studies M15-554 and M15-572.

<!-- image -->

## Population·RA·PsA

<!-- image -->

Orange circles : Observed upadacitinib concentrations from subjects with RA in Phase 3 studies. Blue circles : Observed upadacitinib concentrations from PsA patients.

Closed cycles and error bars represent median and 5 th  and 95 th  percentiles for the binned observed data.

Figure 5 Observed Upadacitinib Concentrations vs Time after Last Dose in Subjects with RA and PsA in Phase 3 Studies

Continuous covariates were included in the model using power functions centred on the median value of each covariate in the dataset. Categorical covariates were tested with a multiplicative model. Intersubject variability (IIV) was modeled assuming a log-normal distribution and residual variability was modeled using a combination of additive and proportional error terms.

## PK datasets

Data from 1694 patients with PsA who received upadacitinib and had at least one measurable upadacitinib concentration were included in the PPK analysis of studies M15-554 and M15-572. This includes patients initially randomised to placebo and assigned to upadacitinib at week 24. PK data up to week 56 were used in the PPK analysis. Samples collected before administration of the first

<div style=\"page-break-after: always\"></div>

upadacitinib dose were excluded. Sampling times represented actual sampling times. PK sample collections that did not have a sampling time recorded were not included in the analysis.

PsA patients were typically female (916/1694; 54.1%) and white (88.8%). Mean (SD) age, weight and creatinine clearance were 51.5 (12.2) years, 86.8 (20.8) kg and 127 (42.1) ml/min, respectively.

Upadacitinib concentrations were measured at two sites, AbbVie laboratory and WuXi laboratory (samples collected in China). Based on a cross-validation analysis, upadacitinib concentrations measured at WuXi site in China were systematically higher compared to samples analysed at AbbVie, by an average of 11%. To account for the analytical difference between the two laboratories, all upadacitinib plasma concentrations for samples analysed at WuXi, upadacitinib exposure were adjusted (decreased) in the dataset by 11% in the PPK analysis.

Outlier identification and data exclusion rules were the same as those used in the PPK model 1 analysis.

The dataset included 10,691 concentrations with 396 records (3.7%) below the LLOQ. The first observed upadacitinib concentration value below the LLOQ was set to one-half of the LLOQ and flagged with '1' in the BLQ column. All subsequent concentrations below the LLOQ recorded after the last dose were flagged with '2' in the BLQ column and ignored in the analysis.

Two hundred (200) concentration records were excluded due to lack of dosing records being associated with sampling times. Additionally, 105 observations recorded more than 168 hours after the last dose were excluded from the model. Finally, 235 concentration records were flagged as outliers. These records were excluded from the PPK model development, but the final model was rerun on the full dataset including the outliers to evaluate the impact of outliers on parameter estimates.

## PPK model development

In the PPK model 1, the PK of upadacitinib were characterized by a two-compartment model with mixed zero and first order absorption with lag time for the extended-release formulation, and linear elimination. Statistically significant covariates were patient population (patients versus healthy), creatinine clearance, and baseline bodyweight on CL/F; and body weight on Vc/F. These covariates were retained in the model and were re-estimated with current data.

The fixed and random effect parameter estimates from the final model updated with data from subjects with PsA were comparable to the prior parameter estimates from the model developed using data from healthy subjects and subjects with RA. Likewise, the 95% CI for the estimates of the covariate effects parameters in the updated model did not include no effect value (zero for continuous covariates and one for categorical covariates) indicating that the previously identified covariates were statistically significant in the model updated with data from PsA studies (Table 8). The CL/F ratio of patients compared to healthy subjects was comparable for PsA and RA patients (0.756 and 0.754, respectively). The parameter estimates were not markedly changed when the model updated with PsA data was re-run with the outlier observations that were excluded during the model development, which supported the robustness of the model.

<div style=\"page-break-after: always\"></div>

Table 8 Parameter Estimates and Variability for Upadacitinib Population PK: Model Updated with Data from Subjects with PsA Compared to Prior Model (PPK model 1)

|                                                                          | Model Updated with PsA Studies   | Model Updated with PsA Studies   | PPK model 1         |
|--------------------------------------------------------------------------|----------------------------------|----------------------------------|---------------------|
| Parameter                                                                | Population Estimate              | 95% Confidence Interval          | Population Estimate |
| CL/F (L/h) a                                                             | 41.3                             | 40.0 - 42.6                      | 40.9                |
| Vc/F (L) a                                                               | 156                              | 151 - 161                        | 156                 |
| Extended-Release KA (1/h)                                                | 0.0539                           | 0.0489 - 0.0595                  | 0.0523              |
| Extended-Release Lag time (h)                                            | 0.153                            | 0.131 - 0.178                    | 0.154               |
| Fraction of ER Dose Absorbed through Zero-Order Process (%)              | 73.1                             | 70.5 - 75.6                      | 74.5                |
| Zero-Order Infusion Duration (h)                                         | 3.32                             | 3.21 - 3.43                      | 3.29                |
| Immediate-Release KA (1/h)                                               | 2.75                             | 2.37 - 3.18                      | 2.77                |
| Immediate-Release Lag time (h)                                           | 0.200                            | 0.185 - 0.216                    | 0.200               |
| Bioavailability of the ER Formulation Relative to the IR Formulation (%) | 76.0                             | 73.9 - 78.0                      | 76.2                |
| Q/F (L/h) a                                                              | 3.22                             | 2.88 - 3.60                      | 3.22                |
| Vp/F (L) a                                                               | 67.4                             | 58.7 - 77.3                      | 68.0                |
| CL/F Ratio of diseased Patients Compared to Healthy Subjects b           | 0.756                            | 0.730 - 0.782                    | 0.754               |
| Covariate Exponent of Creatinine Clearance on CL/F b                     | 0.258                            | 0.214 - 0.302                    | 0.256               |
| Covariate Exponent of Weight on Vc/F b                                   | 0.864                            | 0.744 - 0.984                    | 0.804               |
| Covariate Exponent of Weight on CL/F b                                   | 0.123                            | 0.0569 - 0.189                   | 0.132               |
| ISV on CL/F in Phase 1 (%)                                               | 20.5                             | 18.5 - 22.3                      | 20.5                |
| ISV on Vc/F in Phase 1 (%)                                               | 24.2                             | 20.6 - 27.4                      | 24.4                |
| ISV on Extended-Release KA (%)                                           | 63.8                             | 56.8 - 70.1                      | 66.8                |
| ISV on CL/F in Phase 2/3 (%)                                             | 36.3                             | 34.6 - 38.0                      | 36.5                |
| ISV on Vc/F in Phase 2/3 (%)                                             | 60.7                             | 51.3 - 68.9                      | 53.0                |
| Proportional Error in Phase 1 SD                                         | 0.345                            | 0.325 - 0.364                    | 0.344               |
| Additive Error SD (ng/mL)                                                | 0.0809                           | 0.0529 - 0.101                   | 0.0858              |
| Proportional Error in Phase 2/3 SD                                       | 0.559                            | 0.550 - 0.568                    | 0.543               |

CL/F = apparent clearance; CrCL = creatinine clearance; ER = extended-release; IR = immediate-release; ISV = inter-subject variability; KA = absorption rate constant; PsA = psoriatic arthritis; Q/F = apparent inter-compartmental clearance; RA = rheumatoid arthritis; SD = standard deviation; Vc/F = apparent volume of distribution of central compartment; Vp/F = apparent volume of distribution of peripheral compartment.

%ISV was calculated as SQRT(ω 2 ) × 100

- a. Estimates are for the immediate release (based on immediate release bioavailability).
- b. Typical clearance and volume of central compartment with particular covariate combination:

<!-- formula-not-decoded -->

The following additional covariates were investigated for influence on upadacitinib PK in subjects with PsA by graphical analyses of post hocs vs covariates:

- For CL/F: age, sex, race, (White, Black, Hispanic, Asian), country (Taiwan, Japan, China, South Korea), baseline serum bilirubin, baseline aspartate transaminase (AST), baseline alanine transaminase (ALT), baseline hsCRP, concomitant use of non-biologic DMARDs, concomitant use of any pH-modifying agents, concomitant use of moderate or strong CYP3A inhibitors, and concomitant use of strong CYP3A inducers

<div style=\"page-break-after: always\"></div>

- For Vc/F: sex, race (White, Black, Hispanic, Asian), and country (Taiwan, Japan, China, South Korea)
- For absorption rate of the ER formulation: upadacitinib dose, concomitant use of antacids, concomitant used of H2 receptor antagonists, concomitant use of proton pump inhibitors, concomitant use of any pH-modifying agents, concomitant use of moderate or strong CYP3A inhibitors, and concomitant use of strong CYP3A inducers

In the exploratory plots, a trend for decrease in CL/F with age was present. No clear trend was observed for any other tested covariate. Age was tested as a covariate on CL/F but it was not statistically significant (decreased OFV by only one point). Therefore, age was not included as a covariate and the model summarised in Table 8 was selected as the final model.

The goodness-of-fit plots for the final model are depicted in Figure 6 for the data from Phase 3 PsA studies. Visual predictive checks (VPCs) with 250 replicates for the upadacitinib concentrations in subjects with PsA were plotted against time since last dose and stratified by dose group (Figure 7). Median and 5 th  and 95 th  percentiles of observed exposures lie within the 95% prediction bands for these percentiles for most of the bins shown in the plots indicating that the model adequately describes the pharmacokinetics of upadacitinib in subjects with PsA.

<!-- image -->

Goodness-of-fitplotsfortheindividualpredictedandpopulationpredictedversusobservedconcentrations （topleftandright,respectively)fromupadacitinibPsAPhase3studiesandconditionalweightedresiduals versus time sincelastdose andpopulationpredicted concentrations(bottomleft andright,respectively)

Figure 6 Goodness-of-Fit Plots of Upadacitinib PPK Model (Data from Phase 3 PsA Studies)

<div style=\"page-break-after: always\"></div>

<!-- image -->

The shaded blue areas represent the 95% prediction interval of the 2.5th and 97.5t percentiles of simulated concentrations, the red shaded areas represent the 95% prediction interval ofthe 50\" percentile of simulated concentrations, the solid red line represents median of the observed concentrations and dashed red lines represent the 2.5th and 97.5t percentile of the observed concentrations.

Figure 7 Visual Predictive Checks of Upadacitinib Concentration Plotted Versus Time Since Last Dose for PsA Patients Stratified by Dose.

## Impact of Statistically Significant Covariates on Upadacitinib Exposures

The influence of statistically significant covariates identified in the PPK analyses on upadacitinib steadystate area under the plasma concentration-time curve from time zero to 24 hours (AUC24h) and steadystate maximum observed plasma concentration (Cmax) following administration of the 15 mg and 30 mg extended-release dose are presented in Figure 8. The test and reference groups for the assessment of covariate effects were as follows:

## Body Weight:

- Test groups: &lt; 60 kg and &gt; 100 kg
- Reference group: 60 - 100 kg

## Creatinine clearance (CrCL):

- Test groups: 60 to &lt; 90 mL/min [mild renal impairment] and 30 to &lt; 60 mL/min [moderate renal impairment]
- Reference group: ≥ 90 mL/min

Based on the simulations, subjects with PsA with bodyweight &lt;60 kg or &gt;100 kg were predicted to have 5% higher or 4% lower AUC on average, and 20% higher or 16% lower Cmax, on average, respectively, compared to subjects with bodyweight 60 - 100 kg. Subjects with mild (CrCL 60 to &lt; 90 mL/min) or moderate (30 to &lt; 60 mL/min) renal impairment are predicted to have approximately 15% and 26% higher AUC and 8% and 13% higher Cmax, respectively, compared to subjects with normal renal function.

<div style=\"page-break-after: always\"></div>

Figure 8 Model-Predicted Covariate Effect on Upadacitinib Cmax and AUC24h for Different Subpopulations Relative to the Reference Population.

<!-- image -->

The vertical dashed line shows the exposure ratio of 1 relative to the reference group. The reference group for bodyweight was 60 to100 kg and for creatinine clearance was ≥ 90 mL/min.

## Effect of Commonly Used DMARDs on Upadacitinib Exposures

In the Phase 3 Studies M15-554 and M15-572, upadacitinib was given as monotherapy or concomitantly with disease-modifying anti-rheumatic drugs (DMARDs). The percentages and number of subjects in the PPK dataset who were administered concomitant DMARDs is presented in Table 9.

<div style=\"page-break-after: always\"></div>

Table 9 Concomitantly used disease-modifying anti-rheumatic drugs in the population PK dataset.

|                       |     | 15 mg QD (N = 841)   | 30 mg QD (N = 853)   | ALL SUBJECTS (N = 1694)   |
|-----------------------|-----|----------------------|----------------------|---------------------------|
| Any concomitant DMARD | No  | 168 (20.0%)          | 161 (18.9%)          | 329 (19.4%)               |
| Any concomitant DMARD | Yes | 673 (80.0%)          | 692 (81.1%)          | 1365 (80.6%)              |
|                       | No  | 329 (39.1%)          | 358 (42.0%)          | 687 (40.6%)               |
|                       | Yes | 512 (60.9%)          | 495 (58.0%)          | 1007 (59.4%)              |
|                       | No  | 813 (96.7%)          | 829 (97.2%)          | 1642 (96.9%)              |
|                       | Yes | 28 (3.3%)            | 24 (2.8%)            | 52 (3.1%)                 |
|                       | No  | 841 (100.0%)         | 851 (99.8%)          | 1692 (99.9%)              |
|                       | Yes | 0 (0.0%)             | 2 (0.2%)             | 2 (0.1%)                  |
|                       | No  | 840 (99.9%)          | 852 (99.9%)          | 1692 (99.9%)              |
|                       | Yes | 1 (0.1%)             | 1 (0.1%)             | 2 (0.1%)                  |
| Hydroxy- choloroquine | No  | 832 (98.9%)          | 845 (99.1%)          | 1677 (99.0%)              |
| Hydroxy- choloroquine | Yes | 9 (1.1%)             | 8 (0.9%)             | 17 (1.0%)                 |
|                       | No  | 839 (99.8%)          | 852 (99.9%)          | 1691 (99.8%)              |
|                       | Yes | 2 (0.2%)             | 1 (0.1%)             | 3 (0.2%)                  |
|                       | No  | 800 (95.1%)          | 799 (93.7%)          | 1599 (94.4%)              |
|                       | Yes | 41 (4.9%)            | 54 (6.3%)            | 95 (5.6%)                 |
|                       | No  | 781 (92.9%)          | 789 (92.5%)          | 1570 (92.7%)              |
|                       | Yes | 60 (7.1%)            | 64 (7.5%)            | 124 (7.3%)                |
| Mycophenolate mofetil | No  | 840 (99.9%)          | 853 (100.0%)         | 1693 (99.9%)              |
| Mycophenolate mofetil | Yes | 1 (0.1%)             | 0 (0.0%)             | 1 (0.1%)                  |

Summary statistics of model-estimated upadacitinib steady state Cavg, Cmin and Cmax from the final PPK model were summarized for the different DMARDs, which were used by at least 1% of all subjects included in the PPK analysis; these DMARDs were methotrexate, apremilast, hydroxychloroquine, sulfasalazine, and leflunomide. As demonstrated in Table 10, upadacitinib plasma exposures were similar between subjects who were co-administered apremilast, hydroxychloroquine, sulfasalazine, and leflunomide, and subjects who did not receive these DMARDs, indicating lack of effect of these DMARDs on upadacitinib pharmacokinetics.

<div style=\"page-break-after: always\"></div>

Table 10 Summary Statistics of Model-Estimated Upadacitinib Plasma Exposures for 15 mg and 30 mg QD in Phase 3 PsA Studies Stratified by DMARD Use

| Treatment   | csDMARD              | Use   | N (%)       | Cavg (ng/mL) Median (90% CI)   | Cmax (ng/mL) Median (90% CI)   | Cmin (ng/mL) Median (90% CI)   |
|-------------|----------------------|-------|-------------|--------------------------------|--------------------------------|--------------------------------|
|             | Methotrexate         | Yes   | 512 (60.9%) | 15.4 (9.76 - 28.9)             | 37.9 (27.8 - 49.7)             | 4.42 (1.46 - 19.5)             |
|             | Methotrexate         | No    | 329 (39.1%) | 14.8 (9.52 - 28.3)             | 36.8 (26.5 - 47.9)             | 4.16 (1.55 - 19.2)             |
|             | Apremilast           | Yes   | 28 (3.3%)   | 14.2 (9.35 - 26.5)             | 35.6 (29.4 - 41.9)             | 4.03 (1.69 - 18.5)             |
|             | Apremilast           | No    | 813 (96.7%) | 15.2 (9.59 - 28.7)             | 37.7 (27.1 - 49.3)             | 4.26 (1.49 - 19.6)             |
| 15 mg QD    | Sulfasalazine        | Yes   | 60 (7.1%)   | 15.2 (9.38 - 31.9)             | 37.3 (25.9 - 53.0)             | 4.20 (1.68 - 18.9)             |
|             | Sulfasalazine        | No    | 781 (92.9%) | 15.2 (9.60 - 28.6)             | 37.6 (27.2 - 49.3)             | 4.27 (1.48 - 19.4)             |
|             | Leflunomide          | Yes   | 41 (4.9%)   | 13.8 (9.58 - 19.4)             | 36.2 (26.8 - 47.2)             | 3.56 (1.37 - 10.0)             |
|             | Leflunomide          | No    | 800 (95.1%) | 15.3 (9.59 - 28.8)             | 37.6 (27.2 - 49.3)             | 4.33 (1.56 - 19.6)             |
|             | Hydroxy- chloroquine | Yes   | 9 (1.1%)    | 14.6 (10.7 - 36.0)             | 31.9 (30.1 - 48.2)             | 4.71 (2.13 - 26.0)             |
|             | Hydroxy- chloroquine | No    | 832 (98.9%) | 15.2 (9.58 - 28.7)             | 37.6 (27.1 - 49.3)             | 4.24 (1.48 - 19.3)             |
|             | Methotrexate         | Yes   | 495 (58.0%) | 28.7 (19.5 - 53.2)             | 74.5 (57.0 - 96.9)             | 7.82 (3.21 - 33.2)             |
|             | Methotrexate         | No    | 358 (42.0%) | 29.2 (18.6 - 55.9)             | 73.1 (54.8 - 98.9)             | 8.13 (2.83 - 36.7)             |
|             | Apremilast           | Yes   | 24 (2.8%)   | 31.4 (20.9 - 46.9)             | 71.8 (56.4 - 87.7)             | 8.79 (4.67 - 25.5)             |
|             | Apremilast           | No    | 829 (97.2%) | 28.8 (19.1 - 54.9)             | 74.0 (55.6 - 97.9)             | 7.92 (2.92 - 34.6)             |
|             | Sulfasalazine        | Yes   | 64 (7.5%)   | 26.5 (18.6 - 49.0)             | 76.8 (53.4 - 93.3)             | 6.57 (2.79 - 28.0)             |
| 30 mg QD    | Sulfasalazine        | No    | 789 (92.5%) | 29.0 (19.3 - 55.0)             | 73.8 (56.1 - 98.1)             | 8.13 (3.03 - 35.6)             |
|             | Leflunomide          | Yes   | 54 (6.3%)   | 28.1 (18.6 - 57.1)             | 76.9 (59.9 - 106)              | 7.08 (2.38 - 38.5)             |
|             | Leflunomide          | No    | 799 (93.7%) | 29.0 (19.3 - 53.5)             | 73.8 (55.4 - 96.9)             | 8.06 (2.97 - 34.2)             |
|             | Hydroxy- chloroquine | Yes   | 8 (0.9%)    | 27.8 (23.8 - 57.9)             | 82.3 (71.3 - 95.7)             | 6.23 (4.93 - 36.6)             |
|             | Hydroxy- chloroquine | No    | 845 (99.1%) | 29.0 (19.1 - 54.5)             | 73.9 (55.5 - 97.4)             | 8.06 (2.95 - 34.4)             |

## Exposure-response analyses for efficacy

The objective of efficacy E-R analyses of Studies M15-554 and M15-572 was to characterize the relationships between upadacitinib plasma exposures and efficacy in subjects with moderate to severe PsA. Data from 1916 subjects who received placebo or upadacitinib were included in the efficacy E-R analyses. The following efficacy endpoints were used:

- ACR20 at Weeks 12 and 24
- ACR50 at Weeks 12 and 24
- ACR70 at Weeks 12 and 24
- PASI75 (for subjects with ≥ 3% BSA psoriasis at baseline) at Weeks 16 and 24
- sIGA (0/1) and at least a 2-point improvement from baseline (for subjects with baseline sIGA ≥ 2) at Weeks 16 and 24

For missing efficacy variables, Non-Responder Imputation (NRI) were used. In NRI, subjects who prematurely discontinued study drug were considered to be non-responders on or after discontinuation date.

## Methods

Upadacitinib plasma exposures (Cavg) in subjects with PsA who received the ER dosing regimens were derived using the individual predicted upadacitinib exposures based on the population PK model.

The relationships between upadacitinib Cavg and efficacy endpoints were first explored using quartile plots. Additionally, stepwise logistic regression analyses were constructed to test for relationship between each endpoint and upadacitinib Cavg in subjects with PsA.

For each of the evaluated efficacy variables, logistic regression models with treatment effect and exposure effect function were first evaluated to determine if there was a statistically significant effect

<div style=\"page-break-after: always\"></div>

of upadacitinib exposures on the probability of occurrence of each efficacy and safety variable. The logistic regression model described in Equation 5 was used to test for the statistical significance of treatment and/or plasma exposure effect as follows:

<!-- formula-not-decoded -->

where P ( Yi = 1) is the probability that the observation Y from subject i is equal to 1, with 1 indicating the event of interest occurred, α is the intercept parameter (refl ecting placebo response), β exp is the slope  for  the  exposure  metric  (i.e.,  Cavg),  Exposurei    is  the  exposure  metric  in  subject  i, β trt  is  the estimated magnitude of treatment effect, Treatmenti is the study arm in subject i.

Only efficacy endpoints exhibiting a statistically significant exposure effect (p-value &lt; 0.01 for β exp) were evaluated further using separate exposure-response models. Different drug effect functions such as linear  (Equation  8),  maximum  response  (Emax;  Equation  9),  and  sigmoid  Emax  (Equation  10)  were evaluated to determine the best model describing the effect of upadacitinib plasma exposures on the probability of each efficacy outcome.

Equivalent to Equation 5 the logit of the probabilities to reach the endpoint was described as:

<!-- formula-not-decoded -->

Here, Y denotes the binary variable of response being reached (or not), with P ( Y = 1) representing the probability of the response being reached. Different link functions for correlation with upadacitinib plasma exposures were explored to obtain optimal fits to observed data.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

where Intercept represents  the  logit-transformed  probability  at  zero  concentration  (placebo-treated subjects), C represents the exposure metric (Cavg) and Slope is the slope parameter for linear drug effect models. Emax, EC50 and γ represent the maximum response, the upadacitinib concentration associated with half Emax and the Hill factor in the sigmoid Emax models in the logit domain, respectively. These parameters are to be interpreted on the logistic scale. Exposure-response model selection was based on the  Akaike  Information  Criterion  (AIC)  and  graphical  assessment  of  the  adequacy  of  the  models  to describe the observed data. Additionally, model stability and precision of parameter estimates were used in the model selection process.

Covariate modelling Univariate analysis (evaluating one covariate at a time) was first performed. If more than one covariate was statistically significant, a multivariate assessment was performed. Covariates were tested for statistical significance using the likelihood ratio test by the stepwise forward-inclusion-backward-elimination procedure with p-value thresholds of p &lt; 0.01 and p &lt; 0.001, respectively.

Continuous covariates were centered at their median and included in the model as follows:

<div style=\"page-break-after: always\"></div>

where Pi is the parameter value for individual i with covariate value COVi , COVmed is the median value of the covariate, P is the typical value of the parameter (when COVi = COVmed ) and θ cov is the estimated slope of the covariate relationship.

Binary covariates were included in the model as follows:

<!-- image -->

where θ cov is the estimated slope of the covariate relationship and COVi denotes the binary covariate value of 0 or 1 for individual i , and P is the typical value (reference subject with covariate value of zero) of the parameter.

For each significant covariate in the final model, model predictions for the 15 and 30 mg QD regimen were carried  out  via  bootstrapping  and  stratified  by  pre-specified  categories  (e.g.,  subject  age  was categorized into &lt; 52 y, ≥ 52 y, subject BMI into &lt; 29.6 and ≥ 29.6 and hsCRP into ≤ upper limit of normal [2.87 mg/L] and &gt; upper limit of normal). Finally, median and 90% confidence intervals were calculated for response for each covariate category and shown in forest plots.

The final logistic regression models developed for efficacy endpoints were used to conduct simulations to predict the probabilities of the efficacy endpoints following treatment with placebo, upadacitinib 15 mg QD, and upadacitinib 30 mg QD regimens.

The simulations incorporated inter-individual variability in upadacitinib PK and covariate distributions by resampling exposures and covariates from the subjects enrolled in the Phase 3 Studies M15-554 and M15-572. The variabilities associated with the precision of the parameter estimates in the logistic regression models were also included in the simulations by sampling the parameters from a multivariate random normal distribution with means and covariance terms that were estimated in the logistic regression models. All simulations were conducted with 500 replicates for N = 300 subjects at each treatment group. The percentage of subjects predicted to achieve each of the efficacy endpoints were then calculated for each replicate, and median and 95% CI were calculated across all the replicates.

## Results: ACR responses

Exploratory exposure-response quartile plots for ACR20/50/70 at Week 12 and Week 24 are shown in Figure 9.

<div style=\"page-break-after: always\"></div>

Figure 9 Observed ACR20, ACR50 and ACR70 Responses (NRI) versus predicted Upadacitinib Cavg Quartiles at Week 12 and Week 24

<!-- image -->

For ACR20 (the primary efficacy endpoint in studies M15-572 and M15-554), a statistically significant treatment effect was present at Week 12 and Week 24, but no statistically significant exposureresponse relationship was present at either Week 12 or Week 24. For ACR50 and ACR70, logistic regression analyses revealed statistically significant treatment effect for each endpoint at both Week 12 and Week 24, while significant exposure-response relationships were only present at Week 12.

Therefore, only ACR50 and ACR70 at Week 12 were evaluated further through exposure-response modeling given that these endpoints exhibited statistically significant exposure-response relationship (p-value &lt; 0.01). An Emax with intercept model was chosen as the most appropriate model for both endpoints based on AIC and assessment of the observed and predicted responses.

The following covariates were identified in the forward inclusion process with none removed in the backward elimination step:

- ACR50 at Week 12: Age, BMI and population [history of an inadequate response to nonbiologic DMARDs (DMARD-IR) vs history of an inadequate response to biologic DMARDs (bDMARD-IR)] on the intercept; hsCRP on Emax
- ACR70 at Week 12: Age, sex and population on the intercept; hsCRP on Emax

Final model parameters are shown in Table 11 and final model fit is shown in Figure 10. Figure 11 summarizes the final model simulated ACR50 and ACR70 responses for upadacitinib 15 mg QD, 30 mg QD regimens and placebo at Week 12 stratified by the significant covariates in the final ACR model.

<div style=\"page-break-after: always\"></div>

Table 11 Final  Model  Parameter  Estimates  for  Logistic  Regression  Models  for  the  Relationship between Upadacitinib Cavg and ACR50 and ACR70 Efficacy Endpoints at Week 12

| Parameter                                         | Estimate   | 95% CI       |
|---------------------------------------------------|------------|--------------|
| ACR50                                             |            |              |
| Intercept                                         | -2.42      | -2.73; -2.12 |
| Emax                                              | 2.41       | 1.93; 3.00   |
| EC50                                              | 6.79       | 2.95; 15.7   |
| hsCRP on Emax                                     | 0.15       | 0.10; 0.21   |
| BMI on Intercept                                  | -0.04      | -0.06; -0.02 |
| Relative additive effect of DMARD-IR on Intercept | 0.38       | 0.15; 0.61   |
| Age on Intercept                                  | -0.02      | -0.02; -0.01 |
| ACR70                                             |            |              |
| Intercept                                         | -4.83      | -5.51; -4.15 |
| Emax                                              | 3.53       | 2.77; 4.49   |
| EC50                                              | 8.50       | 3.95; 18.3   |
| hsCRP on Emax                                     | 0.10       | 0.05; 0.15   |
| Relative additive effect of Male on Intercept     | 0.63       | 0.34; 0.92   |
| Age on Intercept                                  | -0.02      | -0.03; -0.01 |
| Relative additive effect of DMARD-IR on Intercept | 0.53       | 0.19; 0.86   |

Left : ACR50 response. Right : ACR70 response. Blue solid line : Median predicted response. Blue shaded area : 95% confidence intervals of the predicted response. Dots and error bars : Median and 95% binomial CIs of binned observed rates.

<!-- image -->

Observed and Model-Predicted ACR50 and ACR70 Responses (NRI) at Week 12 vs predicted Upadacitinib Cavg

Figure 10 Observed and Model-Predicted ACR50 and ACR70 Responses (NRI) at Week 12 vs predicted Upadacitinib Cavg

<div style=\"page-break-after: always\"></div>

## Placebo·15mgQD30mgQD

Figure 11 Model-Predicted ACR50 and ACR70 Responses for 15 mg QD, 30 mg QD Regimens and Placebo at Week 12 Stratified by Covariate Subgroups

<!-- image -->

## Results: PASI75 response

The percentage of subjects with ≥ 3% BSA psoriasis at baseline who achieved PASI 75 response was plotted against predicted upadacitinib Cavg quartiles at Week 16 and Week 24 (Figure 12). There was a statistically significant treatment effect but no significant exposure-response relationship for PASI75 at either Week 16 or Week 24. Therefore, no exposure-response modeling was conducted for PASI75.

<div style=\"page-break-after: always\"></div>

Figure 12 Observed PASI75 Responses (NRI) versus predicted Upadacitinib Cavg Quartiles at Week 16 and Week 24

<!-- image -->

## Results: sIGA 0/1 response

The percentage of subjects achieving sIGA 0/1 and at least a 2-point improvement from baseline (for subjects with baseline sIGA ≥ 2) was plotted against predicted upadacitinib Cavg quartiles at Week 16 and Week 24 (Figure 13).

Figure 13 Observed sIGA 0/1 Responses (NRI) versus predicted Upadacitinib Cavg Quartiles at Week 16 and Week 24

<!-- image -->

Logistic regression analysis revealed that at Week 16 and Week 24 a statistically significant treatment effect was present. In addition, a significant exposure-response relationship for this efficacy endpoint was present at Week 16 and Week 24. The relationship between upadacitinib Cavg and the percentage of subjects achieving sIGA 0/1 at Week 16 and Week 24 was best described by Emax with intercept model.

<div style=\"page-break-after: always\"></div>

Covariate analysis was performed on intercept, EC50 and Emax for the sIGA base model. Body weight was identified as a significant covariate in the forward inclusion process but was then removed in the backward elimination step due to failing to meet the statistically significant threshold (p-value &lt; 0.001). Hence, the base model without covariates was chosen as the final model. Summary of the final model parameters are presented in Table 12, while the final model fit is shown in Figure 14.

Table 12 Final  Model  Parameter  Estimates  for  Logistic  Regression  Models  for  the  Relationship Between Upadacitinib Cavg and sIGA 0/1 at Week 16 and Week 24

| Parameter        | Estimate   | 95% CI       |
|------------------|------------|--------------|
| sIGA 0/1 Week 16 |            |              |
| Intercept        | -2.17      | -2.46; -1.87 |
| Emax             | 2.83       | 2.23; 3.59   |
| EC50             | 9.37       | 4.30; 20.4   |
| sIGA 0/1 Week 24 |            |              |
| Intercept        | -2.08      | -2.36; -1.79 |
| Emax             | 2.57       | 2.03; 3.26   |
| EC50             | 7.43       | 3.12; 17.7   |

60%

40%

Subjects

20%

Percentageofs

0%

30mg

15mg

<!-- image -->

10

20

30

40

UpadacitinibAverage Concentration(ng/mL)

Left :  sIGA 0/1 response at Week 16. Right : sIGA 0/1 response at Week 24. Blue solid line :  Median predicted response. Blue shaded area : 95% confidence intervals of the predicted response. Dots and error bars : Median and 95% binomial CIs of binned observed rates.

Figure 14 Observed  and  Model-Predicted  sIGA  0/1  Responses  at  Week  16  and  Week  24  vs predicted Upadacitinib Cavg

## Exposure-response analyses for safety

The objective of safety E-R analyses of Studies M15-554 and M15-572 was to characterize the relationships between upadacitinib plasma exposures and select safety parameters in subjects with moderate to severe PsA. Data from 1916 subjects who received placebo or upadacitinib were included in the safety E-R analyses.

The adverse events (AEs) and changes in laboratory parameters evaluated for relationships with upadacitinib exposures were:

- Neutropenia Grade 3 or higher (total neutrophils count &lt; 1 × 10 9 /L) at Week 24 (LOCF)
- Lymphopenia Grade 3 or higher (total lymphocytes count &lt; 1 × 10 9 /L) at Week 24 (LOCF)
- Lymphopenia Grade 4 (total lymphocytes count &lt; 0.5 × 10 9 /L) at Week 24 (LOCF)

<div style=\"page-break-after: always\"></div>

- Haemoglobin decrease from baseline by &gt; 2 g/dL (LOCF)
- Haemoglobin decrease from baseline by &gt; 2 g/dL and &lt; lower limit for normal [females: 11.5 g/dL and males: 12.5 g/dL] at Week 24 (LOCF)
- Haemoglobin &lt; 8 g/dL at Week 24 (LOCF)
- Herpes Zoster infection anytime through 24 weeks
- Serious infections anytime through 24 weeks
- Pneumonia anytime through 24 weeks

Missing laboratory parameter values at Week 24 were imputed using the LOCF method. If there was no reportable value at any time (i.e., LOCF imputation cannot be applied), the laboratory parameter was flagged as missing (\"-99\") and excluded from the analysis.

## Methods

As with efficacy endpoints, the relationships between upadacitinib exposures and safety endpoints were first explored using quartile plots followed by logistic regression analyses (Equation 5). Upadacitinib Cavg was used as the exposure metric. Safety endpoints exhibiting a statistically significant exposure effect were evaluated further using separate exposure-response models (linear, Emax and sigmoid Emax).

In addition to using Cavg as the upadacitinib exposure parameter in the logistic regression models, parameters of the final statistically significant models for safety endpoints were re-estimated using upadacitinib Cmax (individual estimates from the PPK model) to enable simulation of the effect of changes in upadacitinib Cmax on the probability of occurrence of the different adverse events or changes in laboratory parameters. Adequacy of model fits with Cmax as exposure metric was confirmed before simulations.

## Covariate modelling for safety endpoints was conducted as with efficacy endpoints.

The final logistic regression models developed for safety were used to conduct simulations to predict the percentage of subjects experiencing each of the safety endpoints following treatment with placebo, upadacitinib 15 mg QD, and upadacitinib 30 mg QD regimens and for scenarios of 25%, 50%, and 75% increase from target 15 mg QD and 30 mg QD exposures.

As with efficacy analyses, the simulations incorporated inter-individual variability in upadacitinib PK and covariate distributions by resampling exposures and covariates from the subjects enrolled in the Phase 3 Studies M15-554 and M15-572. The variabilities associated with the precision of the parameter estimates in the logistic regression models were also included in the simulations by sampling the parameters from a multivariate random normal distribution with means and covariance terms that were estimated in the logistic regression models. All simulations were conducted with 500 replicates for N = 300 subjects at each treatment group. The percentage of subjects predicted to experience each of the safety endpoints were then calculated for each replicate, and median and 95% CI were calculated across all the replicates.

## Results

Exploratory E-R quartile plots for the safety endpoints are shown in Figure 15. Subjects were binned according to their individual predicted Cavg into quartiles, and the percent of subjects with specific safety events/laboratory changes were plotted in each quartile.

<div style=\"page-break-after: always\"></div>

Figure 15 Exploratory Quartile Plots for Observed Safety Endpoints at Week 24 vs Predicted Upadacitinib Cavg

<!-- image -->

For the following endpoints, a logistic regression model could not be fitted due to lack of observations: haemoglobin &lt; 8 g/dL at Week 24, lymphopenia Grade 4, and neutropenia Grade 3 or higher. No statistically significant relationship was observed between upadacitinib Cavg and the percentage of subjects who experienced herpes zoster infection, pneumonia or lymphopenia Grade 3 or higher at Week 24; hence, these endpoints were not analysed further.

There was a statistically significant relationship between upadacitinib Cavg and the percentage of subjects who experienced serious infections up to Week 24, &gt; 2 g/dL haemoglobin decrease from baseline at Week 24, or &gt; 2 g/dL haemoglobin decrease from baseline with haemoglobin &lt; lower limit for normal at Week 24; these endpoints were evaluated further.

The relationship between upadacitinib Cavg and the percentage of subjects experiencing serious infection was best described by a linear model with intercept. Covariate analysis demonstrated that

<div style=\"page-break-after: always\"></div>

subject's age is a significant covariate on intercept. Final model fit is shown in Figure 16 and summary of the model parameters are shown in Table 13.

<!-- image -->

Blue solid line : Median predicted response. Blue shaded area : 95% confidence intervals of the predicted response. Dots and error bars : Median and 95% binomial CIs of binned observed rates.

Figure 16 Observed  and  Model-Predicted  Percentage  of  Subjects  with  Serious  Infections  up  to Week 24 vs predicted upadacitinib Cavg.

Table 13 Final Model Parameter Estimates of the Logistic Regression Model for the Relationship between Predicted Upadacitinib Cavg and Serious Infection up to Week 24

| Parameter        |   Estimate | 95% CI       |
|------------------|------------|--------------|
| Intercept        |      -5.19 | -5.90; -4.49 |
| Slope            |       0.04 | 0.01; 0.06   |
| Age on Intercept |       0.07 | 0.03; 0.10   |

The relationship between upadacitinib Cavg and the percentage of subjects experiencing &gt; 2 g/dL decrease in haemoglobin from baseline was best described by an Emax with intercept model. Covariate analysis demonstrated that baseline haemoglobin was a significant covariate on intercept and subject's age was a statistically significant covariate on EC50. Final model fit is shown in Figure 17 and final model parameters are shown in Table 14.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Blue solid line : Median predicted response. Blue shaded area : 95% confidence intervals of the predicted response. Dots and error bars : Median and 95% binomial CIs of binned observed rates.

Figure 17 Observed  and  Model-Predicted  Percentage  of  Subjects  with  &gt;  2  g/dL  Decrease  in Haemoglobin up to Week 24 vs predicted upadacitinib Cavg.

Table 14 Final Model Parameter Estimates of the Logistic Regression Model for the Relationship between Predicted Upadacitinib Cavg and Subjects with Decrease &gt; 2 g/dL in Haemoglobin up to Week 24

| Parameter                 |   Esti | 95% CI       |
|---------------------------|--------|--------------|
| Intercept                 |  -4.97 | -5.71; -4.23 |
| Emax                      |   6.84 | 2.48; 18.8   |
| EC50                      | 102    | 19.2; 539    |
| Age on EC50               |  -2.51 | -4.39; -0.63 |
| Baseline HBG on Intercept |   0.5  | 0.28; -0.71  |

The relationship between upadacitinib Cavg and the percentage of subjects with PsA experiencing haemoglobin (Hb) decrease from baseline &gt; 2 g/dL with Hb &lt; lower limit for normal at Week 24 was best described by Emax with intercept model. Covariate analysis demonstrated that subject's age on EC50 was the only statistically significant covariate of this model. Final model fit is shown in Figure 18 and final model parameters are shown in Table 15.

<!-- image -->

Blue solid line : Median predicted response. Blue shaded area : 95% confidence intervals of the predicted response. Dots and error bars : Median and 95% binomial CIs of binned observed rates.

Figure 18 Observed and Model-Predicted Percentage of Subjects with Haemoglobin Decrease from Baseline &gt; 2 g/dL with Hb &lt; Lower Limit for Normal up to Week 24 vs predicted upadacitinib Cavg.

<div style=\"page-break-after: always\"></div>

Table 15 Final Model Parameter Estimates of the Logistic Regression Model for the Relationship Between Predicted Upadacitinib Cavg and Subjects with Haemoglobin Decrease from Baseline &gt; 2 g/dL with Haemoglobin &lt; Lower Limit for Normal up to Week 24

| Parameter   |   Estimate | 95% CI       |
|-------------|------------|--------------|
| Intercept   |      -5.79 | -6.94; -4.65 |
| Emax        |       6.95 | 2.92; 16.6   |
| EC50        |      86.5  | 16.2; 463    |
| Age on EC50 |      -2.82 | -5.16; -0.48 |

## Exposure-Safety Models with Cmax

Each of the three safety final Cavg logistic regression analyses were re-run with upadacitinib Cmax and all parameters were re-estimated. Observed and model-predicted percentage of subjects experiencing each of the three safety events versus upadacitinib Cmax are shown in Figure 19. Summary of the model parameters are shown in Table 16.

<!-- image -->

Upadacitinib Maximum Concentration(ng/mL)

<!-- image -->

Figure 19 Observed and Model-Predicted Percentage of Subjects with Serious Infections, Hb Decrease &gt;2 g/dL and Decrease in Hb from Baseline by &gt;2 g/dL with Hb&lt; Lower Limit for Normal up to Week 24

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 16 Final Model Parameter Estimates for Logistic Regression Models of Predicted Upadacitinib Cmax and Safety Variables at Week 24

| Parameter                                                                          | Estimate                                                                           | 95% CI                                                                             |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| SeriousInfection                                                                   | SeriousInfection                                                                   | SeriousInfection                                                                   |
| Intercept                                                                          | -5.20                                                                              | -5.96; -4.43                                                                       |
| Slope                                                                              | 0.02                                                                               | 0.005; 0.03                                                                        |
| Age on Intercept                                                                   | 0.07                                                                               | 0.03; 0.10                                                                         |
| HemoglobinDecrease > 2 g/dLfromBaseline                                            | HemoglobinDecrease > 2 g/dLfromBaseline                                            | HemoglobinDecrease > 2 g/dLfromBaseline                                            |
| Intercept                                                                          | -4.99                                                                              | -5.76; -4.21                                                                       |
| Emax                                                                               | 5.68                                                                               | 1.89; 17.1                                                                         |
| EC50                                                                               | 177                                                                                | 28.7; 1095                                                                         |
| Age on EC5o                                                                        | -2.74                                                                              | -5.05;-0.42                                                                        |
| BaselineHBG onIntercept                                                            | 0.51                                                                               | 0.29; 0.73                                                                         |
| Hemoglobin Decrease > 2 g/dL from Baseline and Hemoglobin < Lower Limit for Normal | Hemoglobin Decrease > 2 g/dL from Baseline and Hemoglobin < Lower Limit for Normal | Hemoglobin Decrease > 2 g/dL from Baseline and Hemoglobin < Lower Limit for Normal |
| Intercept                                                                          | -5.80                                                                              | -6.99; -4.61                                                                       |
| Emax                                                                               | 6.29                                                                               | 2.25; 17.6                                                                         |
| EC50                                                                               | 172                                                                                | 26.5; 1113                                                                         |
| Age on EC50                                                                        | -3.04                                                                              | -5.89; -0.18                                                                       |

## Simulations

The final logistic regression models were used to predict the probability of serious infections and haemoglobin decreases for placebo, upadacitinib 15 mg and 30 mg QD regimen at Week 24 stratified by the significant covariates in the final logistic regression models (Figure 20).

Placebo·15mgQD·30mgQD

<!-- image -->

Dots = median response; Lines = 90% CI. Continuous covariates are split by median values.

Figure 20 Model-predicted Probability of Serious Infections and Decreases in Haemoglobin for Placebo, 15 mg and 30 mg QD Regimen at Week 24 Stratified by Covariate Subgroups

<div style=\"page-break-after: always\"></div>

Furthermore, final logistic regression models for serious infections and haemoglobin decreases were also employed to perform simulations to predict the occurrence of the safety occurrences following 15 mg QD and 30 mg QD regimen of upadacitinib at Week 24. The simulated percentage of subjects for each endpoint following treatment with placebo, upadacitinib 15 mg QD, and upadacitinib 30 mg QD are shown in Table 17.

Table 17 Model-Simulated Percentage of Subjects Experiencing Clinically Relevant Decreases in Haemoglobin or Serious Infections at Week 24

|                                                                                                          |                                                                                                          | Simulated Percentage of Subjects Based on Modeling                                                       | Simulated Percentage of Subjects Based on Modeling                                                       |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Scenario                                                                                                 | Median C avg (ng/mL)                                                                                     | Median                                                                                                   | 90% CI                                                                                                   |
| Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin                                | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin                                | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin                                | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin                                |
| Placebo                                                                                                  | 0                                                                                                        | 1%                                                                                                       | (0% - 2%)                                                                                                |
| 15 mg QD                                                                                                 | 15                                                                                                       | 3%                                                                                                       | (1% - 4%)                                                                                                |
| 30 mg QD                                                                                                 | 29                                                                                                       | 4%                                                                                                       | (2% - 7%)                                                                                                |
| Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin and < Normal Hemoglobin levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin and < Normal Hemoglobin levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin and < Normal Hemoglobin levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Hemoglobin and < Normal Hemoglobin levels |
| Placebo                                                                                                  | 0                                                                                                        | 0%                                                                                                       | (0% - 2%)                                                                                                |
| 15 mg QD                                                                                                 | 15                                                                                                       | 1%                                                                                                       | (0% - 3%)                                                                                                |
| 30 mg QD                                                                                                 | 29                                                                                                       | 3%                                                                                                       | (1% - 6%)                                                                                                |
| Percentage of Subjects with Serious Infections                                                           | Percentage of Subjects with Serious Infections                                                           | Percentage of Subjects with Serious Infections                                                           | Percentage of Subjects with Serious Infections                                                           |
| Placebo                                                                                                  | 0                                                                                                        | 1%                                                                                                       | (0% - 2%)                                                                                                |
| 15 mg QD                                                                                                 | 15                                                                                                       | 2%                                                                                                       | (0% - 3%)                                                                                                |
| 30 mg QD                                                                                                 | 29                                                                                                       | 2%                                                                                                       | (1% - 4%)                                                                                                |

The exposure-response models for safety were utilized to simulate the effects of increase in upadacitinib plasma exposures due to different intrinsic and extrinsic factors on the percentage of subjects with serious infections and decreases in haemoglobin &gt; 2 g/dL at Week 24. Scenarios for increases in exposures by 25% to 75% were simulated which cover the effects of all evaluated intrinsic and extrinsic factors (75% reflect increase in exposures with strong CYP3A inhibitors). The simulations were conducted for increases in upadacitinib Cavg and Cmax (Table 18). The results are overall consistent with previous analyses in RA patients.

Table 18 Model-Simulated Percentage of Subjects Experiencing Safety Outcomes with Increased Upadacitinib Cavg or Cmax Relative to 15 mg QD Dose.

<div style=\"page-break-after: always\"></div>

|                                                                                                            |                                                                                                            | Simulated Percentage of Subjects                                                                           | Simulated Percentage of Subjects                                                                           |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| Scenario                                                                                                   | Median Cavg or Cmax (ng/mL)                                                                                | Median                                                                                                     | 90% Confidence Interval                                                                                    |
| Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin                                 | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin                                 | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin                                 | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin                                 |
| Cavg                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 15                                                                                                         | 2.6%                                                                                                       | (0.7% - 4.4%)                                                                                              |
| 25% Higher Upadacitinib Cavg                                                                               | 19                                                                                                         | 3.3%                                                                                                       | (1.5% - 5.6%)                                                                                              |
| 50% Higher Upadacitinib Cavg                                                                               | 23                                                                                                         | 3.7%                                                                                                       | (1.9% - 5.9%)                                                                                              |
| 75% Higher Upadacitinib Cavg                                                                               | 27                                                                                                         | 4.8%                                                                                                       | (2.2% - 7.8%)                                                                                              |
| Cmax                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 38                                                                                                         | 2.6%                                                                                                       | (1.1% - 4.5%)                                                                                              |
| 25% Higher Upadacitinib Cmax                                                                               | 47                                                                                                         | 3.0%                                                                                                       | (1.1% - 5.2%)                                                                                              |
| 50% Higher Upadacitinib Cmax                                                                               | 56                                                                                                         | 3.3%                                                                                                       | (1.5% - 5.9%)                                                                                              |
| 75% Higher Upadacitinib Cmax                                                                               | 66                                                                                                         | 4.1%                                                                                                       | (1.5% - 7.8%)                                                                                              |
| Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin and < Normal Haemoglobin Levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin and < Normal Haemoglobin Levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin and < Normal Haemoglobin Levels | Percentage of Subjects with > 2 g/dL Decrease from Baseline in Haemoglobin and < Normal Haemoglobin Levels |
| Cavg                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 15                                                                                                         | 1.1%                                                                                                       | (0.4% - 3.0%)                                                                                              |
| 25% Higher Upadacitinib Cavg                                                                               | 19                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.3%)                                                                                              |
| 50% Higher Upadacitinib Cavg                                                                               | 23                                                                                                         | 1.9%                                                                                                       | (0.4% - 4.1%)                                                                                              |
| 75% Higher Upadacitinib Cavg                                                                               | 27                                                                                                         | 2.6%                                                                                                       | (0.7% - 4.8%)                                                                                              |
| Cmax                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 38                                                                                                         | 1.1%                                                                                                       | (0.4% - 2.6%)                                                                                              |
| 25% Higher Upadacitinib Cmax                                                                               | 47                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.3%)                                                                                              |
| 50% Higher Upadacitinib Cmax                                                                               | 56                                                                                                         | 1.9%                                                                                                       | (0.4% - 3.7%)                                                                                              |
| 75% Higher Upadacitinib Cmax                                                                               | 66                                                                                                         | 2.2%                                                                                                       | (0.7% - 4.8%)                                                                                              |
| Percentage of subjects with Serious Infection                                                              | Percentage of subjects with Serious Infection                                                              | Percentage of subjects with Serious Infection                                                              | Percentage of subjects with Serious Infection                                                              |
| Cavg                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 15                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.0%)                                                                                              |
| 25% Higher Upadacitinib Cavg                                                                               | 19                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.0%)                                                                                              |
| 50% Higher Upadacitinib Cavg                                                                               | 23                                                                                                         | 1.9%                                                                                                       | (0.7% - 3.7%)                                                                                              |
| 75% Higher Upadacitinib Cavg                                                                               | 27                                                                                                         | 2.2%                                                                                                       | (0.7% - 4.1%)                                                                                              |
| Cmax                                                                                                       |                                                                                                            |                                                                                                            |                                                                                                            |
| 15 mg QD                                                                                                   | 38                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.0%)                                                                                              |
| 25% Higher Upadacitinib Cmax                                                                               | 47                                                                                                         | 1.5%                                                                                                       | (0.4% - 3.0%)                                                                                              |
| 50% Higher Upadacitinib Cmax                                                                               | 56                                                                                                         | 1.9%                                                                                                       | (0.7% - 3.3%)                                                                                              |
| 75% Higher Upadacitinib Cmax                                                                               | 66                                                                                                         | 2.2%                                                                                                       | (0.7% - 3.7%)                                                                                              |

## 2.3.5. Discussion on clinical pharmacology

## Analytical methods

The analytical phase of bioanalysis in the BE-study were acceptable to the CHMP. This conclusion is also applicable to the plasma concentrations determined for studies M15-554 and M15-572.

## Bioequivalence

Results of study M20-017 Part 1 demonstrated bioequivalence between upadacitinib 15 mg extendedrelease (ER) tablet market-image formulation (formulation currently marketed Rinvoq 15 mg

<div style=\"page-break-after: always\"></div>

prolonged-release tablet) and 15 mg ER tablet Phase 3 formulation (formulation used in Phase 3 PsA studies) under fasting conditions and after a high-fat/high-calorie meal.

Bioequivalence was demonstrated not only for conventional primary PK parameters Cmax, AUCt and AUCinf, but also for partial AUCs (AUC0-12 and AUC12-t). Although AUC0-12 and AUC12-t were not prespecified PK parameters in the protocol, they are recommended parameters in EMA guidance ( Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms EMA/CHMP/EWP/280/96 Rev1) and provide supportive evidence for conclusion of bioequivalence between the formulations. Demonstration of bioequivalence in a multiple dose study is not required for upadacitinib 15 mg ER tablet, because the mean AUCt after a single dose covers more than 90% of mean AUCinf, and consequently a low extent of accumulation is expected (see EMA/CHMP/EWP/280/96 Rev1 and assessment reports for Rinvoq marketing authorisation application). In addition, results for AUC0-12 and AUC12-t support the conclusion of bioequivalence.

The PK sampling scheme adequately covered the absorption and elimination phases: Cmax was not observed at the first sample for any subject and extrapolated AUC was less than 20% for each subject.

An interval of 4 days separated the doses between the four study periods. The washout period should have been longer because pre-dose upadacitinib concentrations were observed in a few subjects (up to 0.2, 0.3, 0.3, and 0.3 ng/mL after administration of Regimen A, B, C and D, respectively; approximately 0.6 to 1.0 % of mean Cmax). This is not expected to affect the overall conclusions of the study and further analyses were not requested by the CHMP. However, the MAH is recommended to plan future studies more carefully.

## Population PK analysis

The methodology for development of the population PK model for patients with PsA is appropriate.

The covariates previously identified in patients with RA were statistically important also in PsA population: patient population (patients versus healthy), creatinine clearance (CrCL), and baseline bodyweight on CL/F; and body weight on Vc/F. No additional covariates were identified. Weight and CrCL are correlated, which can influence the estimated covariate effects. The CHMP did not pursue this point; it is reasonable to use the same model structure as in the previous model (in patients with RA) to facilitate the comparison of the two populations. However, in future population PK analyses, the MAH should consider to re-parametrise the model to avoid correlation between CrCL and body weight. The CL/F ratio of patients compared to healthy subjects was comparable for PsA and RA patients (0.756 and 0.754, respectively), which supports the statement in the product information that upadacitinib pharmacokinetics are consistent between RA and PsA patients.

## Interactions

The population PK analysis suggested no effect by DMARDs methotrexate, apremilast, hydroxychloroquine, sulfasalazine, and leflunomide on PK of upadacitinib. This conclusion is supported by the MAH's review on mechanistic plausibility of pharmacokinetic DDI between upadacitinib and the aforementioned DMARDs.

## Exposure-response analyses

Logistic regression models with treatment effect and exposure effect function were used to describe the efficacy and safety of upadacitinib. Predicted upadacitinib Cavg was used as the primary exposure parameter, predicted Cmax was also tested in the safety analyses.

Several efficacy endpoints were tested, including ACR20/50/70 at week 12 and 24, PASI75 at week 16 and 24, and sIGA at weeks 16 and 24. Time-effect was not formally evaluated as separate models were developed for week 12/16 and 24 data. However, the methodology is sufficient for the intended

<div style=\"page-break-after: always\"></div>

use. The treatment effect (use of upadacitinib compared with placebo) was robustly associated with better clinical response. Of note, higher exposure was only modestly or not at all associated with better clinical response.

Several safety endpoints were included in the exposure-response analyses. A statistically significant relationship between upadacitinib Cavg (and upadacitinib Cmax) and the percentage of subjects who experienced serious infections up to Week 24, &gt; 2 g/dL haemoglobin decrease from baseline at Week 24, or &gt; 2 g/dL haemoglobin decrease from baseline with haemoglobin &lt; lower limit for normal at Week 24. No statistically significant relationship was observed between predicted upadacitinib concentration and the percentage of subjects who experienced herpes zoster infection, pneumonia or lymphopenia Grade 3 or higher. There were too few (n ≤ 2) cases of haemoglobin &lt; 8 g/dL at Week 24, lymphopenia Grade 4, and neutropenia Grade 3 or higher to conduct E-R analyses for these safety endpoints.

Exposures achieved with upadacitinib 15 mg QD are approximately at the plateau for the majority of evaluated efficacy endpoints. Clinically meaningful improvement of efficacy is not expected with the higher upadacitinib dose (30 mg QD). On the other hand, the probability of occurrence of serious infections and decrease in haemoglobin was increased with increasing exposure to upadacitinib. The MAH concluded that the dose of 15 mg QD provides the optimal benefit-risk balance in subjects with PsA and the higher dose (30 mg) tested in the Phase 3 clinical studies is not applied for. The CHMP was of the opinion that the clinical pharmacology data support those conclusions.

## 2.3.6. Conclusions on clinical pharmacology

Upadacitinib pharmacokinetics are consistent between rheumatoid arthritis and psoriatic arthritis patients.

The proposed dose regimen of upadacitinib 15 mg QD was considered appropriate to the CHMP.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No specific dose-response studies were performed for treatment of PsA. The currently approved dose in the treatment of rheumatoid arthritis is 15 mg QD.

The dosages studied in the pivotal studies for PsA, upadacitinib 15 mg and upadacitinib 30 mg QD, are the same doses as in the pivotal studies for rheumatoid arthritis.

The MAH proposes the same ER formulation of upadacitinib 15 mg QD for the treatment of adult patients with active PsA, which is marketed for treatment of patients with RA.

## 2.4.2. Main studies

The clinical development pivotal programme supporting the efficacy of upadacitinib in PsA is composed of 2 randomized, multi-centre, double-blind, parallel-group Phase 3 studies.

- Study M15-572 investigates upadacitinib in subjects who have an inadequate response or intolerance to non-biologic DMARDs (conventional synthetic DMARDs [csDMARDs] and/or targeted synthetic disease-modifying anti-rheumatic drug [tsDMARDs]) or had a contraindication for non-biologic DMARDs. Study M15-572 evaluates upadacitinib versus (vs.)

<div style=\"page-break-after: always\"></div>

placebo and adalimumab, with or without background non-biologic DMARDs, in a non-biologic DMARD-IR population. Radiographic assessment was included in Study M15-572 to evaluate the effect of upadacitinib treatment on progression of structural joint damage in a non-biologic DMARD-IR population.

- Study M15-554 evaluates upadacitinib in subjects who have an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARDs).  Study M15-554 is a placebo-controlled study. Study M15-554 evaluates upadacitinib with or without background non-biologic DMARDs in a bDMARD-IR population without regard to the nature and number of prior bDMARDs.

Long-term efficacy is assessed in each individual study.

An overview of the Phase 3 studies is given in Table 19.

<div style=\"page-break-after: always\"></div>

Table 19

Overview of Upadacitinib Clinical Development Program for PsA - Pivotal Phase 3 Studies

|                                                                        | M15-572 (Select PsA1)                                                                                                                                                                                                                          | M15-554 (Select PsA2)                                                                                                                                                                                                                         |
|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population                                                             | non-biologic DMARD-IRa                                                                                                                                                                                                                         | bDMARD-IR                                                                                                                                                                                                                                     |
| Background                                                             | ≤ 2 non-biologic DMARDsb                                                                                                                                                                                                                       | ≤ 2 non-biologic DMARDsb                                                                                                                                                                                                                      |
| Comparator                                                             | adalimumab, placebo                                                                                                                                                                                                                            | placebo                                                                                                                                                                                                                                       |
| UpadacitinibDose (Extenderdl-Release Formulation)                      | 15 mg QD 30 mg QD                                                                                                                                                                                                                              | 15 mg QD 30 mg QD                                                                                                                                                                                                                             |
| Duration                                                               | Period 1: 56 weeks (24 weeks placebo-controlled and 56 weeks adalimumab-controlled) Period 2: Long-term extension (adalimumab-controlled) (up to a total treatment duration of                                                                 | Period 1: 56 weeks (24 weeks placebo-controlled) Period 2: Long-term extension (up to a total treatment duration of approximately 3 years)                                                                                                    |
| Study Blind                                                            | Double-blind through Week 24 followed by an additional 32 weeks of blinded active comparator-controlled treatment (Weeks 24 - 56). Sponsor was unblinded after Week 24 database lock. Sites and subjects remain blinded until the last subject | Double-blind through Week 24 followed by an additional 32weeks ofblinded treatment (Weeks 24 -56). Sponsor was unblinded after Week 24 database lock. Sites and subjects remain blinded until the last subject completes Week 56 in Period 1. |
| Number of subjects randomized/exposed to at least l dose of study drug | 1705/1704                                                                                                                                                                                                                                      | 642/641                                                                                                                                                                                                                                       |
| Number of subjects randomizetl to each treatment group                 | upadacitinib 15 mg QD: N= 430 upadacitinib 30 mg QD: N= 423 adalimumab (40 mg every other week [eow]):                                                                                                                                         | upadacitinib 15 mg QD: N=211 upadacitinib 30 mg QD: N=219 placebo: N=212                                                                                                                                                                      |
| Prinary Efficacy Endpoint Status                                       | ACR20 response at Week 12c Ongoing                                                                                                                                                                                                             | ACR20 response at Week 12℃ Ongoing                                                                                                                                                                                                            |

- ACR20 response rate was determined based on 20% or greater improvement in tender joint count (TJC) and C. swollen joint count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (Numeric Rating Scale [NRS]), Patient's Global Assessment of Disease Activity (PtGA) (NRS), Physician's Global Assessment (PGA) (NRS), HAQ-DI, and hsCRP.

Since both studies were ongoing at time of submission, interim CSRs are provided in the submission as outlined in Table 20.

<div style=\"page-break-after: always\"></div>

Table 20 Upadacitinib PsA Individual Study Efficacy Data

|                                             | CSRs Included in Submission                                                                         | CSRs Included in Submission   | DataIncluded inISE                                                                                                                            | DataIncluded inISE   |
|---------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Study                                       | Data                                                                                                | Cutoff Date                   | Data                                                                                                                                          | Cutoff Date          |
| PivotalPhase3Studies                        | PivotalPhase3Studies                                                                                | PivotalPhase3Studies          | PivotalPhase3Studies                                                                                                                          | PivotalPhase3Studies |
| M15-572 (non-biologic DMARD-IR) Select PsA1 | Data through Week 24 from all subjects and long-term data (through Week 56) from available subjects | 13 December2019               | Data throughWeek 24 from all subjects who received upadacitinib adalimumab, or placebo (only upadacitinib or placebo for integrated analyses) | Same as CSR          |
| M15-554 (bDMARD-IR) Select PsA2             | Data through Week 24 from all subjects and long-term data (through Week 56) from available subjects | 09 October 2019               | Data throughWeek 24 from all subjects who received upadacitinib or placebo                                                                    | Same as CSR          |

The MAH provided during the procedure a revised interim CSR for study M15-554, dated 16 June 2020. The purpose of the revised CSR is to correct the text describing subjects with disseminated herpes zoster.

After the original submission, all subjects in both Phase 3 Studies M15-572 and M15-554 reached Week 56 or prematurely discontinued. Results through Week 56 were provided for all endpoints proposed for labelling during the procedure.

## Methodology

The methodology is described together for both Phase 3 studies. Results of the studies are described separately for each study and integrated efficacy analyses are also presented.

## Study designs

## Study M15-572

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1.

Study design is presented in Figure 21.

The study includes

- a 35-day screening period;
- a 56-week blinded period which includes 24 weeks of randomized, double-blind, placebocontrolled and active comparator-controlled treatment followed by 32 weeks of active comparator-controlled upadacitinib (Period 1);
- a long-term extension period of up to a total treatment duration of approximately 3 years ([blinded until the last subject completes the last visit of Period 1] Period 2); and

<div style=\"page-break-after: always\"></div>

- a 30-day follow-up call or visit; and a 70-day follow-up call.

Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus ADA for the treatment of signs and symptoms of PsA, including the prevention of structural progression, in subjects with moderately to severely active PsA who are DMARD-IR.

Period 2 is an open-label (blinded until the last subject completes the last visit of Period 1), long-term extension of up to a total treatment duration of approximately 3 years to evaluate the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1.

<!-- image -->

ABT-494=upadacitinib:ACR20=AmericanCollegeofRheumatology 20%response:BL=baseline;PBO=placebo; QD=oncedaily,Wk=week

- a. Allsubjectswillreceivex-raysofhandsandfeetat screening.Wk24,Wk56,Wk104.andWk152/PD
- b. AtWeek 16.rescue therapy will beoffered to subjects classified as non-responders(defined asnotachieving at least20%improvementineitherorboth tenderjointcount(TJC)andswollenjoint count（SJC)atbothWeek12 andWeek16)asdescribedinProtocolSection5.2.3.4.
3. AtWeek24.allplacebosubjectswill switch toupadacitinib15mgQDor30mgQD（1:1ratio)regardlessof response.

Note: Samplesizesrepresentactualnumberofsubjectsrandomized toeachtreatmentsequence.

Figure 21 Study design of study M15-572

## Study M15-554

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease-Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2

Study design is presented in Figure 22.

The study includes the following periods:

- a 35-day screening period;

<div style=\"page-break-after: always\"></div>

- a 24-week blinded randomized, double-blind, parallel-group, placebo-controlled period followed by an additional 32 weeks of blinded upadacitinib treatment (Weeks 24 - 56) (Period 1);
- a long-term extension period of up to a total treatment duration of approximately 3 years (blinded until the last subject completes the last visit of Period 1 - Period 2); and
- a 30-day follow-up call or visit.

<!-- image -->

ACR20=American CollegeofRheumatology20%response;BL=baseline;PBO=placebo:QD=once daily; Wk=week

- AtWeek16,rescue therapywas tobeoffered to subjectsclassified asnon-responders(defined asnotachievingat a. least20%improvement in eitherorboth tenderjoint count(TJC)and swollenjoint count (SJC)atbothWeek12 andWeek16)asdescribed inProtocolSection5.2.3.4.
- b. AtWeek24,allplacebosubjectswereto switch toupadacitinib15mgQDor30mgQD(1:1ratio)regardlessof response.

Figure 22 Study design of study M15-554

Since the original submission of the variation application, Study M15-572 protocol has been amended to extend its long-term extension period from 3 years to 5 years (Protocol Amendment Version 6, dated 15 May 2020, Voluntary Harmonisation Procedure (VHP) approval on 10 July 2020).

Study M15-554 protocol has been amended in selected countries (Belgium, Czech Republic, France, Greece, Hungary, Japan, New Zealand, and Portugal) in order to provide continued upadacitinib therapy after Week 152 until regulatory approval, and/or applicable local reimbursement approval of the study drug, or at such time that development or pursuit of regulatory approval is discontinued (Protocol Amendment Version 7.1, dated 23 July 2020). Hence, final results for both studies are anticipated to be submitted in year 2025. The submission of the results for the long term extension for both studies is included in the RMP.

## Study participants

Both pivotal, Phase 3 studies enrolled adult male or female subjects at least 18 years old who were diagnosed with PsA with symptom onset at least 6 months prior to the Screening Visit and had moderately to severely active disease. Stable doses of NSAIDs, acetaminophen/paracetamol, low-

<div style=\"page-break-after: always\"></div>

potency opiates (tramadol or combination of acetaminophen and codeine or hydrocodone), oral corticosteroids (equivalent to prednisone ≤ 10 mg/day) were allowed. Changes in the upadacitinib dose were not permitted during either study in order to avoid confounding of interpretation of the safety results.

Study M15-572 evaluates upadacitinib in subjects who have an inadequate response (IR) or intolerance to non-biologic DMARDs (conventional synthetic DMARDs [csDMARDs] and/or tsDMARDs) or had a contraindication for nonbiologic DMARDs as follows: IR to ≥ 1 non -biologic DMARD (MTX, sulfasalazine [SSZ], leflunomide, cyclosporine, apremilast, bucillamine or iguratimod) or an intolerance to or contraindication for DMARDs as defined by the investigator prior to the screening visit. Subjects were not to have had prior exposure to any biologic immunomodulation agents, JAK inhibitors, current treatment with &gt; 2 non-biologic DMARDs or use of DMARDs other than protocol-specified DMARDs.

In study M15572, at screening, subjects were to have had either ≥ 1 erosion on x -ray as determined by central imaging review or high-sensitivity C-reactive protein (hs-CRP) &gt; laboratory defined upper limit of normal (ULN). The requirements for existing erosions in X-rays and/or higher CRP levels were selected for this study only in order to enrol a population appropriate for assessment of radiographic progression and to increase the power for detection of a treatment effect for upadacitinib on the radiographic endpoints.

Study M15-554 evaluates upadacitinib in subjects who have an IR or intolerance to biologic diseasemodifying anti-rheumatic drugs (bDMARDs) as follows: IR (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bDMARD.

Subjects must have discontinued all bDMARDs prior to the first dose of study drug. Subjects who need to discontinue bDMARDs prior to the Baseline Visit to comply with this inclusion criterion must follow the procedure specified below or at least five times the mean terminal elimination halflife of a drug: ≥ 4 weeks for etanercept; ≥ 8 weeks for adali mumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab;≥ 16 weeks for secukinumab;≥ 12 weeks for ustekinumab; ≥ 1 year for rituximab OR ≥ 6 months if B cells have returned to pre-treatment level or normal reference range (local lab) if pre-treatment levels are not available. Subject who is on current treatment with concomitant nonbiologic DMARDs at study entry must be on ≤ 2 non -biologic DMARDs (except the combination of MTX and leflunomide) at the following doses: MTX (≤ 25 mg/week), SSZ (≤ 3000 mg/day), leflunomide (LEF) (≤ 20 mg/day), apremilast (≤ 60 mg/day), HCQ (≤ 400 mg/day), bucillamine (≤ 300 mg/day) and iguratimod (≤ 50 mg/day) for ≥ 12 weeks and at stable dose for ≥ 4 weeks prior to the Baseline Visit. No other DMARDs are permitted during the study.

In both studies, subjects were to have had active disease at baseline defined as ≥ 3 tender joints (based on 68 joint counts) and ≥ 3 swollen joints (based on 66 joint counts) at screening and baseline visits. Clinical diagnosis of PsA was to include symptom onset at least 6 months prior to the screening visit and fulfilment of the Classification Criteria for PsA (CASPAR) criteria. Diagnosis of active plaque psoriasis or documented history of plaque psoriasis was also required.

In both studies, exclusion criteria included current treatment with &gt; 2 non-biologic DMARDs or use of DMARDs other than MTX, SSZ, LEF, apremilast, HCQ, bucillamine or iguratimod or use of MTX in combination with LEF at Baseline. Subjects with prior exposure to JAKi were excluded.

Subjects were to have no history of fibromyalgia; any arthritis with onset prior to age 17 years; or current diagnosis of inflammatory joint disease other than PsA; prior history of reactive arthritis or axial SpA including ankylosing spondylitis and non-radiographic axial SpA were permitted if documentation of change in diagnosis to PsA or additional diagnosis of PsA was made.

<div style=\"page-break-after: always\"></div>

Patients with current or past history of infection were excluded in both studies: history of recurrent or disseminated (even a single episode) herpes zoster; disseminated (even a single episode) herpes simplex; known invasive infection (e.g., listeriosis and histoplasmosis); active human immunodeficiency virus (defined as confirmed positive anti-HIV antibody (HIV Ab) test) or immunodeficiency syndrome  ; active TB or meets TB exclusionary parameters; active infection(s) requiring treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior to the Baseline Visit; chronic recurring infection and/or active viral infection that based on the investigator's clinical assessment makes the subject an unsuitable candidate for the study; active HBV or HCV. For subjects in Japan only: Positive result of beta-D-glucan or two consecutive indeterminate results of beta-D-glucan (screening for pneumocystis jiroveci infection).

Subjects with history or current underlying medical diseases or problems including but not limited to the following were excluded: moderate to severe congestive heart failure; recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting; uncontrolled hypertension; recipient of an organ transplant which requires continued immunosuppression; gastrointestinal perforation (other than appendicitis or penetrating injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment; conditions that could interfere with drug absorption including but not limited to short bowel syndrome; any malignancy except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix; demyelinating disease such as Multiple Sclerosis or neurologic symptoms suggestive of demyelinating disease (including myelitis); clinically significant medical conditions or any other reason which in the opinion of the investigator would interfere with the subject's participation in this study or would make the subject an unsuitable candidate to receive study drug or would put the subject at risk.

Other exclusion criteria included e.g. to following:

- Use of the following concomitant psoriasis treatments within the specified timeframe: Oral retinoids within 4 weeks of the Baseline visit; Fumarates within 1 week of the Baseline Visit: Psoralens and Ultraviolet A (PUVA) within 4 weeks of the Baseline visit; Ultraviolet A (UVA) or Ultraviolet B (UVB); or Laser therapy within 2 weeks of the Baseline visit; All topical psoriasis treatments, including medicated shampoos, within 2 weeks of the Baseline visit. The following exceptions are allowed: Bland (without beta or alpha hydroxy acids, urea or salicylic acids) emollients, and low potency (Class VI or VII) topical corticosteroids on the palms, soles, face, inframammary area and groin only; and topical anti-itch treatment with no expected effect on psoriatic skin lesions.
- Systemic use of known strong cytochrome P450 (CYP) 3A inhibitors or strong CYP3A inducers from Screening through the last dose of the study drug
- Receipt of any live vaccine within 4 weeks (8 weeks in Japan) prior to the Baseline Visit, or expected need of live vaccination during study participation including at least 4 weeks (8 weeks in Japan) after the last dose of oral study drug, and including at least 70 days after the last dose of subcutaneous study drug.
- Subject has received oral or parenteral Traditional Chinese Medicines within 4 weeks prior to Baseline, has received opioid analgesics (except for tramadol or combination of acetaminophen and codeine or hydrocodone which are allowed) within 1 week prior to Baseline, or use of inhaled marijuana within 2 weeks prior to Baseline.
- History of an allergic reaction or significant sensitivity to constituents of the study drugs (including adalimumab or its excipients) and/or other products in the same class.

<div style=\"page-break-after: always\"></div>

- History of clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months preceding the Baseline Visit.
- Laboratory values meeting the following criteria within the Screening period:

Serum aspartate transaminase (AST) &gt; 2 × ULN; Serum alanine transaminase (ALT) &gt; 2 × ULN; Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula &lt; 40 mL/min/1.73 m2; Total white blood cell count (WBC) &lt; 2,500 /μL; Absolute neutrophil count (ANC) &lt; 1,500/μL; Platelet count &lt; 100,000/μL; Absolute lymphocyte count &lt; 800/μL; Haemoglobin &lt; 10 g/dL.

- Active skin disease other than psoriasis that would interfere with the assessment of psoriasis.
- Subject with extra-articular manifestations of PsA (e.g., PsO, uveitis, or IBD) that are not clinically stable for at least 30 days prior to study entry.
- Subject has had joint surgery at joints to be assessed within this study or has been treated with intra-articular, intramuscular, intravenous, trigger point or tender point, intra-bursa, or intra-tendon sheath corticosteroids in the preceding 8 weeks prior to the Baseline visit.
- Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive upadacitinib or adalimumab or subject has any contraindication to adalimumab, according to the local label.

## Treatments

## Study M15-572

Active study drugs in this study are upadacitinib and adalimumab. The different phases of the study and administration of study medication is given earlier in this AR in Figure 21 and later under the heading of Randomisation.

## Study M15-554

The active study drug in this study is upadacitinib (see Figure 22 for the different phases of the study).

## Objectives

The objectives of both studies are listed below. The studies were on-going at the time of the submission and the efficacy results were only available up to week 24 of both studies. During the procedure, results up to Week 56 were submitted.

## Study M15-572

## Period 1

## Primary Objective

To compare the efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus adalimumab (ADA) for the treatment of signs and symptoms of PsA in subjects with moderately to severely active PsA who have an inadequate response or intolerance to 1 or more non-biologic DMARD (DMARD-IR).

<div style=\"page-break-after: always\"></div>

## Secondary Objective

To compare the efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo for the prevention of structural  progression  in  subjects  with  moderately  to  severely  active  PsA  who  have  an  inadequate response or intolerance to 1 or more non-biologic DMARD (DMARD-IR).

To compare the safety and tolerability of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus adalimumab in subjects with moderately to severely active PsA who and have an inadequate response or intolerance to 1 or more non-biologic DMARD (DMARD-IR).

## Period 2

To evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1.

Period 2 is ongoing and planned to last up to ~5 years for evaluation of long-term maintenance of efficacy and safety.

## Study M15-554

## Period 1

1. To compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in subjects with moderately to severely active PsA who have had an inadequate response or intolerance to bDMARDs (Bio-IR), and

2. To compare the safety and tolerability of upadacitinib 15 mg QD and 30 mg QD versus placebo in subjects with moderately to severely active PsA who have had an inadequate response or intolerance to bDMARDs.

The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1.

Period 2 is ongoing and planned to last up to ~3 years for evaluation of long-term maintenance of efficacy and safety.

## Outcomes/endpoints

## Primary efficacy endpoint

The primary efficacy endpoint in both studies is the proportion of subjects achieving ACR 20% response (ACR20) at Week 12.

- ACR20: standard criteria of American College of Rheumatology to evaluate the effectiveness of investigation drug in RA clinical trials reflecting improvement of response outcomes. ACR20 is defined as at least 20% improvement (compared to baseline values) in tender and swollen joint counts and at least 20 improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function and acute phase reactant hsCRP).

The multiplicity-adjusted primary and ranked key secondary endpoints for both studies are given in Table 21. The key multiplicity adjusted secondary efficacy endpoints are for each dose of upadacitinib vs. combined placebo unless noted otherwise.

<div style=\"page-break-after: always\"></div>

Table 21 Primary and Ranked Key Secondary Endpoints for Pivotal Phase 3 Studies (MultiplicityAdjusted)

|                                                 | StudyMI15-572                                                                      | StudyM15-554            |
|-------------------------------------------------|------------------------------------------------------------------------------------|-------------------------|
| PrimaryEfficacyEndpoints                        | ACR20response atWeek12                                                             | ACR20response atWeek12  |
| Ranked Key Secondary Efficacy Endpoints Ranking |                                                                                    |                         |
| 1                                               | HAQ-DIatWeek12                                                                     | HAQ-DIatWeek12          |
| 2                                               | sIGA 0/1 atWeek16                                                                  | sIGA0/1 at Week16       |
| 3                                               | PASI75responseatWeek16                                                             | PASI75response atWeek16 |
| 4                                               | △SHSatWeek 24a                                                                     | SF-36PCSatWeek12        |
| 5                                               | MDA atWeek 24                                                                      | AFACIT-FatWeek12        |
| 6                                               | Resolution ofenthesitis (LEI=0)atWeek 24                                           | MDA atWeek24            |
| 7                                               | ACR20response atWeek12 (non-inferiority of upadacitinib vs.adalimumab)             | △SAPSatWeek16           |
| 8                                               | △SF-36PCSatWeek12                                                                  |                         |
| 9                                               | △FACIT-FatWeek12                                                                   |                         |
| 10                                              | ACR20response atWeek12 (superiority ofupadacitinibvs.adalimumab)                   |                         |
| 11                                              | Resolution of dactylitis (LDI=0)at Week 24                                         |                         |
| 12                                              | Patient'sAssessment ofPain NRSatWeek 12 (superiority of upadacitinibvs.adalimumab) |                         |
| 13                                              | HAQ-DI at Week 12 （superiority ofupadacitinibvs.adalimumab)                        |                         |
| 14                                              | △SAPSatWeek16                                                                      |                         |

ACR20=American College of Rheumatology 20%:FACIT-F=Functional Assessment of ChronicIllnessTherapyFatigue:HAQ-DI=Health Assessment Questionnaire-Disability Index:LDI=LeedsDactylitisIndex:LEI=Leeds Enthesitis Index,MDA=minimal disease activity:NRS=NumericRating Scale:PASI=Psoriasis Area Severity Index;PCS=Physical Component Summary,SAPS=Self-Assessment ofPsoriasisSymptoms;SF-36=36-ItemShort Form Health Survey,SHS= Sharp/van der Heijde Score (equivalent to van der Heijde modified Total Sharp Score [mTSS]:sIGA 0/1=StaticInvestigator Global Assessment ofPsoriasis of0 or 1 and at least a 2-point improvement from baseline;vs.=versus

## Additional key secondary efficacy endpoints

Studies  M15-572  and  M15-554: ACR  50%/70%  response  (ACR50/70)  at  Week  12  and  ACR20 response at Week 2.

Additional efficacy analyses included the following endpoints obtained at multiple scheduled time points during the course of the study:

## Study M15-572

- Proportion of subjects with no radiographic progression defined as:
- Change from baseline in SHS ≤ 0;
- Change from baseline in SHS ≤ 0.5;
- Change from baseline in joint space narrowing (JSN) score and joint erosion score;

<div style=\"page-break-after: always\"></div>

- Change from baseline in individual components of ACR response;
- Change from baseline in Tender Joint Count (TJC) (0 -68);
- Change from baseline in Swollen Joint Count (SJC) (0 -66);
- Change from baseline in Physician Global Assessment (PGA) -Disease Activity (NRS);
- Change from baseline in Patient's Global Assessment (PtGA) -Disease Activity (NRS);
- Change from baseline in Patient's Assessment of Pain Numerical Rating Scale (NRS);
- Change from baseline in Health Assessment Questionnaire -Disability Index (HAQ-DI);
- Change from baseline in high-sensitivity C-reactive protein (hs-CRP);
- ACR 20/50/70 response rates;
- Proportion of subjects achieving MDA;
- Change from baseline in Leeds Dactylitis Index (LDI) (for subjects with baseline LDI &gt; 0);
- Change from baseline in dactylitis count (for subjects with baseline LDI &gt; 0);
- Proportion of subjects with resolution of dactylitis (for subjects with baseline LDI &gt; 0);
- Change from baseline in Leeds Enthesitis Index (LEI) (for subjects with baseline LEI &gt; 0);
- Proportion of subjects with resolution of enthesitis defined as LEI = 0 (for subjects with baseline LEI &gt; 0);
- Change  from  baseline  in  Spondyloarthritis  Research  Consortium  of  Canada  (SPARCC)  Enthesitis Index (for subjects with baseline SPARCC Enthesitis Index &gt; 0);
- Proportion of subjects with resolution of enthesitis defined as SPARCC Enthesitis Index = 0 (for subjects with baseline SPARCC Enthesitis Index &gt; 0);
- Change from baseline in total enthesitis count (for subjects with baseline total enthesitis count &gt; 0);
- Proportion of subjects with resolution of enthesitis defined as total enthesitis count = 0 (for subjects with baseline total enthesitis count &gt; 0);
- Psoriasis Area Severity Index 75, 90, 100 (PASI 75/90/100) response rates (for subjects with ≥ 3% BSA psoriasis at baseline);
- Proportion of subjects achieving sIGA 0/1 (for subjects with baseline sIGA ≥ 2);
- Change from baseline in BSA-Ps (for subjects with baseline BSA-Ps &gt; 0);
- Modified Psoriatic Arthritis Response Criteria (PsARC) response rate;
- Change from baseline in Disease Activity Score (DAS) 28 joints (DAS28) (C-reactive protein [CRP]);
- Change from baseline in DAS28 (erythrocyte sedimentation rate [ESR]);
- Change from baseline in PsA DAS (PASDAS);
- Change from baseline in Disease Activity in Psoriatic Arthritis (DAPSA) score;
- Change from baseline in Short Form 36 (SF-36) Health Questionnaire;
- Change  from  baseline  in  Functional  Assessment  of  Chronic  Illness  Therapy-Fatigue  (FACIT-F) Questionnaire;

<div style=\"page-break-after: always\"></div>

- Change from baseline in EuroQoL -5 Dimensions -5 Levels (EQ-5D-5L) Questionnaire and visual analogue scale score;
- Change from baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire;
- Health Resource Utilization (HRU);
- Change from baseline in SAPS Questionnaire;
- Change  from  baseline  in  Bath  Ankylosing  Spondylitis  Disease  Activity  Index  (BASDAI)  (out  of subjects with presence of psoriatic spondylitis at baseline);
- BASDAI 50 response rates (out of subjects with psoriatic spondylitis);
- Change from baseline in morning stiffness (mean of BASDAI Questions 5 and 6);
- Change from baseline in morning stiffness severity 0 - 10 (BASDAI Question 5);
- Change from baseline in morning stiffness duration 0 - 10 (BASDAI Question 6);
- Change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) (out of subjects with presence of psoriatic spondylitis);
- Proportion  of  subjects  with  ASDAS  Inactive  Disease  (out  of  subjects  with  presence  of  psoriatic spondylitis);
- Proportion of subjects with ASDAS Major Improvement (out of subjects with presence of psoriatic spondylitis);
- Proportion of subjects with ASDAS Clinically Important Improvement (out of subjects with presence of psoriatic spondylitis);
- Proportion of subjects achieving a clinically meaningful improvement in HAQ-DI ( ≥ 0.35).

## Study M15-554:

- Change from baseline in individual components of ACR response;
- ACR20/50/70 response rates;
- Change from baseline in Leeds Dactylitis Index (LDI)
- Change from baseline in dactylitis count;
- Proportion of subjects with resolution of dactylitis;
- Change from baseline in Leeds Enthesitis Indices (LEI);
- Proportion of subjects with resolution of enthesitis sites included in the LEI;
- Change  from  baseline  in  Spondyloarthritis  Research  Consortium  of  Canada  (SPARCC)  Enthesitis Index;
- Proportion of subjects with resolution of enthesitis sites included in the SPARCC Enthesitis Index;
- Change from baseline in total enthesitis count;
- Proportion of subjects with resolution of enthesitis;
- PASI 75/90/100 response rates (for subjects with ≥ 3% BSA psoriasis at baseline);
- Proportion of subjects achieving a sIGA score of 0 or 1 and at least a 2-point improvement from baseline;

<div style=\"page-break-after: always\"></div>

- Change from baseline in body surface area - psoriasis (BSA-Ps) (for subjects with BSA-PS &gt; 0);
- Modified Psoriatic Arthritis Response Criteria (PsARC) response rate;
- Change from baseline in Disease Activity Score 28 joints (DAS28) (C-reactiveprotein [CRP]);
- Change from baseline in DAS28 (erythrocyte sedimentation rate [ESR]);
- Change from baseline in PsA Disease Activity Score (PASDAS);
- Change from baseline in Disease Activity in Psoriatic Arthritis (DAPSA) score;
- Change from baseline in SF-36 PCS;
- Change from baseline in FACIT-Fatigue (FACIT-F);
- Change from baseline in EuroQoL-5 Dimensions - 5 Levels (EQ-5D-5L);
- Change from baseline in Work Productivity and Activity Impairment (WPAI);
- Health Resource Utilization (HRU);
- Proportion of subjects achieving MDA;
- Change from baseline in SAPS;
- Change  from  baseline  in  Bath  Ankylosing  Spondylitis  Disease  Activity  Index  (BASDAI)  (among subjects with psoriatic spondylitis);
- 50% improvement of the initial BASDAI (BASDAI 50) response rates (among subjects with psoriatic spondylitis);
- Change from baseline in morning stiffness (mean of BASDAI Questions 5 and 6);
- Change from baseline in morning stiffness duration;
- Change from baseline in morning stiffness severity;
- Change from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) (among subjects with psoriatic spondylitis);
- Proportion of subjects with ASDAS Inactive Disease (among subjects with psoriatic spondylitis);
- Proportion of subjects with ASDAS Major Improvement (among subjects with psoriatic spondylitis);
- Proportion of subjects with ASDAS Clinically Important Improvement (among subjects with psoriatic spondylitis);
- Proportion of subjects achieving a clinically meaningful improvement in HAQ-DI ( ≥ 0.35).

## Sample size

## Study M15-572

The planned sample size of approximately 1640 for this study (with 2:2:2:1:1 randomization ratio for upadacitinib 15 mg, upadacitinib 30 mg, adalimumab and placebo subjects) was estimated to provide at least 90% power for a 20% difference in ACR20 response rate (assuming a placebo ACR20 response rate of 30%). It was estimated to also provide at least 90% power for the majority of the key secondary endpoints. With the given sample size, the MAH states that there is approximately 90% power to detect a standardized effect size of 0.26 in change from baseline in SHS for each upadacitinib dose group versus the combined placebo group at Week 24. This sample size was calculated to also provide at least 85%

<div style=\"page-break-after: always\"></div>

power for evaluating noninferiority for each upadacitinib dose group vs. ADA in ACR20 response rate at Week 12 assuming 50% ACR20 response rates for ADA and upadacitinib and 30% ACR20 response rates for placebo. All power and sample size calculations were performed at two-sided significance level of 0.025  and  accounting  for  a  10%  dropout  rate.  The  pre-specified  approach  to  testing  NI  of  each upadacitinib dose versus ADA for ACR20 response rate at Week 12 was based on the placebo-subtracted treatment difference using Koch's 3-arm test statistic.  The test aims to show that upadacitinib preserves at least 50% of the placebo-subtracted adalimumab effect. If statistical significance is achieved for the non-inferiority assessment, superiority of upadacitinib versus adalimumab will be tested for ACR20.

## Study M15-554

According to the MAH, the planned total sample size of 630 for this study provides at least 90% power for a 20% difference in ACR20 response rate (assuming a placebo ACR20 response rate of 20%). It will also provide at least 90% power for the majority of the key secondary endpoints. All power and sample size calculations are performed at a two-sided significance level of 0.025 and accounting for a 10% dropout rate.

## Randomisation

## Study M15-572

Subjects who met eligibility criteria were stratified by extent of psoriasis (≥ 3% body surface area [BSA] or &lt; 3% BSA), current use of at least 1 DMARD, presence of dactylitis, and presence of enthesitis, except for subjects from China and Japan, where randomization for each country was stratified by extent of psoriasis  (≥  3%  BSA  or  &lt;  3%  BSA)  only,  and  then  randomized  in a  2:2:2:1:1  ratio  to  one  of  five treatment groups:

- Group 1: Upadacitinib 15 mg QD (N = 410)
- Group 2: Upadacitinib 30 mg QD (N = 410)
- Group 3: ADA 40 mg every other week (EOW) (N = 410)
- Group 4: Placebo followed by upadacitinib 15 mg QD (N = 205)
- Group 5: Placebo followed by upadacitinib 30 mg QD (N = 205)

No  more  than  approximately  15%  of  subjects  were  to  be  enrolled  with  concomitant  use  of hydroxychloroquine (HCQ), sulfasalazine (SSZ), bucillamine, or iguratimod.

## Study M15-554

Subjects were stratified by extent of psoriasis (≥ 3% body surface area [BSA] or &lt; 3% BSA), current use of at least 1 DMARD (Yes or No), and number of prior failed biologic DMARDs (1 vs &gt; 1), except for subjects from Japan, for which randomization was stratified by extent of psoriasis (≥ 3% body surface area [BSA] or &lt; 3% BSA) only.

No more than approximately 40% of subjects will be enrolled with &lt; 3% BSA extent of psoriasis and no more  than  approximately  30%  of  subjects  were  to  be  enrolled  with  prior  failure  of  more  than 1 biologic DMARD.

<div style=\"page-break-after: always\"></div>

## Blinding (masking)

In both studies, MAH's personnel with direct oversight of the conduct and management of the trial (with the exception of Drug Supply Management Team), the Investigator, study site personnel, and the subject will remain blinded to each subject's treatment. In order to maintain the blind, the upadacitinib/placebo tablets and adalimumab/matching placebo syringes provided for the study are identical in appearance.

After the last subject completed the Week 24 visit, an unblinded analysis was conducted for the purpose of regulatory submission. Study sites and subjects will remain blinded until all subjects have reached Week 56 (end of Period 1).

An independent external Data Monitoring Committee (DMC) is used to review unblinded safety data at regular intervals during the conduct of the studies.

## Statistical methods

Since the available CSR for both Phase 3 studies only coversed the first 24 weeks of the study at the time of original submission, the statistical methodology is presented mainly for Period 1 of the studies.

The data cut-off date for the interim analyses are for study M15-572 13 December 2019 and for study 15-554 09 October 2019.

There were five protocol amendments and one administrative change in study M15-572 and six amendments and two administrative changes in the protocol for study M15-554. All of these were dated prior to data cut-off. There was an update of the statistical analysis plan (SAP) for the integrated summary of efficacy dated 01 October 2019, also before data cut-off dates.

## Analysis populations

## Full Analysis Set (FAS)

The FAS includes all randomized subjects who received at least one dose of study drug. The FAS is used for all efficacy and baseline analyses.

## Per Protocol Analysis Set

The Per Protocol Analysis Set represents a subset of the FAS and consists of all FAS subjects who did not meet any major protocol deviations that are determined to have a potential impact on the primary efficacy endpoint up to Week 12 in Period 1 of the study.  Additional analysis of the primary efficacy endpoint are conducted on the Per Protocol analysis set, in order to evaluate the impact of major protocol deviations.

## Safety Analysis Set

The Safety Analysis Set consists of all subjects who received at least one dose of study drug. For the Safety Analysis Set, subjects are analysed \"as treated,\" regardless of the treatment randomized. \"As treated\" is determined by the treatment the subject received during the majority of the subject's drug exposure time in the analysis period.

## Analysis of results

Demographic and baseline characteristics information were collected at the Baseline and summarized for the FAS. The number of observations, mean, standard deviation, median, minimum and maximum were summarized for continuous variables. Categorical or discrete variables were summarized via frequencies and percentages. Summary statistics were computed for each treatment group and overall.

<div style=\"page-break-after: always\"></div>

No statistical comparison was performed for medical history reporting.

Prior and concomitant medications were summarized by each randomized treatment group as well as overall for FAS.

Protocol deviations based on ICH deviation criteria, summarized and listed by treatment group, are categorized as follows:

1. Those who entered the study even though they did not satisfy the entry criteria
2. Those who developed withdrawal criteria during the study and were not withdrawn
3. Those who received the wrong treatment or incorrect dose, and
4. Those who received an excluded or prohibited concomitant medication.

## Patient disposition

The following will be summarized by randomized treatment group as well as overall: number of subjects randomized; number of subjects included in key analysis populations (FAS and Per Protocol Analysis Set for efficacy analysis, Safety Analysis Set for safety analysis); number of subjects who completed Period 1 study participation; number of subjects who entered Period 2; number of subjects who completed overall study (Period 1 and Period 2) participation (if applicable).

Premature discontinuation details will be further summarized separately for Period 1 and Period 2. The number and percentage of subjects completed Period 1 and prematurely discontinued in Period 1 are summarized by randomized treatment group, separately by study drug and study participation completion/discontinuation, with the reason for discontinuation collected from CRF by the following categories: Adverse event (AE), Withdrew consent, Lost to follow-up, Lack of efficacy, Other.

## Study drug exposure

For short term up to Week 24, the duration of exposure to study drug is summarized for the safety analysis set by the randomized treatment groups.

Study drug compliance was summarized for each treatment group at Week 24. The summary was performed for UPA/PBO tablets and ADA/PBO injections separately.

## Efficacy analysis

Of the two sets of planned efficacy analysis: efficacy analysis through Week 24 and long-term efficacy analysis, this AR focuses on the analysis through Week 24, for which period results are available. Unless otherwise noted, all efficacy analyses were carried out using the FAS population.

## Efficacy Analysis by Week 24

Standard efficacy analysis by randomized treatment groups (upadacitinib 15 mg QD, upadacitinib 30 mg QD, adalimumab 40 mg EOW and the combined placebo groups) was performed on efficacy data up to Week 24.

For ACR20 response at Week 12 of study M15-572, analysis was conducted to assess the noninferiority of each upadacitinib dose versus adalimumab on the placebo-subtracted treatment difference using Koch's 3-arm test statistic (described in Appendix C of the statistical analysis plan). The test aims to show that upadacitinib preserves at least 50% of the placebo-subtracted adalimumab effect.

<div style=\"page-break-after: always\"></div>

Since statistical significance was achieved for the non-inferiority assessment of ACR20 response at Week 12 compared with adalimumab for both upadacitinib doses, superiority of upadacitinib versus adalimumab was tested for ACR20 subsequently.

- Multiple Imputation and tipping point analysis:

Tipping point analysis was performed for the primary endpoint (ACR20 at Week 12) by multiple imputations using logistic regression, allowing the imputed ACR response rate to systematically vary from 0% to 100% in both upadacitinib and placebo, respectively. Supportive analysis was also conducted on the Per Protocol Analysis Set.

Tipping point analysis was performed also for the key secondary non-radiographic continuous endpoints.

## Adjustment for Covariates

All efficacy analyses were performed adjusting for the stratification factor of current DMARD use. Continuous variables were also analysed adjusting for baseline values. No other adjustment for covariates was performed.

## Missing data handling included

- Non-responder imputation (NRI) for binary endpoints: subjects who prematurely discontinued from study drug were considered as non-responders for all subsequent visits after discontinuation; and any subject with any missing value for the binary endpoints at a specific visit was treated as non-responder for that visit.

- As observed (AO): The AO data handling does not impute values for missing evaluations, and thus a subject who does not have an evaluation on a scheduled visit will be excluded from the AO analysis for that visit. Regardless of premature discontinuation of study drug or use of rescue medication, all observed data will be used in the analysis. The intention-to-treat (ITT) principle for the analysis using AO data, AO (with imputation), where additional missing data will be imputed as non-responders, is used for the supplementary analysis of the primary and key secondary binary endpoints.

- Mixed-Effect Model Repeat Measurement (MMRM): The repeated measure analysis was conducted using mixed models including observed data at all visits. For the MMRM analysis, data collected after premature discontinuation of study drug was excluded. The mixed model includes the categorical fixed effects of treatment, visit, treatment-by-visit interaction, the stratification factor current DMARD use (yes/no) and the continuous fixed covariates of baseline measurement. An unstructured variance covariance matrix was used. The parameter estimations were based on the assumption of data being missing at random (MAR) and using the method of restrictive maximum likelihood (REML). MMRM will be used for the primary estimand of the non-radiographic continuous endpoints.

Linear extrapolation will be used to facilitate the primary estimand for radiographic endpoints.  The multiple imputation model was used for radiographic continuous endpoints. The model for the change from baseline in SHS score was based on the linearity assumption for the subjects with missing data including those due to premature discontinuation of study drug or meeting the rescue criteria. The regression method used imputed missing Week 24 observations by regression upon all previous visits including baseline and Week 16, stratified by treatment group. The imputation model included baseline demographics and key baseline characteristics as appropriate. Analysis of covariance (ANCOVA) was performed on each of the multiple imputed datasets.

<div style=\"page-break-after: always\"></div>

## Handling of multiplicity

The overall type I error rate of the primary and ranked key secondary endpoints for the two doses was controlled using a graphical multiple testing procedure. The graph for the testing procedures is provided for each study in Figures 23 and 2 4. In the graphs, the arrows specify the α transfer paths. Once an endpoint is rejected (i.e., deemed significant) at its assigned significance level, its significance level will be transferred to subsequent endpoint(s) following the arrow(s). The numbers on the arrows denote the weights for transferring significance levels. Specifically, the weight 1 denotes 100% transfer of significance level. (Note: in the Figure 23, 'Humira' denotes the adalimumab product used in the study).

<div style=\"page-break-after: always\"></div>

Figure 23 Graphical Multiple Testing Procedure (Study M15-572)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Superiority Testing Sequence at level a

Figure 24 Graphical Multiple Testing Procedure (Study M15-572)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 25 Graphical Multiple Testing Procedure (Study M15-554)

<!-- image -->

## Subgroup analyses

Table 22 presents the subgroups in study M15-572 for efficacy analyses on the primary efficacy endpoint. Treatment difference between each upadacitinib dose and the combined placebo group is presented with point estimate and 95% confidence interval using normal approximation. No p-value is provided for subgroup analyses.

In study M15-554, the same subgroups were analysed as in M15-572, except that instead of the subgroup 'Number of prior non-biologic DMARDs' the subgroup 'Number of prior failed biologic DMARDs [= 1, &gt;1] was analysed.

<div style=\"page-break-after: always\"></div>

Table 22 Subgroups for efficacy analysis (Study M15-572)

| SubgroupFactor                   | Categories                                                                           |
|----------------------------------|--------------------------------------------------------------------------------------|
| Age                              | <65.≥65-<75.≥75years（ifsamplesize allows)                                            |
| Sex                              | Male orFemale                                                                        |
| BMI                              | <25kg/m²or≥25kg/m²                                                                   |
| Race                             | White,Non-white                                                                      |
| Geographicregion                 | North America,Western Europe and Oceania.Eastern Europe.Latin-America,Asia,and Other |
| Duration ofPsA diagnosis         | ≤5,>5-≤10,>10years                                                                   |
| Baseline hsCRP                   | ≤ULNor>ULN                                                                           |
| Number ofpriornon-biologicDMARDs | ≤1.>1                                                                                |
| Currentuseofnon-biologicDMARDs   | Yes or No                                                                            |

## Methodology of integrated efficacy analyses

The integrated summary of efficacy (ISE) of the dossier presents short-term integrated analyses conducted on the 24 week placebo-controlled period data from the two pivotal Phase 3 global trials Study M15-554 and Study M15-572.

The main objectives of the ISE were 1) to assess the efficacy of upadacitinib on key endpoints in the integrated dataset; 2) to assess the efficacy in subgroups defined by demographic and baseline disease characteristics in the integrated dataset; 3) to examine the efficacy of upadacitinib as monotherapy vs in combination with background non-biologic DMARDs; and 4) to examine the efficacy of upadacitinib in combination with methotrexate (MTX) vs with other non-biologic DMARDs respectively.

Data from the three treatment arms of upadacitinib 15 mg QD, upadacitinib 30 mg QD, and placebo were included. All analyses for ISE were to be performed on the FAS population, which includes all randomized subjects who have received at least one dose of study drug. Data from the FAS is presented by the treatment group assigned at the time of randomization, even if the subject did not receive the correct treatment or did not follow the protocol until completion.

Demographic and baseline characteristics were summarized for the ISE.

Table 23 summarises the efficacy analyses conducted for the ISE.

<div style=\"page-break-after: always\"></div>

## Table 23

| Analyses Outline                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis of Key Efficacy Endpoints ACR20/50/70, HAQ-DI, sIGA, PASI75, and MDA Dactylitis and Enthesitis related endpoints                                                                    |
| Subgroup Analysis for ACR20 Assessment of efficacy in subgroups by demographic and baseline disease characteristics                                                                          |
| Upadacitinib monotherapy vs in combination with background non-biologic DMARDs Examine the efficacy of upadacitinib as monotherapy vs. in combination with background non-biologic DMARDs    |
| Upadacitinib in combination with MTX vs with other background non-biologic DMARDs Examine the efficacy of upadacitinib in combination with different types of background non-biologic DMARDs |

The MAH informs that handling of missing data and intercurrent events is consistent with the primary estimand and primary analysis in the individual studies. Analyses in the ISE are considered by the MAH to be supportive of the efficacy results obtained from the individual studies and are not intended to be interpreted without this context.

For binary endpoints, the point estimate and 95% CI for the response rate for each group as well as the point estimate, 95% CI and p-value for the treatment difference between each upadacitinib group and placebo are provided using the Cochran-Mantel-Haenszel analysis adjusting for study as a stratification factor.

For continuous endpoints, the LS mean and 95% CI for each group as well as the LS mean treatment difference, the associated 95% CI and the p-value for the treatment difference between each upadacitinib group and placebo is provided using MMRM model adjusting for study as a stratification factor. Additionally, the MI analysis based on all data as observed (AO) has been performed as supplementary analysis.

No multiplicity adjustment was planned or conducted for any ISE analyses.

## Results

## Study M15-572

## Participant flow

A total of 1705 subjects were randomized at 281 sites located in 44 countries, of whom 1704 subjects received study drug. Number of screened subjects is not available.

A total of 1,626 subjects (95.4%) and 1,548 subjects (90.8%) were continuing the study drug at Week 12 (primary endpoint) and Week 24 (cut-off for interim CSR), respectively.

The most frequent primary reason for study drug discontinuation by Week 24 was withdrawal by subject for the placebo group, AE and withdrawal by subject for the upadacitinib 15 mg group, and AE for the upadacitinib 30 mg and adalimumab (ADA) groups (table 24). As of the data cut-off date of the CSR, 649 subjects (38.1%) had completed Period 1 (Week 56) study drug, 240 subjects (14.1%) had discontinued study drug during Period 1, and 816 subjects were ongoing in Period 1. However, the MAH provided in the response to the RSI the 56 week results for all efficacy endpoints proposed by the

<div style=\"page-break-after: always\"></div>

MAH to be included in the PI, since all subjects had reached Week 56 or were prematurely discontinued by submission of the response (see assessment in ancillary analysis section).

Table 24 Study Drug Disposition of Subjects (All Randomized Subjects)

|                                                 | Placebo (N = 423)   | ADA 40 mg EOW (N = 429)   | Upadacitinib 15 mg QD (N = 430)   | Upadacitinib 30 mg QD (N = 423)   | Overall Total (N =1705)   |
|-------------------------------------------------|---------------------|---------------------------|-----------------------------------|-----------------------------------|---------------------------|
| Randomized, n                                   | 423                 | 429                       | 430                               | 423                               | 1705                      |
| FAS, n                                          | 423                 | 429                       | 429                               | 423                               | 1704                      |
| Per Protocol Analysis Set, n                    | 413                 | 424                       | 402                               | 394                               | 1633                      |
| Safety Analysis Set, n                          | 423                 | 429                       | 429                               | 423                               | 1704                      |
| Completed study drug up to Week 12, n (%)       | 399 (94.3)          | 410 (95.6)                | 412 (95.8)                        | 405 (95.7)                        | 1626 (95.4)               |
| Discontinued study drug (primary reason), n (%) | 24 (5.7)            | 19 (4.4)                  | 18 (4.2)                          | 18 (4.3)                          | 79 (4.6)                  |
| Adverse event                                   | 9 (2.1)             | 8 (1.9)                   | 5 (1.2)                           | 12 (2.8)                          | 34 (2.0)                  |
| Withdrawal by subject                           | 9 (2.1)             | 7 (1.6)                   | 7 (1.6)                           | 5 (1.2)                           | 28 (1.6)                  |
| Lost to follow up                               | 2 (0.5)             | 1 (0.2)                   | 4 (0.9)                           | 0                                 | 7 (0.4)                   |
| Lack of efficacy                                | 1 (0.2)             | 2 (0.5)                   | 0                                 | 0                                 | 3 (0.2)                   |
| Other                                           | 3 (0.7)             | 1 (0.2)                   | 2 (0.5)                           | 1 (0.2)                           | 7 (0.4)                   |
| Completed study drug up to Week 24, n (%)       | 377 (89.1)          | 388 (90.4)                | 395 (91.9)                        | 388 (91.7)                        | 1548 (90.8)               |
| Discontinued study drug (primary reason), n (%) | 44 (10.4)           | 36 (8.4)                  | 31 (7.2)                          | 34 (8.0)                          | 145 (8.5)                 |
| Adverse event                                   | 11 (2.6)            | 18 (4.2)                  | 10 (2.3)                          | 19 (4.5)                          | 58 (3.4)                  |
| Withdrawal by subject                           | 19 (4.5)            | 10 (2.3)                  | 10 (2.3)                          | 10 (2.4)                          | 49 (2.9)                  |
| Lost to follow up                               | 3 (0.7)             | 3 (0.7)                   | 5 (1.2)                           | 2 (0.5)                           | 13 (0.8)                  |
| Lack of efficacy                                | 7 (1.7)             | 3 (0.7)                   | 1 (0.2)                           | 0                                 | 11 (0.6)                  |
| Other                                           | 4 (0.9)             | 2 (0.5)                   | 5 (1.2)                           | 3 (0.7)                           | 14 (0.8)                  |

ADA = adalimumab; EOW = every other week; FAS = Full Analysis Set; QD = once daily

## Recruitment

The first subject first visit occurred on 27 April 2017. The submitted interim CSR presents efficacy results up to Week 24 in Period 1, short-term safety results up to Week 24, and long-term safety results up to the data cut-off date of 13 December 2019.

Study M15-572 was designed to enrol approximately 1640 subjects at approximately 350 study centres worldwide. Finally, the study is being conducted in 281 sites in 44 participating countries.

## Conduct of the study

There were five protocol amendments and one administrative change in study M15-572, all dated prior to data cut-off. Each amendment contained multiple updates, mostly clarifications on inclusion and exclusion criteria, permitted concomitant treatments and their dose changes, administrative changes, contraception recommendations, and linguistic changes. Some amendments were performed due to the concerns on increased thrombosis risk associated to the JAKi class.

<div style=\"page-break-after: always\"></div>

According to the MAH, all studies were conducted in accordance with GCP and applicable local laws and regulations. Three investigative site audits were conducted by the sponsor. No regulatory inspections are reported in the submission.

Protocol deviations were defined in accordance with the ICH guidelines and included but were not limited to: inclusion/exclusion criteria violation, receipt of wrong treatment or incorrect dose of study drug, development of withdrawal criteria without being withdrawn, and use of prohibited concomitant medications. In addition, all non-ICH deviations were reviewed. Deviations were assessed for their impact on analyses and data integrity or subject safety. Subjects judged to have deviations with a potential impact on the primary variable were excluded from the PP analysis set. The deviations were not considered by the MAH to have affected the overall study outcome or interpretation of the study results or conclusions.

## Baseline data

Demographic characteristics were generally balanced across the upadacitinib, ADA, and placebo groups (Table 25). The mean age of study subjects was 50.8 years, they had been diagnosed with PsA for a mean of 6.1 years, and experienced symptoms of PsA for a mean of 9.2 years. There were slightly more women than men. Subjects had active disease as indicated by mean TJC68 of 20.0, mean SJC66 of 11.2, and 49.6% of subjects had psoriasis with BSA ≥ 3%.

Table 25 Demographic characteristics (FAS)

|                                         | Placebo (N=423)   | ADA 40mgEOW (6tF=N)   | Upadacitinib 15mgQD (N=429)   | Upadacitiuib 20mgQD (=N)   | Total (N=1704)   |
|-----------------------------------------|-------------------|-----------------------|-------------------------------|----------------------------|------------------|
| Sex.n(0)                                |                   |                       |                               |                            |                  |
| Female                                  | 211(49.9)         | 222(51.7)             | 238(55.5)                     | 236(55.8)                  | 907 (53.2)       |
| Male                                    | 212(50.1)         | 207(483)              | 191(44.5)                     | 187(44.2)                  | 797(46.8)        |
| Age (years)                             |                   |                       |                               |                            |                  |
| Mean (SD)                               | 50.4(1221)        | 51.4(12.04)           | 516(12.19)                    | 49.9 (12.41)               | 50.8(1222)       |
| Medan (mn max)                          | 50.0(20.0,81.0)   | 52.0(21.0,77.0)       | 52.0(22.0.83.0)               | 51.0(19.0,82.0)            | 0806D015         |
| Age (years）.n ()                        |                   |                       |                               |                            |                  |
| 65                                      | 367(86.8)         | 362 (84.4)            | 367 (85.5)                    | 371 (87.7)                 | 1467 (86.1)      |
| 65-75                                   | 52(12.3)          | 61(142)               | 52 (12.1)                     | 46(10.9)                   | 211(12.4)        |
| 275                                     | 4(0.9)            | 6(14)                 | 1023)                         | 6(1.4)                     | 26(15)           |
| Race                                    |                   |                       |                               |                            |                  |
| White                                   | 377(89.1)         | 375 (87.4)            | 386(90.0)                     | 377 (89.1)                 | 1515 (889)       |
| Black or Afncan American                |                   |                       |                               |                            |                  |
| Amencan Indian/Alaska Native            |                   |                       |                               |                            |                  |
| Native Hawaan or otber Pacific Islander |                   |                       |                               |                            |                  |
| Asian                                   | 37(8.7)           | 41(9.6)               | 98                            | 34(8.0)                    | 149(8.7)         |
| Multiple                                | 3(0.7)            | 7(1.6)                | 5(1.2)                        | 6(1.4)                     | 21(1.2)          |

<div style=\"page-break-after: always\"></div>

| Ethnicity                     |                      |                      |                      |                      |                     |
|-------------------------------|----------------------|----------------------|----------------------|----------------------|---------------------|
| Hispanic or Latino            | 66 (15.6)            | 65 (15.2)            | 59 (13.8)            | 53(12.5)             | 243(14.3)           |
| NotHispanicorLatino           | 357(84.4)            | 364 (84.8)           | 370 (86.2)           | 370 (87.5)           | 1461(85.7)          |
| Weight (kg)                   |                      |                      |                      |                      |                     |
| Mean (SD)                     | 87.4 (21.36)         | 87.8 (21.90)         | 84.8 (18.89)         | 85.5 (18.83)         | 86.4 (20.32)        |
| Median (min,max)              | 85.0(41.0.168.6)     | 85.0(43.0,217.2)     | 83.0(46.3,160.1)     | 84.0 (44.2.143.0)    | 84.0(41.0,217.2)    |
| Height(cm)                    |                      |                      |                      |                      |                     |
| Mean (SD)                     | 169.5 (10.29)        | 169.2 (10.01)        | 167.8(9.12)          | 168.7 (10.05)        | 168.8 (9.89)        |
| Median (min, max)             | 169.0 (144.0, 200.7) | 170.0 (144.7, 193.0) | 167.6 (145.1, 194.5) | 168.0 (139.0, 199.0) | 168.0 (139.0,200.7) |
| Bodymassindex(kg/m²)          |                      |                      |                      |                      |                     |
| Mean (SD)                     | 30.4 (6.79)          | 30.7 (7.24)          | 30.1(6.40)           | 30.1(6.77)           | 30.3(6.81)          |
| Median(min,max)               | 29.5 (15.6.61.9)     | 29.8(16.5,87.0)      | 29.1(17.9,56.0)      | 29.3(16.7,57.3)      | 29.5 (15.6,87.0)    |
| Bodymassindex(kg/m²),n(%) <25 | 94(22.2)             | 95 (22.1)            | 87 (20.3)            | 104 (24.6)           | 380 (22.3)          |
| Tobacco/nicotine use,a n (%)  |                      |                      |                      |                      |                     |
| Current                       | 74 (17.5)            | 85 (19.8)            | 82 (19.1)            | 64 (15.1)            | 305 (17.9)          |
| Former                        | 84 (19.9)            | 78 (18.2)            | 85 (19.8)            | 91 (21.5)            | 338 (19.8)          |
| Never                         | 265 (62.6)           | 266 (62.0)           | 262 (61.1)           | 268 (63.4)           | 1061 (62.3)         |
| Alcohol use, n (%)            |                      |                      |                      |                      |                     |
| Current                       | 160 (37.8)           | 187 (43.6)           | 161 (37.6)           | 156 (36.9)           | 664 (39.0)          |
| Former                        | 36 (8.5)             | 23 (5.4)             | 38 (8.9)             | 40 (9.5)             | 137 (8.0)           |
| Never                         | 227 (53.7)           | 219 (51.0)           | 229 (53.5)           | 227 (53.7)           | 902 (53.0)          |
| Unknown                       | 0                    | 0                    | 1                    | 0                    |                     |

ADA = adalimumab; EOW = every other week; Max = maximum; min = minimum; QD = once daily; SD = standard deviation

A subject that was a current user of any type of tobacco is counted under \"current.\" Otherwise, a subject that was a former user of any type of tobacco is counted under \"fomer.\"A subject whohad never used any tobacco is counted under\"never.\"

The disease-related baseline characteristics were overall balanced across the upadacitinib, ADA, and placebo groups, incl. duration of symptoms and diagnosis, RF and anti-CCP status, indicators of disease activity, status of structural changes, and PROs. Dactylitis was present (defined as LDI&gt;0) in 30.3 % and enthesitis (defined as total enthesitis count &gt; 0) in 77.2% of study subjects. One third (31.3 %) of subjects had psoriatic spondylitis at baseline. About half of subjects (49.6 %) had total body surface area affected by psoriasis (BSA-Ps) ≥ 3% at baseline. (Table 26)

The requirement for either at least one erosion on x-ray or elevated hsCRP in inclusion criteria were selected in order to enrol a population appropriate for assessment of radiographic progression and to increase the power for detection of a treatment effect for upadacitinib on the radiographic endpoints. However, less than half (39.2 %9 of study subjects had ≥ 1 erosion at baseline. The mean hsCRP was 11.22 mg/L (median 6.21 mg/L).

<div style=\"page-break-after: always\"></div>

Table 26 Disease-Related Baseline Characteristics (FAS)

|                                    | Placebo (N =423) n (%)   | ADA 40 mg E0W (N = 429) n (%)   | Upadacitinib 15 mg QD (N = 429) n (%)   | Upadacitinib 30 mg QD (N = 423) n (%)   | Total (N =1704) n (%)   |
|------------------------------------|--------------------------|---------------------------------|-----------------------------------------|-----------------------------------------|-------------------------|
| Duration ofPsAsymptoms(years)      |                          |                                 |                                         |                                         |                         |
| n                                  | 423                      | 428                             | 429                                     | 423                                     | 1703                    |
| Mean (SD)                          | 9.3 (8.58)               | 9.1 (8.78)                      | 9.2 (8.63)                              | 9.3 (8.28)                              | 9.2 (8.56)              |
| Median (min, max)                  | 6.4 (0.6, 55.0)          | 6.0 (0.6, 55.3)                 | 6.7 (0.6, 44.4)                         | 6.7 (0.6, 54.3)                         | 6.4 (0.6, 55.3)         |
| Duration of PsA diagnosis (years)  |                          |                                 |                                         |                                         |                         |
| Mean (SD)                          | 6.2 (7.01)               | 5.9 (7.06)                      | 6.2 (7.41)                              | 5.9 (6.37)                              | 6.1 (6.97)              |
| Median (min, max)                  | 3.5 (0.1, 45.0)          | 3.5 (0.1, 40.9)                 | 3.5 (0.1, 41.0)                         | 3.4 (0.1, 33.2)                         | 3.5 (0.1, 45.0)         |
| RF status, n (%)                   |                          |                                 |                                         |                                         |                         |
| Positive                           | 20 (4.7)                 | 13 (3.0)                        | 15 (3.5)                                | 23 (5.4)                                | 71 (4.2)                |
| Negative                           | 403 (95.3)               | 416 (97.0)                      | 414 (96.5)                              | 400 (94.6)                              | 1633 (95.8)             |
| Anti-CCP status, n (%)             |                          |                                 |                                         |                                         |                         |
| Positive                           | 16 (3.8)                 | 11 (2.6)                        | 9 (2.1)                                 | 17 (4.0)                                | 53 (3.1)                |
| Negative                           | 406 (96.0)               | 418 (97.4)                      | 419 (97.7)                              | 405 (95.7)                              | 1648 (96.7)             |
| Missing                            | 1 (0.2)                  | 0                               | 1 (0.2)                                 | 1 (0.2)                                 | 3 (0.2)                 |
| TJC68                              |                          |                                 |                                         |                                         |                         |
| Mean (SD)                          | 20.0 (14.34)             | 20.1 (13.82)                    | 20.4 (14.72)                            | 19.4 (13.32)                            | 20.0 (14.05)            |
| Median (min, max)                  | 15.0 (3.0, 68.0)         | 16.0 (3.0, 66.0)                | 16.0 (2.0, 68.0)                        | 15.0 (3.0, 66.0)                        | 16.0 (2.0, 68.0)        |
| SJC66                              |                          |                                 |                                         |                                         |                         |
| Mean (SD)                          | 11.0 (8.16)              | 11.6 (8.75)                     | 11.6 (9.31)                             | 10.6 (7.06)                             | 11.2 (8.37)             |
| Median (min, max)                  | 9.0 (3.0, 56.0)          | 9.0 (3.0, 52.0)                 | 9.0 (3.0, 59.0)                         | 9.0 (1.0, 56.0)                         | 9.0 (1.0, 59.0)         |
| Patient's Assessment of Pain (NRS) |                          |                                 |                                         |                                         |                         |
| n1                                 | 421                      | 428                             | 425                                     | 421                                     | 1695                    |
| Mean (SD)                          | 6.1 (2.14)               | 6.0 (2.08)                      | 6.2 (2.07)                              | 5.9 (2.05)                              | 6.0 (2.09)              |
| Median (min, max)                  | 6.0 (0.0, 10.0)          | 6.0 (0.0, 10.0)                 | 6.0 (0.0, 10.0)                         | 6.0 (0.0, 10.0)                         | 6.0 (0.0, 10.0)         |
| PGA - Disease Activity (NRS)       |                          |                                 |                                         |                                         |                         |
|                                    | 423                      | 429                             | 429                                     | 423                                     | 1704                    |
| Mean (SD)                          | 6.5 (1.64)               | 6.6 (1.65)                      | 6.7 (1.62)                              | 6.5 (1.68)                              | 6.5 (1.65)              |
| Median (min, max)                  | 7.0 (1.0, 10.0)          | 7.0 (0.0, 10.0)                 | 7.0 (1.0, 10.0)                         | 7.0 (1.0, 10.0)                         | 7.0 (0.0, 10.0)         |
| PtGA - Disease Activity (NRS)      |                          |                                 |                                         |                                         |                         |
| n                                  | 421                      | 428                             | 425                                     | 421                                     | 1695                    |
| Mean ± SD                          | 6.3 (2.04)               | 6.3 (2.03)                      | 6.6 (2.03)                              | 6.4 (2.07)                              | 6.4 (2.04)              |
| Median (min, max)                  | 6.0 (0.0, 10.0)          | 6.0 (1.0, 10.0)                 | 7.0 (0.0, 10.0)                         | 6.0 (0.0, 10.0)                         | 7.0 (0.0, 10.0)         |
| HAQ-DI                             |                          |                                 |                                         |                                         |                         |
|                                    | 421                      | 428                             | 425                                     | 421                                     | 1695                    |
| Mean±SD                            | 1.12 (0.639)             | 1.12 (0.626)                    | 1.15 (0.653)                            | 1.09(0.630)                             | 1.12(0.637)             |
| Median (min mx)                    | 1.13 (0.00.2.88)         | 1.13 (0.00,3.00)                | 1.13 (0.00.2.75)                        | 1.13 (0.00.2.88)                        | 1.13 (0.00.3.00)        |
| hs-CRP (mg/L)                      |                          |                                 |                                         |                                         |                         |
| Mean±SD                            | 11.48 (15.800)           | 10.91 (15.463)                  | (016+1)0011                             | 11.49 (15.355)                          | 11.22(15.373)           |
| Median (min,max)                   | 6.34 (0.20. 152.00)      | 5.40 (0.20,117.00)              | 6.66(0.20,141.00)                       | 6.89(0.20,169.00)                       | 6.21(0.20.169.00)       |
| BSA-psoniasis (Ps)                 |                          |                                 |                                         |                                         |                         |
| %E>                                | 212 (50.1)               | (805)817                        | 215 (50.1)                              | 213 (50.4)                              | 858 (50.4)              |
| 2.3%                               | 211 (49.9)               | 211 (49.2)                      | 214 (49.9)                              | 210 (49.6)                              | 846 (49.6)              |
| BSA-Ps (for baseline > 0%)         |                          |                                 |                                         |                                         |                         |
|                                    | 400                      | 397                             |                                         | 397                                     | 1588                    |
| Mean±SD                            | 9.41 (16.108)            | 7.98 (13.650)                   | 8.29 (15.496)                           | 8.18 (14.095)                           | 8.47 (14.869)           |
| Median (man,max)                   | 3.00 (0.10,90.00)        | 3.00(0.03,90.00)                | 3.00(0.10.97.00)                        | 3.00(0.10.87:00)                        | 3.00 (0.03,97.00)       |

<div style=\"page-break-after: always\"></div>

| sIGA of psoriasis score 0                                      | 24 (5.7)                                                       | 34 (7.9)               | 34 (7.9)              | 21 (5.0)              | 113 (6.6)              |
|----------------------------------------------------------------|----------------------------------------------------------------|------------------------|-----------------------|-----------------------|------------------------|
| 1                                                              | 86 (20.3)                                                      | 65 (15.2)              | 73 (17.0)             | 78 (18.4)             | 302 (17.7)             |
| 2                                                              | 167 (39.5)                                                     | 181 (42.2)             | 170 (39.6)            | 173 (40.9)            | 691 (40.6)             |
| 3                                                              | 119 (28.1)                                                     | 132 (30.8)             | 133 (31.0)            | 128 (30.3)            | 512 (30.0)             |
| 4                                                              | 27 (6.4)                                                       | 17 (4.0)               | 19 (4.4)              | 23 (5.4)              | 86 (5.0)               |
| PASI (for baseline BSA-Ps ≥3%)                                 | PASI (for baseline BSA-Ps ≥3%)                                 |                        |                       |                       |                        |
| n                                                              | 211                                                            | 211                    | 214                   | 210                   | 846                    |
| Mean ± SD                                                      | 11.21 (11.425)                                                 | 9.42 (8.535)           | 9.78 (9.954)          | 9.45 (8.750)          | 9.97 (9.746)           |
| Median (min, max)                                              | 6.60 (0.10, 57.70)                                             | 6.30 (0.10, 53.70)     | 6.80 (0.10, 70.80)    | 6.45 (0.10, 47.20)    | 6.60 (0.10, 70.80)     |
| PASDAS                                                         |                                                                |                        |                       |                       |                        |
| n                                                              | 421                                                            | 428                    | 425                   | 421                   | 1695                   |
| Mean (SD)                                                      | 6.18 (1.064)                                                   | 6.15 (1.032)           | 6.31 (1.046)          | 6.17 (1.021)          | 6.20 (1.042)           |
| Median (min, max)                                              | 6.14 (2.73, 9.27)                                              | 6.07 (3.45, 9.97)      | 6.21 (2.92, 9.66)     | 6.15 (2.81, 9.40)     | 6.14 (2.73, 9.97)      |
| DAS28 (CRP)                                                    |                                                                |                        |                       |                       |                        |
| n                                                              | 421                                                            | 428                    | 425                   | 421                   | 1695                   |
| Mean (SD)                                                      | 4.90 (1.008)                                                   | 4.88 (1.063)           | 4.94 (1.045)          | 4.88 (0.995)          | 4.90 (1.028)           |
| Median (min, max)                                              | 4.86 (1.86, 7.81)                                              | 4.84 (2.01, 8.38)      | 4.87 (1.86, 8.17)     | 4.85 (1.84, 7.58)     | 4.85 (1.84, 8.38)      |
| Presence of ≥ 1 erosion, n (%)                                 |                                                                |                        |                       |                       |                        |
| Yes                                                            | 161 (38.1)                                                     | 183 (42.7)             | 165 (38.5)            | 159 (37.6)            | 668 (39.2)             |
| No                                                             | 227 (53.7)                                                     | 218 (50.8)             | 241 (56.2)            | 234 (55.3)            | 920 (54.0)             |
| Missing                                                        | 35 (8.3)                                                       | 28 (6.5)               | 23 (5.4)              | 30 (7.1)              | 116 (6.8)              |
| Presence of dactylitis (defined as LDI > 0)                    |                                                                |                        |                       |                       |                        |
| Yes                                                            | 126 (29.8)                                                     | 127 (29.6)             | 136 (31.7)            | 127 (30.0)            | 516 (30.3)             |
| No                                                             | 297 (70.2)                                                     | 302 (70.4)             | 293 (68.3)            | 296 (70.0)            | 1188 (69.7)            |
| Leeds Dactylitis Index (for baseline LDI > 0)                  | Leeds Dactylitis Index (for baseline LDI > 0)                  |                        |                       |                       |                        |
| 11                                                             | 126                                                            | 127                    | 136                   | 127                   | 516                    |
| Mean (SD)                                                      | 87.65 (114.764)                                                | 99.00 (163.109)        | 88.99 (106.495)       | 80.17 (132.391)       | 88.95 (130.428)        |
| Median (min, max)                                              | 39.11 (10.00, 600.04)                                          | 52.91 (10.00, 1310.57) | 55.96 (10.00, 726.44) | 34.92 (10.00, 893.63) | 41.88 (10.00, 1310.57) |
| Presence of enthesitis (defined as Total Enthesitis Count > 0) | Presence of enthesitis (defined as Total Enthesitis Count > 0) |                        |                       |                       |                        |
| Yes                                                            | 322 (76.1)                                                     | 330 (76.9)             | 333 (77.6)            | 331 (78.3)            | 1316 (77.2)            |
| No                                                             | 101 (23.9)                                                     | 99 (23.1)              | 96 (22.4)             | 92 (21.7)             | 388 (22.8)             |
| Leeds enthesitis Index (for baseline LEI >0)                   | Leeds enthesitis Index (for baseline LEI >0)                   |                        |                       |                       |                        |
|                                                                | 241                                                            | 265                    | 270                   | 267                   | 1043                   |
| Mean (SD)                                                      | 27(1.52)                                                       | 2.5 (1.42)             | 2.6(1.55)             | 2.6 (1.49)            | 2.6 (1.50)             |
| Medan (min,max)                                                | 2.0 (1.0,6.0)                                                  | 2.0 (1.0,6.0)          | 2.0(1.0,6.0)          | 2.0 (1.0,6.0)         | 2.0(1.0,6.0)           |
| Moming Stiffness score                                         |                                                                |                        |                       |                       |                        |
|                                                                | 420                                                            | 427                    | 423                   | 421                   | 1691                   |
| Mean (SD)                                                      | 5.29 (2.536)                                                   | 5.24(2.588)            | 5.65 (2.563)          | 5.34 (2.631)          | 5.38 (2.582)           |
| Median (min, max)                                              | 5.50 (0.00,10.00)                                              | 5.00 (0.00,10.00)      | 6.00 (0.00,10.00)     | 5:50 (0.00,10.00)     | 5.50 (0.00,10.00)      |
| Presence of psoniatic spondylitis                              |                                                                |                        |                       |                       |                        |
|                                                                | 130 (30.7)                                                     | 127 (29.6)             | 139 (32.4)            | 138 (32.6)            | 534 (31.3)             |
| ON                                                             | 293 (69.3)                                                     | 302(70.4)              | 290 (67.6)            | 285 (67.4)            | 1170 (68.7)            |
| ASDAS (CRP) (among subjects with psoriatic spondylits)         | ASDAS (CRP) (among subjects with psoriatic spondylits)         |                        |                       |                       |                        |
|                                                                | 130                                                            | 125                    | 138                   | LEI                   | 530                    |
| Mean (SD)                                                      | (6660)6                                                        | 3.24 (0.973)           | (1160)EE              | 3.41(0.911)           | 3.37(0.948)            |
| Median (min.max)                                               | 3.29 (1.19.5.92)                                               | 3.32 (0.76.5.75)       | 3.54(0.36.6.05)       | 3.37(0.97.5.75)       | 337 (0.36.6.05)        |

<div style=\"page-break-after: always\"></div>

| BASDAI(amongsubjectswithpsoriaticspondylitis)   | BASDAI(amongsubjectswithpsoriaticspondylitis)   | BASDAI(amongsubjectswithpsoriaticspondylitis)   | BASDAI(amongsubjectswithpsoriaticspondylitis)   | BASDAI(amongsubjectswithpsoriaticspondylitis)   | BASDAI(amongsubjectswithpsoriaticspondylitis)   |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| n                                               | 130                                             | 125                                             | 138                                             | 137                                             | 530                                             |
| Mean(SD)                                        | 5.81 (1.863)                                    | 5.69 (2.193)                                    | 5.94 (2.026)                                    | 5.91(2.119)                                     | 5.84(2.049)                                     |
| Median(min,max)                                 | 5.80(1.40.10.00)                                | 5.90(0.00,9.80)                                 | 6.10(1.20,9.50)                                 | 6.20(0.50,10.00)                                | 6.00(0.00,10.00)                                |
| SHS                                             |                                                 |                                                 |                                                 |                                                 |                                                 |
| 1n                                              | 388                                             | 401                                             | 406                                             | 393                                             | 1588                                            |
| Mean(SD)                                        | 13.32 (31.211)                                  | 14.97 (38.867)                                  | 13.14(42.448)                                   | 11.20 (24.539)                                  | 13.17 (35.052)                                  |
| Median(min,max)                                 | 1.00(0.00, 242.50)                              | 1.50(0.00,382.00)                               | 1.00(0.00.465.00)                               | 1.50(0.00,164.00)                               | 1.50(0.00.465.00)                               |

ADA=adalimumab;Anti-CCP=anti-cyclic citrullinated peptide;ASDAS=ankylosing SpondylitisDisease Activity Score;BASDAI=BathAnkylosingSpondylitisDisease Activity Index;BSA=body surface area;CRP=C-reactiveprotein;DAS28=DiseaseActivityScore(28joints);EOW=every otherweek:FAS=Full AnalysisSet;HAQDI=HealthAssessment Questionnaire-DisabilityIndex:hs-CRP=high-sensitivity C-reactiveprotein:LDI=LeedsDactylitisIndex;LEI=LeedsEnthesitisIndex; Max=maximum;min=minimum;NRS=Numerical RatingScale;PASDAS=PsoriaticArthritisDiseaseActivityScore;PASI=PsoniasisAreaSeverityIndex;

PGA=Physician's Global Assessment;Ps=psoriasis;PsA=psoriatic arthritis;PtGA=Patient's Global Assessment;QD=once daily,RF=rheumatoid factor;SD=standard deviation;SHS=Sharp/vanderHeijdeScore:sIGA=staticInvestigatorGlobalAssessment;SJC=SwollenJoint Count:TJC=TenderJoint Count a. MorningstiffnessscoreisthemeanofBASDAIquestions5and6

The study arms were overall similar regarding medical and surgical history.

## Prior use of DMARDs

All but 4 subjects had used one or more prior non-biologic DMARDs, including 65.6% of subjects who used 1 prior non-biologic DMARD, 25.4% who used 2 prior non-biologic DMARDs, and 8.8% who had used 3 or more prior non-biologic DMARDs. Methotrexate was the most frequently reported (91.7%) prior non-biologic DMARD overall.

## DMARD use concomitantly with study medication

Through Week 24, most subjects (99.0%) reported use of concomitant medications for any indication. The majority (82.3%) of subjects reported concomitant use of non-biologic DMARDs (Table 27), 66.3% of subjects reported concomitant use of NSAIDs, and a minority (20.0%) of subjects reported concomitant use of systemic corticosteroids.

Table 27 Concomitant Non-Biologic DMARDs up to Week 24 (FAS)

| GenericName（WHOQ12018)           | Placebo to UPA15mgQD （N=211） n（%）   | Placebo to UPA 30mgQD （N=212） n（%）   |            | A11 Placebo （N=423) n（）   | ADA 40mgEOW (N=429) n（%）   | 15mgQD （N=429) n（8）   | 30mgQD (N=423) n（%）   |         | Total （N=1704) n（%）   |
|----------------------------------|-------------------------------------|--------------------------------------|------------|---------------------------|----------------------------|-----------------------|-----------------------|---------|-----------------------|
| AnyConcomitantNon-BiologicDMARDs | 176(83.4)                           | 178(84.0)                            |            | 354 (83.7)                | 348 (81.1)                 | 355 (82.8)            | 346 (81.8)            |         | 1403(82.3)            |
| APREMILAST                       | 6 (4.3)                             | 4 (1.9)                              |            | 13 (3.1)                  | 6 (2.1)                    | 7 (1.6)               | 9 (2.1)               |         | 38(2.2)               |
| BUCILLAMINE                      | 0                                   | 0                                    |            | 0                         | 0                          | (0.2)                 | 0                     |         | 1(<0.1)               |
| CHLOROQUINE                      | 0                                   | 1 (0.5)                              |            | (0.2)                     | 1 (0.2)                    | 0                     | 2 (0.5)               |         | 4(0.2）                |
| CICLOSPORIN                      | 0                                   | 1 (0.5)                              |            | 1 (0.2)                   | 0                          | 1(0.2)                | 1 (0.2)               |         | 3(0.2）                |
| HYDROXYCHLOROQUINE               | (1.4)                               | 3 (1.4)                              |            | (1.4)                     | 7 (1.6)                    | (1.9)                 | 2                     | (0.5)   | 23(1.3)               |
| IGURATIMOD                       | 1(0.5)                              |                                      |            | 1(0.2）                    | 0                          | 1(0.2)                | 0                     |         | 2(0.1)                |
| LEFLUNOMIDE                      |                                     | 7(3.3)                               | 17(8.0)    | 24 (5.7)                  | 25(5.8)                    | 29(6.8)               | 29                    | (6.9)   | 107(6.3)              |
| METHOTREXATE                     |                                     | 151(71.6)                            | 145 (68.4) | 296 (70.0)                | 286(66.7)                  | 299 (69.7)            | 295                   | (69.7)  | 1176 (69.0)           |
| SULFASALAZINE                    |                                     | 21(10.0)                             | 22（10.4)   | 43(10.2)                  | 44(10.3)                   | 32(7.5)               |                       | 38(9.0) | 157(9.2)              |

Note:This table includes all medications administered up to Week 24 treatment period. Thus all medications with an end date prior to the first study drug dose or a start date after the first dose date at the Week 24 are excluded.For the subjects who discontinued before Week 24 first dose date,the medications taken withinl day of thelast dose of study drug for the subjects onupadacitinib and placebo,and within l4 day of the last doseof study drug for the subjects on adalimumab,are included.

Through Week 24, mean treatment compliance was 99.4% and 98.7% in the upadacitinib 15 mg and 30 mg groups, respectively, and 98.3% in the ADA group (after two outliers in the upadacitinib groups were excluded who discontinued study drug on the same day or one day after the baseline visit and did not return the study drug).

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint

The primary endpoint was the proportion of subjects achieving ACR20 response at Week 12. A statistically significantly greater percentage of subjects in the upadacitinib 15 mg QD and 30 mg QD groups demonstrated an ACR20 response at Week 12 compared with the placebo group based on the FAS using NRI (Table 28). Results from supplementary analyses using As Observed [AO] on the FAS and Non-Responder Imputation (NRI) on the Per Protocol Analysis Set were consistent with the primary analysis (data not shown in this AR for brevity). The results of the tipping point analysis for ACR20 at Week 12 showed that results of the primary efficacy analysis using NRI data handling are robust to missing data assumptions.

The difference in the response rate was retained up to Week 24, where after the response rate in subjects transferred from placebo arms to upadacitinib achieved the response rate of subjects who had used upadacitinib or adalimumab from the start of the study (Figure 26, results given as observed (AO)). Of note, the study is ongoing, and the results after Week 24 represent the subjects who had already reached the respective time points in the study.

Table 28 ACR20 response at Week 12 (FAS)

<!-- formula-not-decoded -->

| Imputation Treatment   | N   | Responder n（8）   | Response Rate （958CI）[A]   | -ResponseRateDiff（UPA-Placebo)- Point Estimate   | 958CI[B]    | P-value [C]   |
|------------------------|-----|------------------|----------------------------|--------------------------------------------------|-------------|---------------|
| NRI                    |     |                  |                            |                                                  |             |               |
| Placebo                | 423 | 153(36.2)        | 36.2(31.6,40.7)            |                                                  |             |               |
| ADA 40mgEOW            | 429 | 279(65.0)        | 65.0（60.5， 69.5)           |                                                  |             |               |
| UPA15mgQD              | 429 | 303(70.6)        | 70.6(66.3,74.9)            | 34.5                                             | (28.2,40.7) | <0.0001*      |
| UPA30mgQD              | 423 | 332(78.5)        | 78.5（74.6,82.4)            | 42.3                                             | (36.3,48.3) | <0.0001*      |
| AO                     |     |                  |                            |                                                  |             |               |
| Placebo                | 395 | 151(38.2)        | 38.2(33.4,43.0)            |                                                  |             |               |
| ADA 40mg EOW           | 407 | 275(67.6)        | 67.6 (63.0, 72.1)          |                                                  |             |               |
| UPA15mgQD              | 411 | 301(73.2)        | 73.2.（69.0, 77.5)          | 35.0                                             | (28.6,41.4) | <0.0001*      |
| UPA30mgQD              | 406 | 333(82.0)        | 82.0(78.3,85.8)            | 43.8                                             | (37.7,49.9) | <0.0001*      |
| Ao(withimputation)     |     |                  |                            |                                                  |             |               |
| Placebo                | 423 | 151(35.7)        | 35.7(31.1,40.3)            |                                                  |             |               |
| ADA 40mg EOW           | 429 | 275 (64.1)       | 64.1 (59.6, 68.6)          |                                                  |             |               |
| UPA15mgQD              | 429 | 301 (70.2)       | 70.2 (65.8, 74.5)          | 34.5                                             | (28.2,40.8) | <0.0001*      |
| UPA 30mgQD             | 423 | 333(78.7)        | 78.7 (74.8,82.6)           | 43.0                                             | (37.0,49.0) | <0.0001*      |

[A]: 95e CI for response rate are calculated based on normal approximation to the binomial distribution.

[B]:95e CIfor responserate difference arecalculated based on normalapproximation.

*Statistically significant at o.o5level.

[C]: Nominal p-value is constructed using Cochran-Mantel-Haenszel test adjusting for the main stratification factor of current DMARD use (yes/no).

<div style=\"page-break-after: always\"></div>

Figure 26 ACR20 response rate over time by treatment sequence - in Period 1 (AO, FAS)

<!-- image -->

Results on primary endpoint analysed for demographic subgroups based on age, sex, BMI, race, and geographic  region  were  consistent  with  the  primary  analysis.    Additionally,  the  results  for  different subgroups  based  on  disease  characteristics  showed  benefit  for  upadacitinib  compared  with  placebo (Figure 27). Neither the number of prior non-biologic DMARDs nor presence of concomitant non-biologic DMARDs had effect on efficacy.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 27 Forest Plot of ACR20 Response Rate (UPA vs PBO) at Week 12 by Disease Characteristic Subgroups (NRI) (FAS)

The ACR20 response rate was of the same order of magnitude in patients using and not using nonbiologic DMARDs concomitantly (Table 29).

Table 29 Subgroup Analysis of ACR20 Response Rate at Week 12 by Current Use of Non-Biologic DMARDs (NRI) (FAS)

| Subgroup Treatment            | 2T          | Responder n（8）                | Response Rate （958CI）[A]                        | -Response Rate Diff （UPA-Placebo) Point Estimate   | 958CI[B]    |
|-------------------------------|-------------|-------------------------------|-------------------------------------------------|----------------------------------------------------|-------------|
| Placebo ADA 40mgEOW UPA15mgQD | 347 347 353 | 130(37.5) 223(64.3) 255（72.2） | 37.5(32.4,42.6) 64.3(59.2,69.3) 72.2(67.6,76.9) |                                                    |             |
|                               |             |                               |                                                 | 34.8                                               | (27.9,41.7) |
| UPA30mgQD                     | 346         | 273(78.9)                     | 78.9(74.6,83.2)                                 | 41.4                                               | （34.8,48.1) |
| No                            | No          | No                            | No                                              | No                                                 | No          |
| Placebo                       | 76          | 23(30.3)                      | 30.3(19.9,40.6)                                 |                                                    |             |
| ADA 40mgEOW                   | 82          | 56 (68.3)                     | 68.3（58.2,78.4)                                 |                                                    |             |
| UPA 15mg QD                   | 76          | 48 (63.2)                     | 63.2（52.3,74.0)                                 | 32.9                                               | (17.9,47.9) |
| UPA 30mgQD                    | 77          | 59(76.6)                      | 76.6(67.2,86.1)                                 | 46.4                                               | (32.4,60.4) |

[A]: 9s&amp; CI for response rate are calculated based on normal approximation to the binomial distribution. [B]:95&amp; CI for response ratedifference are calculated based on normal approximation.

The proportion of responders and non-responders by study arms and subsets of non-responders is given in Table 30. The number of subjects classified as non-responders due to discontinuation of study drug or missing values was relatively small.

Table 30 ACR20 response at week 12 by intercurrent events (NRI; FAS)

<!-- formula-not-decoded -->

|                       | Placebo   | ADA40mgE0W   | 15mgQD    | 30QD      |
|-----------------------|-----------|--------------|-----------|-----------|
|                       | (N=423）   | （N=429）      | (N=429）   | (N=423）   |
| Responders,_n （）      | 153(36.2) | 279(65.0)    | 303(70.6) | 332(78.5) |
| Non-responders,n(e)   | 270(63.6) | 150(35.0)    | 126(29.4) | 91(21.5)  |
| Discontinuedstudydrug | 21 (5.0)  | 19(4.4)      | 16(3.7)   | 16(3.8)   |
| Missing measurements  | 8 (1.9)   | 1(0.2)       | 3 (0.7)   | 3(0.7)    |
| Observed              | 241(57.0) | 130.(30.3)   | 107(24.9) | 72(17.0)  |

## Key secondary endpoints

The results for key secondary endpoints versus placebo were consistent with that of the primary endpoint (Table 31). Upadacitinib 15 mg and 30 mg showed statistically significant efficacy compared with placebo for change in baseline in HAQ-DI, SF-36 PCS, and FACIT-F at Week 12, the proportion of subjects achieving sIGA 0/1 and PASI 75 at Week 16, the change from baseline in SHS and the proportion of subjects achieving MDA and resolution of enthesitis at Week 24. The difference between upadacitinib and placebo in improvement of dactylitis was no statistically significant.

The study also showed statistical significance for the NI of ACR20 response at Week 12 compared with ADA for both upadacitinib doses. The percentages of ADA effect preservation, which was calculated by (upadacitinib - placebo)/(ADA - placebo), were 119.4% (confidence interval [CI]: 98.0, 147.9) and 146.6% (CI: 122.8, 180.4) in upadacitinib 15 mg and 30 mg groups, respectively. For both upadacitinib doses, the lower bound of the 95% CI exceeded the pre-specified NI ratio of at least 50% of the placebo-subtracted ADA effect.

The response rate differences in ACR20 at Week 12 between the upadacitinib 15 and 30 mg doses and ADA using the FAS were 5.6% (CI: -0.6, 11.8) and 13.5% (CI: 7.5, 19.4), respectively. The analysis

<div style=\"page-break-after: always\"></div>

on the Per Protocol Analysis Set showed consistent results for both response rate difference and ADA effect preservation.

The ACR20 response was larger already at Week 2 in the upadacitinib arms vs. placebo.

The response in skin symptoms was assessed by the key secondary endpoints 75 percent improvement in Psoriasis Area and Severity Index (PASI75), static Investigator Global Assessment of Psoriasis (sIGA), and Self-Assessment of Psoriasis Symptoms (SAPS). All comparisons except the difference in SAPS response were statistically significant.

<div style=\"page-break-after: always\"></div>

Table 31 Summary of Key Secondary Endpoints (FAS)

|                                                                                                 |                                                                                                 |                                                                                                 | BetweenGroupDifference(Upadacitinib-Control)                                                    | BetweenGroupDifference(Upadacitinib-Control)                                                    | BetweenGroupDifference(Upadacitinib-Control)                                                    |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Endpointa Treatment                                                                             | N                                                                                               | WithinGroupPoint Estimate(95% CI)                                                               | PointEstinate (95%CI)                                                                           | Nominal P-Value                                                                                 | Adjusted P-Value                                                                                |
| ChangefrombaselineinHAQ-DIatWeek12                                                              |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 392                                                                                             | -0.14(-0.18,-0.09)                                                                              |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15mg                                                                               | 404                                                                                             | -0.42 (-0.47,-0.37)                                                                             | -0.28(-0.35,-0.22)                                                                              | <0.0001                                                                                         | <0.0001                                                                                         |
| Upadacitinib30mg                                                                                | 398                                                                                             | -0.47(-0.52.-0.42)                                                                              | -0.34(-0.40,-0.27)                                                                              | <0.0001                                                                                         | <0.0001                                                                                         |
| sIGA0/1 atWeek16b                                                                               |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 313                                                                                             | 10.9 (7.4,14.3)                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15mg                                                                               | 322                                                                                             | 41.9(36.5,47.3)                                                                                 | 31.1(24.7,37.5)                                                                                 | <0.0001                                                                                         | <0.0001                                                                                         |
| Upadacitinib30mg                                                                                | 324                                                                                             | 54.0(48.6,59.4)                                                                                 | 43.1(36.7,49.6)                                                                                 | <0.0001                                                                                         | <0.0001                                                                                         |
| PASI75responseatWeek16(forsubjectswith≥3%BSApsoriasis atbaseline)                               | PASI75responseatWeek16(forsubjectswith≥3%BSApsoriasis atbaseline)                               | PASI75responseatWeek16(forsubjectswith≥3%BSApsoriasis atbaseline)                               |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 211                                                                                             | 21.3 (15.8,26.9)                                                                                |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib15mg                                                                                | 214                                                                                             | 62.6 (56.1, 69.1)                                                                               | 41.3(32.8,49.8)                                                                                 | <0.0001                                                                                         | <0.0001                                                                                         |
| Upadacitinib 30 mg                                                                              | 210                                                                                             | 62.4 (55.8,68.9)                                                                                | 41.1(32.5,49.6)                                                                                 | <0.0001                                                                                         | <0.0001                                                                                         |
| ChangefrombaselineinSHSatWeek24                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 372                                                                                             | 0.25(0.13,0.36)                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15mg                                                                               | 391                                                                                             | -0.04(-0.16.0.07)                                                                               | -0.29 (-0.44,-0.14)                                                                             | 0.0002                                                                                          | 0.0004                                                                                          |
| Upadacitinib30mg                                                                                | 383                                                                                             | 0.03(-0.08.0.15)                                                                                | -0.21(-0.36,-0.06)                                                                              | 0.0069                                                                                          | 0.0069                                                                                          |
| Placebo                                                                                         | 423                                                                                             | 12.3 (9.2,15.4)                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15 mg                                                                              | 429                                                                                             | 36.6(32.0,41.2)                                                                                 | 24.3(18.8.29.8)                                                                                 | <0.0001                                                                                         | 0.0004                                                                                          |
| Upadacitinib30mg                                                                                | 423                                                                                             | 45.4(40.6,50.1)                                                                                 | 33.1(27.4.38.8)                                                                                 | <0.0001                                                                                         | 0.0069                                                                                          |
| Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) | Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) | Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) | Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) | Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) | Proportionof subjectswithresolutionofenthesitisatWeek24(LEI=0)(For subjectswith baseline LEI>0) |
| Placebo                                                                                         | 241                                                                                             | 32.4(26.5,38.3)                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15 mg                                                                              | 270                                                                                             | 53.7(47.8,59.7)                                                                                 | 21.3(13.0.29.7)                                                                                 | <0.0001                                                                                         | 0.0004                                                                                          |
| Upadacitinib 30mg                                                                               | 267                                                                                             | 57.7(51.8,63.6)                                                                                 | 25.3(16.9.33.7)                                                                                 | <0.0001                                                                                         | 0.0069                                                                                          |
| ACR20responserateatWeek12(NIofUPAvs.ADA)                                                        |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 423                                                                                             | 36.2 (31.6,40.7)                                                                                |                                                                                                 |                                                                                                 |                                                                                                 |
| ADA40mg                                                                                         | 429                                                                                             | 65.0 (60.5,69.5)                                                                                |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib 15mg                                                                               | 429                                                                                             | 70.6 (66.3,74.9)                                                                                | 119.381(97.987.147.942)                                                                         | <0.0001                                                                                         | 0.0004                                                                                          |
| Upadacitinib30mg                                                                                | 423                                                                                             | 78.5(74.6.82.4)                                                                                 | 146.604(122.817.180.398)                                                                        | <0.0001                                                                                         | 0.0069                                                                                          |
| SF-36PCSchangefrombaselineatWeek12                                                              |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Placebo                                                                                         | 394                                                                                             | 3.19(2.41,3.96)                                                                                 |                                                                                                 |                                                                                                 |                                                                                                 |
| Upadacitinib15mg                                                                                | 405                                                                                             | 7.86(7.09,8.63)                                                                                 | 4.67 (3.67,5.67)                                                                                | <0.0001                                                                                         | 0.0004                                                                                          |
| Upadacitinib30mg                                                                                | 398                                                                                             | 8.90(8.13,9.68)                                                                                 | 5.72(4.71,6.72)                                                                                 | <0.0001                                                                                         | 0.0069                                                                                          |

<div style=\"page-break-after: always\"></div>

| Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                                   | Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                                   | Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                                   | Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                                   | Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                   | Changefrombaseline inHAQ-DI atWeek12（superiority ofUPAvsADA)                   |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Placebo                                                                                        | 392                                                                                            | -0.14(-0.18,-0.09)                                                                             |                                                                                                |                                                                                |                                                                                |
| ADA40mg                                                                                        | 406                                                                                            | -0.34(-0.38,-0.29)                                                                             |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 404                                                                                            | -0.42(-0.47,-0.37)                                                                             | -0.08(-0.15,-0.01)                                                                             | 0.0162 (vs.ADA)                                                                | 0.8970                                                                         |
| Upadacitinib30mg                                                                               | 398                                                                                            | -0.47(-0.52.-0.42)                                                                             | -0.14(-0.20,-0.07)                                                                             | <0.0001(vs. ADA)                                                               | 0.8970                                                                         |
| SAPSchangefrombaseline atWeek16                                                                |                                                                                                |                                                                                                |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 388                                                                                            | -8.2(-10.2,-6.3)                                                                               |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 396                                                                                            | -25.3(-27.3,-23.4)                                                                             | -17.1(-19.6,-14.6)                                                                             | <0.0001                                                                        | 0.8970                                                                         |
| Upadacitinib30mg                                                                               | 395                                                                                            | -28.1(-30.0,-26.1)                                                                             | -19.8(-22.3,-17.3)                                                                             | <0.0001                                                                        | 0.8970                                                                         |
| ACR50responserateatWeek12                                                                      |                                                                                                |                                                                                                |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 423                                                                                            | 13.2(10.0.16.5)                                                                                |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 429                                                                                            | 37.5 (32.9.42.1)                                                                               | 24.3 (18.7,29.9)                                                                               | <0.0001                                                                        |                                                                                |
| Upadacitinib30mg                                                                               | 423                                                                                            | 51.8 (47.0,56.5)                                                                               | 38.5 (32.8,44.3)                                                                               | <0.0001                                                                        |                                                                                |
| ACR70responserateatWeek12                                                                      |                                                                                                |                                                                                                |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 423                                                                                            | 2.4(0.9,3.8)                                                                                   |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 429                                                                                            | 15.6(12.2.19.1)                                                                                | 13.3(9.5,17.0)                                                                                 | <0.0001                                                                        |                                                                                |
| Upadacitinib30mg                                                                               | 423                                                                                            | 25.3(21.2.29.4)                                                                                | 22.9 (18.5.27.3)                                                                               | <0.0001                                                                        |                                                                                |
| FACIT-FchangefrombaselineatWeek12                                                              |                                                                                                |                                                                                                |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 394                                                                                            | 2.8 (1.9,3.7)                                                                                  |                                                                                                |                                                                                |                                                                                |
| Upadacitinib 15 mg                                                                             | 404                                                                                            | 6.3(5.4,7.2)                                                                                   | 3.5 (2.4.4.7)                                                                                  | <0.0001                                                                        | 0.0004                                                                         |
| Upadacitinib30mg                                                                               | 398                                                                                            | 7.1(6.2.8.0)                                                                                   | 4.3 (3.1,5.5)                                                                                  | <0.0001                                                                        | 0.0069                                                                         |
| ACR20responserateatWeek12(superiorityofUPAvsADA)                                               | ACR20responserateatWeek12(superiorityofUPAvsADA)                                               | ACR20responserateatWeek12(superiorityofUPAvsADA)                                               |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 423                                                                                            | 36.2(31.6,40.7)                                                                                |                                                                                                |                                                                                |                                                                                |
| ADA40mg                                                                                        | 429                                                                                            | 65.0 (60.5,69.5)                                                                               |                                                                                                |                                                                                |                                                                                |
| Upadacitinib 15 mg                                                                             | 429                                                                                            | 70.6(66.3.74.9)                                                                                | 5.6(-0.6,11.8)                                                                                 | 0.0815(VS.ADA)                                                                 | 0.0815                                                                         |
| Upadacitinib30mg                                                                               | 423                                                                                            | 78.5(74.6.82.4)                                                                                | 13.5(7.5,19.4)                                                                                 | <0.0001(vs. ADA)                                                               | 0.0069                                                                         |
| Proportionof subjectswithresolutionof dactylitis atWeek24(LDI=0)(ForsubjectswithbaselineLDI>0) | Proportionof subjectswithresolutionof dactylitis atWeek24(LDI=0)(ForsubjectswithbaselineLDI>0) | Proportionof subjectswithresolutionof dactylitis atWeek24(LDI=0)(ForsubjectswithbaselineLDI>0) | Proportionof subjectswithresolutionof dactylitis atWeek24(LDI=0)(ForsubjectswithbaselineLDI>0) |                                                                                |                                                                                |
| Placebo                                                                                        | 126                                                                                            | 39.7(31.1,48.2)                                                                                |                                                                                                |                                                                                |                                                                                |
| Upadacitinib 15 mg                                                                             | 136                                                                                            | 76.5(69.3,83.6)                                                                                | 36.8 (25.7,47.9)                                                                               | <0.0001                                                                        | 0.0815                                                                         |
| Upadacitinib30mg                                                                               | 127                                                                                            | 79.5(72.5.86.5)                                                                                | 39.8 (28.8.50.9)                                                                               | <0.0001                                                                        | 0.0815                                                                         |
| ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA)                 | ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA)                 | ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA)                 | ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA)                 | ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA) | ChangefrombaselineinPatient'sAssessmentofPain atWeek12(superiorityof UPAvsADA) |
| Placebo                                                                                        | 392                                                                                            | -0.9(-1.2,-0.7)                                                                                |                                                                                                |                                                                                |                                                                                |
| ADA40mg                                                                                        | 406                                                                                            | -2.3(-2.5,-2.1)                                                                                |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 404                                                                                            | -2.3(-2.5,-2.0)                                                                                | 0.0(-0.3,0.3)                                                                                  | 0.8970(Vs.ADA)                                                                 | 0.8970                                                                         |
| Upadacitinib 30 mg                                                                             | 398                                                                                            | -2.7(-2.9.-2.5)                                                                                | -0.5(-0.7,-0.2)                                                                                | 0.0028(Vs.ADA)                                                                 | 0.0815                                                                         |
| ACR20responserate atWeek2                                                                      |                                                                                                |                                                                                                |                                                                                                |                                                                                |                                                                                |
| Placebo                                                                                        | 423                                                                                            | 12.1 (9.0.15.2)                                                                                |                                                                                                |                                                                                |                                                                                |
| Upadacitinib15mg                                                                               | 429                                                                                            | 28.2(23.9,32.5)                                                                                | 16.1(10.9,21.4)                                                                                | <0.0001                                                                        |                                                                                |
| Upadacitinib30mg                                                                               | 423                                                                                            | 38.3 (33.7,42.9)                                                                               | 26.2 (20.7,31.8)                                                                               | <0.0001                                                                        |                                                                                |

ACR20/50/70=American College ofRheumatology 20%,50%,70%response;ADA=adalimumab;ANCOVA= analysisofcovariance;BSA=body surface area;

CI=confidenceinterval;FACIT-F=Functional Assessment of ChronicIllnessTherapy-Fatigue;FAS=Full AnalysisSet;HAQ-DI=HealthAssessment Questionnaire-

DisabilityIndex;LDI=LeedsDactylitisIndex,LEI=LeedsEnthesitisIndex;MDA=minimal disease activity;MMRM=Mixed-EffectsModelRepeatedMeasures;NI=noninferiority;NRI=Non-ResponderImputation;PASI=PsoriasisAreaSeverityIndex;SAPS=Self-Assessment of PsoriasisSymptoms;SF-36PCS=36-Item ShortFormHealth SurveyPhysical ComponentScore;SHS=Sharp/van derHeijdeScore;sIGA=StaticInvestigator GlobalAssessment ofPsoriasis;UPA=upadacitinib a. Resultsforbinary endpointsexceptforMDAatWeek24arebasedonNRI.ResultsforMDA,resolutionofenthesitis,andresolutionofdactylitisatWeek24arebasedon NRIwithadditionalrescuehandling,wheresubjectsrescuedatWeek16isimputedasnon-responders.ResultsforSHSwerebasedonANCOVAwithlinearextrapolation formissingdata andrescuehandling.ResultsforothercontinuousendpointswerebasedonMMRMmodel.

b. sIGA0/1forsubjectswithbaselinesIGA≥2.

C. NItestofUPAvs.ADAwasbasedonthreearmNItestingaimingUPApreservesatleast50%oftheplacebo-subtractedADAeffect.

AdjustedP-valuesareprovidedformultiplicity-adjustedendpoints.

In subsequent testing of superiority versus ADA, upadacitinib 30 mg, but not 15 mg, showed superiority versus ADA in the primary endpoint ACR20 at Week 12, with ACR20 response rates of 65.0 (ADA), 70.6 (upadacitinib 15 mg, adjusted P-value against ADA 0.0815), and 78.5 (upadacitinib 30 mg, adj. P-value 0.0069).

<div style=\"page-break-after: always\"></div>

## Additional efficacy endpoints

## Structural changes

Analyses of structural joint damage were conducted based on linear extrapolation as the primary analysis and AO data as a supplementary analysis. In addition, a sensitivity analysis was conducted using a random coefficient model.

At Week 24, inhibition of radiographic progression was observed in the upadacitinib 15 mg and 30 mg groups compared with the placebo group, as shown by a statistically smaller mean increase from baseline in SHS (equivalent to modified Total Sharp Score [mTSS], key secondary endpoint) and nominally smaller increase in Joint Erosion Score and JSN Score at Week 24 (additional secondary endpoints). Consistent results were obtained by linear extrapolation and AO (Table 32). The Random coefficient model gave similar results.

<div style=\"page-break-after: always\"></div>

Table 32 Summary  of  Change  from  Baseline  in  SHS,  Joint  Erosion  Score,  and  JSN  Score  at Week 24 (Linear Extrapolation and AO; FAS)

|                     |     |               |            | ChangefromBaseline   | ChangefromBaseline                            | ChangefromBaseline                            |
|---------------------|-----|---------------|------------|----------------------|-----------------------------------------------|-----------------------------------------------|
| Measure Imputation  |     |               |            | Within Group         | BetweenGroupComparison (Upadacitinib-Placebo) | BetweenGroupComparison (Upadacitinib-Placebo) |
| Treatment           | N   | Baseline Mean | Visit Mean | LS Mean (95%CI)      | LSMeanDiff(95%CI)a                            | P-Valuea                                      |
| SHS                 |     |               |            |                      |                                               |                                               |
| LinearExtrapolation |     |               |            |                      |                                               |                                               |
| Placebo             | 372 | 13.05         | 13.31      | 0.25(0.13,0.36)      |                                               |                                               |
| ADA40mg             | 384 | 14.89         | 14.92      | 0.01 (-0.11,0.13)    |                                               |                                               |
| Upadacitinib 15mg   | 391 | 13.44         | 13.42      | -0.04(-0.16,0.07)    | 0.29(-0.44,-0.14)                             | 0.0002                                        |
| Upadacitinib 30mg   | 383 | 11.36         | 11.41      | 0.03(-0.08,0.15)     | -0.21(-0.36,-0.06)                            | 0.0069                                        |
| AO                  |     |               |            |                      |                                               |                                               |
| Placebo             | 365 | 13.27         | 13.53      | 0.24(0.12.0.35)      |                                               |                                               |
| ADA40mg             | 391 | 15.31         | 15.35      | 0.01(-0.10,0.13)     |                                               |                                               |
| Upadacitinib 15mg   | 387 | 13.58         | 13.55      | -0.05(-0.16,0.07)    | -0.28(-0.43,-0.14)                            | 0.0002                                        |
| Upadacitinib 30mg   | 381 | 11.22         | 11.27      | 0.03(-0.08,0.14)     | -0.21(-0.35,-0.06)                            | 0.0061                                        |
| JointErosion Score  |     |               |            |                      |                                               |                                               |
| LinearExtrapolation |     |               |            |                      |                                               |                                               |
| Placebo             | 372 | 5.95          | 6.07       | 0.12 (0.06.0.17)     |                                               |                                               |
| ADA40mg             | 384 | 6.72          | 6.74       | 0.01(-0.04.0.07)     |                                               |                                               |
| Upadacitinib 15 mg  | 391 | 6.19          | 6.16       | -0.03 (-0.08,0.02)   | -0.15(-0.22,-0.08)                            | <0.0001                                       |
| Upadacitinib 30mg   | 383 | 5.00          | 5.03       | 0.03(-0.03.0.08)     | -0.09(-0.16,-0.02)                            | 0.0105                                        |
| AO                  |     |               |            |                      |                                               |                                               |
| Placebo             | 365 | 6.05          | 6.17       | 0.12 (0.06.0.17)     |                                               |                                               |
| ADA40mg             | 391 | 6.88          | 6.90       | 0.01(-0.04,0.07)     |                                               |                                               |
| Upadacitinib 15 mg  | 387 | 6.26          | 6.23       | -0.03(-0.08,0.02)    | -0.15(-0.22,-0.08)                            | <0.0001                                       |
| Upadacitinib30mg    | 381 | 4.92          | 4.96       | 0.03(-0.02,0.08)     | -0.09(-0.15,-0.02)                            | 0.0121                                        |
| JSN                 |     |               |            |                      |                                               |                                               |
| LinearExtrapolation |     |               |            |                      |                                               |                                               |
| Placebo             | 372 | 7.10          | 7.22       | 0.10(0.04,0.17)      |                                               |                                               |
| ADA40mg             | 384 | 8.17          | 8.16       | -0.02(-0.09,0.04)    |                                               |                                               |
| Upadacitinib 15mg   | 391 | 7.24          | 7.25       | 0.00(-0.07,0.06)     | -0.11(-0.19,-0.02)                            | 0.0159                                        |
| Upadacitinib 30mg   | 383 | 6.35          | 6.38       | 0.01(-0.06,0.08)     | -0.09(-0.18,-0.01)                            | 0.0325                                        |
| AO                  |     |               |            |                      |                                               |                                               |
| Placebo             | 365 | 7.22          | 7.33       | 0.10(0.03,0.16)      |                                               |                                               |
| ADA40mg             | 391 | 8.44          | 8.43       | -0.02(-0.08,0.04)    |                                               |                                               |
| Upadacitinib 15 mg  | 387 | 7.31          | 7.32       | 0.00(-0.06,0.06)     | -0.10(-0.18,-0.02)                            | 0.0169                                        |
| Upadacitinib 30 mg  | 381 | 6.29          | 6.31       | 0.00(-0.06,0.07)     | -0.09(-0.17,-0.01)                            | 0.0251                                        |

ANCOVA=analysis of covariance;AO=AsObserved;CI=confidenceinterval;Diff =difference;DMARD=disease-modifyingantirheumaticdrug;EOW=every other week;

a. WithingroupLSmeanand95%CI,andbetweengroupLSmeandifferenceand95%CIandnominalp-valuewerebasedonANCOVAmodelincludingtreatment andthe stratificationfactor currentDMARDuse(yes/no)asfixedfactors andbaselinevalueascovariate.

Inhibition of progression of structural joint damage was also measured by the proportion of subjects with no radiographic progression , defined in 2 ways: as a change from baseline in SHS ≤ 0, and as ≤ 0.5 (additional secondary endpoints) (table 33). It is noteworthy that the nominal difference in proportion of responders to upadacitinib and placebo was less than 5 %.

No difference was seen between upadacitinib and ADA in any of the investigated parameters for structural progression (Table 33).

<div style=\"page-break-after: always\"></div>

Table 33 Proportion of Subjects with No Radiographic Progression (Change from Baseline in SHS ≤ 0 or SHS ≤ 0.5) at Week 24 (FAS)

| Endpoint Definition   |     |                 | Response Rate Difference (Upadacitinib-Placebo)   | Response Rate Difference (Upadacitinib-Placebo)   | ResponseRateDifference (Upadacitinib-Adalimumab)   | ResponseRateDifference (Upadacitinib-Adalimumab)   |
|-----------------------|-----|-----------------|---------------------------------------------------|---------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Imputation Treatment  | N   | Responder n (%) | PointEstinate (95%CI）a                            | P-ralueb                                          | PointEstimate (95%CTa                              | P-valueb                                           |
| SHS0                  |     |                 |                                                   |                                                   |                                                    |                                                    |
| Linear Extrapolation  |     |                 |                                                   |                                                   |                                                    |                                                    |
| Placebo               | 372 | 332(89.2)       |                                                   |                                                   |                                                    |                                                    |
| Adalimumab40mgeow     | 384 | 357(93.0)       |                                                   |                                                   |                                                    |                                                    |
| Upadacitinib 15mg QD  | 165 | 365(93.4)       | 4.1(0.1,8.1)                                      | 0.0448                                            | 0.4(-32,3.9)                                       | 0.8352                                             |
| Upadacitinib 30mg QD  | 383 | 358(93.5)       | 4.2(0.2,8.2)                                      | 0.0401                                            | 0.5(-3.1,4.1)                                      | 0.7815                                             |
| As Observed           |     |                 |                                                   |                                                   |                                                    |                                                    |
| Placebo               | 365 | 324(88.8)       |                                                   |                                                   |                                                    |                                                    |
| Adalimumab40 mgeow    |     | 362(92.6)       |                                                   |                                                   |                                                    |                                                    |
| Upadacitinib15mgQD    | 387 | 360(93.0)       | 4.3(0.1,8.4)                                      | 0.0427                                            | 0.4(-32.4.1)                                       | 0.8202                                             |
| Upadacitinib 30mgQD   | 381 | 356(93.4)       | 4.7(0.6.8.8)                                      | 0.0263                                            | 0.9(-2.7,4.5)                                      | 0.6378                                             |
| SHS≤0.5               |     |                 |                                                   |                                                   |                                                    |                                                    |
| Linear Extrapolation  |     |                 |                                                   |                                                   |                                                    |                                                    |
| Placebo               | 372 | 342(91.9)       |                                                   |                                                   |                                                    |                                                    |
| Adalimumab40 mgeow    | 384 | 364(94.8)       |                                                   |                                                   |                                                    |                                                    |
| Upadacitinib15mgQD    | 391 | 376(96.2)       | 4.2(0.9,7.6)                                      | 0.0135                                            | 1.4(-1.6,4.3)                                      | 0.3582                                             |
| Upadacitinib 30mgQD   | 383 | 364(95.0)       | 3.1(-0.4,6.6)                                     | 0.0861                                            | 0.2(-2.9,3.4)                                      | 0.8753                                             |
| As Observed           |     |                 |                                                   |                                                   |                                                    |                                                    |
| Placebo               | 365 | 336 (92.1)      |                                                   |                                                   |                                                    |                                                    |
| Adalimumab40mgeow     | 391 | 371 (94.9)      |                                                   |                                                   |                                                    |                                                    |
| Upadacitinib 15 mg QD | 387 | 371 (95.9)      | 3.8 (0.4, 7.2)                                    | 0.0283                                            | 1.0 (-2.0, 3.9)                                    | 0.5199                                             |
| Upadacitinib 30 mg QD | 381 | 363 (95.3)      | 3.2 (-0.3, 6.7)                                   | 0.0745                                            | 0.4 (-2.7, 3.4)                                    | 0.7967                                             |

a. 95% CIs for response rate difference were calculated based on normal approximation.

b. Nominal p-value was constructed using CMH test adjusting for the main stratification factor of current DMARD use (yes/no).

## Components of ACR response and ACR response over time

Components of ACR20/50/70 response include TJC68, SJC66, HAQ-DI, PtGA, PGA, Patient's Assessment of Pain, and hsCRP. All of these additional efficacy endpoints demonstrated a greater numerical improvement from baseline in all components of the ACR20/50/70 response at Week 12 compared with placebo. Further improvements were generally observed between Week 12 and Week 24 for subjects in both upadacitinib 15 mg QD and 30 mg QD groups (Table 34). The observed improvement was in general slightly larger with the 30 mg QD dose.

<div style=\"page-break-after: always\"></div>

Table 34 Change from Baseline at Week 12 in Components of ACR20/50/70 Response (MMRM;

|                                  | M15-572 (Non-Biologic DMARD-IR)   | M15-572 (Non-Biologic DMARD-IR)   | M15-572 (Non-Biologic DMARD-IR)                                               | M15-572 (Non-Biologic DMARD-IR)                                             |
|----------------------------------|-----------------------------------|-----------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| ACR Component                    | Placebo                           | Adalimumab 40 mg eow              | Upadacitinib 15 mg QD                                                         | Upadacitinib 30 mg                                                          |
| TJC68                            |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -7.1                              | -10.3                             | -11.3 < 0.0001 (vs. placebo)                                                  | -12.6 <0.0001 (vs. placebo) 0.1590 (vs. adalimumab) 0.0007 (vs. adalimumab) |
| SJC66                            |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -5.3                              | -7.6                              | -7.9 < 0.0001 (vs. placebo)                                                   | -8.0 < 0.0001 (vs. placebo) 0.4167 (vs.adalimumab) 0.2389 (vs. adalimumab)  |
| HAQ-DI                           |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -0.13                             | -0.34                             | -0.42 < 0.0001 (vs. placebo) 0.0152 (vs. adalimumab)< 0.0001 (vs. adalimumab) | -0.47 < 0.0001 (vs. placebo)                                                |
| PtGA NRS                         |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -1.2                              | -2.6                              | -2.7 < 0.0001 (vs. placebo) 0.6300 (vs. adalimumab) 0.0004 (vs. adalimumab)   | -3.1 < 0.0001 (vs. placebo)                                                 |
| PGA NRS                          |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -2.1                              | -3.4                              | -3.6 < 0.0001 (vs. placebo)                                                   | -3.8 < 0.0001 (vs. placebo) 0.2590 (vs. adalimumab) 0.0017 (vs. adalimumab) |
| Patient's Assessment of Pain NRS |                                   |                                   |                                                                               |                                                                             |
| LS mean P-value vs. control      | -0.9                              | -2.3                              | -2.3 < 0.0001 (vs. placebo) 0.9005(vs.adalimumab)0.0025(vs.adalimumab)        | -2.7 < 0.0001 (vs. placebo)                                                 |
| hsCRP (mg/L)                     |                                   |                                   |                                                                               |                                                                             |
| LS mean                          |                                   | -7.6                              | -7.1 < 0.0001 (vs. placebo)                                                   | -7.4 < 0.0001 (vs. placebo)                                                 |
| P-value vs. control              | -1.3                              |                                   | 0.5641 (vs. adalimumab) 0.8391 (vs. adalimumab)                               |                                                                             |

P-values are for comparisons between upadacitinib groups and placebo and between upadacitinib groups and adalimumab. LS mean is the within group LS mean for change from baseline.

Treatment with upadacitinib 15 mg QD demonstrated a statistically significantly greater improvement from baseline in HAQ-DI at Week 12 and Week 24, PtGA at Week 24, and numerical larger improvement in Patient's Assessment of Pain at Week 24 compared with the adalimumab group (nominal P &lt; 0.05).

## Additional efficacy endpoints

A great number of other additional efficacy endpoints were studied. The results of these measures of musculoskeletal manifestations (joint, dactylitis, enthesitis, spinal), structural join damage, skin manifestations, physical function, quality of life (QoL) and other patient reported outcomes (PROs) and comprehensive disease control (measured by MDA percentage) are given in table 35. Most comparisons were not multiplicity controlled. The results that were statistically significant in the multiplicity-controlled analysis for upadacitinib vs. placebo are marked with the symbol '~'.

<div style=\"page-break-after: always\"></div>

Similar improvement was seen with upadacitinib 15 mg and adalimumab on the musculoskeletal manifestations of PsA. Upadacitinib 15 mg was more efficacious than placebo in all comparisons.

All measures of skin manifestations were nominally alleviated by upadacitinib 15 mg when compared with placebo.  Significantly better results with upadacitinib than placebo groups, respectively, were obtained at Week 16 by multiplicity-controlled analysis in PASI75: 62.6 % vs. 21.3 %, and sIGA: 0/1 41.9% vs. 10.9%.

In the QoL measures and other PROs, the results were uniformly nominally better in the upadacitinib than placebo group. Multiplicity-controlled analyses gave significantly better results for the upadacitinib 15 mg vs. placebo group, respectively, in the following measures: ΔSF -36 PCS (LS mean 7.86 vs. 3.19) and ΔFACIT -F (LS mean 6.3 vs. 2.8).

In subjects determined by the investigator to have psoriatic spondylitis at baseline (534/1704, 31 %), subjects in the upadacitinib 15 mg group had greater improvement from baseline in BASDAI and ASDAS, and a greater proportion of subjects achieved BASDAI 50, ASDAS inactive disease, ASDAS major improvement, and ASDAS clinically important improvement at Week 12 and Week 24 compared with subjects in the placebo group, with nominal P-values &lt; 0.05. Further improvement in BASDAI and ASDAS scores were observed at Week 24 for both the upadacitinib 15 mg and 30 mg groups. The subjects with psoriatic spondylitis at baseline in the upadacitinib 15 mg group also showed greater nominal improvement from baseline in BASDAI and ASDAS and a greater proportion of subjects achieved ASDAS major improvement and clinically important improvement at Week 24 compared with subjects in the ADA group. The mean baseline BASDAI values were in the range of 5.69 to 5.98 in patients assessed by the investigator to have psoriatic spondylitis. At Week 12, the LS mean change in BASDAI was -1.00 (-1.39, -0.62) in the placebo arm,  -2.35 (-2.74, -1.96) in the adalimumab arm, and  -2.20 (-2.57, -1.82) in the upadacitinib 15 mg arm. ASDAI showed improvement as well.

Similarly, the results on morning stiffness as measured by overall morning stiffness (mean of BASDAI Questions 5 and 6), morning stiffness severity, and morning stiffness duration at Week 12 and through Week 24 was nominally better in the upadacitinib group compared with subjects in the placebo group (nominal P &lt; 0.05). Subjects in the upadacitinib 30 mg group at Weeks 12 and 24 and subjects in the upadacitinib 15 mg group at Week 12 had greater improvement in overall morning stiffness, morning stiffness severity, and morning stiffness duration compared to the ADA group (nominal P &lt; 0.05).

<div style=\"page-break-after: always\"></div>

Table 35 Select Efficacy Results Across PsA Domains Through Week 56 for Study M15-572 (FAS)

| Domain Outcome                                                        | PBO   | ADA     | UPA 15 mg   | UPA 30 mg   | PBO   | ADA     | UPA 15 mg   | UPA 30 mg   | PBO to UPA 15 mga   | PBO to UPA 30 mg2   | ADA      | UPA 15 mg   | UPA 30 mg   |
|-----------------------------------------------------------------------|-------|---------|-------------|-------------|-------|---------|-------------|-------------|---------------------|---------------------|----------|-------------|-------------|
| Musculoskeletalmanifestations (joint, dactylitis, enthesitis, spinal) |       | Week 12 | Week 12     | Week 12     |       | Week 24 | Week 24     | Week 24     | Week 56b            | Week 56b            | Week 56b | Week 56b    | Week 56b    |
| ACR20 (%)                                                             | 36.2  | 65.0    | 70.6~       | 78.5~&      | 45.2  | 67.1    | 73.4*#      | 78.5*#      | 82.3                | 93.5                | 82.4     | 83.5        | 85.3        |
| ACR50 (%)                                                             | 13.2  | 37.5    | 37.5*       | 51.8*#      | 18.9  | 44.3    | 52.4*#      | 60.5*#      | 62.0                | 76.9                | 61.1     | 67.6        | 69.4        |
| ACR70 (%)                                                             | 2.4   | 13.8    | 15.6*       | 25.3*#      | 5.2   | 22.6    | 28.7*#      | 36.4*#      | 31.6                | 41.8                | 36.9     | 44.1        | 48.2        |
| Modified PsARC (%)                                                    | 54.6  | 75.5    | 78.3*       | 83.5*#      | 59.3  | 76.7    | 83.7*#      | 82.0*       | 92.4                | 93.7                | 88.6     | 90.0        | 92.9        |
| △DAPSA (LS mean)                                                      | -15.7 | -30.0   | -30.7*      | -33.9*#     | -20.6 | -33.6   | -36.4*#     | -38.0*#     | -38.9               | -44.3               | -39.7    | -40.9       | -42.5       |
| △PASDAS (LS mean)                                                     | -1.09 | -2.13   | -2.29*      | -2.61*#     | -1.51 | -2.58   | -2.95*#     | -3.13*#     | -3.06               | -3.56               | -3.17    | -3.40       | -3.53       |
| △DAS28 (CRP) (LS mean)                                                | -0.90 | -1.68   | -1.86*#     | -2.13*#     | -1.21 | -2.01   | -2.32*#     | -2.45*#     | -2.38               | -2.82               | -2.42    | -2.54       | -2.65       |
| △Patient's Assessment of Pain (NRS) (LS mean)                         | -0.9  | -2.3    | -2.3*       | -2.7*#      | -1.4  | -2.6    | -3.0*#      | -3.2*#      | -3.2                | -3.8                | -3.2     | -3.4        | -3.4        |
| Resolution of dactylitis (LDI = 0) (%)                                | 42.1  | 71.7    | 73.5*       | 79.5*       | 39.7  | 74.0    | 76.5*       | 79.5*       | 80.8                | 100                 | 91.4     | 94.4        | 96.2        |
| Resolution of enthesitis (LEI = 0) (%)d                               | 32.8  | 46.8    | 47.4*       | 51.3*       | 32.4  | 47.2    | 53.7~       | 57.7~,#     | 61.4                | 75.6                | 73.7     | 72.8        | 73.5        |
| Resolution of enthesitis (SPARCC Enthesitis Index =0) (%)             | 27.6  | 39.6    | 36.3*       | 43.4*       | 28.2  | 43.0    | 47.6*       | 53.2*#      | 66.7                | 70.0                | 67.9     | 62.8        | 70.0        |
| △BASDAI (LS mean)f                                                    | -1.00 | -2.35   | -2.20*      | -2.60*      | -1.70 | -2.55   | -3.12*#     | -3.16*#     | -2.58               | -2.95               | -3.15    | -3.37       | -3.55       |
| BASDAI 50 (%)f                                                        | 15.4  | 42.5    | 37.4*       | 50.7*       | 26.9  | 44.1    | 59.0*#      | 52.9*       | 55.0                | 50.0                | 60.4     | 72.0        | 75.0        |
| ASDAS (LS mean)f                                                      | -0.38 | -1.47   | -1.40*      | -1.62*      | -0.70 | -1.41   | -1.76*#     | -1.92*#     | -1.55               | -1.95               | -1.81    | -1.88       | -2.18       |
| ASDAS inactive disease (%)f                                           | 6.2   | 29.9    | 23.0*       | 34.1*       | 13.1  | 35.4    | 41.7*       | 49.3*#      | 31.6                | 42.9                | 47.8     | 54.2        | 60.4        |
| Structural joint damage                                               |       | Week 12 | Week 12     | Week 12     |       | Week 24 | Week 24     | Week 24     | Week 56b            | Week 56b            | Week 56b | Week 56b    | Week 56b    |
| △SHS (LS mean)                                                        |       |         |             |             | 0.25  | 0.01    | -0.04~      | 0.03~       |                     | \"                   |          |             |             |
| Joint erosion score (LS mean)                                         |       |         |             |             | 0.12  | 0.01    | -0.03*      | 0.03*       |                     |                     |          |             |             |
| △JSN score (LS mean)                                                  |       |         |             |             | 0.10  | -0.02   | -0.00*      | 0.01*       |                     |                     |          |             |             |
| No radiographic progression (△SHS ≤0) (%)                             |       |         |             |             | 89.2  | 93.0    | 93.4*       | 93.5*       |                     |                     |          |             |             |
| No radiographic progression (△SHS ≤0.5) (%)                           |       |         |             |             | 91.9  | 94.8    | 96.2*       | 95.0        |                     |                     |          |             |             |
| Skin manifestations                                                   |       | Week 16 | Week 16     | Week 16     |       | Week 24 | Week 24     | Week 24     |                     | Week 56b            | Week 56b | Week 56b    | Week 56b    |
| PASI 75 (%)h                                                          | 21.3  | 53.1    | 62.6~       | 62.4~       | 26.5  | 58.8    | 64.0*       | 62.4*       | 63.9                | 76.2                | 71.4     | 72.9        | 76.5        |
| PASI 90 (%)h                                                          | 12.3  | 38.9    | 38.3*       | 49.5*#      | 16.6  | 45.0    | 41.6*       | 48.1*       | 52.8                | 64.3                | 56.0     | 54.1        | 63.0        |
| PASI 100 (%)h                                                         | 7.1   | 19.9    | 23.8*       | 33.8*#      | 10.0  | 27.5    | 26.6*       | 38.1*#      | 30.6                | 47.6                | 34.5     | 37.6        | 49.4        |
| sIGA 0/1 (%)                                                          | 10.9  | 38.5    | 41.9~       | 54.0~#      | 11.5  | 40.6    | 45.3*       | 52.5*#      | 39.3                | 58.5                | 52.2     | 52.4        | 64.1        |
| △BSA-Ps (LS mean)j                                                    | -1.66 | -5.26   | -5.88*      | -6.24*      | -1.63 | -5.74   | -6.29*      | -6.50*      | -5.69               | -7.47               | -7.03    | -6.23       | -7.30       |
| △SAPS (LS mean)                                                       | -8.2  | -22.7   | -25.3*#     | -28.1*#     | -9.7  | -24.4   | -28.3*#     | -29.4*#     | -27.7               | -33.4               | -27.9    | -30.8       | -33.3       |

<div style=\"page-break-after: always\"></div>

| Physical function                                           | Week 12   | Week 12   | Week 12   | Week 12   | Week 24   | Week 24   | Week 24        | Week 24        | Week 56b   | Week 56b   | Week 56b   | Week 56b   | Week 56b   |
|-------------------------------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|----------------|----------------|------------|------------|------------|------------|------------|
| HAQ-DI (LS mean)                                            | 0.14      | -0.34     | -0.42~#   | -0.47~#   | -0.19     | -0.39     | -0.51*#-0.51*# |                | -0.40      | -0.53      | -0.50      | -0.55      | -0.55      |
| HAQ-DI clinically meaningfulimprovement (△HAQ-DI≤-0.35) (%) | 33.4      | 47.2      | 57.9*#    | 62.0*#    | 37.3      | 51.8      | 59.8*#         | 63.1*#         | 58.2       | 71.4       | 64.6       | 69.1       | 71.5       |
| QoL and other PROs                                          |           |           |           |           |           |           |                |                |            |            |            |            |            |
| △SF-36 PCS (LS mean)                                        | 3.19      | 6.82      | 7.86~#    | 8.90~#    | 4.26      | 7.80      | 9.82*#         | 9.85*#         | 8.33       | 10.12      | 8.60       | 10.81      | 10.14      |
| △SF-36 MCS (LS mean)                                        | 2.21      | 3.59      | 3.91*     | 3.42*     | 2.44      | 4.06      | 4.66*          | 4.32*          | 2.28       | 4.28       | 4.95       | 5.77       | 4.55       |
| EQ-5D-5L index (LS mean)                                    | 0.08      | 0.16      | 0.16*     | 0.18*     | 0.10      | 0.16      | 0.18*#         | 0.19*#         | 0.16       | 0.21       | 0.18       | 0.21       | 0.20       |
| FACIT-F (LS mean)                                           | 2.8       | 5.7       | 6.3~      | 7.1~#     | 3.8       | 6.8       | 7.9*           | 8.0*           | 6.8        | 9.1        | 8.1        | 9.1        | 8.5        |
| Moming stiffness overall (LS mean)                          | -0.99     | -2.13     | -2.41*    | -2.66*#   | -1.41     | -2.49     | -3.02*#        | -3.06*#        | -2.74      | -3.32      | -2.80      | -3.24      | -3.33      |
| △Moming stiffness severity (LS mean)                        | -1.1      | -2.3      | -2.6*     | -3.0*#    | -1.7      | -2.8      | -3.4*#         | -3.5*,#        | -3.2       | -3.6       | -3.2       | -3.6       | -3.7       |
| Morming stiffness duration(LS mean)                         | -0.8      | -2.0      | -2.2*     | -2.3*#    | -1.2      | -2.2      | -2.6*#         | -2.6*#         | -2.3       | -3.0       | -2.4       | -2.8       | -2.9       |
| WPAI overall work impairment (LS mean)k                     | -5.04     | -17.12    | -20.11*   | -19.50*   | -8.25     | -20.33    |                | -23.23*-22.63* | -18.82     | -21.35     | -19.63     | -23.42     | -22.40     |
| Comprehensive disease control                               |           |           |           |           |           |           |                |                |            |            |            |            |            |
| MDA (%)                                                     | 6.4       | 24.9      | 24.7*     | 35.5*#    | 12.3      | 33.3      | 36.6~          | 45.4~#         | 40.5       | 56.8       | 46.1       | 52.3       | 54.7       |

ACR20/50/70 = American College of Rheumatology 20/50/70%; ADA = adalimumab; ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BSA-Ps = body surface area - psoriasis; CRP = C-reactive protein; DAPSA = Disease Activity in Psoriatic Arthritis; DAS28 = Disease HAQ-DI =Health Assessment Questionnaire - Disability Index; JSN = joint space narrowing; LDI = Leeds Dactylitis Index; LEI =Leeds Enthesitis Index; LS = 1east square; MCS=Mental Component Summary;MDA =minimal disease activity;PASDAS =PsoriaticArthritisDisease Activity Score;PASI=Psoriasis Area SeverityIndex; PBO=placebo;PCS=Physical Component Summary,PRO=patient-reported outcome;PsA=psoriatic arthritis;PsARC=PsoriaticArthritis Response Criteria;QoL=quality Canada;UPA =upadacitinib;WPAI=WorkProductivity and ActivityImpaiment

- a. Treatment switch was at Week 24.
- b. Available efficacy data are presented at Week 56. Through the data cutoff for Study M15-572, 39.7% of subjects completed Week 56 study participation. Data are subject to change when all subjects have completedWeek 56 or otherwise prematurely discontinued study participation.
- C. For subjects with baselineLDI&gt;0.
- d. For subjects with baseline LEI &gt; 0.
- e. For subjects withbaselineSPARCCEnthesitis Index&gt;O.
6. f Forsubjectswithpsoriaticspondylitis at baseline.
7. g Negative sign was omitted from 0.00 value in Study M15-572 CSR Iable 10 and Table 14.2\\_4.3. The value was corrected to -0.00 in this table (i.e., Table 4) as well as IntegratedSummaryof Efficacy (ISE)Table1.27.8.
- h. Forsubjectswith≥3%BSA-Ps atbaseline
9. 1 ForsubjectswithbaselineStaticInvestigatorGlobalAssessmentofPsoriasis(sIGA)≥2.
10. For subjects with baselineBSA-Ps &gt;0.
11. k For subjects employed at baseline.
12. Nominal P &lt; 0.05 for upadacitinib vs. placebo.
13. Nominal P &lt; 0.05 for upadacitinib vs. adalimumab.
14. Statistically significant in themultiplicity-controlled analysisfor upadacitinibvs. placebo.

The data submitted by the MAH in their response results on the SF-36 physical component score (PCS) and mental component score (MCS).

<div style=\"page-break-after: always\"></div>

<!-- image -->

:Maxisthe maximum observationbelow Q3+1.5iQRand mln is the minlmum observation above Q1-1.5*iQR.

BoxPlotof Change fromBaseline inSmPC EndpointsforStudy M15-S72(Full AnalysisSet)

Variable:SF-36MCS

Baseline

Change from

-25

Statisties

Q3

Max\"

Median

Mean

Min\"

Placebo

6.94

23.12

1.54

3.86

1.66

-18.10

WEEK12

WEEK24

PlaceboADA40mgEOWUPA15mgQDUPA30mgQD

ADA40mgEOWUPA15mgQDUPA30mgQO

7.85

21.78

2.75

25.90

25.64

2.78

9.03

3.55

-1.53

-15.31

-17.15

8.65

1.48

3.09

-3.13

-19.39

24.62

Placebo

8.00

1.99

3.60

2.11

-19.64

22.39

ADA40mgEOWUPA15mgQOUPA30mgQD

8.69

11.28

3.04

-0.76

4.12

-14,05

Figure 28 Change from baseline in SF-36 PCS and MCS (full analysis set)

## Study M15-554

## Participant flow and numbers analysed

A total of 642 subjects were randomized at 123 sites located in 16 countries, of whom 641 subjects received study drug. Number of screened subjects is not available. A total of 591 subjects (92.1 %)

49

26.87

4.29

-1.99

4.50

-18.88

29.70

10.39

2.40

-2.99

PO'E

-22.69

-2.39

Q1

55

35

15

口

00

<div style=\"page-break-after: always\"></div>

and 543 subjects (84,6 %) completed study drug by Week 12 (primary endpoint) and Week 24, respectively.

The most frequent primary reason for study drug discontinuation by Week 24 was lack of efficacy for the placebo group, and AE for the upadacitinib group (table 36). As of the data cut-off date for this CSR, 297 subjects (46.3%) had completed Period 1 (Week 56), 182 subjects (28.3%) had discontinued study drug during Period 1, and 163 subjects were ongoing in Period 1. Of the 182 subjects who discontinued by data cut-off, the most frequent primary reason for study drug discontinuation was lack of efficacy for the placebo and upadacitinib 15 mg groups, and AE for the upadacitinib 30 mg group.

The MAH provided in the response to the RSI 56 week, results for all efficacy endpoints. All study subjects had reached Week 56 or were prematurely discontinued by submission of the response.

Table 36 Study Drug Disposition of Subjects (All Randomized Subjects)

|                                                 | Placebo (N =212)   | Upadacitinib 15 mg QD (N =211)   | Upadacitinib 30 mg QD (N =219)   | Overall Total (N= 642)   |
|-------------------------------------------------|--------------------|----------------------------------|----------------------------------|--------------------------|
| Randomized, n                                   | 212                | 211                              | 219                              | 642                      |
| FAS, n                                          | 212                | 211                              | 218                              | 641                      |
| Per Protocol Analysis Set, n                    | 203                | 192                              | 196                              | 591                      |
| Safety Analysis Set, n                          | 212                | 211                              | 218                              | 641                      |
| Completed study drug up to Week 12, n (%)       | 183 (86.3)         | 202 (95.7)                       | 206 (94.1)                       | 591 (92.1)               |
| Discontinued study drug (primary reason), n (%) | 29 (13.7)          | 9 (4.3)                          | 13 (5.9)                         | 51 (7.9)                 |
| Adverse event                                   | 6 (2.8)            | 4 (1.9)                          | 6 (2.7)                          | 16 (2.5)                 |
| Withdrawal by subject                           | 12 (5.7)           | 0                                | 3 (1.4)                          | 15 (2.3)                 |
| Lost to follow up                               | 4 (1.9)            | 3 (1.4)                          | 1 (0.5)                          | 8 (1.2)                  |
| Lack of efficacy                                | 7 (3.3)            | 0                                | 1 (0.5)                          | 8 (1.2)                  |
| Other                                           | 0                  | 2 (0.9)                          | 2 (0.9)                          | 4 (0.6)                  |
| Completed study drug up to Week 24, n (%)       | 169 (79.7)         | 185 (87.7)                       | 189 (86.3)                       | 543 (84.6)               |
| Discontinued study drug (primary reason), n (%) | 43 (20.3)          | 26 (12.3)                        | 30 (13.7)                        | 99 (15.4)                |
| Adverse event                                   | 9 (4.2)            | 15 (7.1)                         | 16 (7.3)                         | 40 (6.2)                 |
| Withdrawal by subject                           | 13 (6.1)           | 0                                | 7 (3.2)                          | 20 (3.1)                 |
| Lost to follow up                               | 5 (2.4)            | 4 (1.9)                          | 1 (0.5)                          | 10 (1.6)                 |
| Lack of efficacy                                | 14 (6.6)           | 5 (2.4)                          | 2 (0.9)                          | 21 (3.3)                 |
| Other                                           | 2 (0.9)            | 2 (0.9)                          | 4 (1.8)                          | 8 (1.2)                  |

FAS = Full Analysis Set; QD = once daily

## Recruitment

The first subject first visit occurred 01 May 2017 and the last subject last visit for the Period 1 up to 24 weeks was 09 October 2019. Discussion of results for the remainder of Period 1 (Weeks 24 through 56) is not included in the interim CSR, however, some data are presented for the remainder of Period 1 (24 to 56 weeks). All study subjects had reached Week 56 or were prematurely discontinued by submission of the response to the RSI; hence, the results were submitted by the MAH (see assessment in Ancillary Analyses of this AR).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

There were six protocol amendments and two administrative changes in the protocol for study M15-554. All of these were dated prior to data cut-off. Each amendment contained multiple updates, mostly clarifications on inclusion and exclusion criteria, permitted concomitant treatments and their dose changes, administrative changes, contraception recommendations, measures to ensure safety of study subjects, and linguistic changes.

According to the MAH, all studies were conducted in accordance with GCP and applicable local laws and regulations. Two investigative site audits were conducted by the sponsor. No regulatory inspections are reported in the submission.

Receipt of excluded or prohibited medications was the most common protocol deviation. A total of 77 (12.0%) subjects had such a deviation. However, after the database lock for the interim report, 10 of these 77 subjects were deemed to have been erroneously included in this category. These 10 subjects all received corticosteroids &gt; 10 mg/day of prednisone or equivalent after implementation of Amendment 3, which did not state that such doses of corticosteroids were prohibited after Week 36. These protocol deviations will according to the MAH be removed from the database prior to the final clinical study report for the study.

## Baseline data

Demographic characteristics were generally balanced across the upadacitinib 15 mg, 30 mg, and placebo groups (Table 37). The mean age of the study subjects was 53.4 years, with a small majority of females.

<div style=\"page-break-after: always\"></div>

Table 37 Demographic characteristics (FAS)

|                                       | Placebo (N=212)      | Upadacitinib 15mgQD (N=211)   | Upadacitinib 30mgQD (N=218)   | Total (N=641)        |
|---------------------------------------|----------------------|-------------------------------|-------------------------------|----------------------|
| Sex.n (%)                             |                      |                               |                               |                      |
| Female                                | 120 (56.6)           | 113 (53.6)                    | 115 (52.8)                    |                      |
| Male                                  | 92 (43.4)            | 98 (46.4)                     | 103 (47.2)                    | 293 (45.7)           |
| Age (yean)                            |                      |                               |                               |                      |
| Mean SD                               | 54.1 (11:53)         | 53.0 (12.02)                  | 53.0 (11.94)                  | 53.4 (11.83)         |
| Median (min, max)                     | 55.0 (22.0.83.0)     | 54.0 (25.0,80.0)              | 53.0 (26.0,79.0)              | 54.0 (22.0, 83.0)    |
| Age (years）.n (%)                     |                      |                               |                               |                      |
| 65                                    | 170 (80.2)           | 174 (82.5)                    | 173 (79.4)                    | 517(80.7)            |
| 65-<75                                | 37 (17.5)            | 31 (14.7)                     | 38 (17.4)                     | 106 (16.5)           |
| 275                                   | 5 (2.4)              | 6 (2.8)                       | 7 (3.2)                       | 18 (2.8)             |
| Race                                  |                      |                               |                               |                      |
| White                                 | 186 (87.7)           | 183 (86.7)                    | 196 (89.9)                    | 565 (88.1)           |
| Black or Afrcan Amercan               | 7 (3.3)              | 5(2.4)                        | 5 (2.3)                       | 17 (2.7)             |
| AmericanIndian/AlaskaNative           |                      |                               |                               |                      |
| NativeHawatlan orotherPacifieIslander |                      |                               |                               |                      |
| Asian                                 | 17 (8.0)             | 19 (9.0)                      | 16(7.3)                       | 52 (8.1)             |
| Multiple                              |                      |                               |                               |                      |
| Ethnicity                             |                      |                               |                               |                      |
| Hispanic or Latino                    | 53 (25.0)            | 36 (17.1)                     | 50 (22.9)                     | 139 (21.7)           |
| Not Hispanic or Latino                | 159 (75.0)           | 175 (82.9)                    | 168 (77.1)                    | 502 (78.3)           |
| Weight (kg)                           |                      |                               |                               |                      |
| Mean ±SD                              | 90.0 (23.02)         | 89.3 (23.56)                  | 87.1 (21.71)                  | 88.8 (22.76)         |
| Median (min, max)                     | 87.5 (43.0, 180.3)   | 86.6 (47.2, 188.2)            | 86.1 (41.9, 181.8)            | 86.6 (41.9, 188.2)   |
| Height (cm)                           |                      |                               |                               |                      |
| n                                     | 211                  | 211                           | 218                           | 640                  |
| Mean ± SD                             | 168.2 (10.87)        | 168.1 (9.99)                  | 167.9 (9.21)                  | 168.1 (10.02)        |
| Median (min, max)                     | 169.0 (140.0, 198.1) | 167.6 (145.0, 200.7)          | 167.6 (144.0, 196.0)          | 167.6 (140.0, 200.7) |
| Body mass index (kg/m2)               |                      |                               |                               |                      |
| n                                     | 211                  | 211                           | 218                           | 640                  |
| Mean ± SD                             | 31.8 (7.47)          | 31.5 (7.37)                   | 30.8 (7.00)                   | 31.3 (7.28)          |
| Median (min, max)                     | 30.5 (15.8, 61.7)    | 30.3 (17.5, 64.9)             | 30.0 (16.3, 61.1)             | 30.4 (15.8, 64.9)    |
| Body mass index (kg/m), n (%)         |                      |                               |                               |                      |
| <25                                   | 39 (18.4)            | 40 (19.0)                     | 39 (17.9)                     | 118 (18.4)           |
| ≥25                                   | 172 (81.1)           | 171 (81.0)                    | 179 (82.1)                    | 522 (81.4)           |
| missing                               | 1 (0.5)              | 0                             | 0                             | 1 (0.2)              |
| Tobacco/nicotine use,\" n (%)          |                      |                               |                               |                      |
| Current                               | 49 (23.1)            | 56 (26.5)                     | 50 (22.9)                     | 155 (24.2)           |
| Former                                | 54 (25.5)            | 56 (26.5)                     | 76 (34.9)                     | 186 (29.0)           |
| Never                                 | 109 (51.4)           | 99 (46.9)                     | 92 (42.2)                     | 300 (46.8)           |
| Alcohol use,a n (%)                   |                      |                               |                               |                      |
| Current                               | 114 (53.8)           | 106 (50.2)                    | 126 (57.8)                    | 346 (54.0)           |
| Former                                | 18 (8.5)             | 22 (10.4)                     | 11 (5.0)                      | 51 (8.0)             |
| Never                                 | 80 (37.7)            | 83 (39.3)                     | 81 (37.2)                     | 244 (38.1)           |

Max=maximum;min=minimum;QD=once daily;SD=standard deviation

A subject that was a current user of any type of tobacco is counted under\"current.\" Otherwise, a subject that was a former user of any type of tobacco is counted under \"former.\" A subject who had never used any tobacco is counted under \"never.\"

At baseline, the disease-related characteristics were generally balanced across the upadacitinib and placebo arms, including duration of symptoms and diagnosis, RF and anti-CCP status, indicators of disease activity, status of psoriasis, and PROs (Table 38). Subjects had been diagnosed with PsA for a mean of 10.1 years, and experienced symptoms of PsA for a mean of 13.4 years. Subjects had active disease as indicated by mean TJC68 of 24.8 and mean SJC66 of 12.1.

<div style=\"page-break-after: always\"></div>

Table 38 Disease-Related Baseline Characteristics (FAS)

|                                   | Placebo (N=212) n(%)   | Upadacitinib 15 mg QD (N =211) n (%)   | Upadacitinib 30 mg QD (N=218) n(%)   | Total (N=641) n (%)   |
|-----------------------------------|------------------------|----------------------------------------|--------------------------------------|-----------------------|
| Duration of PsA symptoms (years)  |                        |                                        |                                      |                       |
| n                                 | 209                    | 211                                    | 217                                  | 637                   |
| Mean ± SD                         | 14.6± 11.70            | 12.2± 8.81                             | 13.3 ± 10.84                         | 13.4±10.54            |
| Median (min, max)                 | 10.8 (0.7, 59.2)       | 10.3 (0.8, 47.2)                       | 10.1 (0.8, 52.4)                     | 10.4 (0.7, 59.2)      |
| Duration of PsA diagnosis (years) |                        |                                        |                                      |                       |
| Mean± SD                          | 11.0±10.33             | 9.6±8.36                               | 9.7± 8.71                            | 10.1±9.18             |
| Median (min, max)                 | 7.6 (0.1, 54.8)        | 7.5 (0.1, 47.2)                        | 7.0 (0.1, 42.9)                      | 7.3 (0.1, 54.8)       |
| RF status, n (%)                  |                        |                                        |                                      |                       |
| Positive                          | 6 (2.8)                | 11 (5.2)                               | 8 (3.7)                              | 25 (3.9)              |
| Negative                          | 206 (97.2)             | 200 (94.8)                             | 210 (96.3)                           | 616 (96.1)            |
| Anti-CCP status, n (%)            |                        |                                        |                                      |                       |
| Positive                          | 10 (4.7)               | 7 (3.3)                                | 5 (2.3)                              | 22 (3.4)              |
| Negative                          | 202 (95.3)             | 203 (96.2)                             | 213 (97.7)                           | 618 (96.4)            |
| Missing                           | 0                      | 1 (0.5)                                | 0                                    | 1 (0.2)               |
| TJC68                             |                        |                                        |                                      |                       |
| Mean± SD                          | 25.3 ± 17.62           | 24.9 ± 17.27                           | 24.2 ± 15.87                         | 24.8 ± 16.91          |
| Median (min, max)                 | 21.0 (3.0, 68.0)       | 20.0 (3.0, 68.0)                       | 20.0 (3.0, 68.0)                     | 20.0 (3.0, 68.0)      |
| SJC66                             |                        |                                        |                                      |                       |
| Mean ± SD                         | 12.0±8.85              | 11.3 ±8.19                             | 12.9±9.41                            | 12.1±8.85             |
| Median (min, max)                 | 10.0 (3.0, 56.0)       | 9.0 (3.0, 57.0)                        | 10.0 (3.0, 57.0)                     | 10.0 (3.0, 57.0)      |
| Patient's Assessment ofPain (NRS) |                        |                                        |                                      |                       |
| n                                 | 209                    | 208                                    | 218                                  | 635                   |
| Mean ± SD                         | 6.6±2.12               | 6.4±2.13                               | 6.2±2.21                             | 6.4±2.16              |
| Median (min, max)                 | 7.0 (0.0, 10.0)        | 7.0 (0.0, 10.0)                        | 6.0 (1.0, 10.0)                      | 7.0 (0.0, 10.0)       |
| PGA -Disease Activity (NRS)       |                        |                                        |                                      |                       |
| Mean ± SD                         | 6.5± 1.76              | 6.5 ± 1.80                             | 6.6± 1.73                            | 6.5 ± 1.76            |
| Median (min, max)                 | 7.0 (2.0, 10.0)        | 7.0 (1.0, 10.0)                        | 7.0 (0.0, 10.0)                      | 7.0 (0.0, 10.0)       |
| PIGA -Disease Activity (NRS)      |                        |                                        |                                      |                       |
| n                                 | 209                    | 208                                    | 218                                  | 635                   |
| Mean± SD                          | 6.8± 2.04              | 6.8± 1.91                              | 6.7±2.15                             | 6.8± 2.04             |
| Median (min, max)                 | 7.0 (0.0, 10.0)        | 7.0 (2.0,10.0)                         | 7.0 (0.0, 10.0)                      | 7.0 (0.0, 10.0)       |
| HAQ-DI                            |                        |                                        |                                      |                       |
| n                                 | 209                    | 208                                    | 218                                  | 635                   |
| Mean± SD                          | 1.23 ± 0.69            | 1.10± 0.61                             | 1.19 ±0.66                           | 1.17±0.66             |
| Median (min, max)                 | 1.25 (0.00, 3.00)      | 1.13 (0.00, 2.50)                      | 1.13 (0.00, 2.63)                    | 1.13 (0.00, 3.00)     |
| hs-CRP (mg/L)                     |                        |                                        |                                      |                       |
| Mean ± SD                         | 10.40 ± 18.46          | 11.16± 18.55                           | 10.53± 17.21                         | 10.69 ± 18.05         |
| Median (min, max)                 | 4.06 (0.20, 135.00)    | 3.95 (0.22, 128.00)                    | 4.24 (0.20, 107.00)                  | 4.08 (0.20, 135.00)   |
| BSA -psoriasis (Ps)               |                        |                                        |                                      |                       |
| <3%                               | 81 (38.2)              | 81 (38.4)                              | 87 (39.9)                            | 249 (38.8)            |
| ≥3%                               | 131 (61.8)             | 130 (61.6)                             | 131 (60.1)                           | 392 (61.2)            |
| BSA-Ps (for baseline > 0%)        |                        |                                        |                                      |                       |
| n                                 | 198                    | 202                                    | 202                                  | 602                   |
| Mean ± SD                         | 12.76± 18.39           | 9.95 ± 15.73                           | 10.03 ± 15.76                        | 10.90± 16.68          |
| Median (min, max)                 | 4.00 (0.10, 95.00)     | 3.50 (0.20, 83.00)                     | 4.00 (0.10, 80.00)                   | 4.00 (0.10, 95.00)    |
| sIGA ofpsoriasis score            |                        |                                        |                                      |                       |
| 0                                 | 17 (8.0)               | 9 (4.3)                                | 16 (7.3)                             | 42 (6.6)              |
| 1                                 | 32 (15.1)              | 31 (14.7)                              | 38 (17.4)                            | 101 (15.8)            |
| 2                                 | 59 (27.8)              | 82 (38.9)                              | 78 (35.8)                            | 219 (34.2)            |
| 3                                 | 88 (41.5)              | 78 (37.0)                              | 77 (35.3)                            | 243 (37.9)            |
| 4                                 | 16 (7.5)               | 11 (5.2)                               | 9 (4.1)                              | 36 (5.6)              |
| PASI (for baseline BSA-Ps ≥3%)    |                        |                                        |                                      |                       |
|                                   | 131                    | 130                                    | 131                                  | 392                   |
| Mean ± SD                         | 11.68 ±11.43           | 10.13 ±9.20                            | 8.91±9.09                            | 10.24± 10.00          |
| Median (min, max)                 | 8.30 (0.30, 64.80)     | 6.55 (0.20, 48.10)                     | 5.80 (0.20, 47.50)                   | 6.80 (0.20, 64.80)    |

<div style=\"page-break-after: always\"></div>

| PASDAS                                                  |                        | 207                           | 217                            | 633                   |
|---------------------------------------------------------|------------------------|-------------------------------|--------------------------------|-----------------------|
| Men± SD                                                 | 6.38±1.22              | 626±1.07                      | 6.28± 1.15                     | 631± 1.15             |
| Median (man, mx)                                        | 6.23 (3.54,9.63)       | 6.13 (3.20.9.89)              | 6.25 (3.01,9.69)               | 6.20 (3.01.9.89)      |
| DAS28(CRP)                                              |                        |                               |                                |                       |
|                                                         |                        | 208                           | 218                            | 635                   |
| Meana SD                                                | 5:15 ± 1.03            | 5.14±0.99                     | 5.13 ± 1.13                    | 5.14±1.05             |
| Median (min, m)                                         | 5.11 (2.59,7.63)       | 5.03 (1.77.8.10)              | 5.03 (2.01.7.85)               | 5.05 (1.77.8.10)      |
| Presence of dactytis (defined as LDI>0)                 |                        |                               |                                |                       |
| Yes                                                     | 64 (30.2)              | 55-(26.1)                     | 50 (22.9)                      | 169 (26.4)            |
| No                                                      | 148 (69.8)             | 156 (73.9)                    | 168 (77.1)                     | 472 (73.6)            |
| Leeds Dactyits Index (for baselie>0)                    |                        |                               |                                |                       |
|                                                         | 64                     | 55                            | 50                             | 169                   |
| Mean ± SD                                               | 124.19 ±178.76         | 96.27 ± 97.87                 | E51+8686                       | 107.47±148.66         |
| Median (min, mx)                                        | 64,00 (10.00, 1056.47) | 68.77 (10.00, 477.75)         | 52.16 (10.00, 947.64)          | 59.58 (10.00,1056.47) |
| Presence of enthesms (defined as Totl Enthess Count >0) |                        |                               |                                |                       |
| Ya                                                      | 173 (81.6)             | 173 (82.0)                    | 181 (83.0)                     | 527 (822)             |
| No                                                      | (81)65                 | 37(17.5)                      | 36(16.5)                       | 112(17.5)             |
| Missing                                                 | 0                      | 1(0.5)                        | 1 (0.5)                        | 2(0.3)                |
|                                                         | Placebo (N=212)        | Upadacitinib 15 mg QD (N=211) | Upadacitinib 30 mg QD (N =218) | Total (N = 641)       |
|                                                         | n (%)                  | n (%)                         | n (%)                          | n (%)                 |
| Leeds Enthesitis Index (for baseline > 0)               |                        |                               |                                |                       |
| n                                                       | 144                    | 133                           | 152                            | 429                   |
| Mean ± SD                                               | 3.3 ± 1.70             | 3.0±1.64                      | 2.9±1.57                       | 3.0± 1.64             |
| Median (min, max)                                       | 3.0 (1.0, 6.0)         | 2.0 (1.0, 6.0)                | 2.0 (1.0, 6.0)                 | 3.0 (1.0, 6.0)        |
| ASDAS (CRP) (among subjects with psoriatic spondylitis) |                        |                               |                                |                       |
| n                                                       | 74                     | 75                            | 68                             | 217                   |
| Mean ± SD                                               | 3.44±1.02              | 3.31±0.93                     | 3.26± 1.10                     | 3.34±1.01             |
| Median (min, max)                                       | 3.40 (1.24, 5.69)      | 3.25 (1.06, 5.54)             | 3.31 (0.62, 5.62)              | 3.29 (0.62, 5.69)     |
| BASDAI (among subjects with psoriatic spondylitis)      |                        |                               |                                |                       |
| n                                                       | 74                     | 75                            | 68                             | 217                   |
| Mean ± SD                                               | 6.54±1.88              | 5.90± 2.14                    | 6.04± 2.41                     | 6.16±2.15             |
| Median (min, max)                                       | 7.00 (1.10, 9.80)      | 6.20 (1.20, 10.00)            | 6.10 (0.00, 10.00)             | 6.40 (0.00, 10.00)    |
| Moming Stiffness score (NRS)a                           |                        |                               |                                |                       |
| n                                                       | 208                    | 208                           | 218                            | 634                   |
| Mean ± SD                                               | 5.84±2.53              | 5.97 ±2.46                    | 5.70± 2.70                     | 5.84±2.57             |
| Median (min, max)                                       | 6.00 (0.00, 10.00)     | 6.00 (0.00, 10.00)            | 5.50 (0.00, 10.00)             | 6.00 (0.00, 10.00)    |
| Presence of psoriatic spondylitis                       |                        |                               |                                |                       |
| Yes                                                     | 75 (35.4)              | 76 (36.0)                     | 68 (31.2)                      | 219 (34.2)            |
| No                                                      | 137 (64.6)             | 135 (64.0)                    | 149 (68.3)                     | 421 (65.7)            |
| Missing                                                 | 0                      | 0                             | 1 (0.5)                        | 1 (0.2)               |

Anti-CCP=anti-cycliccitrullinatedpeptide;ASDAS=ankylosingSpondylitisDiseaseActivityScore;BASDAI=BathAnkylosingSpondylitisDiseaseActivityIndex; BSA=body surface area;CRP=C-reactiveprotein;DAS28=DiseaseActivityScore(28joints);FAS=FullAnalysisSet;HAQ-DI=HealthAssessment Questionnaire-DisabilityIndex;hs-CRP=high-sensitivity C-reactiveprotein:LDI=LeedsDactylitisIndex:Max=maximum:min=minimum;NRS=NumericalRatingScale: PASDAS=PsoriaticArthritisDiseaseActivity Score;PASI=PsoriasisArea SeverityIndex;PGA=Physician's Global Assessment;Ps=psoriasis;PsA=psoriaticarthritis: PtGA=Patient's Global Assessment ofDiseaseActivity,QD=oncedaily,RF=rheumatoidfactor;SD=standard deviation:sIGA=StaticInvestigator Global Assessment of Psoriasis;SJC66=numberofswollenjointsoutof66assessedjoints;TJC68=numberoftenderjointsoutof68assessedjoints a. MomingstiffnessscoreisthemeanofBASDAIquestionsSand6.

The study arms were overall similar regarding medical and surgical history.

Overall, 61.0% of subjects had failed 1 prior bDMARD, 18.1% had failed 2 prior bDMARDs, and 12.9% had failed 3 or more prior bDMARDs. Of the subjects, 8 % entered the study after intolerance but not failure of a prior bDMARD. Adalimumab was the most frequently reported (46.6%) prior bDMARD overall.

Background non-biologic DMARD therapy is optional this study; subjects are permitted to use up to 2 concomitant non-biologic DMARDs, and subjects who are on non-biologic DMARD therapy at baseline are to remain on a stable dose through Week 36. In total, 53.8% of subjects reported no concomitant use of non-biologic DMARDs at baseline. The use of concomitant non-biologic DMARD was similar across groups (Table 39). Methotrexate was used concomitantly by 39.3 % of subjects. Concomitant use of other non-biologic DMARDs was much lower. Any systemic corticosteroids were used by 15.3%

<div style=\"page-break-after: always\"></div>

of study subjects: 19.8 % in the placebo arms, 15.6 % in the upadacitinib 15 mg arm, and 10.6 % in the upadacitinib 30mg arm.

Table 39 Concomitant Non-Biologic DMARDs up to Week 24 (FAS)

| GenericName（WHOQl_2018)          | Placebo to UPA15mgQD (N=106) n（各）   | Placebo to UPA30mgQD (N=106) n（s）   | A11 Placebo （N=212） n（8）   | 15mgQD 30mgQD （N=211） (N=218) n（名） n（）   |           | Total （N=641) n（8）   |
|----------------------------------|-------------------------------------|-------------------------------------|----------------------------|------------------------------------------|-----------|----------------------|
| AnyConcomitantNon-BiologicDMARDs | 60 (56.6)                           | 53(50.0)                            | 113（53.3)                  | 101(47.9)                                | 66 （45.4) | 313(48.8)            |
| APREMILAST                       | 5 (4.7)                             | 6 (5.7)                             | 11(5.2)                    | 11 (5.2)                                 | 6 (4.1)   | 31(4.8)              |
| HYDROXYCHLOROQUINE               | 0                                   | 1 (6'0)                             | 1 (0.5)                    | 0                                        | 3 (1.4)   | 4 (0.6)              |
| IGURATIMOD                       | 0                                   | 1 (6°0)                             | 1(0.5)                     | 1 (0.5)                                  | 0         | 2 (0.3)              |
| LEFLUNOMIDE                      | 4 (3.8)                             | 7 (6.6)                             | 11(5.2)                    | 3 (1.4)                                  | 7 (3.2)   | 21(3.3)              |
| METHOTREXATE                     | 51 (48.1)                           | 41 (38.7)                           | 92 (43.4)                  | 82 (38.9)                                | 78 (35.8) | 252(39.3)            |
| MYCOPHENOLICACID                 | 0.                                  | 0                                   | 0                          | 1 (0.5)                                  | 0         | 1(0.2)               |
| SULFASALAZINE                    | 5 (4.7)                             | (1.9)                               | 7 (3.3)                    | 11(5.2)                                  | 11 (5.0)  | 29（4.5)              |
| TACROLIMUS                       | 1(0.9)                              | 0                                   | 1(0.5)                     | 0                                        | 0         | 1(0.2)               |

Note: This table includes all medications administered up to Week 24 treatment period.Thus all medications with an end date prior to the firststudydrugdose orastart dateafter the firstdosedateatWeek24areexcluded.

Through Week 24, the mean treatment compliance was 98.7% and 97.1% in the upadacitinib 15 mg and 30 mg groups, respectively.

## Outcomes and estimation

## Primary endpoint

The primary endpoint was change in ACR20 at Week 12. A statistically significantly greater percentage of subjects achieved an ACR20 response in the upadacitinib 15 mg and 30 mg groups compared with the placebo group. Table 40 presents the results for FAS, AO and AO with imputation. The results on the per protocol analysis set were consistent with the primary analysis (Table 41).

The results of the tipping point analysis for ACR20 at Week 12 showed that results of the primary efficacy analysis using Non-Responder Imputation (NRI) data handling are robust.

<div style=\"page-break-after: always\"></div>

Table 40 ACR20 Response Rate at Week 12 (FAS)

Table 41 ACR20 Response Rate at Week 12 (Per Protocol Analysis Set)

|                    |     |                 |                        | ResponseRateDifference (Upadacitinib-Placebo)   | ResponseRateDifference (Upadacitinib-Placebo)   | ResponseRateDifference (Upadacitinib-Placebo)   |
|--------------------|-----|-----------------|------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Treatment          | N   | Responder n (%) | ResponseRate (95% CI)a | Point Estimate                                  | 95% CIb                                         | P-Valuec                                        |
| FAS, NRI           |     |                 |                        |                                                 |                                                 |                                                 |
| Placebo            | 212 | 51 (24.1)       | 24.1 (18.3, 29.8)      |                                                 |                                                 |                                                 |
| Upadacitinib 15 mg | 211 | 120 (56.9)      | 56.9 (50.2, 63.6)      | 32.8                                            | (24.0, 41.6)                                    | <0.0001                                         |
| Upadacitinib 30 mg | 218 | 139 (63.8)      | 63.8 (57.4, 70.1)      | 39.7                                            | (31.1, 48.3)                                    | <0.0001                                         |
| FAS,AO             |     |                 |                        |                                                 |                                                 |                                                 |
| Placebo            | 185 | 50 (27.0)       | 27.0 (20.6,33.4)       |                                                 |                                                 |                                                 |
| Upadacitinib 15 mg | 205 | 119 (58.0)      | 58.0 (51.3, 64.8)      | 31.0                                            | (21.7, 40.3)                                    | <0.0001                                         |

The mean difference in the response rate was retained up to Week 24, where after the response rate in subjects transferred from placebo arms to upadacitinib achieved the response rate of subjects who had used upadacitinib already from the start of the study (Figure 29, results given as observed (AO) up to end of Period 1, 56 weeks). Of note, the study is ongoing, and the results after Week 24 represent the proportion of subjects who had already reached the respective study time points.

<div style=\"page-break-after: always\"></div>

Figure 34 ACR20 response per patient in study M15-554

<!-- image -->

## Efficacy in subgroups using upadacitinib as monotherapy and as combined with methotrexate

With the response to the 1st RSI, the MAH submitted efficacy results analysed for subgroups of subjects using upadacitinib 15 mg QD as monotherapy vs. subjects using the combination of upadactinib 15 mg and methotrexate.

Across all treatment groups, ~ 30% of subjects in the PBO-Controlled Analysis Set reported no concomitant use of non-biologic DMARDs at baseline compared to ~70% of subjects who reported concomitant use of non-biologic DMARDs at baseline; 60% of subjects reported concomitant MTX with or without another non-biologic DMARD and 56% of subjects reported concomitant use of only MTX. The distribution of background non-biologic DMARD use per study is presented in Table 50.

<div style=\"page-break-after: always\"></div>

Table 50 Distribution of Background Non-Biologic DMARD Use in Studies M15-572 and M15-554

|                                  | MI5-572(SELECTPsA-1) N=1704   | MI5-572(SELECTPsA-1) N=1704   | MI5-572(SELECTPsA-1) N=1704   | MI5-572(SELECTPsA-1) N=1704   | MI5-554(SELECTPsA-2) N=641   | MI5-554(SELECTPsA-2) N=641   | MI5-554(SELECTPsA-2) N=641   |
|----------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|------------------------------|------------------------------|------------------------------|
|                                  | PBO N=423                     | UPA 15mg N=429                | UPA 30mg N=423                | ADA 40ng N=429                | PBO N=212                    | UPA 15mg N=211               | UPA 30mg N=218               |
|                                  | N(%)                          | N(%)                          | N(%)                          | N(%)                          | N(%)                         | N(%)                         | N(%)                         |
| Anynon-biologicDMARD             | 347(82)                       | 353 (82)                      | 346 (82)                      | 347 (81)                      | 100 (47)                     | 98(40)                       | 98(45)                       |
| MTX Only                         | 267(63)                       | 279 (65)                      | 268 (63)                      | 270 (63)                      | 75 (35)                      | 74(35)                       | 73(34)                       |
| MTX+AnotherAmy non-biologicDMARD | 26(6.1)                       | 20(4.7)                       | 27(6.4)                       | 61 (14.2)                     | 7(3)                         | 6(2.8)                       | 5(2.3)                       |
| Any MTXa                         | 293(69)                       | 299 (70)                      | 295 (70)                      | 331(77)                       | 82(39)                       | 80(38)                       | 78(36)                       |

Source:M15-572CSRTable14.1 3.3.M15-5S4 CSRIable14.1 3.3

- a The Any MTXgroup includessubjects treated with MTXwith orwithout anothernon-biologicDMARD

Across endpoints, consistent point estimates of the placebo-subtracted treatment effect and associated overlapping CIs were observed between subjects who were on UPA 15 mg monotherapy and those who were on combination therapy with MTX only. Results from this analysis support the use of UPA with or without concomitant MTX (Figure 35 Figure 36).

<!-- image -->

Ncte:Pointestmateand95coidenceintervalsforbetweengroupdifferencearebasedonManteHaenszelestmatonadjustingforstudy

[C]Only forSubjects with &gt;= 3% BSA Psoriasis at Baseline.

Figure 35 Forest Plot for Key Binary Endpoints by Upadacitinib 15 mg QD Monotherapy vs. Upadacitinib 15 mg QD with Methotrexate Only (NRI)

<div style=\"page-break-after: always\"></div>

<!-- image -->

.2

Note:BetweengroupLSmean95%ClarebasedonMixed-EffectModelRepeatedMeasurement(MMRM）analysiswithunstructuredvanance-covariancematrix,including treatmentvisittreatment-by-visitinteraction

LC1=Lowerlimitof95%Cl.UC1=Upperlimitof95%Cl.

studyasfixedfactorsand thecontinuousfixed covariate ofbaselinemeasurement

Chgin HAQ-DI=Change fromBaselinein HealthAssessmentQuestionnaireDisability Index:ChginTJC68=Change fromBaseline inTender JointCount68:

ChainCRP=Chanoe fromBaselineinhs-CRP.

Figure 36 Forest Plot for Components of ACR Response by Upadacitinib 15 mg QD Monotherapy vs. Upadacitinib 15 mg QD with Methotrexate Only (MMRM)

<!-- image -->

Note: Between group LS mean difference and 95% Cl are based on ANCOVA model including treatment as fixed factors and baseline value as covariate. LCI = Lower limit of 95% Cl. UCI = Upper limit of 95% Cl.

Figure 37 Forest Plot for Radiographic Endpoints by Upadacitinib 15 mg QD Monotherapy vs. Upadacitinib 15 mg QD with MTX Only (Linear Extrapolation) (M15-572)

A vast majority of all patients had no change in radiographic endpoints during the study. Therefore, Figure 37 should not be overinterpreted to indicate true difference in the monotherapy and combination therapy groups.

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 51 Summary of Efficacy for trial M15-572

| Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1   | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                          | M15-572 (EudraCT number: 016-004130-24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | M15-572 (EudraCT number: 016-004130-24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | M15-572 (EudraCT number: 016-004130-24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                                                                                    | This is a Phase 3 multicenter study that includes two periods. Period 1 is 56 weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled and active comparator-controlled period followed by an additional 32 weeks of blinded, active comparator-controlled treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus adalimumab 40 mg every other week (eow) in subjects with moderately to severely active PsA and have an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo for the prevention of structural progression. Period 2 is an open-label (blinded until the last subject completes the last visit of Period 1), long-term extension of up to a total treatment duration of approximately 3 years to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1. | This is a Phase 3 multicenter study that includes two periods. Period 1 is 56 weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled and active comparator-controlled period followed by an additional 32 weeks of blinded, active comparator-controlled treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus adalimumab 40 mg every other week (eow) in subjects with moderately to severely active PsA and have an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo for the prevention of structural progression. Period 2 is an open-label (blinded until the last subject completes the last visit of Period 1), long-term extension of up to a total treatment duration of approximately 3 years to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1. | This is a Phase 3 multicenter study that includes two periods. Period 1 is 56 weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled and active comparator-controlled period followed by an additional 32 weeks of blinded, active comparator-controlled treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo and versus adalimumab 40 mg every other week (eow) in subjects with moderately to severely active PsA and have an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo for the prevention of structural progression. Period 2 is an open-label (blinded until the last subject completes the last visit of Period 1), long-term extension of up to a total treatment duration of approximately 3 years to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who have completed Period 1. |
|                                                                                                                                                                                                                                                                                           | Duration of double-blind, placebo-controlled period: Duration of double-blind active-controlled period: Duration of extension period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Duration of double-blind, placebo-controlled period: Duration of double-blind active-controlled period: Duration of extension period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24 weeks 56 weeks Up to Week 260                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                                                                                                                                                | Superiority (upadacitinib vs placebo); Non-inferiority (upadacitinib vs adalimumab) and Superiority (upadacitinib vs adalimumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Superiority (upadacitinib vs placebo); Non-inferiority (upadacitinib vs adalimumab) and Superiority (upadacitinib vs adalimumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Superiority (upadacitinib vs placebo); Non-inferiority (upadacitinib vs adalimumab) and Superiority (upadacitinib vs adalimumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                         | Upadacitinib 15mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Upadacitinib 15mg QD for up to 5 years; n = 430                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Upadacitinib 15mg QD for up to 5 years; n = 430                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                                                                         | Upadacitinib 30mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Upadacitinib 30mg QD for up to 5 years; n = 423                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Upadacitinib 30mg QD for up to 5 years; n = 423                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                                                                         | Adalimumab 40mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Adalimumab 40mg EOW for 5 years; n = 429                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Adalimumab 40mg EOW for 5 years; n = 429                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                                         | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Placebo for 24 weeks; Total n = 423 After week 24: Placebo to UPA 15mg; n = 211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Placebo for 24 weeks; Total n = 423 After week 24: Placebo to UPA 15mg; n = 211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                                                 | Primary endpoint (Upadacitinib 15 and 30 mg vs placebo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Proportion of subjects achieving ACR20 response at Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Proportion of subjects achieving ACR20 response at Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                           | Ranked key secondary endpoints (at Week 12 unless otherwise specified)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | The key multiplicity adjusted secondary efficacy endpoints (each dose of upadacitinib versus placebo unless noted) are: 1. Change from baseline in HAQ-DI; 2. Proportion of subjects achieving a static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | The key multiplicity adjusted secondary efficacy endpoints (each dose of upadacitinib versus placebo unless noted) are: 1. Change from baseline in HAQ-DI; 2. Proportion of subjects achieving a static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                    | Ranked key secondary endpoints (at Week 12 unless otherwise specified)   | Ranked key secondary endpoints (at Week 12 unless otherwise specified)                                                                  | Ranked key secondary endpoints (at Week 12 unless otherwise specified)                                                                  | 3. Psoriasis Area Severity Index (PASI) 75 response at subjects with ≥ 3% BSA psoriasis at baseline);4. Change baseline in SHS at Week 24; 5. Proportion of subjects achieving MDA at Week 24; 6. Proportion of subjects with resolution of enthesitis (LEI Week 24; 7. ACR 20 response rate (non-inferiority of upadacitinib adalimumab); 8. Change from baseline in SF-36 PCS; 9. Change from baseline in FACIT-Fatigue Questionnaire; 10. ACR 20 response rate (superiority of upadacitinib vs. adalimumab); 11. Proportion of subjects with resolution of dactylitis (LDI Week 24; 12. Change from baseline in Patient's Assessment of Pain (superiority of upadacitinib vs. adalimumab); 13. Change from baseline in HAQ-DI (superiority of upadacitinib adalimumab);   | 3. Psoriasis Area Severity Index (PASI) 75 response at subjects with ≥ 3% BSA psoriasis at baseline);4. Change baseline in SHS at Week 24; 5. Proportion of subjects achieving MDA at Week 24; 6. Proportion of subjects with resolution of enthesitis (LEI Week 24; 7. ACR 20 response rate (non-inferiority of upadacitinib adalimumab); 8. Change from baseline in SF-36 PCS; 9. Change from baseline in FACIT-Fatigue Questionnaire; 10. ACR 20 response rate (superiority of upadacitinib vs. adalimumab); 11. Proportion of subjects with resolution of dactylitis (LDI Week 24; 12. Change from baseline in Patient's Assessment of Pain (superiority of upadacitinib vs. adalimumab); 13. Change from baseline in HAQ-DI (superiority of upadacitinib adalimumab);   | 3. Psoriasis Area Severity Index (PASI) 75 response at subjects with ≥ 3% BSA psoriasis at baseline);4. Change baseline in SHS at Week 24; 5. Proportion of subjects achieving MDA at Week 24; 6. Proportion of subjects with resolution of enthesitis (LEI Week 24; 7. ACR 20 response rate (non-inferiority of upadacitinib adalimumab); 8. Change from baseline in SF-36 PCS; 9. Change from baseline in FACIT-Fatigue Questionnaire; 10. ACR 20 response rate (superiority of upadacitinib vs. adalimumab); 11. Proportion of subjects with resolution of dactylitis (LDI Week 24; 12. Change from baseline in Patient's Assessment of Pain (superiority of upadacitinib vs. adalimumab); 13. Change from baseline in HAQ-DI (superiority of upadacitinib adalimumab);   |
|------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                      | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)        | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)                                                                       | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)                                                                       | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Week 24 database lock: 21 JAN 2020 (Data Cutoff Date 13 DEC 2019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Results and Analysis               | Results and Analysis                                                     | Results and Analysis                                                                                                                    | Results and Analysis                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Analysis description               | Analysis description                                                     | Primary Analysis                                                                                                                        | Primary Analysis                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Analysis population and time point | Analysis population and time point                                       | Week 12 (unless otherwise specified), Full Analysis Set (includes all randomized subjects who received at least one dose of study drug) | Week 12 (unless otherwise specified), Full Analysis Set (includes all randomized subjects who received at least one dose of study drug) | Week 12 (unless otherwise specified), Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Week 12 (unless otherwise specified), Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Week 12 (unless otherwise specified), Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect Estimate per Comparison     | Effect Estimate per Comparison                                           | Treatment Group                                                                                                                         | Placebo                                                                                                                                 | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Adalimumab 40 mg EOW Upadacitinib 15 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Upadacitinib 30mg QD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                    |                                                                          | Number of subjects                                                                                                                      | 423                                                                                                                                     | 423                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 429 429                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 423                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Primary                            | Primary                                                                  | Endpoint:                                                                                                                               | Endpoint:                                                                                                                               | Endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Endpoint:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                    |                                                                          | ACR20 %responders Diff. (95% CI) p-value                                                                                                | 36.2                                                                                                                                    | 36.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 65.0 70.6 UPA vs Placebo 34.5 (28.2, 40.7) < 0.0001*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 78.5 UPA vs Placebo 42.3 (36.3, 48.3) < 0.0001*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                    |                                                                          | Ranked Key Secondary Endpoints:                                                                                                         | Ranked Key Secondary Endpoints:                                                                                                         | Ranked Key Secondary Endpoints:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Ranked Key Secondary Endpoints:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Ranked Key Secondary Endpoints:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                    |                                                                          | HAQ-DI change from baseline LS Mean                                                                                                     | -0.14                                                                                                                                   | -0.14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | -0.34 -0.42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -0.47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Effect Estimate per Comparison   | Treatment Group                                                                                       | Placebo   | Adalimumab 40 mg EOW   | Upadacitinib 15 mg QD                                                                | Upadacitinib 30mg QD                                                                   |
|----------------------------------|-------------------------------------------------------------------------------------------------------|-----------|------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Effect Estimate per Comparison   | Diff. (95% CI) p-value                                                                                |           |                        | UPA vs Placebo -0.28 (-0.35, -0.22) < 0.0001* UPA vs ADA -0.08 (-0.15, -0.01) 0.0162 | UPA vs Placebo -0.34 (-0.40, -0.27) < 0.0001* UPA vs ADA -0.14 (-0.20, -0.07) < 0.0001 |
| Effect Estimate per Comparison   | sIGA 0/1 at Week 16 a %responders Diff. (95% CI) p-value                                              | 10.9      | 38.5                   | 41.9 UPA vs Placebo 31.1 (24.7, 37.5) < 0.0001* UPA vs ADA 3.4 (-4.1, 11.0) 0.3857   | 54.0 UPA vs Placebo 43.1 (36.7, 49.6) < 0.0001* UPA vs ADA 15.5 (8.0, 23.1) < 0.0001   |
| Effect Estimate per Comparison   | PASI75 at Week 16 b %responders Diff. (95% CI) p-value                                                | 21.3      | 53.1                   | 62.6 UPA vs Placebo 41.3 (32.8, 49.8) < 0.0001* UPA vs ADA 9.5 (0.2, 18.9) 0.0528    | 62.4 UPA vs Placebo 41.1 (32.5, 49.6) < 0.0001* UPA vs ADA 9.3 (-0.1, 18.7) 0.0516     |
| Effect Estimate per Comparison   | Modified PsA Sharp/van der Heijde Score (mTSS) change from baseline at Week 24 LS Mean Diff. (95% CI) | 0.25      | 0.01                   | -0.04 UPA vs Placebo -0.29 (-0.44, -0.14) 0.0002*                                    | 0.03 UPA vs Placebo -0.21 (-0.36, -0.06) 0.0069*                                       |
| Effect Estimate per Comparison   | Treatment Group                                                                                       | Placebo   | Adalimumab 40 mg EOW   | Upadacitinib 15 mg QD                                                                | Upadacitinib 30mg QD                                                                   |
|                                  | MDA at Week 24 %responders                                                                            | 12.3      | 33.3                   |                                                                                      |                                                                                        |
|                                  | Diff. (95% CI) p-value                                                                                |           |                        |                                                                                      |                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                                                          |       |       | 36.6 UPA vs Placebo 24.3 (18.8, 29.8) < 0.0001* UPA vs ADA 3.3 (-3.1, 9.6) 0.3218   | 45.4 UPA vs Placebo 33.1 (27.4, 38.8) < 0.0001* UPA vs ADA 12.1 (5.5, 18.6) 0.0003    |
|--------------------------------------------------------------------------|-------|-------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Resolution of Enthesitis at Week 24 c %responders Diff. (95% CI) p-value | 32.4  | 47.2  | 53.7 UPA vs Placebo 21.3 (13.0, 29.7) < 0.0001* UPA vs ADA 6.5 (-1.9, 15.0) 0.1500  | 57.7 UPA vs Placebo 25.3 (16.9, 33.7) < 0.0001* UPA vs ADA 10.5 (2.1, 18.9) 0.0169    |
| ACR20 %responders Diff. (95% CI) p-value                                 | 36.2  | 65    | 70.6 UPA vs ADA 5.6 (-0.6, 11.8) Non-inferiority: < 0.0001* Superiority: 0.0815     | 78.5 UPA vs ADA 13.5 (7.5, 19.4) Non-inferiority: < 0.0001* Superiority: < 0.0001*    |
| SF-36 PCS change from baseline LS Mean Diff. (95% CI) p-value            |  3.19 |  6.82 | 7.86 UPA vs Placebo 4.67 (3.67, 5.67) < 0.0001* UPA vs ADA 1.00 (0.01, 2.00) 0.0475 | 8.90 UPA vs Placebo 5.72 (4.71, 6.72) < 0.0001* UPA vs ADA 2.08 (1.09, 3.08) < 0.0001 |
| FACIT-F change from baseline LS Mean Diff. (95% CI)                      |  2.8  |  5.7  | 6.3 UPA vs Placebo 3.5 (2.4, 4.7) < 0.0001* UPA vs ADA 0.7                          | 7.1 UPA vs Placebo 4.3 (3.1, 5.5) < 0.0001* UPA vs ADA 1.4                            |

<div style=\"page-break-after: always\"></div>

| Effect Estimate per Comparison   | Treatment Group                                                                  | Placebo   | Adalimumab 40 mg EOW   | Upadacitinib 15 mg QD                                                                  | Upadacitinib 30mg QD                                                                    |
|----------------------------------|----------------------------------------------------------------------------------|-----------|------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|                                  | p-value                                                                          |           |                        | (-0.5, 1.8) 0.2678                                                                     | (0.3, 2.6) 0.0157                                                                       |
|                                  | Resolution of dactylitis at Week 24 d %responders Diff. (95% CI) p-value         | 39.7      | 74.0                   | 76.5 UPA vs Placebo 36.8 (25.7, 47.9) < 0.0001 UPA vs ADA 2.5 (-8.0, 12.9) 0.5615      | 79.5 UPA vs Placebo 39.8 (28.8, 50.9) < 0.0001 UPA vs ADA 5.5 (-4.9, 15.9) 0.2792       |
|                                  | Patient's Assessment of Pain change from baseline LS Mean Diff. (95% CI) p-value | -0.9      | -2.3                   | -2.3 UPA vs Placebo -1.3 (-1.6, -1.0) < 0.0001 UPA vs ADA 0.0 (-0.3, 0.3) 0.8970       | -2.7 UPA vs Placebo -1.8 (-2.1, -1.5) < 0.0001 UPA vs ADA -0.5 (-0.7, -0.2) 0.0028      |
|                                  | SAPS change from baseline at Week 16 LS Mean Diff. (95% CI) p-value              | -8.2      | -22.7                  | -25.3 UPA vs Placebo -17.1 (-19.6, -14.6) < 0.0001 UPA vs ADA -2.5 (-5.0, -0.0) 0.0498 | -28.1 PA vs Placebo -19.8 (-22.3, -17.3) < 0.0001 UPA vs ADA -5.2 (-7.7, -2.7) < 0.0001 |

## Notes

p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error.

- a. In patients with sIGA ≥ 2 at baseline (n = 313, 330, 322, and 324, respectively).
- b. In patients with ≥ 3% BSA psoriasis at baseline (n = 211, 211, 214, and 210, respectively).
- c. In patients with enthesitis at baseline (n = 241, 265, 270, and 267, respectively).
- d. In patients with dactylitis at baseline (n = 126, 127, 136, and 127, respectively).

<div style=\"page-break-after: always\"></div>

## Table 52 Summary of Efficacy for trial M15-554

| Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2   | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) - SELECT - PsA 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                     | Study M15-554 (EudraCT Number: 2016-004152-30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study M15-554 (EudraCT Number: 2016-004152-30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study M15-554 (EudraCT Number: 2016-004152-30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                               | A Phase 3 multicenter study that includes two periods. Period 1 is 56-weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled period followed by an additional 32 weeks of blinded treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo in subjects with moderately to severely active PsA who have an inadequate response to bDMARDs (Bio-IR). Period 2 is an open label (blinded until the last subject completes the last visit of Period 1) long-term extension of up to a total treatment duration of approximately 3 years (or until approval in certain countries) to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD, and 30 mg QD, in subjects with PsA who have completed Period 1. | A Phase 3 multicenter study that includes two periods. Period 1 is 56-weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled period followed by an additional 32 weeks of blinded treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo in subjects with moderately to severely active PsA who have an inadequate response to bDMARDs (Bio-IR). Period 2 is an open label (blinded until the last subject completes the last visit of Period 1) long-term extension of up to a total treatment duration of approximately 3 years (or until approval in certain countries) to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD, and 30 mg QD, in subjects with PsA who have completed Period 1. | A Phase 3 multicenter study that includes two periods. Period 1 is 56-weeks in duration and includes a 24-week randomized, double-blind, parallel-group, placebo- controlled period followed by an additional 32 weeks of blinded treatment (Weeks 24 - 56). Period 1 is designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD versus placebo in subjects with moderately to severely active PsA who have an inadequate response to bDMARDs (Bio-IR). Period 2 is an open label (blinded until the last subject completes the last visit of Period 1) long-term extension of up to a total treatment duration of approximately 3 years (or until approval in certain countries) to evaluate the safety, tolerability and efficacy of upadacitinib 15 mg QD, and 30 mg QD, in subjects with PsA who have completed Period 1. |
| Design                                                                                                                                                                                                                                                               | Duration of double-blind, placebo-controlled period: Duration of additional blinded treatment period: Duration of open-label extension period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Duration of double-blind, placebo-controlled period: Duration of additional blinded treatment period: Duration of open-label extension period:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24 weeks 32 weeks Up to 2 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hypothesis                                                                                                                                                                                                                                                           | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                    | Upadacitinib 15 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Upadacitinib 15 mg QD for up to 3 years, n = 211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Upadacitinib 15 mg QD for up to 3 years, n = 211                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                                    | Upadacitinib 30 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Upadacitinib 30 mg QD for up to 3 years, n = 219                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Upadacitinib 30 mg QD for up to 3 years, n = 219                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                                    | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Placebo for 24 weeks; Total n = 212 After Week 24: Placebo to UPA 15mg; n = 106                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Placebo for 24 weeks; Total n = 212 After Week 24: Placebo to UPA 15mg; n = 106                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                            | Primary endpoint (Upadacitinib 15 and 30 mg vs placebo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Proportion of subjects achieving ACR20 response at Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Proportion of subjects achieving ACR20 response at Week 12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                      | Ranked key secondary endpoints (at Week 12 unless otherwise specified)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | The key multiplicity adjusted secondary efficacy endpoints (each dose of upadacitinib versus placebo) are: 1. Change from baseline in HAQ-DI 2. Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16 (For Subjects with Baseline sIGA ≥ 2) 3. Psoriasis Area Severity Index (PASI) 75 response at Week 16 (for subjects with ≥ 3% BSA psoriasis at baseline) 4. Change from baseline in SF-36 PCS                                                                                                                                                                                                                                                                                                                                                                                           | The key multiplicity adjusted secondary efficacy endpoints (each dose of upadacitinib versus placebo) are: 1. Change from baseline in HAQ-DI 2. Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16 (For Subjects with Baseline sIGA ≥ 2) 3. Psoriasis Area Severity Index (PASI) 75 response at Week 16 (for subjects with ≥ 3% BSA psoriasis at baseline) 4. Change from baseline in SF-36 PCS                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                                                                                                     |                                                                                                                     |                                                                                                                     | 6. Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24 7. Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16   | 6. Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24 7. Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16   | 6. Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24 7. Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16   |                                 |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Database lock                                                                                                       | Week 24 interim database lock: Oct 23, 2019 (Data Cutoff Date 09 OCT 2019)                                          | Week 24 interim database lock: Oct 23, 2019 (Data Cutoff Date 09 OCT 2019)                                          | Week 24 interim database lock: Oct 23, 2019 (Data Cutoff Date 09 OCT 2019)                                                                                                       | Week 24 interim database lock: Oct 23, 2019 (Data Cutoff Date 09 OCT 2019)                                                                                                       | Week 24 interim database lock: Oct 23, 2019 (Data Cutoff Date 09 OCT 2019)                                                                                                       |                                 |
| Results and Analysis                                                                                                | Results and Analysis                                                                                                | Results and Analysis                                                                                                |                                                                                                                                                                                  |                                                                                                                                                                                  |                                                                                                                                                                                  |                                 |
| Analysis description                                                                                                | Analysis description                                                                                                | Primary Analysis                                                                                                    | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 | Primary Analysis                                                                                                                                                                 |                                 |
| Analysis population and time point                                                                                  | Analysis population and time point                                                                                  | Week 12, Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)          | Week 12, Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                       | Week 12, Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                       | Week 12, Full Analysis Set (includes all randomized subjects who received at least one dose of study drug)                                                                       |                                 |
| Effect Estimate per Comparison Treatment Group                                                                      | Effect Estimate per Comparison Treatment Group                                                                      | Effect Estimate per Comparison Treatment Group                                                                      | Placebo                                                                                                                                                                          | Upadacitinib 15 mg QD                                                                                                                                                            | Upadacitinib 30 mg QD                                                                                                                                                            |                                 |
| Number of subjects                                                                                                  | Number of subjects                                                                                                  | Number of subjects                                                                                                  | 212                                                                                                                                                                              | 211                                                                                                                                                                              | 218                                                                                                                                                                              |                                 |
| Primary endpoint:                                                                                                   | Primary endpoint:                                                                                                   | Primary endpoint:                                                                                                   | Primary endpoint:                                                                                                                                                                | Primary endpoint:                                                                                                                                                                | Primary endpoint:                                                                                                                                                                | Primary endpoint:               |
| ACR20 at Week %responders vs placebo: Diff. (95% CI)                                                                | ACR20 at Week %responders vs placebo: Diff. (95% CI)                                                                | ACR20 at Week %responders vs placebo: Diff. (95% CI)                                                                | 24.1                                                                                                                                                                             | 56.9 32.8 (24.0, 41.6) < 0.0001*                                                                                                                                                 | 63.8 39.7 (31.1, 48.3) < 0.0001*                                                                                                                                                 |                                 |
| Ranked Key Secondary Endpoints:                                                                                     | Ranked Key Secondary Endpoints:                                                                                     | Ranked Key Secondary Endpoints:                                                                                     | Ranked Key Secondary Endpoints:                                                                                                                                                  | Ranked Key Secondary Endpoints:                                                                                                                                                  | Ranked Key Secondary Endpoints:                                                                                                                                                  | Ranked Key Secondary Endpoints: |
| HAQ-DI change baseline at Week LS Mean vs placebo:                                                                  | HAQ-DI change baseline at Week LS Mean vs placebo:                                                                  | HAQ-DI change baseline at Week LS Mean vs placebo:                                                                  | -0.10                                                                                                                                                                            | -0.30 -0.21 (-0.30, -0.12) < 0.0001*                                                                                                                                             | -0.41 -0.31 (-0.40, -0.22) < 0.0001*                                                                                                                                             |                                 |
| p-value sIGA 0/1 at Week %responders vs placebo: Diff. (95% CI) p-value                                             | p-value sIGA 0/1 at Week %responders vs placebo: Diff. (95% CI) p-value                                             | p-value sIGA 0/1 at Week %responders vs placebo: Diff. (95% CI) p-value                                             | 9.2                                                                                                                                                                              | 36.8 27.6 (19.2, 36.1) < 0.0001*                                                                                                                                                 | 40.2 31.0 (22.3, 39.8) < 0.0001*                                                                                                                                                 |                                 |
|                                                                                                                     |                                                                                                                     |                                                                                                                     | 16.0                                                                                                                                                                             | 52.3 36.3 (25.6, 46.9) < 0.0001*                                                                                                                                                 | 56.5 40.5 (29.9, 51.0) < 0.0001*                                                                                                                                                 |                                 |
| Effect Estimate                                                                                                     | Effect Estimate                                                                                                     | Effect Estimate                                                                                                     | Placebo                                                                                                                                                                          | Upadacitinib 15 mg QD                                                                                                                                                            | Upadacitinib 30 mg QD                                                                                                                                                            |                                 |
| SF-36 PCS change baseline at Week LS Mean vs placebo: Diff. (95% CI) p-value FACIT-Fatigue baseline at Week LS Mean | SF-36 PCS change baseline at Week LS Mean vs placebo: Diff. (95% CI) p-value FACIT-Fatigue baseline at Week LS Mean | SF-36 PCS change baseline at Week LS Mean vs placebo: Diff. (95% CI) p-value FACIT-Fatigue baseline at Week LS Mean | 1.3                                                                                                                                                                              | 5.0 3.7 (2.0, 5.4) < 0.0001*                                                                                                                                                     | 6.1 4.8 (3.1, 6.4) < 0.0001*                                                                                                                                                     |                                 |
| p-value Minimal (MDA) at %responders vs placebo: Diff. (95% CI)                                                     | p-value Minimal (MDA) at %responders vs placebo: Diff. (95% CI)                                                     | p-value Minimal (MDA) at %responders vs placebo: Diff. (95% CI)                                                     | 2.8                                                                                                                                                                              | 25.1 22.3 (16.0, 28.6) < 0.0001*                                                                                                                                                 | 28.9 26.1 (19.7, 32.5) < 0.0001*                                                                                                                                                 |                                 |
| Disease Week p-value                                                                                                | Disease Week p-value                                                                                                | Disease Week p-value                                                                                                | Disease Week p-value                                                                                                                                                             |                                                                                                                                                                                  |                                                                                                                                                                                  |                                 |

<div style=\"page-break-after: always\"></div>

| Psoriasis at Week 16 LS Mean   | Psoriasis at Week 16 LS Mean                                                                                                                                                                                           | Self-Assessment of Symptoms (SAPS)                                                                                                                                                                                     | -1.5                                                                                                                                                                                                                   | -24.4 -22.9 (-27.4, -18.4) < 0.0001*                                                                                                                                                                                   | -29.7 -28.2 (-32.7, -23.8) < 0.0001*                                                                                                                                                                                   |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                |                                                                                                                                                                                                                        | vs placebo: Diff. (95% CI) p-value                                                                                                                                                                                     |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |                                                                                                                                                                                                                        |
| Notes                          | p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error. a. In patients with sIGA ≥ 2 at baseline (n = 163, 171, and 164, respectively). | p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error. a. In patients with sIGA ≥ 2 at baseline (n = 163, 171, and 164, respectively). | p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error. a. In patients with sIGA ≥ 2 at baseline (n = 163, 171, and 164, respectively). | p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error. a. In patients with sIGA ≥ 2 at baseline (n = 163, 171, and 164, respectively). | p-values with * are statistically significant in the multiplicity adjusted analysis, under strong control of the overall type I error. a. In patients with sIGA ≥ 2 at baseline (n = 163, 171, and 164, respectively). |

## Analysis performed across trials (pooled analyses and meta-analysis)

## Integrated efficacy analyses

One integrated analysis set of the Phase 3 studies was defined for the purpose of short-term integrated efficacy analyses. The integrated analysis set combines efficacy data during the 24-week placebo-controlled period from Study M15-572 (non-biologic DMARD-IR) and Study M15-554 (bDMARD-IR). The integrated analysis set is referred to as the 'Placebo-Controlled Analysis Set'. Subjects receiving upadacitinib 15 mg QD, upadacitinib 30 mg QD, or placebo were included in this analysis set. The randomization ratio between upadacitinib and control is the same in both studies being integrated.

The following integrated efficacy analyses were conducted using the Placebo-Controlled Analysis Set: ACR20/50/70, HAQ-DI, sIGA 0/1, PASI 75/90/100, and MDA.

The following key efficacy endpoints were examined at the specified time points: ACR20/50/70 response rates at Week 12; Change from baseline in HAQ-DI at Week 12; Proportion of subjects achieving sIGA 0/1 at Week 16 (for subjects with baseline sIGA ≥ 2); PASI 75/90/100 response rates at Week 16 (for subjects with ≥ 3% BSA -Ps at baseline); and proportion of subjects achieving MDA at Weeks 16 and 24.

For MDA and additional secondary endpoints related to dactylitis and enthesitis, results were also evaluated at Week 16 in addition to point Week 24 to assess MDA prior to the initiation of potential rescue therapies.

Overall, the results of the above-mentioned integrated analyses are concordant with the results of the individual studies. Therefore, the results are not shown here except for the primary endpoint in different treatment combinations.

## Primary endpoint in different DMARD combinations

Primary endpoint (ACR20 response rate at Week 12) results in the specific subgroups with different combinations of upadacitinib, MTX and other non-biologic DMARDs in the 'placebo-controlled upadacitinib 15 mg and 30 mg analysis set' are given in Table 53.

<div style=\"page-break-after: always\"></div>

Table 53 ACR20 Response Rate at Week 12 by Upadacitinib with MTX vs. Upadacitinib with Other Non-Biologic DMARDs (Placebo-Controlled Upadacitinib 15 mg and 30 mg Analysis Set)

<!-- image -->

| Parameter                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subgroup                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                     | Responder                                                                                                                                                                                                                                                           | Response Rate                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Treatment                                                                                                                                                                                                                                                           | N                                                                                                                                                                                                                                                                   | n（%）                                                                                                                                                                                                                                                                | （958CI）[A]                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| ACR20                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Upadacitinib with MTX                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Placebo                                                                                                                                                                                                                                                             | 375                                                                                                                                                                                                                                                                 | 126(33.6)                                                                                                                                                                                                                                                           | 33.6(28.8,38.4)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA 15mgQD                                                                                                                                                                                                                                                          | 379                                                                                                                                                                                                                                                                 | 267(70.4)                                                                                                                                                                                                                                                           | 70.4(65.9,75.0)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA30mgQD                                                                                                                                                                                                                                                           | 373                                                                                                                                                                                                                                                                 | 282(75.6)                                                                                                                                                                                                                                                           | 75.6(71.2,80.0)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| With MTX Alone                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Placebo                                                                                                                                                                                                                                                             | 342                                                                                                                                                                                                                                                                 | 120(35.1)                                                                                                                                                                                                                                                           | 35.1(30.0,40.1)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA 15mgQD                                                                                                                                                                                                                                                          | 353                                                                                                                                                                                                                                                                 | 251(71.1)                                                                                                                                                                                                                                                           | 71.1(66.4,75.8)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA 30mgQD                                                                                                                                                                                                                                                          | 341                                                                                                                                                                                                                                                                 | 254(74.5)                                                                                                                                                                                                                                                           | 74.5(69.9,79.1)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| With MTx and Other                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Non-Biologic DMARDs                                                                                                                                                                                                                                                 | 33                                                                                                                                                                                                                                                                  | 6(18.2)                                                                                                                                                                                                                                                             | 18.2（5.0,31.3)                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Placebo UPA 15mgQD                                                                                                                                                                                                                                                  | 26                                                                                                                                                                                                                                                                  | 16(61.5)                                                                                                                                                                                                                                                            | 61.5(42.8,80.2)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA30mgQD                                                                                                                                                                                                                                                           | 32                                                                                                                                                                                                                                                                  | 28(87.5)                                                                                                                                                                                                                                                            | 87.5(76.0,99.0)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. | [A]:95e confidence intervals for response rate are calculated based on normal approximation to the binomial distribution. [B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study. |
| Parameter                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Subgroup                                                                                                                                                                                                                                                            | N                                                                                                                                                                                                                                                                   | Responder                                                                                                                                                                                                                                                           | Response Rate                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Treatment                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     | n（8）                                                                                                                                                                                                                                                                | （958CI）[A]                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Upadacitinib with Other                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Non-Biologic DMARDs Placebo                                                                                                                                                                                                                                         | 72 72                                                                                                                                                                                                                                                               | 31(43.1)                                                                                                                                                                                                                                                            | 43.1(31.6,54.5) 62.5 (51.3,73.7)                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA15mgQD                                                                                                                                                                                                                                                           | 71                                                                                                                                                                                                                                                                  | 45(62.5) 50（70.4)                                                                                                                                                                                                                                                   | 70.4(59.8,81.0)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA30mgQD                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Any APREMILAsT without MTX                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA15mgQD UPA 30mgQD                                                                                                                                                                                                                                                | 15                                                                                                                                                                                                                                                                  | 9(60.0)                                                                                                                                                                                                                                                             | 60.0 (35.2, 84.8)                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 8(61.5)                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     | 13                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Any LEFLUNOMIDE without MTX                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 61.5(35.1,88.0)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Placebo UPA15mgQD                                                                                                                                                                                                                                                   | 29                                                                                                                                                                                                                                                                  | 16(55.2)                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA30mgQD                                                                                                                                                                                                                                                           | 30 35                                                                                                                                                                                                                                                               | 20(66.7)                                                                                                                                                                                                                                                            | 55.2（37.1,73.3) 66.7 (49.8,83.5)                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 28（80.0)                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 80.0（66.7,93.3)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Any SULFASALAZINE without XIW                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     | 26                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| Placebo UPA15mgQD                                                                                                                                                                                                                                                   | 24                                                                                                                                                                                                                                                                  | 15(62.5)                                                                                                                                                                                                                                                            | 34.6(16.3,52.9)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
| UPA30mgQD                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 62.5（43.1,81.9)                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 9(34.6)                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 68.2                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | 15(68.2)                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     | (48.7,87.6)                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                     | 22                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                     |

[A]:95&amp; confidence intervals for response rate are calculated based on normal approximation to the binomial distribution.

[B]:Point estimate and 95e confidence intervals for between group difference are based on Mantel-Haenszel estimation adjusting for study.

<div style=\"page-break-after: always\"></div>

## Supportive studies

## Health economics and outcomes research reports

## Short-Form Health Survey Version 2 (SF-36v2)

To evaluate the extent to which upadacitinib improves HRQoL among patients with PsA, the MAH evaluated the change in SF-36v2 questionnaire score from baseline to Week 12 was in studies M15-572 and M15-554, of upadacitinib in adults with active PsA. The SF-36v2 includes 36 items across eight subscales that assess functional health and well-being: physical functioning, bodily pain, vitality, social functioning, mental health, general health perceptions, and role limitations due to physical problems (hereafter referred to as rolephysical) and emotional problems. Additionally, a Physical Component Summary (PCS), Mental Component Summary (MCS), and preference-based health utility index can be derived from the SF-36v2.

The modified version of the original questionnaire, the SF-36v2, was created in 1996. The content validity of the SF-36v2 is supported by qualitative and quantitative study findings published in the literature, which document that HRQoL impacts as measured by the SF-36v2 are important and relevant to the PsA experience.

The SF-36v2 is fit for the purpose of evaluating the Phase 3 efficacy hypotheses that upadacitinib improves HRQoL associated with PsA.

## Functional Assessment of Chronic Illness Therapy- Fatigue

PsA can result in fatigue, which has been reported in the literature and noted in clinical trials to be important and relevant to patients with PsA.

The FACIT-Fatigue's  items  assess  fatigue  experience  and  fatigue  impact  (i.e.,  severity,  impacts  to  daily activities, emotional impacts) on a five-point scale ranging from 0 (\"not at all\") to 4 (\"very much\") with a recall period of the \"past 7 days. A total score is calculated by summing the item scores, after reversing items that are worded in the negative direction, resulting in a maximum score of 52 and a minimum score of 0; lower scores indicate greater fatigue. The MAH evaluated the mean change in FACIT-Fatigue total scores from Baseline to Week 12 between secondary endpoint for fatigue upadacitinib and the combined placebo group. These results are consistent with other studies of the FACIT-Fatigue scores in PsA patient populations as reported in the scientific literature. Data generated from this study M15-554 were used to create clinically important difference (CID) and clinically important response (CIR) estimates. These values can be compared with results from Cella et al. (2019), which indicated a CID of 3.1 points for the FACIT-Fatigue total score in a PsA patient population and a responder definition estimated as a 4-point improvement in total score.

## Patient Reported Outcomes Evidence for Fatigue as a Clinically Meaningful Symptom of Psoriatic Arthritis and a Unique Endpoint in AbbVie's Phase 3 Measurement Strategy -

## Position Paper

This report addresses the FDA's concerns regarding the clinical meaningfulness of fatigue in PsA, and its redundancy with other endpoints, in an effort to support the FACIT-Fatigue as a key secondary endpoint in the Phase 3 trials of upadacitinib in adults ≥18 years of age with ac tive PsA.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) - Outcome Measures in  Rheumatology  (OMERACT)  PsA  working  group  includes  fatigue  as  one  of  the  core  outcomes  of  PsA treatment. Conclusion: Improvement in fatigue captures a treatment benefit that is both meaningful from the patient and physician perspectives, and unlike any other primary and secondary endpoints in the MAH outcome measurement strategy.

## Self-Assessment of Psoriasis Symptoms (SAPS)

Specific to the present dossier, the effect of upadacitinib on patient-reported psoriasis signs and symptoms in  patients  with  active  PsA  was  evaluated,  hypothesizing  that  greater  improvement  in  patient-reported

<div style=\"page-break-after: always\"></div>

psoriasis symptoms, as measured by the SAPS total score from Baseline to Week 16, would be observed in patients treated with upadacitinib compared to placebo (ranked secondary endpoint).

The SAPS is an 11-item patient-reported outcome (PRO) questionnaire that assesses pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, cracking, and joint pain at their worst in the 24 hours prior to the assessment on an 11-point NRS ranging from 0 ('no [sign/symptom] at all') to 10 ('worst possible [sign/symptom]'). A total score is computed by summing the item scores. The SAPS score ranges from 0 to 110, where higher scores represent more severe signs and symptoms.

Development and content validity: Informed by best measurement development practices, as well as the FDA PRO Guidance, the SAPS was developed based on concepts identified as relevant to plaque psoriasis in the  peer-reviewed  literature,  clinical  experts  in  the  field  of  dermatology  (N=3),  and  concept  elicitation interviews with patients with chronic plaque psoriasis (N=40; including those with concomitant PsA [n=15]). Following its development, confirmation of the relevance of item-concepts and evaluation of the readability and comprehensibility of the questionnaire were conducted in a patient population of adults with chronic plaque psoriasis (N=20). The results indicated that the concepts measured by the SAPS are relevant to the condition, and the items themselves are presented in ways that respondents can easily read and understand and to which they can provide meaningful responses.

Measurement properties: The measurement properties of the SAPS were studied in the MAH's Phase 3 clinical study for PsA, M15-554 (SELECT-PsA 2) (N=638). Data generated from these participants at Baseline, Week 16, and Week 24 were used to evaluate the psychometric performance of the SAPS total score when collected during the Phase 3 study. Quality of completion of the SAPS items, an indicator of compliance with assessment, was high at all time points, with no missing items for more than 99.0% of participants across all  time  points.  Descriptive  data  at  Baseline  for  item  scores  generated  by  the  SAPS  demonstrated  that respondents used the entire range of the response scale. The findings from the psychometric evaluation demonstrated that the SAPS produced a total score that was reliable (with high internal consistency reliability and test-retest reliability), valid in terms of measuring the construct it is intended to measure, capable of distinguishing between groups known to be clinically different, and sensitive to change over time. These conclusions  are  supported  by  results  from  AbbVie's  Phase  2  clinical  study  of  ABT-122  in  PsA,  M14-197 (N=240), in which the measurement properties of the SAPS were also studied.

Interpretation of scores: Interpretation of scores produced by the SAPS total score was also examined in the MAH's Phase 3 clinical study for PsA, M15-554 (SELECT-PsA 2), and supported by results from M14-197. Data generated from these clinical studies were used to create clinically important difference (CID) and clinically  important  response  (CIR)  estimates  that  could  be  used  to  facilitate  the  meaning  of  observed differences and within-person change, respectively, in the SAPS total score. In M15-554, distribution- based statistics were produced for the SAPS total score at Baseline. Anchor-based analyses produced mean change in  SAPS  total  score  from  Baseline  to  Weeks  16  and  24  for  each  anchor  group,  cumulative  distribution functions, probability distribution functions, and receiver operating characteristic curves to specify the change score  that  optimally  discriminates  between  each  group  defined  by  the  anchors.  Distribution-based  and anchor-based  methods  were  used  to  determine  a  CID  and  a  CIR  for  the  SAPS  total  score.  These interpretations are supported by results from M14-197.

Conclusion by the MAH: The SAPS is according to the MAH fit for the purpose of evaluating the Phase 3 efficacy hypotheses that upadacitinib improves patient-reported psoriasis signs and symptoms among adult patients with active PsA. This conclusion is supported by evidence of the content validity of the SAPS (i.e., the items measure concepts that are important and relevant to patients with PsA and does so in ways that respondents  can  understand  and  to  which  they  can  provide  meaningful  responses),  measurement characteristics (i.e., the instrument generate scores that are reliable, valid, and sensitive to change), and interpretability  (i.e.,  identified  changes  in  scores  can  clearly  be  distinguished  as  meaningful  from  the perspective of the patient seeking treatment).

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

Based on the clinical data and PPK modelling, the MAH concluded that the dose of 15 mg QD provides the optimal benefit-risk balance in subjects with PsA, with only modestly increased efficacy and decreased safety compared with the 30 mg QD dose. The higher dose tested in the Phase 3 clinical studies is not applied for. Therefore, the discussion focuses on the results obtained with the 15 mg QD dose.

Clinical studies in PsA include two Phase 3 trials (M15-572 and M15-554).

The two Phase 3 trials were conducted in subjects with moderate to severe PsA who had not responded adequately or were intolerant to prior treatment: M15-572 in patients with prior non-biologic DMARD treatment, and Study M15-554 in patients with prior bDMARDs. Due to the inclusion criteria, patients had moderate to severe PsA, since they were required to have active joint disease defined as ≥ 3 tender joints (based on 68 joint counts) and ≥ 3 swollen joints (based on 66 joint counts) at baseline, symptom onset at least 6 months prior to screening, fulfilment of the CASPAR criteria, and diagnosis of active plaque psoriasis or documented history of plaque psoriasis. In study M15-572, additionally, subjects were required to have had either ≥ 1 erosion on x-ray as determined by central imaging review or high-sensitivity C-reactive protein (hs-CRP) &gt; laboratory defined upper limit of normal (ULN).

The proposed indication does not include any statement on the degree of severity of PsA. No universally agreed definition for mild, moderate and severe PsA exist. According to treatment guidelines, pharmacological treatment of PsA is initiated with anti-inflammatory medications and local corticosteroid injections in affected joints and insertions of tendons, ligaments and joint capsule fibres. Treatment with DMARDs is only started for subjects not responding adequately to the abovementioned treatments; therefore, it is acceptable to CHMP that subjects with mild disease that can be controlled without DMARDs were not included. In absence of a universally agreed definition of moderate or severe PsA it is considered appropriate to the CHMP that disease severity is not included in the indication.

Both phase 3 studies are still ongoing, and the initial MA submission includes the data for first 24 weeks of Period 1 (56 weeks) of the studies. With the response to the 1st RSI, results up to week 56 were received for all outcomes proposed to be included in the SmPC.

## Design and conduct of clinical studies

The clinical development pivotal programme supporting the efficacy of upadacitinib in PsA is considered in principle adequate to the CHMP. Both Phase 3 studies are randomized, multi-centre, double-blind, parallel-group studies with a 35-day screening period, a 56-week blinded period, and a long-term extension period of up to a total treatment duration of approximately 3 years. Both studies are ongoing, and efficacy results up to 24 weeks of the 56-week double-blind Period 1 are included in the clinical study reports, with some incomplete results up to 56 weeks in the clinical overview and clinical efficacy summary. Further 56-week data was received with the MAH's response, at which time all subjects had reached Week 56 or were prematurely discontinued by submission of the response.

Study M15-572 evaluates upadacitinib in subjects who have an inadequate response or intolerance to non-biologic DMARDs (conventional synthetic DMARDs [csDMARDs] and/or tsDMARDs) or had a contraindication for non-biologic DMARDs.

Study M15-554 evaluates upadacitinib in subjects who have an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARDs).

<div style=\"page-break-after: always\"></div>

Using ACR20 as primary endpoint is in line with the Guideline on clinical investigation of medicinal products for the treatment of psoriatic arthritis (CHMP/EWP/438/04) and considered acceptable to the CHMP. The time point of 12 weeks for the primary endpoint is considered relatively early; however, this has been accepted in the SA and shows difference of effect. Long-term effects on maintenance of effect will be seen with completion of the ongoing trials. Efficacy results up to 56 weeks have been provided. Furthermore, supportive data from RA are available which is of relevance since the mode of action is expected to be similar in PsA as in RA.

There are multiple and partly overlapping secondary efficacy endpoints for investigation of activity of psoriatic arthritis (e.g., ACR20/50/70, MDA, DAS28, DAPSA, several measures on resolution of dactylitis and enthesitis, and in study M15-572, radiographic progression of joint disease); skin involvement (sIGA, PASI, SAPS), spondyloarthropathy (BASDAI, ASDAS), and PROs (HAQ-DI, FACIT-F, SF-36 PCS, patient's assessment of pain, morning stiffness, EQ-5D-5L, pain, WPAI, etc). Inclusion of all endpoints in the studies is for the MAH to choose and, therefore, acceptable to the CHMP. However, only multiplicity-controlled and/or clinically relevant outcomes should be included in the SmPC. In line with this statement, the MAH was requested to shorten the proposed Section 5.1 of the SmPC during the review. The MAH accepted the CHMP's requests and submitted an updated SmPC accordingly; see details below.

The MAH has under development a tool (questionnaire) the Self-Assessment of Psoriasis Symptoms (SAPS) to evaluate signs and symptoms of psoriasis. The SAPS is an 11-item patient-reported outcome (PRO) questionnaire that assesses pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, cracking, and joint pain at their worst in the 24 hours prior to the assessment on an 11point NRS ranging from 0 to 10. A total score is computed by summing the item scores. The SAPS score ranges from 0 to 110, where higher scores represent more severe signs and symptoms. As signs and symptoms of psoriasis are an important and relevant treatment outcome in PsA, the MAH evaluated the change in SAPS total score from Baseline to Week 16 between upadacitinib and the combined placebo group in the course of its clinical trials. Measurement properties and the interpretation of the scores, including clinically important response estimates, were evaluated in the MAH PsA development programme.

The CHMP was of the opinion that it wasn't possible at this stage to determine whether this was an appropriate tool in general or to support improved assessment of psoriasis signs and symptoms in PsA or fit for any labelling purposes. For example, lack of comparative data with validated standard instruments are, to date, scarce/lacking. Thus, it was considered premature to include any data on this instrument in the SmPC.

There were several protocol amendments, which did not concern major aspects of the study plans and occurred prior to data cut-off.

The statistical plans are overall considered acceptable by the CHMP. Number of subjects with missing data at various time points was overall small and is adequately described. Variation was large for most outcomes within each treatment group, hence, responses were partly overlapping. Additionally, the onset of efficacy was variable with some subjects reaching the primary endpoint ACR20 already at 2 weeks and some only by 56 weeks from onset of upadacitinib treatment. Only statistically significant and clinically relevant results qualify for inclusion in the SmPC. Therefore, the MAH was requested to update the proposed Section 5.1 of the SmPC during the review. The MAH accepted the CHMP's requests and submitted an updated SmPC accordingly.

The efficacy analyses were conducted for the FAS, which includes all randomized subjects who received at least 1 dose of study drug; instead of the recommended ITT population. Since these populations

<div style=\"page-break-after: always\"></div>

only differ by 1 subject in the 15 mg and 1 subject in the 30 mg upadacitinib group, this is not deemed to affect the results.

Doses selection of upadacitinib 15 mg and 30 mg was the same as for studies in RA. The observed binned plasma concentration versus time profiles of upadacitinib between subjects with RA and subjects with PsA were comparable.  The choice of adalimumab as active control in Study M15-572 is deemed appropriate, and the adalimumab dose, 40 mg subcutaneous EOW, is the dose approved for treatment of patients with PsA.

The MAH has confirmed that the studies were conducted in accordance with ICH and GCP guidelines.

## Efficacy data and additional analyses

A total of 2347 subjects were randomized and 2345 received at least 1 dose of study drug in the global pivotal Phase 3 studies, including 640 subjects who were initially randomized to and received at least 1 dose of upadacitinib 15 mg QD. More than 90% of subjects continued the study up to the primary endpoint (12 weeks) in both studies: 95.4% and 92.1% in studies M15-572 and M15-554, respectively. Most common reasons for discontinuation were lack of efficacy (M15-572) and withdrawal by subject (M15-554) in the placebo groups and AEs in the active-treated groups.

At baseline, the participants in both Phase 3 studies had active joint disease, with mean (SD) TJC68 of 20.0 (14.05) in study M15-572 and 24.8 (16.91) in study M15-554. The corresponding SJC66 was 11.2 (837) and 12.1 (8.85) in studies M15-572 and M15-554, respectively. The proportion of subjects with dactylitis at baseline was 30.3% and 26.4 %, with enthesitis 77.2 % and 82.2 %, and with psoriatic spondylitis 31.3 % and 34.2 % in studies M15-572 and M15-554, respectively. There were slightly more women in both studies. The studies represent different steps in the treatment algorithm for PsA: participants in study M15-572 were required to be intolerant or have inadequate response or contraindication to non-biologic DMARDs, whereas the participants in M15-554 are intolerant or have inadequate response or contraindication to biologic DMARDs. The mean duration of PsA diagnosis was consequently shorter in M15-572 (6.1 years), than in M15-554 (10.1 years).

Both Phase 3 studies met the primary endpoint at Week 12, with a statistically significantly greater percentage of subjects achieving an ACR20 response in the upadacitinib 15 mg and 30 mg QD groups compared with the placebo group. The 30 mg dose showed numerically somewhat more effect than the 15 mg dose. Since only the 15 mg dose is applied for, this discussion focuses on the results for the 15 mg dose.

In study M15-572, ACR 20 response was obtained at 12 weeks by 70.6 % of subjects in the upadacitinib 15 mg arm, 65.0 % in the adalimumab 40 mg EOW arm, and 36.2 % in the placebo arm. The difference between ACR20 response rate in the upadacitinib 15 mg and placebo groups was 34.5 (28.2, 40.7, p&lt;0.0001 in the multiplicity-adjusted analysis). Upadacitinib 15 mg QD was non-inferior to adalimumab 40 mg EOW in the primary endpoint: the percentage of adalimumab effect preservation, which was calculated by (upadacitinib - placebo)/(adalimumab - placebo), was 119.4% (confidence interval [CI]: 98.0, 147.9) in the upadacitinib 15 mg group, exceeding the lower bound of the 95% CI of the pre-specified NI ratio of at least 50% of the placebo-subtracted adalimumab effect.

Ranked key secondary endpoints of study M15-572 included comparison of non-inferiority of upadacitinib vs. adalimumab at Week 12 in the primary endpoint, ACR20 response rate, and superiority of upadacitinib vs, adalimumab in ACR20 response rate, change from baseline in Patient's Assessment of Pain NRS, and change in HAQ-DI at Week 12. Non-inferiority in the primary endpoint was met. However, upadacitinib 15 mg was not statistically superior to adalimumab in any of the above-mentioned multiplicity-controlled comparisons. Hence, the nominal differences in HAQ-DI and

<div style=\"page-break-after: always\"></div>

pain between upadacitinib 15 mg and adalimumab are not eligible to be included in the SmPC, as originally proposed by the MAH. It is acceptable to include in the SmPC the information that upadacitinib 15 mg was non-inferior to adalimumab. In addition, further justifications for inclusion of some additional secondary endpoints in the SmPC were requested by the CHMP and the SmPC was modified with the omission of improvement in Patient's Assessment of Pain NRS compared to adalimumab (as statistically non-significant), the non-multiplicity controlled endpoints change from baseline in ASDAS and PASI 100 response, and the multiplicity-controlled endpoints sIGA 0/1 response and SAPS.

In study M15-554, ACR 20 response was obtained at 12 weeks by 23.6 % of subjects in the placebo arm and 56.8 % in the upadacitinib 15 mg arm. The difference in the response rate was 33.1 (95 % CI 24.0, 42.3), and the difference was in multiplicity-adjusted analysis statistically significant (p&lt;0.0001).

For study M15-554, the ACR20 response rate at Week 12 for subjects with exclusively intolerance to prior bDMARDs and with inadequate response to prior bDMARDs was in the upadacitinib 15 mg vs. placebo arms, respectively, 73.3 % vs. 38.9 % for the patients with intolerance and 55.4 % vs. 22.7 % for patients with inadequate response. Hence, the patients with prior inadequate response were more treatment-resistant, but the improvement with upadacitinib compared to placebo was of similar clinically relevant magnitude. The MAH has not submitted corresponding subgroup analyses for study M15-572, which recruited patients with intolerance, inadequate response or contraindication to prior non-biologic DMARDs. However, there is no reason to assume differential effects in these subgroups in M15-572; hence, this issue was not pursued further by the CHMP.

Additionally, MDA at week 24 showed significant improvement in the upadacitinib 15 mg group than placebo group in both Phase 3 trials. The proportion of subjects achieving MDA was in study M15-572, 36.6 % vs. 12.3 % (between-group difference 24.3, 95 % CI 18.8, 29.9) and in study M15-554, 25.1 % vs. 2.8% (between-group difference 22.3, 95 % CI 16.0, 28.6).

In both studies, the results were significantly better with upadacitinib vs. placebo irrespective of the number of prior DMARDs used by the patient (1 or &gt;1). Other prespecified subgroup results gave as well consistent results with those obtained for the primary endpoint.

Subgroup analyses for subjects using upadacitinib as monotherapy vs. in combination with background non-biologic DMARDs were conducted in the integrated placebo-controlled analysis sets (separately for both upadacitinib doses). The number of subjects with monotherapy or combination therapy in the integrated set with placebo or upadacitinib 15 mg was the following: for monotherapy, placebo (n = 188), upadacitinib 15 mg (n = 189) and for combination therapy, placebo (n = 447), upadacitinib 15 mg (n = 452). These analyses were performed for the following endpoints: ACR20/50/70 response rate at Week 12, change from baseline in HAQ-DI at Week 12, proportion of subjects with sIGA 0/1 at Week 16 (for subjects with baseline sIGA ≥ 2), PASI 75/90/100 response rate at Week 16 (for subjects with ≥ 3% BSA-Ps at baseline), proportion of subjects achieving MDA at Week 16 and Week 24, and proportion of subjects achieving resolution of dactylitis (LDI = 0) (for subjects with baseline LDI &gt; 0) and resolution of enthesitis (LEI = 0) (for subjects with baseline LEI &gt; 0) at Week 24. The response rate (%, 95% CI) in monotherapy for ACR20 at week 12 was 25.0 (18.8, 31.2) in the placebo group and 58.7 (51.7, 65.7) in the upadacitinib 15 mg group. The respective results in combination therapy were 35.1 (30.7, 39.5) in the placebo and 69.2 (64.9, 73.4) in the upadacitinib 15 mg group. The other endpoints analysed separately for monotherapy and combination therapy also demonstrated better effect of upadacitinib vs. placebo independent of the treatment mode (monotherapy or combination therapy).

The numbers of subjects using other non-biologic DMARDs than MTX in combination with upadacitinib are relatively low in the integrated placebo-controlled data set. For the upadacitinib 15 mg group for

<div style=\"page-break-after: always\"></div>

which the indication is applied, there were 15 subjects with the combination of upadacitinib and aprelimast, 30 subjects with upadacitinib + leflunomide, and 22 subjects with upadacitinib + sulfasalazine. Other DMARDs were used by an even lower number of subjects, some medications only by one or two subjects. In addition, the response rate difference vs. placebo in ACR20 is lower in the non-MTX combination therapy (19.4; 95 % CI 3.8, 35.1) than when upadacitinib is used with MTX (36.8; 95% CI 30.2, 43.4), with wider variation, the lower limit for 95% CI being only 3.8. Therefore, the data on the different combination treatments is not considered currently sufficient for the indication on combination treatments except for combination upadacitinib with MTX, also taking into consideration the worse safety profile with these non-MTX combinations. A major objection was raised during the review and the MAH agreed to modify the indication to limit the concomitant use of upadacitinib to methotrexate. This was considered acceptable to the CHMP.

The response in skin symptoms was assessed by the key secondary endpoints 75 percent improvement in PASI75, sIGA, and SAPS. All measures showed improvement in skin condition with upadacitinib 15 mg vs. placebo, and the differences were statistically significant except for SAPS. In the integrated efficacy analysis population, the proportion of responders defined by PASI75 (%, 95 % CI) at Week 16 was  58.7 (53.5, 63.9) in the upadacitinib 15 mg group and 19.3 (15.1, 23.5) in the placebo group.

Presence of dactylitis and enthesitis were stratification factors only in study M15-572; and resolution of enthesitis and dactylitis were multiplicity-controlled key outcome measures in study M15-572. In both studies, change in measures of enthesitis and dactylitis were conducted only on the proportion of patients with these symptoms at baseline; and in both studies, the proportion of subjects with dactylitis and enthesitis decreased numerically more in the upadacitinib 15 mg arm than placebo arm. In study M15 572, proportion of subjects with resolution of enthesitis (LEI = 0; %, 95 % CI) at Week 24 was 53.7 (47.8, 59.7) in the upadacitinib 15 mg group and 32.4 (26.5, 38.3) in the placebo group. Resolution of dactylitis at Week 24 was achieved in M15-572 by 76.5 % (69.3, 83.6) and 39.7 % (31.1, 48.2) in the upadacitinib 15 mg and placebo groups, respectively.  In study M15-554, the corresponding figures were in the same order of magnitude as in study M15-572 for enthesitis and dactylitis.

Improvement in activity of spondylitis was evaluated by BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS (Ankylosing Spondylitis Disease Activity Score Based on CRP) were examined in subjects with psoriatic spondylitis at baseline (study M15-572: 31 %, study M15-554:35.4 %). In both studies, subjects in the upadacitinib 15 mg group had greater improvement from baseline in BASDAI and ASDAS, and a greater proportion of subjects achieved BASDAI 50, ASDAS inactive disease, ASDAS major improvement, and ASDAS clinically important improvement at Week 12 compared with subjects in the placebo group. The MAH justified the inclusion of the results for BASDAI in the SmPC as inclusion of one measure of efficacy of spondylitis is clinically relevant for prescribers. This was acceptable to the CHMP. At the CHMP's request, the MAH removed ASDAS from the SmPC since the two measures are largely overlapping.

In both pivotal Phase 3 studies, treatment with upadacitinib 15 mg QD and 30 mg QD demonstrated a numerically greater improvement from baseline in all the individual components of the ACR20/50/70 (TJC68, SJC66, HAQ-DI, PtGA, PGA, Patient's Assessment of Pain, and hsCRP) response at Week 12 compared with placebo. Multifaceted function of the subjects was evaluated by change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12, 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS), and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue in multiplicity-adjusted analyses. In line with results for the primary endpoint, these measures demonstrated statistically significant improvement by upadacitinib 15 mg compared with placebo in multiplicity-controlled analyses. E.g., the HAQ-DI index decreased (improved) from 1.15 at baseline to 0.74 at Week 12 in the upadacitinib 15 mg group and from 1.11 at baseline to 0.98

<div style=\"page-break-after: always\"></div>

at Week 12 in the placebo group (LS mean difference between upadacitinib 15 mg and placebo -0.28, 95% CI  0.35, -0.22, p &lt;0.0001) in Study M15-572. Corresponding figures for Study M15-554 were change from 1.08 to 0.79 in the upadacitinib 15 mg group and from 1.23 to 1.12 in the placebo group (LS mean difference between upadacitinib 15 mg and placebo -0.21, 95% CI -0.30, -0.12, p &lt;0.0001). However, the effect of upadacitinib on mental health was considered to be very modest in comparison with that on physical health based on the SF-36 MCS and PCS. Therefore, at the CHMP's request, the MAH removed from the SmPC the non-multiplicity-controlled and clinically non-relevant results of SF36 MCS.

The ACR20 response was in both studies statistically significantly better with upadacitinib 15 mg vs. placebo already at 2 weeks and the effect was retained up to 24 weeks in both studies. Efficacy results for 56 weeks confirmed maintenance of effect of upadacitinib up to 56 weeks. The data were deemed acceptable for inclusion of these results in the SmPC. However, within-group variation in response was marked for several outcome measures, as was onset of efficacy which varied e.g. for the primary endpoint from 2 weeks to 56 weeks. A large amount of data from patients with RA have demonstrated sustainable effect by upadacitinib. It is therefore plausible that the effect would be maintained also in PsA.

The MAH initially provided only 24-week data on radiographic progression in one of the PsA-studies (M15 572), with PsA-population intended to be enriched with patients with active joint disease (at least 1 X-ray erosion at baseline or increased CRP). The final study population included only 39.2 % of subjects with at least one joint erosion. Even though 75.1 % of subjects had hsCRP &gt; upper limit of normal, the mean and median level of hsCRP was only 11.22 and 6.21 mg/L, respectively, with a range of 0.20 to 169 mg/L. Hence, the population did not have very active joint erosive disease in general. The change from baseline in SHS (equivalent to modified Total Sharp Score [mTSS]), Joint Erosion Score, and JSN Score at Week 24 all showed improvement by upadacitinib 15 mg compared with placebo. The difference in SHS (with the predefined primary linear extrapolation analysis) is small for the comparison of upadacitinib 15 mg with placebo (LS mean, 95% CI): -0.29 (-0.44, -0.14).  No difference was seen in the comparison of upadacitinib 15 mg and adalimumab. The MAH has used in their sample size calculation the value 0.26 as a 'standardized effect size in change from baseline in SHS versus placebo at week 24'. This effect size was met. Most subjects had no radiographic progression at week 24: 89.2% in the placebo group, 93.0% in the adalimumab group and 93.4 % in upadacitinib 15 mg group (with linear extrapolation and change from baseline in SHS &lt;0).  Although the time when a patient would develop radiographic progression can vary in PsA, it is reported that up to two thirds of patients will experience progressive joint damage, which can subsequently result in functional loss and disability. Therefore, current EULAR guidelines recommend a treat-to-target approach, similarly to the approach in rheumatoid arthritis management, even though the mechanism causing joint damage in PsA is not well defined. It is important that radiographic progression is investigated for sufficiently long period. Current EMA guidelines state that the observation period needed is not less than two years, showing sustained effects for the effects after the first year. The proportion of patients with no radiographic progression was still very high at week 56 in all study arms: 89 % (95% CI 86, 92) even for patients who received placebo for 24 week before switching to upadacitinib, 97 % (96, 99) for subjects who received upadacitinib 15 mg from the beginning, and 94 % (92, 97) for patients who received ADA from the beginning up to 56 weeks. However, the CIs are narrow for this measure, and the CIs of the placebo and upadacitinib groups no more overlap at week 56. Thus, even though there seemed to be radiographically slower progression with upadacitinib when measured by the change in SHS, the proportions of subjects who had no progression of structural damage is a more robust parameter from a clinical perspective. Contrary to the SHS-scores, the proportions of subjects who had no progression of structural damage showed very small difference (4.2 %) between placebo and upadacitinib treatment arms, potentially due to the fact that most

<div style=\"page-break-after: always\"></div>

subjects had no radiographic progression during this time period. This may reflect the importance of longer-term radiographic data in showing benefit in radiographic measures. Nevertheless, the CHMP concluded that the completed 56-week efficacy data supports the inclusion of the radiographic results in the SmPC.

## 2.4.4. Conclusions on the clinical efficacy

The 24-week data from the two phase 3 studies, one in subjects intolerant or with inadequate response to non-biologic DMARDs and one in subjects intolerant or with inadequate response to bDMARDs, show that upadacitinib 15mg compared with placebo was robustly associated with better clinical efficacy for the treatment of the 3 major manifestations of psoriatic disease (joint, soft tissue and skin), and provided improvement of physical function and health-related quality of life in adults with active psoriatic arthritis. Higher exposure by upadacitinib 30 mg QD vs. 15 mg QD was only modestly or not at all associated with better clinical response in efficacy as observed in the clinical trials and according to the population PK analysis. Upadacitinib 15 mg QD was non-inferior to adalimumab 40 mg EOW in the treatment of patients with inadequate response or intolerance to nonbiologic DMARDs.

Based on the totality of the efficacy data and analyses, the same posology as for RA is supported for PsA, i.e. 15 mg once daily. The MAH's proposal to use upadacitinib concomitantly with a non-MTX nonbiologic DMARD in the treatment of PsA was not endorsed by the CHMP as the efficacy of combination of upadacitinib 15mg with another non-biologic DMARD than MTX was considered insufficient due to scarcity of subjects administered these combinations. In addition, the use of upadacitinib concomitantly with a non-MTX non-biologic DMARD seems to be associated with a higher frequency of adverse events, including serious and severe events. Since the number of subjects are small, there are considerable remaining uncertainties regarding the safety profile when upadacitinib is used concomitantly with non-MTX agents or with a combination of MTX and a non-MTX agent. The MAH agreed to modify the therapeutic indication in the treatment of psoriatic arthritis in monotherapy or in combination with methotrexate. This was considered acceptable to the CHMP as the efficacy of upadacitinib used as monotherapy and in combination with methotrexate was shown to be comparable.

Long-term data up to 56 weeks for all phase 3 study subjects confirm the maintenance of the therapeutic effect.

The CHMP considered that the efficacy of upadacitinib in the following indication is supported by the data submitted by the MAH: ' RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate .'

## 2.5. Clinical safety

## Introduction

Upadacitinib was authorised for its original RA indication in the United States in August 2019, by the European Commission in December 2019, and has also been authorised in multiple other countries. Within the RA studies, the most commonly reported adverse drug reactions (ADRs) were upper respiratory tract infections, bronchitis, nausea, blood creatine phosphokinase (CPK) increased and cough. The most common serious adverse reactions were serious infections. The current SmPC includes special warnings and precautions for conditions  including  serious  infections,  viral  reactivation,  malignancies,  haematological  abnormalities, cardiovascular risk and lipids, hepatic transaminase elevations and venous thromboembolism. Upadacitinib

<div style=\"page-break-after: always\"></div>

is  contraindicated in patients with hypersensitivity to the active substance or excipients, in patients with active tuberculosis or active serious infections, in severe hepatic impairment, and during pregnancy.

To support the current variation application, upadacitinib was studied in 2 pivotal randomised, double-blind, Phase 3 studies in PsA patients. Study M15-572 was a placebo- and adalimumab -controlled study in nonbiologic  DMARD-IR  patients,  and  study  M15-554  was  a  placebo-controlled  study  in  biologic  DMARD-IR patients. Whereas 2 doses of upadacitinib (15 mg and 30 mg QD) were evaluated in the studies, only the 15 mg dose is being proposed for marketing authorisation. The treatment groups and numbers of enrolled patients are depicted in Table 54.

Table 54 Pivotal Phase 3 PsA Studies (Safety Analysis Set)

|                          | M15-572                  | M15-554                  |
|--------------------------|--------------------------|--------------------------|
| Population               | non-biologic DMARD-IR    | bDMARD-IR                |
| Treatment Groups (N)     | Upadacitinib 15 QD (430) | Upadacitinib 15 QD (211) |
| Treatment Groups (N)     | Upadacitinib 30 QD (423) | Upadacitinib 30 QD (218) |
| Treatment Groups (N)     | Placebo (423)            | Placebo (212)            |
| Treatment Groups (N)     | Adalimumab 40 EOW (429)  |                          |
| Placebo/ActiveComparator | 24 (placebo)             | 24 (placebo)             |
| Duration (Weeks)         | 152 (adalimumab)         |                          |

intolerant or inadequate responder; EOW =every other week; IR =inadequate response; PsA =psoriatic arthritis; QD = once daily

Data cut-offs were 09 October 2019 for study 554 and 13 December 2019 for study 572. These cut-off dates enable inclusion of all data from all subjects through Week 24, and long-term data is included through the respective cut-off date for each study into the clinical study reports and integrated analyses.

For purposes of safety assessment, safety data from the two studies were integrated into two analysis sets as outlined in Table 55. Data presentations include frequency tables by treatment group as well as exposureadjusted event rates and/or incidence rates. Although not part of the formal integrated analysis, data from subjects treated with adalimumab in study 572 is displayed within the tabulations to enable comparison with an authorised active control.

<div style=\"page-break-after: always\"></div>

Table 55 Integrated Safety Analysis Sets

| Analysis Set                   | Analysis Set Rationale and Description                                                                                                                                                                                                                                                     | Analyses                 | Pooled Studies   | Summarized Treatment Group(s)                                                                                                                                   | Treatment Comparison(s)b                                                                                                                                       |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PBO-controlled Analysis Set    | This analysis set assesses short-term safety through 24weeks ofupadacitinib15 mgQD andupadacitinib30mgQDversusplacebo.It includes subjects who received upadacitinib 15 mg QD, upadacitinib 30 mg QD, and placeboduringthe24-weekplacebo-controlled period in Studies M15-554 and M15-572. | Short-term (24 weeks)    | M15-554 M15-572  | Upadacitinib 15 mg QD Upadacitinib 30 mg QD Placebo                                                                                                             | Upadacitinib 15 mg QD versus placebo Upadacitinib 30 mg QD versus placebo                                                                                      |
| Any Upadacitinib Analysis Seta | This analysisset istoassesseslong-termsafety of upadacitinib 15 mg QD and upadacitinib 30 mgQD.It includes all subjects who received upadacitinib 15mgQD or upadacitinib 30 mg QD from Studies M15-554 and M15-572. This analysis set was based on all cumulative exposure.                | Long-term (Al1 exposure) | M15-554 M15-572  | ·Upadacitinib 15 mg QD (No Cross-over from Placebo)c Upadacitinib 30 mg QD (No Cross-over from Placebo)c  Any Upadacitinib 15 mg QDd Any Upadacitinib 30 mg QDd | Upadacitinib 30 mg QD (No Cross-over from Placebo) versus UPA 15 mg QD (No Cross-over from Placebo) Any Upadacitinib 30 mg QD versus Any Upadacitinib 15 mg QD |

PBO=placebo;QD=oncedaily;UPA=upadacitinib

a. All subjectswhoreceived atleast onedoseofupadacitinib

b. Treatment comparison for overview of treatment-emergent adverse event (TEAE),overview of treatment-emergent AESI, andpotentially clinically significant(PCS) laboratory values.

- C. Included anyUPA15mgQD/30mgQDexposureof subjectsstartingonUPA15mgQD/30mgQDatrandomization.
- d. QD/30 mg QD.

In both studies, subjects initially randomised to placebo switched to blinded upadacitinib 15 mg or 30 mg (based on pre-specified treatment assignment at Baseline) at Week 24. Switching between upadacitinib doses was not permitted at any stage in either study.

To further characterise the safety profile of long-term upadacitinib exposure, cumulative long-term safety data from the RA programme (comprising 11,201.0 PY of exposure among a total of 5,579 subjects), with a data cut-off date of 31 December 2019, and a summary of post-marketing experience until 31 January 2020 (with  cumulative  exposure  of  about  3,100  PY),  were  provided  as  supportive  information  for  the  current submission.

## Patient exposure

## Extent of exposure

A total of 1,827 subjects received at least 1 dose of upadacitinib (15 mg QD or 30 mg QD) in the Phase 3 studies, with a total of approximately 1,639 patient-years (PY) of upadacitinib exposure included in the safety analyses. Between the 2 studies, 907 subjects received at least 1 dose of upadacitinib 15 mg, representing a total of 816.9 PY of upadacitinib exposure. At the time of data cutoff, 359 subjects had been treated with upadacitinib 15 mg for at least 12 months (Table 56).

<div style=\"page-break-after: always\"></div>

Table 56 Number and Percentage of Subjects Exposed to Study Drug by Duration Intervals (Any Upadacitinib Analysis Set)

|                    | Upadacitinib                                     | Upadacitinib                                     | Upadacitinib             | Upadacitinib       |
|--------------------|--------------------------------------------------|--------------------------------------------------|--------------------------|--------------------|
| Days               | 15mgQD (No Cross-Over from Placebo) (N=640) n(%) | 30mgQD (No Cross-Over from Placebo) (N=641) n(%) | Any 15mgQD (N=907) n (%) | 30mgQD (06=N n (%) |
| ≥2weeks            | 636(99.4)                                        | 637(99.4)                                        | 897(98.9)                | 909(98.8)          |
| ≥1month            | 628 (98.1)                                       | 633 (98.8)                                       | 866(95.5)                | 882 (95.9)         |
| ≥3months           | 605 (94.5)                                       | 603(94.1)                                        | 796 (87.8)               | 800 (87.0)         |
| ≥6months           | 564 (88.1)                                       | 553 (86.3)                                       | 701 (77.3)               | 701(76.2)          |
| ≥9months           | 401 (62.7)                                       | 397 (61.9)                                       | 490 (54.0)               | 491 (53.4)         |
| ≥12months          | 303 (47.3)                                       | 299 (46.6)                                       | 359(39.6)                | 363(39.5)          |
| ≥18months          | 128 (20.0)                                       | 128 (20.0)                                       | 142 (15.7)               | 143 (15.5)         |
| ≥2years            | 28(4.4)                                          | 28 (4.4)                                         | 29 (3.2)                 | 28 (3.0)           |
| Meanduration(days) | 372.0                                            | 368.7                                            | 329.0                    | 326.4              |

QD=once daily

Notes:

Duration ofexposure to study drug in this analysis is Period l and Peniod 2 combined exposue.Exposure is presented by treatment actially received.

Subjects could be inchuded in more than one treatment column.

Exposure to upadacitinb 15mg= date oflast study medication of upadacitinib 15 mg-date of first study medicationofupadacitinb 15 mg +1.

Exposure to upadacitinib30 mg = date of last study medication of upadacitinib 30 mg-date of first study medication.ofupadacitimib30 mg +1.

## Demographic and baseline characteristics

In the PBO-controlled Analysis Set, demographic characteristics were generally balanced across the upadacitinib and placebo groups. Across the treatment groups, 52-55% were female, and about 89% were white. Mean age was 51-52 years and mean BMI was 30-31 kg/m^2. Some 13-14% of patients in each treatment group were &gt;= 65 years of age, but less than 3% were 75 years or older. Whereas 44-50% of enrolled subjects had mild renal impairment (eGFR &gt;= 60 and &lt;90 mL/min/1.73 m^2), the number of patients with moderate renal impairment was small; only 4-6% of subjects across the treatment groups had an eGFR &lt;60 mL/min/1.73 m^2 (subjects with a screening eGFR &lt;40 mL/min/1.73 m^2 were excluded from the studies). The majority of subjects were from Eastern Europe (34-37%) and North America (32-33%).

Apart from the Skin and subcutaneous tissue disorders SOC, the most common medical/surgical history SOCs ( ≥ 40% in any treatment group) were vascular disorders, metabolism and nutrition disorders, and musculoskeletal and connective tissue disorders (Table 57).

<div style=\"page-break-after: always\"></div>

Table 57 Most Common Medical/Surgical History by SOC ( ≥ 40% in Any Treatment Group) and by PT Within the Most Common SOC (PBO-controlled Analysis Set)

| Svstem Organ Class MedDRA22.0Preferred Term      | Placebo (N=635) n(%)   | Upadacitinib 15 mgQD (0t9=N) n(%)   | Upadacitinib 30mgQD (N=641) n(9)   |
|--------------------------------------------------|------------------------|-------------------------------------|------------------------------------|
| Metabolism and mutition disorders                | 287 (45.2)             | 288(45.0)                           | 274(42.7)                          |
| Hyperlipidemia                                   | 80(12.6)               | 65 (10.2)                           | 83 (12.9)                          |
| Obesity                                          | 60 (9.4)               | 69 (10.8)                           | 79 (12.3)                          |
| Hypercholesterolemia                             | 57 (9.0)               | 46 (7.2)                            | 43 (6.7)                           |
| Diabetes mellitus                                | 51 (8.0)               | 50 (7.8)                            | 42(6.6)                            |
| Type2 diabetesmellitis                           | 37 (5.8)               | 26 (4.1)                            | 42(6.6)                            |
| VitaminD deficiency                              | 41 (6.5)               | 47 (7.3)                            | 42(6.6)                            |
| Hyperuricemia                                    | 30 (4.7)               | 27 (4.2)                            | 29 (4.5)                           |
| Dyslipidemia                                     | 17 (2.7)               | 23 (3.6)                            | 21(3.3)                            |
| Glucose tolerance impaired                       | 17 (2.7)               | 11 (1.7)                            | 8 (1.2)                            |
| Overweight                                       | 13 (2.0)               | 5 (0.8)                             | 3(0.5)                             |
| Vascular disorders                               | 301 (47.4)             | 311(48.6)                           | 267 (41.7)                         |
| Hypertension                                     | 283 (44.6)             | 288(45.0)                           | 248 (38.7)                         |
| Varicose vein                                    | 17 (2.7)               | 15 (2.3)                            | 11 (1.7)                           |
| Musculoskeletal and connective tissue disorders. | 259(40.8)              | 257(40.2)                           | 264 (41.2)                         |
| Osteoarthritis                                   | 100 (15.7)             | 87(13.6)                            | 93 (14.5)                          |
| Back pain                                        | 42(6.6)                | 32 (5.0)                            | 39(6.1)                            |
| Spinal osteoarthritis                            | 35 (5.5)               | 28 (4.4)                            | 33(5.1)                            |
| Osteoporosis                                     | 28(4.4)                | 29 (4.5)                            | 32(5.0)                            |
| Intervertebral disc degeneration                 | 21(3.3)                | 25 (3.9)                            | 25 (3.9)                           |
| Arthralgia                                       | 25 (3.9)               | 21 (3.3)                            | 19 (3.0)                           |
| Intervertebral discprotrusion                    | 25 (3.9)               | 15 (2.3)                            | 18(2.8)                            |
| Rotator cuff syndrome                            | 6(0.9)                 | 16 (2.5)                            | 18(2.8)                            |
| Osteopemia                                       | 15(2.4)                | 23(3.6)                             | 17(2.7)                            |
| Psoriatic arthropathy                            | 18 (2.8)               | 14(2.2)                             | 17 (2.7)                           |
| Muscle spasms                                    | 12(1.9)                | 21 (3.3)                            | 15(2.3)                            |

MedDRA =Medical Dictionary for Regulatory Activities;PBO =placeboPT =prefened tenm;QD=once daily;

SOC=system organ class

Percentages caleulated onnon-missing values.

## Concomitant DMARD and corticosteroid use

In the PBO-controlled Analysis Set, approximately 70% of subjects were receiving concomitant therapy with a non-biologic DMARD at Baseline (Table 58). The most commonly used DMARD was MTX, either alone or in combination with another non-biologic DMARD.

<div style=\"page-break-after: always\"></div>

Table 58 Concomitant Non-Biologic DMARD at Baseline (PBO-controlled Analysis Set)

| Variable                          | Placebo (N = 635) (%) uI   | Upadacitinib 15 mg QD (N = 640) (%) uI   | Upadacitinib 30 mg QD (N = 641) n (%)   |
|-----------------------------------|----------------------------|------------------------------------------|-----------------------------------------|
| MTX alone                         | 342 (53.9)                 | 353 (55.2)                               | 341 (53.2)                              |
| MTX and other non-biologic DMARD  | 33 (5.2)                   | 26 (4.1)                                 | 32 (5.0)                                |
| Non-biologic DMARD other than MTX | 72 (11.3)                  | 72 (11.3)                                | 71 (11.1)                               |
| None                              | 188 (29.6)                 | 189 (29.5)                               | 197 (30.7)                              |

DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; PBO = placebo; QD = once daily

Note: Percentages calculated on non-missing values.

When the two studies are compared, one or more background DMARDs were used by 82% of subjects in study 572 (non-biologic DMARD-IR population), compared to 49% in study 554 (biologic DMARD-IR population). According to the MAH, this is expected and explained by more subjects in the non-biologic DMARD-IR population continuing on the last therapy they were on instead of washing it out as compared to the biologic DMARD-IR population. In both studies, MTX was clearly the most commonly used background DMARD (69% in study 572 and 39% in study 554). In study 572, about 9% of subjects were on sulfasalazine and about 6% of patients on leflunomide, whereas in study 554, about 5% of subjects were on apremilast and also about 5% on sulfasalazine.

About 15% of subjects in study 554 and about 20% of subjects in study 572 were using a concomitant systemic corticosteroid at Baseline. In both studies, the most commonly used corticosteroids were prednisone and methylprednisolone.

About 61% of subjects in study 554 and about 66% of subjects in study 572 were using a concomitant NSAID at Baseline. In both studies, most commonly used NSAIDs included acetylsalicylic acid, diclofenac, ibuprofen, meloxicam and naproxen.

## Adverse events

## Overview of adverse events

An overview of adverse events in the PBO-controlled Analysis Set is displayed in Table 59, and a corresponding display of exposure-adjusted event/incidence rates in the long-term Any Upadacitinib Analysis Set is provided in Table 60.

<div style=\"page-break-after: always\"></div>

Table 59 Overview of Subjects with Treatment-Emergent Adverse Events (PBO-controlled Analysis

|                                                                    | Placebo (N = 635) n (%) [SSA %]   | Upadacitinib 15 mg QD (N = 640) (%) uI [SSA %]   | Upadacitinib 30 mg QD (N = 641) n (%) [SSA %]   | Adalimumab 40 mgE0Wc (N = 429) n (%)   |
|--------------------------------------------------------------------|-----------------------------------|--------------------------------------------------|-------------------------------------------------|----------------------------------------|
| Any AE                                                             | 391 (61.6) [61.6]                 | 422 (65.9) [65.9]                                | 476 (74.3) [74.2]                               | 278 (64.8)                             |
| Any SAE                                                            | 17 (2.7) [2.7]                    | 26 (4.1) [4.1]                                   | 44 (6.9) [69]                                   | 16 (3.7)                               |
| Any AE leading to discontinuation of study drug                    | 24 (3.8) [3.8]                    | 28 (4.4) [4.4]                                   | 41 (6.4) [6.4]                                  | 22 (5.1)                               |
| Any severe AE                                                      | 24 (3.8) [3.8]                    | 34 (5.3) [5.3]                                   | 43 (6.7) [6.7]                                  | 28 (6.5)                               |
| Any AE with reasonable possibility of being related to study druga | 173 (27.2) [27.2]                 | 212 (33.1) [33.1]                                | 265 (41.3) [41.4]                               | 168 (39.2)                             |
| Any AE leading to death                                            | 2 (0.3) [0.3]                     | 0                                                | 0                                               | 0                                      |
| Deathsb                                                            | 2 (0.3) [0.3]                     | 0                                                |                                                 | 0                                      |

AE = adverse event; EOW = every other week; PBO = placebo; QD = once daily, SAE = serious adverse event; SSA = study size adjusted

a. As assessed by investigator.

b. Includes both treatment-emergent and non-treatment-emergent deaths.

C. Adalimumab was administered only in Study M15-572.

Note: Events with unknown toxicity grade or Grade 3 and above based on CTCAE v5.0 was counted as severe. Events with unknown relationship to study drug was counted as having a reasonable possibility of being related to study drug.

<div style=\"page-break-after: always\"></div>

Table 60 Overview of Treatment-Emergent Adverse Events per 100 PY (Any Upadacitinib Analysis Set)

|                                                              | Upadacitinib                                          | Upadacitinib                                          | Upadacitinib                   | Upadacitinib                    |                                        |
|--------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|--------------------------------|---------------------------------|----------------------------------------|
|                                                              | 15mgQD (No Cross-Over from Plaeebo) (09=N) (PY=651.S) | 30mgQD (NoCross-Over from Placebe) (N=641) (PY=647.1) | Any 15mg QD (N=907) (PY=S16.9) | Any 30 mg QD (N=920) (PY=812.3) | Adalimumab 40mgEow- (N=429) (PY=394.5) |
| Exposare-adjusted event rate                                 | E(E/100 PY) [SSAE/100 PY]                             | E(E/100 PY) [SSAE/100 PY]                             | E(E/100 PY) [SSAE/100 PY]      | E(E/100 PY) [SSAE/100 PY]       | E(E/100 PY)                            |
| Any AE                                                       | [23.9]                                                | 2638(407.7) [407.6]                                   | [308.8]                        | 3120 (379.4) [379.5]            | 1294 (328.0)                           |
| Any SAE                                                      | 76 (11.7) [11.6]                                      | 98 (15.1) [15.1]                                      | 89 (10.9) [10.9]               | 122 (14.8) [14.8]               | 43.(10.9)                              |
| Any AE leading todiscootiniation of study drug               | 59(9.1) [9.0]                                         | [10.8]                                                | 69 (8.4) [8.5]                 | 78(9.5) [9.5]                   | 40(10.1)                               |
| Any severe AE                                                | 88(13.5) [13.5]                                       | 118(18.2) [18.2]                                      | 101(12.4) [124]                | 150(18.2) [18.2]                | 51(12.9)                               |
| Any AEwithreasonablepossibility ofbeingrelatedto stady drug\" | [117:2]                                               | 1087 (168.0) [167.9]                                  | 901(110.3) [110.2]             | 1256 (152.7) [szs]              | 594 (150.6)                            |
| Any AE leading to death                                      | 1(0.2) [0.2]                                          |                                                       | 1(0.1) [0.1]                   | 1(0.1) [0.1]                    | 0                                      |
| Exposure-adjusted incidence rate                             | [SSA n/100 PY]                                        | [SSA n/100 PY]                                        | [SSA n/100 PY]                 | [SSA n/100 PY]                  | u/PY (n/100 PY)                        |
| Deathsb                                                      | 1/652.0 (0.2) [0.2]                                   | 1/647.2 (0.2) [0.2]                                   | 1/817.1 (0.1) [0.1]            | 2/8229 (0.2) [0.2]              | S16E/0                                 |

AE-advere eventEOW-every other week,PY-paent-year QD=ce daly, SAE-senous advee event,SSA=study size adsed

IL As assessed by investgator

b Included both teatmeal-emegeit and mon-treatment ecergent deaths

Adaluumab was administered onlyinStudy Ml5-S72

Note:

Subjects could be included in tmore than one treatment columm

Events with nmkmowm loxiciry grade or Grade 3 and above based on CTCAE v5.0 will be counted as severe.

Evets wit mknw reltonship to study drug is being coumted as bawing areasonable possbility of beingrelated to stady drig

## Common adverse events

In the PBO-controlled Analysis Set, the most frequent TEAEs (&gt;= 10% of subjects in either upadacitinib group) were in the Infections and infestations, GI disorders, Investigations, and Musculoskeletal and connective tissue disorders SOCs. In the placebo group, the most frequently affected SOCs were Infections and infestations, GI disorders, and Musculoskeletal and connective tissue disorders.

- Within the Infections and infestations SOC, TEAEs were reported in 33.1% of subjects on placebo, 37.0% of subjects on upadacitinib 15 mg, and 45.1% of subjects on upadacitinib 30 mg.
- Within the GI disorders SOC, TEAEs were reported in 11.7% of subjects on placebo, 15.0% of subjects on upadacitinib 15 mg, and 15.8% of subjects on upadacitinib 30 mg.
- Within the Investigations SOC, TEAEs were reported in 7.6% of subjects on placebo, 13.9% of subjects on upadacitinib 15 mg, and 19.7% of subjects on upadacitinib 30 mg.
- Within the Musculoskeletal and connective tissue disorders SOC, TEAEs were reported in 11.5% of subjects on placebo, 10.3% of subjects on upadacitinib 15 mg, and 9.8% of subjects on upadacitinib 30 mg.

At the PT level, the most frequently reported TEAEs were upper respiratory tract infection (URTI) (8.9%) and increased blood CPK (6.6%) in the upadacitinib 15 mg group; URTI (9.7%), increased blood CPK (8.3%), nasopharyngitis (7.2%), and increased ALT (5.5%) in the upadacitinib 30 mg

<div style=\"page-break-after: always\"></div>

group; and URTI (6.9%) and nasopharyngitis (6.0%) in the placebo group. The most frequently reported TEAEs are summarised in Table 61.

Table 61 TEAEs  Reported  in ≥ 2%  of  Subjects  in  Any  Group  by  Decreasing  Frequency  in  the Upadacitinib 15 mg Group (PBO-controlled Analysis Set)

| MedDRA 22.0 Preferred Term        | Placebo (N = 635) n (%) [SSA %]   | Upadacitinib 15 mg QD (N=640) n (%) [SSA %]   | Upadacitinib 30 mg QD (N = 641) n (%) [SSA %]   |
|-----------------------------------|-----------------------------------|-----------------------------------------------|-------------------------------------------------|
| Upper fespiratory tract infection | 44 (6.9) [6.9]                    | 57 (8.9) [8.9]                                | 62 (9.7) [9.7]                                  |
| Blood CPK increased               | 10 (1.6) [1.6]                    | 42 (6.6) [6.5]                                | 53 (8.3) [8.3]                                  |
| Nasopharyngitis                   | 38 (6.0) [6.0]                    | 31 (4.8) [4.8]                                | 46 (7.2) [7.2]                                  |
| Urinary tract infection           | 22 (3.5) [3.5]                    | 27 (4.2) [4.2]                                | 26 (4.1) [4.0]                                  |
| Bronchitis                        | 14 (2.2) [2.2]                    | 24 (3.8) [3.8]                                | 31 (4.8) [4.8]                                  |
| Diarrhea                          | 22 (3.5) [3.5]                    | 23 (3.6) [3.6]                                | 26 (4.1) [4.0]                                  |
| ALT increased                     | 13 (2.0) [2.0]                    | 21 (3.3) [3.3]                                | 35 (5.5) [5.5]                                  |
| Headache                          | 16 (2.5) [2.5]                    | 21 (3.3) [3.3]                                | 26 (4.1) [4.1]                                  |
| Hypertension                      | 19 (3.0) [3.0]                    | 20 (3.1) [3.1]                                | 16 (2.5) [2.5]                                  |
| Influenza                         | 8 (1.3) [1.3]                     | 19 (3.0) [3.0]                                | 17 (2.7) [2.6]                                  |
| Cough                             | 10 (1.6) [1.6]                    | 16 (2.5) [2.5]                                | 21 (3.3) [3.3]                                  |
| Psoriatic arthropathy             | 24 (3.8) [3.8]                    | 16 (2.5) [2.5]                                | 10 (1.6) [1.6]                                  |
| AST increased                     | 9 (1.4) [1.4]                     | 14 (2.2) [2.2]                                | 22 (3.4) [3.4]                                  |
| Nausea                            | 15 (2.4) [2.4]                    | 13 (2.0) [2.0]                                | 24 (3.7) [3.7]                                  |
| Back pain                         | 10 (1.6) [1.6]                    | 12 (1.9) [1.9]                                | 14 (2.2) [2.2]                                  |
| Sinusitis                         | 15 (2.4) [2.4]                    | 12 (1.9) [1.9]                                | 13 (2.0) [2.0]                                  |
| Leukopenia                        | 4 (0.6) [0.6]                     | 10 (1.6) [1.6]                                | 13 (2.0) [2.0]                                  |
| Gastroenteritis                   | 7 (1.1) [1.1]                     | 8 (1.3) [1.3]                                 | 19 (3.0) [3.0]                                  |
| Oral herpes                       | [6'0] (60) 9                      | 7 (1.1) [1.1]                                 | 22 (3.4) [3.4]                                  |
| Herpes zoster                     | 5 (0.8) [0.8]                     | 7 (1.1) [1.1]                                 | 13 (2.0) [2.0]                                  |
| Neutropenia                       | 2 (0.3) [0.3]                     | [6'0] (6'0) 9                                 | 18 (2.8) [2.8]                                  |
| Pyrexia                           | 5 (0.8) [0.8]                     | [6'0] (6'0) 9                                 | 16 (2.5) [2.5]                                  |
| Lymphopenia                       | 5 (0.8) [0.8]                     | 5 (0.8) [0.8]                                 | 15 (2.3) [2.4]                                  |
| Anemia                            | 4 (0.6) [0.6]                     | 4 (0.6) [0.6]                                 | 20 (3.1) [3.1]                                  |
| Psoriasis                         | 15 (2.4) [2.4]                    | 4 (0.6) [0.6]                                 | 5 (0.8) [0.8]                                   |

MedDRA =Medical Dictionary for Regulatory Activities; PBO = placebo; QD = once daily; SSA = study size adjusted; TEAE = treatment-emergent adverse event

Also in the long-term Any Upadacitinib Analysis Set, the most common TEAEs ( ≥ 5 E/100 PY in either upadacitinib group) included URTI, increased blood CPK, nasopharyngitis, urinary tract infection, bronchitis, ALT increased, hypertension, diarrhoea, AST increased, herpes zoster and oral herpes. Apart from hypertension, exposure-adjusted event rate (EAERs) for the events were higher in the 30 mg group than the 15 mg group.

<div style=\"page-break-after: always\"></div>

Frequently reported TEAEs in study 572 are displayed in Table 62. Increased blood CPK and herpes zoster were more frequent on upadacitinib, whereas increased ALT and neutropenia as well as injection site reactions were more frequent with adalimumab.

Table 62 Treatment-Emergent Adverse Events Reported in ≥ 5 Events per 100 PY in any Treatment Group by Decreasing Frequency in the Upadacitinib 15 mg Group - Long-Term (Safety Analysis Set; Study M15-572)

| MedDRA 22.0 Preferred Term        | ADA 40 mg E0W (N = 429) (PY =394.5) E (E/100 PY)   | Upadacitinib 15 mg QD (N = 617) (PY = 524.1) E (E/100 PY)   | Upadacitinib 30 mg QD (N = 612) (PY = 526.0) E (E/100 PY)   |
|-----------------------------------|----------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Blood CPK increased               | 36 (9.1)                                           | 75 (14.3)                                                   | 113 (21.5)                                                  |
| Upper respiratory tract infection | 62 (15.7)                                          | 91 (17.4)                                                   | 98 (18.6)                                                   |
| Nasopharyngitis                   | 52 (13.2)                                          | 51 (9.7)                                                    | 64 (12.2)                                                   |
| ALT increased                     | 44 (11.2)                                          | 46 (8.8)                                                    | 43 (8.2)                                                    |
| Urinary tract infection           | 18 (4.6)                                           | 39 (7.4)                                                    | 55 (10.5)                                                   |
| AST increased                     | 27 (6.8)                                           | 32 (6.1)                                                    | 30 (5.7)                                                    |
| Headache                          | 25 (6.3)                                           | 31 (5.9)                                                    | 24 (4.6)                                                    |
| Hypertension                      | 13 (3.3)                                           | 31 (5.9)                                                    | 20 (3.8)                                                    |
| Bronchitis                        | 12 (3.0)                                           | 30 (5.7)                                                    | 42 (8.0)                                                    |
| Diarrhea                          | 18 (4.6)                                           | 26 (5.0)                                                    | 28 (5.3)                                                    |
| Herpes zoster                     | 2 (0.5)                                            | 16 (3.1)                                                    | 32 (6.1)                                                    |
| Cough                             | 9 (2.3)                                            | 14 (2.7)                                                    | 28 (5.3)                                                    |
| Oral herpes                       | 15 (3.8)                                           | 13 (2.5)                                                    | 46 (8.7)                                                    |
| Neutropenia                       | 18 (4.6)                                           | 12 (2.3)                                                    | 29 (5.5)                                                    |
| Injection site reaction           | 24 (6.1)                                           | 0                                                           | 2 (0.4)                                                     |

ADA = adalimumab; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; EOW = every other week, MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year; QD = once daily

Note: Subjects in upadacitinib 15 mg or 30 mg group included those who started upadacitinib 15 mg or 30 mg at the beginning of the study and those who switched from placebo to upadacitinib 15 mg or 30 mg at Week 24.

In the PBO-controlled Analysis Set, severe AEs reported in more than 2 subjects in any group comprised pneumonia (4 subjects in the upadacitinib 30 mg group), lymphopenia (3 subjects in the upadacitinib 15 mg group), and ALT increased (3 subjects in the upadacitinib 30 mg group). In the long-term Any Upadacitinib Analysis Set, the most common severe TEAEs (&gt;=0.5 study size adjusted E/100 PY) were lymphopenia and increased blood CPK in the upadacitinib 15 mg group, and anaemia, bronchitis, herpes zoster, pneumonia, increased blood CPK, back pain, and COPD in the 30 mg group.

The MAH analysed the safety data per applicable CIOMS Guidelines (CIOMS III and V) in order to identify any new adverse drug reactions for labelling. Based on this analysis, two new ADR's are proposed to be included in the SmPC, with frequencies based on the PBO-controlled Analysis set:

- Bronchitis (grouped term including bronchitis, bronchitis viral, bronchitis bacterial, and tracheobronchitis): 2.7% in the placebo group vs 3.9% in upadacitinib 15 mg group
- Acne: 0.3% in placebo group vs 1.3% in upadacitinib 15 mg group

Currently labelled ADRs had no significant change in their rates compared with those reported for the RA dataset, with the exception of herpes zoster and herpes simplex, which were observed at a higher

<div style=\"page-break-after: always\"></div>

rate (&gt; 1%) in the upadacitinib 15 mg group during the 24-week placebo-controlled period of the PsA studies:

- Herpes zoster: 1.1% in PsA vs 0.7% in RA
- Herpes simplex (grouped term including herpes simplex and oral herpes): 1.4% in PsA vs 0.8% in RA

## Adverse events of special interest (AESI)

For identification of AESI, the MAH considered the safety concerns associated with the JAK inhibitor drug class, safety concerns identified from upadacitinib preclinical studies and the RA development programme, as well as those of customary regulatory interest for novel small molecule immunomodulatory products. According to this reasoning, the following AESI were identified and analysed in detail:

- serious infection;
- opportunistic infection excluding TB and herpes zoster;
- herpes zoster;
- active TB;
- malignancy (including malignant tumours, NMSC, malignant tumours excluding NMSC, and lymphoma);
- hepatic disorders;
- adjudicated GI perforation;
- adjudicated MACE (defined as CV death, non-fatal myocardial infarction [MI] and non-fatal stroke);
- adjudicated venous thromboembolic events (VTE), defined as pulmonary embolism (PE) and deep vein thrombosis (DVT) and other venous and arterial thromboembolic events (noncardiac, non-neurologic);
- anaemia;
- neutropenia;
- lymphopenia;
- renal dysfunction; and
- CPK elevation.

Forest plots of selected AESI for the proposed registration dose of 15 mg are displayed in Figures 38 and 39, and each AESI is discussed below in further detail.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 38 Forest Plot of Risks for Upadacitinib 15 mg QD Compared to Placebo in Non-Biologic DMARD-IR and bDMARD-IR Subjects Through Week 24 (Placebo-Controlled Analysis Set)

Figure 39 Forest Plot of Risks for Upadacitinib 15 mg QD Compared to Adalimumab in Non Biologic DMARD-IR Subjects Through Week 24 (Study M15-572)

<!-- image -->

## Serious infections

In the PBO-controlled Analysis Set, the percentage of subjects with serious infections was 0.8% for placebo, 0.9% for upadacitinib 15 mg and 2.7% for upadacitinib 30 mg group, and the most frequently reported serious infection was pneumonia (2 events each in the placebo and 15 mg groups, 6 events in the 30 mg group; Table 63). No serious infections were reported as resulting in death.

<div style=\"page-break-after: always\"></div>

Table 63 Number and Percentage of Subjects with Treatment-Emergent Serious Infections (PBOcontrolled Analysis Set)

| System Organ Class MIedDRA 22.0 Preferred Term   | Placebo (N = 635) n (%) [SSA %]   | Upadacitinib 15 mg QD (N = 640) n (%) [SSA %]   | Upadacitinib 30 mg QD (N = 641) n (%) [SSA %]   |
|--------------------------------------------------|-----------------------------------|-------------------------------------------------|-------------------------------------------------|
| Any adverse event                                | 5 (0.8) [0.8]                     | [6'0] (6:0) 9                                   | 17 (2.7) [2.7]                                  |
| Anal abscess                                     | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Appendicitis                                     | 1 (0.2) [0.2]                     | 0                                               | 1 (0.2) [0.2]                                   |
| Atypical pneumonia                               | 0                                 | 0                                               | 2 (0.3) [0.3]                                   |
| Bacteremia                                       | 0                                 | 0                                               | 2 (0.3) [0.3]                                   |
| Breast cellulitis                                | 1 (0.2) [0.2]                     | 0                                               | 0                                               |
| Bronchitis                                       | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Bursitis infective staphylococcal                | 1 (0.2) [0.2]                     | 0                                               | 0                                               |
| Erysipelas                                       | 0                                 | 1 (0.2) [0.2]                                   | 0                                               |
| Extradural abscess                               | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Laryngitis                                       | 0                                 | 1 (0.2) [0.2]                                   | 0                                               |
| Lung infection                                   | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Pneumocystisjirovecii pneumonia                  | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Pneumonia                                        | 2 (0.3) [0.3]                     | 2 (0.3) [0.3]                                   | 6 (0.9) [0.9]                                   |
| Sepsis                                           | 0                                 | 2 (0.3) [0.3]                                   | 0                                               |
| Urinary tract infection                          | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |
| Urosepsis                                        | 0                                 | 0                                               | 1 (0.2) [0.2]                                   |

MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo; QD = once daily; SSA = study size adjusted

Note: The sum of the total mumber of subjects reporting each of the preferred terms should be greater than or equal to the system organ class total. A subject who reported two or more different preferred terms which were in

the same system organ class was counted only once in the system organ class total.

In the long-term Any Upadacitinib Analysis Set, the EAERs of serious infections were 2.3 E / 100 PY in the upadacitinib 15 mg group and 6.0 E / 100 PY in the upadacitinib 30 mg group (Table 64). The most common serious infection in the upadacitinib 15 mg group was pneumonia (4 subjects). The most common serious infections in the upadacitinib 30 mg group were pneumonia (8 subjects) and herpes zoster (5 subjects). Two subjects, both in the upadacitinib 30 mg group had Pneumocystis jirovecii pneumonia (PJP).

According to the MAH, an infection was not reported as the cause of death in any subject. However, in Study 554, 1 male subject who received upadacitinib 30 mg experienced events of PJP and CMV infection preceding his death. In addition, in Study 572, 1 subject on upadacitinib 30 mg developed bronchitis followed by unspecified interstitial pneumonitis and dermatomyositis; this subject died several weeks after last dose of study drug.

<div style=\"page-break-after: always\"></div>

Table 64 Treatment-Emergent Serious Infection EAERs ≥ 0.2  E/100 PY (In Either Dose Group) (Any Upadacitinib Analysis Set)

|                                            | Upadacitinib                                                 | Upadacitinib                                                | Upadacitinib                        | Upadacitinib                        |
|--------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------|-------------------------------------|
| System Organ Class MedDRA22.0PreferredTerm | 15 mg QD (No Cross-Over from Placebo) (N = 640) (PY = 651.8) | 30 mgQD (No Cross-Over from Placebo) (N = 641) (PY = 647.1) | Any 15 mg QD (N = 907) (PY = 816.9) | Any 30 mg QD (N = 920) (PY = 822.3) |
|                                            | E (E/100 PY) [SSA E/100 PY]                                  | E (E/100 PY) [SSA E/100 PY]                                 | E (E/100 PY) [SSA E/100 PY]         | E (E/100 PY) [SSA E/100 PY]         |
| Anyseriousinfection                        | 15 (2.3) [2.3]                                               | 39 (6.0) [6.0]                                              | 19 (2.3) [2.3]                      | 49 (6.0) [6.0]                      |
| Infections andinfestations                 |                                                              |                                                             |                                     |                                     |
| Appendicitis                               | 1 (0.2) [0.2]                                                | 1 (0.2) [0.2]                                               | 1 (0.1) [0.1]                       | 2 (0.2) [0.2]                       |
| Atypical pneumonia                         | 0                                                            | 2 (0.3) [0.3]                                               | 0                                   | 2 (0.2) [0.2]                       |
| Bacteremia                                 | 0                                                            | 2 (0.3) [0.3]                                               | 0                                   | 2 (0.2) [0.2]                       |
| Bronchitis                                 | 1 (0.2) [0.2]                                                | 3 (0.5) [0.5]                                               | 1 (0.1) [0.1]                       | 3 (0.4) [0.4]                       |
| Cellulitis                                 | 1 (0.2) [0.2]                                                | 1 (0.2) [0.2]                                               | 1 (0.1) [0.1]                       | 2 (0.2) [0.2]                       |
| Gastroenteritis                            | 0                                                            | 2 (0.3) [0.3]                                               | 0                                   | 2 (0.2) [0.2]                       |
| Gastroenteritis viral                      | 1 (0.2) [0.2]                                                | 1 (0.2) [0.2]                                               | 1 (0.1) [0.1]                       | 2 (0.2) [0.2]                       |
| Herpes zoster                              | 1 (0.2) [0.2]                                                | 4 (0.6) [0.6]                                               | 1 (0.1) [0.1]                       | 5 (0.6) [0.6]                       |
| Pneumocystis jirovecii pneumonia           | 0                                                            | 1 (0.2) [0.2]                                               | 0                                   | 2 (0.2) [0.2]                       |
| Pneumonia                                  | 4 (0.6) [0.6]                                                | [6:0] (6'0) 9                                               | 4 (0.5) [0.5]                       | 8 (1.0) [1.0]                       |
| Sepsis                                     | 2 (0.3) [0.3]                                                | 1 (0.2) [0.2]                                               | 2 (0.2) [0.2]                       | 1 (0.1) [0.1]                       |
| Urinary tract infection                    | 0                                                            | 2 (0.3) [0.3]                                               | 0                                   | 2 (0.2) [0.2]                       |

EAER = exposure-adjusted event rate; MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year, QD = once daily, SSA = study size adjusted

Subgroup analyses based on a number of demographic and baseline characteristics (race, age group, sex, BMI group, baseline renal function status, history of COPD, Type 2 diabetes or cardiovascular events, use of corticosteroids at baseline) did not demonstrate any striking clustering of events; the rate of serious infections was higher among patients &gt;= 65 years in all treatment groups, including placebo. It should however be noted that many of these analyses were impacted by very small sample sizes within several subgroups, precluding robust conclusions.

For both upadacitinib treatment groups, treatment-emergent serious infections were more frequent among subjects on combination therapy than subjects on upadacitinib monotherapy (Table 65). Among subjects on combination therapy, there were no consistent differences between subjects using MTX vs other non-biologic DMARDs; the highest EAERs in the upadacitinib 15 mg group were observed in subjects on both MTX and another non-biologic DMARD, whereas in the upadacitinib 30 mg group, the highest EAERs were observed among subjects on a non-MTX DMARD only (Table 66). Furthermore, the sample sizes for individual non-MTX DMARDs are very small and the overall results should thus be interpreted with caution.

<div style=\"page-break-after: always\"></div>

Table 65 Treatment-Emergent Serious Infection EAERs by Upadacitinib Monotherapy vs. Upadacitinib Combination Therapy (Any Upadacitinib Analysis Set)

|                                                           |                                                                       |                                                                       | Upadacitinib                                   | Upadacitinib                                  |
|-----------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------|
|                                                           | 15mgQD (No Cross-Over from Placebo) Events (E/100PYs) [SSA E/100 PYs] | 30mgQD (No Cross-Over from Placebo) Events (E/100PYs) [SSA E/100 PYs] | Any15 mg.QD Events (E/100 PYs) [SSA E/100 PYs] | Any30 mgQD Events (E/100 PYs) [SSA E/100 PYs] |
| Upadacitinibmonotherapyvs. upadacitinibcombinationtherapy |                                                                       |                                                                       |                                                |                                               |
| Upadacitinib monotherapy Any adverse event                | （N=189,PYs=192.2） 1(0.5）[0.5]                                         | （086=6L61=N） 8（4.0)[3.9]                                              | （N=255，PYs=228.5) 3（1.3）[1.3]                  | （N=276，PYs=253.2） 11（4.3）[4.2]                |
| Upadacitinibcombination therapy Any adverse event         | （N=451，PY8=459.7） 14(3.0)[3.0]                                        | （N=444,PYs=448.8) 31(6.9)[6.9]                                        | （N=652，PYs=588.4) 16(2.7)[2.7]                 | （N=644,PYs=569.1） 38(6.7)[6.7]                |

<!-- image -->

Table 66 Treatment-Emergent Serious Infection EAER by Concomitant Non-Biologic DMARD Use at Baseline (Any Upadacitinib Analysis Set)

<!-- image -->

|                                                     | 15mgQD (No Cross-Over from Placebo) Events (E/100 PYs) [SSA E/100 PYs]   | Upadacitinib 30mgQD (No Cross-Over from Placebo) Events (E/100 PYs) [SSA E/100 PYs]   | Any15 Events (E/100 PYs) [SSA E/100 PYs]        | Any30 mgQD Events (E/100 PYs) [SSA E/100 PYs]   |
|-----------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Concomitant non-biologic DMARDs use at baseline     | Concomitant non-biologic DMARDs use at baseline                          | Concomitant non-biologic DMARDs use at baseline                                       | Concomitant non-biologic DMARDs use at baseline | Concomitant non-biologic DMARDs use at baseline |
| MTX alone Any adverse event                         | （N=353,PYs=357.8) 10(2.8）[2.8]                                           | （N=341,PYs=344.4） 24(7.0）[7.0]                                                        | （N=516,PYs=463.3） 12(2.6）[2.6]                  | （N=486,PYs=433.4) 29(6.7）[6.7]                  |
| MTX and other non-biologic DMARD Any adverse event  | (N=26,PYs=26.2) 2（7.6)[7.1]                                              | （N=32，PYs=33.9) 1（3.0）[2.7]                                                           | (N=37,PYs=34.7） 2.（5.8)[5.5]                    | （N=48,PYs=43.3） 2(4.6）[4.9]                     |
| Non-biologic DMARD other than MTX Any adverse event | （N=72，PYs=75.6） 2(2.6）[2.7]                                              | （N=71,PYs=70.5) 6(8.5)[8.5]                                                           | （N=99，PYs=90.4) 2（2.2）[2.2]                     | （N=110,PYs=92.3） 7(7.6)[7.7]                    |
| Any APREMILAST without MTX Any adverse event        | (N=15,PYs=20.5） 1(4.9）[5.1]                                              | （N=13,PYs=14.9） 2（13.5）[13.9]                                                         | （N=23,PYs=25.8） 1（3.9}[3.9]                     | （N=18,PYs=17.4) 2(11.5)[11.5]                   |
| Any LEFLUNOMIDE without MTX Any adverse event       | （N=30，PYs=28.9） 0                                                        | （N=35，PYs=35.5） 4(11.3)[11.9]                                                         | (N=37，PYs=33.9) 0                               | （N=56，PYs=46.7) 5（10.7)[10.7]                   |
| Any SULFASALAZINE without MTX Any adverse event     | （N=22，PYs=20.9） 1（4.8)[4.5]                                              | (N=24,PYs=21.3） 0                                                                     | （N=36,PYs=27.5） 1（3.6）[3.2]                     | （N=33,PYs=26.0） 0                               |
| None                                                | （N=189,PYs=192.2)                                                        | （N=197,PYs=198.3)                                                                     | （N=255,PYs=228.5)                               | （N=276,PYs=253.2）                               |
| Any adverse event                                   | 1(0.5）[0.5]                                                              | 8（4.0）[3.9]                                                                           | 3（1.3)[1.3]                                     | 11(4.3)[4.2]                                    |

oforal study drug,and no morethan 30 days after the last dose of upadacitinib and placebo. E/loo PYs=Events per l00 patient-years. SsA=Study size adjusted. Patients could be included in more than one treatment group.

In Study 572, the long-term EAERs of treatment-emergent serious infections were 1.5 E/100 PY for adalimumab, 2.1 E/100 PY for upadacitinib 15 mg and 5.5 E/100 PY for upadacitinib 30 mg.

## Opportunistic infections (excluding TB and herpes zoster)

In the PBO-controlled Analysis Set, the percentage of subjects with treatment-emergent opportunistic infections excluding TB and herpes zoster was 0.2% (1 subject) in the upadacitinib 15 mg group and 0.6% (4 subjects) in the upadacitinib 30 mg group; none were reported in the placebo group. Treatment-emergent opportunistic infections included candida urethritis in 1 subject in the upadacitinib 15 mg group and candidiasis of trachea, CMV infection, oropharyngeal candidiasis, and PJP in 1 subject each in the upadacitinib 30 mg group; the event of PJP was a serious event and considered by the investigator to have a reasonable possibility of being related to study drug. During the placebocontrolled period, there were no deaths that were considered by the investigators to be related to

<div style=\"page-break-after: always\"></div>

opportunistic infections, and no subject had an event of opportunistic infection that led to discontinuation of study drug.

Long-term EAERs for opportunistic infections excluding TB and herpes zoster are summarised in Table 67. The most commonly reported events were related to mucosal candida infections. One subject (0.1 E/100 PY) in the upadacitinib 15 mg group discontinued study drug due to a nonserious opportunistic infection of coccidioidomycosis.

Table 67 Treatment-Emergent Opportunistic Infections Excluding TB and Herpes Zoster EAER per 100 PY (Any Upadacitinib Analysis Set)

|                                              | Upadacitinib                                                | Upadacitinib                                                 | Upadacitinib                        | Upadacitinib                       |
|----------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------|------------------------------------|
| System Organ Class MedDRA 22.0Preferred Term | 15 mg QD (No Cross-Over from Placebo) (N =640) (PY = 651.8) | 30 mg QD (No Cross-Over from Placebo) (N = 641) (PY = 647.1) | Any 15 mg QD (N = 907) (PY = 816.9) | Any 30 mg QD (N =920) (PY = 822.3) |
|                                              | E (E/100 PY) [SSA E/100 PY]                                 | E (E/100 PY) [SSA E/100 PY]                                  | E (E/100 PY) [SSA E/100 PY]         | E (E/100 PY) [SSA E/100 PY]        |
| Any opportunistic infection                  | 3 (0.5) [0.5]                                               | 7 (1.1) [1.1]                                                | 4 (0.5) [0.5]                       | 9 (1.1) [1.1]                      |
| Infections and infestations                  |                                                             |                                                              |                                     |                                    |
| Bronchopulmonary aspergillosis               | 1 (0.2) [0.2]                                               | 0                                                            | 1 (0.1) [0.1]                       | 0                                  |
| Candida urethritis                           | 1 (0.2) [0.2]                                               | 0                                                            | 1 (0.1) [0.1]                       | 0                                  |
| Candidiasis of trachea                       | 0                                                           | 1 (0.2) [0.2]                                                | 0                                   | 1 (0.1) [0.1]                      |
| Coccidioidomycosis                           | 1 (0.2) [0.2]                                               | 0                                                            | 1 (0.1) [0.1]                       | 0                                  |
| Cytomegalovirus infection                    | 0                                                           | 1 (0.2) [0.2]                                                | 0                                   | 2 (0.2) [0.2]                      |
| Oesophageal candidiasis                      | 0                                                           | 0                                                            | 1 (0.1) [0.1]                       | 0                                  |
| Oral fungal infection                        | 0                                                           | 2 (0.3) [0.3]                                                | 0                                   | 2 (0.2) [0.2]                      |
| Oropharyngeal candidiasis                    | 0                                                           | 2 (0.3) [0.3]                                                | 0                                   | 2 (0.2) [0.2]                      |
| Pneumocystis jirovecii pneumonia             | 0                                                           | 1 (0.2) [0.2]                                                | 0                                   | 2 (0.2) [0.2]                      |

EAER = exposure-adjusted event rate; MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year, QD = once daily; SSA = study size adjusted

In the long-term analysis set, three serious events (0.4 E/100 PY) of opportunistic infections excluding TB and herpes zoster were reported in two subjects in the upadacitinib 30 mg group. In addition to the subject with PJP mentioned above, another subject also had an event of PJP as well as CMV infection; both events were serious and considered to have a reasonable possibility of being related to study drug. Although there were no deaths attributed to opportunistic infections by the investigator, the events of PJP and CMV preceded the death of the subject in question.

In Study 572, the EAERs of treatment-emergent opportunistic infection excluding TB and herpes zoster were 0.4 E/100 PY (N=2) in the upadacitinib 15 mg group and 1.0 E/100 PY (N=5) in the upadacitinib 30 mg group. No events were reported in the adalimumab group.

## Herpes zoster

Herpes zoster is an important identified risk for upadacitinib, and subjects with a history of recurrent or disseminated herpes zoster or disseminated herpes simplex were excluded from participating in the global Phase 3 PsA studies with upadacitinib. In these studies, 4.4% and 4.7% in the upadacitinib 15 mg and 30 mg group, respectively, had a history of zoster vaccination.

<div style=\"page-break-after: always\"></div>

In the PBO-controlled Analysis Set, the frequencies of herpes zoster were 0.8% for placebo, 1.0% for upadacitinib 15 mg and 2.0% for upadacitinib 30 mg. There were no serious TEAEs of herpes zoster. Events leading to discontinuation of study drug were reported in 1 subject each in the upadacitinib 15 mg and placebo groups and 2 subjects in the upadacitinib 30 mg group,

In the Any Upadacitinib Analysis Set, EAERs for TEAEs of herpes zoster were 3.6 E/100 PY (N=29) in the upadacitinib 15 mg group and 7.9 E/100 PY (N=65) in the upadacitinib 30 mg group. Over 85% of herpes zoster cases in both treatment groups involved a single dermatome or two dermatomes on the same side. About 3% (1/29) of cases with 15 mg and about 12% (8/65) of cases with 30 mg were considered severe in intensity, and one event in the upadacitinib 15 mg and 5 events in the upadacitinib 30 mg group were considered serious. Two events each in the upadacitinib 15 mg and 30 mg groups led to discontinuation of study drug.

Subgroup analyses demonstrated a higher frequency of herpes zoster in Asia compared to other regions, and an increased risk in subjects &gt;= 50 years. Although the number of subjects with a history of zoster vaccination is too small for definite conclusions, a vaccination did not seem to confer reliable protection against a subsequent recurrence.

In Study 572, the EAERs of treatment-emergent herpes zoster were 3.4 E/100 PY in the upadacitinib 15 mg group, 6.5 E/100 PY in the 30 mg group and 0.5 E/100 PY in the adalimumab group.

## Active TB

Subjects with evidence of active TB were not permitted to enrol in the Phase 3 PsA clinical studies. However, subjects with latent TB were allowed to enrol in the study after initiation of TB prophylaxis at least 2 weeks prior to first administration of study drug (or per local guidelines, whichever was longer).

In the PsA clinical programme, 4.4%, 4.5%, and 5.1% of subjects in the placebo, upadacitinib 15 mg and upadacitinib 30 mg groups had positive TB test results at Screening. No events of treatmentemergent active TB were reported in the clinical studies.

## Malignancy

In the long-term Any Upadacitinib Analysis Set, the EAIRs of malignancy other than NMSC were 0.9 n/100 PY (N=7) for both upadacitinib 15 mg and 30 mg. Other than NMSC, individual malignancy types (per coded PT) were each reported in 1 subject ( ≤ 0.1 n/100 PY), with the exception of prostate cancer in the upadacitinib 15 mg group and squamous cell carcinoma in the upadacitinib 30 mg group, which were each reported in 2 subjects (although based on medical review, the 2 events of squamous cell carcinoma were determined to represent NMSC). Based on a Kaplan-Meier analysis, the risk of subjects experiencing any malignancy other than NMSC when receiving upadacitinib 15 mg in the global Phase 3 studies did not appear to increase over time.

In Study 572, the EAIR of treatment-emergent malignancy other than NMSC was 0.6 n/100 PY in the upadacitinib 15 mg group, 0.4 n/100 PY in the upadacitinib 30 mg group, and 1.0 n/100 PY in the adalimumab group.

A standard incidence ratios (SIR) analysis for malignancy other than NMSC using age-gender specific malignancy data from the Surveillance, Epidemiology, and End Results 18 Registry Research Data 2000 - 2015 for the general population yielded a SIR estimate for TEAEs of malignancy other than NMSC of 1.17 (95% CI: 0.47 - 2.42) for the upadacitinib 15 mg group and 1.16 (95% CI: 0.47 - 2.39) for the upadacitinib 30 mg group. For both doses, there were 7 observed malignancies other than NSMC, compared to 6 expected.

In the long-term Any Upadacitinib Analysis Set, there were 5 cases of treatment-emergent NMSC in the 15 mg group and 7 cases in the 30 mg group. A Kaplan-Meier analysis did not demonstrate an

<div style=\"page-break-after: always\"></div>

increase in NMSC over time. In Study 572, the rate of NMSC was 0.4 n/100 PY in the upadacitinib 15 mg group, 0.8 n/100 PY in the upadacitinib 30 mg group, and 0.5 n/100 PY in the adalimumab group.

No events of lymphoma occurred in the global Phase 3 studies. An abnormal lymphocyte morphology was reported in two subjects; however, these were not reported in subsequent laboratory testing for either subject.

## Hepatic disorders

In the PBO-controlled Analysis Set, a modest increase from baseline to Week 24 in ALT and AST was observed for upadacitinib 15 mg (ALT: 6.3 U/L, AST: 6.0 U/L) and upadacitinib 30 mg (ALT: 8.3 U/L, AST: 7.5 U/L), compared to no increase with placebo (ALT: -0.9 U/L, AST: -0.8 U/L). Most cases of transaminase elevations were Grade 2 (i.e. 3 - 5 x ULN). Consistent with this, most TEAEs of hepatic disorders were also related to transaminase elevations. The frequencies of a TEAE of hepatic disorder leading to discontinuation of study drug were 0.2% (N=1) in the placebo group, 0.3% (N=2) in the upadacitinib 15 mg group and 0.9% (N=9) in the upadacitinib 30 mg group.

In the Any Upadacitinib Analysis Set, mean increases from baseline to Week 56 for ALT and AST were observed for both the upadacitinib 15 mg group (7.5 U/L and 6.2 U/L, respectively) and the upadacitinib 30 mg group (11.2 U/L and 8.9 U/L, respectively). The increases developed rapidly, with a plateau observed from Week 2 onward. Similar to the short-term analysis set, most cases of transaminase elevations were Grade 2 (i.e. 3 - 5 x ULN), and most TEAEs of hepatic disorders were related to transaminase elevations. In the long-term analysis set, the EAERs of a TEAE of hepatic disorder leading to discontinuation of study drug were 0.2 E/100 PY (N=2) in the upadacitinib 15 mg group and 1.3 E/100 PY (N=11) in the upadacitinib 30 mg group; most events resolved even when upadacitinib was continued.

There were no serious events of hepatic disorders, and no subjects meeting the biochemical criteria of Hy's Law, with either 15 mg or 30 mg upadacitinib.

In Study 572, Grade 3 increases in ALT and AST were similar across the upadacitinib 15 mg, upadacitinib 30 mg, and adalimumab groups (ALT: 1.2%, 1.0% and 1.2%, respectively, AST: 0.5%, 0.8%, and 0.5%, respectively). The EAER of treatment-emergent hepatic disorders was 22.5 E/100 PY and 24.3 E/100 PY in the upadacitinib 15 mg and 30 mg groups, respectively, and 30.9 E/100 PY in the adalimumab group.

## GI perforation

According to the MAH, all potential events of GI perforation in the programme were adjudicated against a pre-specified case definition by internal experts who were independent of the clinical study team and blinded to subject treatment assignment. Subjects with a history of GI perforation (other than appendicitis or penetrating injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment were excluded from the Phase 3 studies.

In the Any Upadacitinib Analysis Set, there was one treatment-emergent adjudicated GI perforation event (gastric ulcer perforation) reported in a 69-year old male subject who was receiving upadacitinib 15 mg. The event occurred about 9 months after first dose of upadacitinib. The event was serious and led to discontinuation of study drug. The subject was on concomitant NSAIDs and MTX at the time of the event.

## Anaemia

In the PBO-controlled Analysis Set, mean decrease from baseline to Week 24 in haemoglobin was -0.2 g/L in the placebo group, -1.6 g/L in the upadacitinib 15 mg group and -3.6 g/L in the 30 mg group. Grade 2 haemoglobin decreases (i.e. decrease to between 80 and 100 g/L) were reported in 12

<div style=\"page-break-after: always\"></div>

subjects (1.9%) on placebo, 10 subjects (1.6%) on 15 mg and 19 subjects (3.0%) on 30 mg. There were 3 subjects (0.5%) with a Grade 3 haemoglobin decrease (i.e. decrease to &lt; 80 g/L) in the upadacitinib 30 mg group.

In the PBO-controlled Analysis Set, a TEAE of anaemia was reported in 0.9% of subjects on placebo, 1.1% of subjects on upadacitinib 15 mg and 5.3% of subjects on upadacitinib 30 mg. One subject in each of the upadacitinib 15 mg and 30 mg groups had a TEAE of anaemia that was considered serious; the event in the upadacitinib 15 mg group led to discontinuation of study drug.

Mean haemoglobin values over time in the Any Upadacitinib Analysis Set are depicted in Figure 40. The pattern is characterised by a dose-related decrease until Week 16 and a partial recovery thereafter. Grade 2 haemoglobin decreases were reported in 16 subjects (1.8%) on 15 mg and 37 subjects (4.1%) on 30 mg, and Grade 3 decreases in 1 subject (0.1%) on 15 mg and 6 subjects (0.7%) on 30 mg. The EAERs of TEAEs of anaemia were 2.8 E/100 PY for 15 mg and 6.9 E/100 PY for 30 mg. A serious TEAE of anaemia was reported for 1 subject on 15 mg and 3 subjects on 30 mg, and anaemia led to study drug discontinuation in 3 subjects in both groups.

Variable(unit):HEMOGLOBIN(G/L)

| ARMA   |   635 | 616 612   |   619 |   598 |   598 |   583 |   574 |   524 |   470 |   438 | 361 266   |
|--------|-------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-----------|
| ARMB   |   638 | 625 624   |   619 |   611 |   598 |   588 |   568 |   529 |   467 |   429 | 357 268   |
| ARMC   |   878 | 616 612   |   619 |   598 |   598 |   583 |   574 |   765 |   686 |   639 | 525 388   |
| ARMD   |   896 | 625 624   |   619 |   611 |   598 |   588 |   568 |   781 |   695 |   644 | 527 395   |

<!-- image -->

ARMA=Upadacitinib15 mg QD(NoCross-OverfromPlacebo),ARM B=Upadacitinib30 mg QD(NoCross-OverfromPlacebo),ARM C=AnyUpadacitinib 15mg QD, ARM D=AnyUpadacitinib30mgQD.

- Baselinemeanincludessubjectswithnon-missingbaseline and atleastonepost-baselinevalue. #LSmeanisbased onANcovAmodelwithtreatment as amainfactor,andbaselineand studyascovariates.
- Note:Patients could beincluded inmore than one treatment group.

Figure 40 Plot of Mean Change from Baseline in Haemoglobin Values Over Time (Any Upadacitinib Analysis Set)

In Study 572, the percentages of subjects with a Grade 2 haemoglobin decrease were 0.5%, 1.0% and 4.0% for adalimumab, upadacitinib 15 mg and 30 mg, respectively. A Grade 3 haemoglobin decrease was reported in 0.5%, 0.2% and 0.3% of subjects in the adalimumab, upadacitinib 15 mg and 30 mg groups, respectively. The EAERs of treatment-emergent anaemia were 2.9 E/100 PY and 7.2 E/100 PY in the upadacitinib 15 mg and 30 mg groups, respectively, and 1.5 E/100 PY in the adalimumab group.

## Neutropenia

In the PBO-controlled Analysis Set, mean neutrophil counts decreased from baseline to Week 24 in both the upadacitinib 15 mg and 30 mg groups (-0.442 × 10E9/L and -0.758 × 10E9/L, respectively), whereas an increase of 0.018 × 10E9/L from baseline to Week 24 was seen in the placebo group. The decrease in mean values with upadacitinib was evident already at Week 2 and mean values remained stable thereafter.

<div style=\"page-break-after: always\"></div>

A summary of neutrophil decreases based on CTC grading is displayed in Table 68. No Grade 4 decreases were seen in any treatment group. The percentage of subjects with a reported TEAE of neutropenia was 0.3% in the placebo group, 0.9% in the upadacitinib 15 mg group and 4.2% in the upadacitinib 30 mg group. No TEAE of neutropenia was serious or led to discontinuation of study drug.

Table 68 Number and Percentage of Subjects Meeting Criteria for Potentially Clinically Significant Values for Neutrophils (PBO-controlled Analysis Set)

| Neutrophils (109/L)   | Placebo (N = 635)   | Upadacitinib 15 mg QD (N = 640)   | Upadacitinib 30 mg QD (N = 641)   |
|-----------------------|---------------------|-----------------------------------|-----------------------------------|
|                       | n/N_0BS (%) [SSA %] | n/N_0BS (%) [SSA %]               | n/N_0BS (%) [SSA %]               |
| Grade 2 (1.0 -< 1.5)  | 5/627               | 20/635                            | 43/638                            |
|                       | (0.8) [0.8]         | (3.1) [3.2]                       | (6.7) [6.7]                       |
| Grade 3 (0.5 - ≤ 1.0) | 2/627               | 4/635                             | 10/638                            |
|                       | (0.3) [0.3]         | (0.6) [0.6]                       | (1.6) [1.6]                       |
| Grade 4 (< 0.5)       | 0/627               | 0/635                             | 0/638                             |
| ≥ Grade 3             | 2/627               | 4/635                             | 10/638                            |
|                       | (0.3) [0.3]         | (0.6) [0.6]                       | (1.6) [1.6]                       |

CTC = Common Terminology Criteria; NCI = National Cancer Institute; OBS = observed; PBO = placebo; QD = once daily; SSA = study size adjusted

Note: Toxicity grading scale is based on NCI CTC v4.03. Grade must also be more extreme than the baseline grade. N\\_OBS indicates the number of subjects with both baseline and postbaseline values up to Week 24 for the respective parameter.

Mean neutrophil counts over time in the Any Upadacitinib Analysis Set are depicted in Figure 41. Mean change from baseline to Week 56 was -0.360 × 10E9/L in the upadacitinib 15 mg group and -0.531 × 10E9/L in the upadacitinib 30 mg group. Grade 2 and 3 decreases were seen in 4.4% and 0.7% of subjects in the upadacitinib 15 mg group, and 7.9% and 1.7% of subjects in the upadacitinib 30 mg group. No subjects had Grade 4 decreases in neutrophils. No SAEs of neutropenia were reported and no subjects discontinued study drug permanently due to TEAEs of neutropenia.

Variable(unit):NEUTROPHILS(10^9/L)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 41 Plot of Mean Change from Baseline in Neutrophil Count Over Time (Any Upadacitinib Analysis Set)

In Study 572, Grade 3 neutropenias were seen in 0.5% of subjects in the upadacitinib 15 mg and adalimumab groups and 1.7% of subjects in the upadacitinib 30 mg group. There were no Grade 4 neutropenias.

## Lymphopenia

In the PBO-controlled Analysis Set, a small increase from baseline to Week 24 in mean lymphocyte count was seen across all treatment groups (0.042 × 10E9/L for placebo, 0.035 × 10E9/L for upadacitinib 15 mg and 0.075 × 10E9/L for upadacitinib 30 mg). On the other hand, Grade 2 to 3 decreases were more frequent with upadacitinib than placebo (Table 69). Most of the Grade 3 decreases in lymphocytes occurred at a single time point (the study protocols mandated study drug interruption if ALC was below 0.5 x 10E9/L). The percentages of subjects with TEAEs of lymphopenia were 0.8% for placebo, 1.3% for upadacitinib 15 mg and 2.7% for upadacitinib 30 mg. Two subjects (0.3%) in both upadacitinib 15 mg and 30 mg groups discontinued study medication permanently due to lymphopenia. No SAEs of lymphopenia were reported.

Table 69 Number and Percentage of Subjects Meeting Criteria for Potentially Clinically Significant Values for Lymphocytes (PBO-controlled Analysis Set)

| Lymphocytes (109/L)   | Placebo (N = 635)   | Upadacitinib 15 mg QD (N = 640)   | Upadacitinib 30 mg QD (N = 641)   |
|-----------------------|---------------------|-----------------------------------|-----------------------------------|
|                       | n/N_0BS (%) [SSA %] | n/N_0BS (%) [SSA %]               | n/N_0BS (%) [SSA %]               |
| Grade 2 (0.5 -< 0.8)  | 24/627 (3.8) [3.8]  | 32/635 (5.0) [5.0]                | 54/638 (8.5) [8.5]                |
| Grade 3 (0.2 - < 0.5) | 1/627 (0.2) [0.2]   | 5/635 (0.8) [0.8]                 | 11/638 (1.7) [1.7]                |
| Grade 4 (< 0.2)       | 0/627               | 0/635                             | 0/638                             |

CTC = Common Terminology Criteria; NCI = National Cancer Institute; OBS = observed; PBO = placebo;

QD = once daily; SSA = study size adjusted

Note: Toxicity grading scale is based on NCI CTC v4.03. Grade must also be more extreme than the baseline grade. N\\_OBS indicates the number of subjects with both baseline and postbaseline values up to Week 24 for the frespective parameter.

Mean lymphocyte counts over time in the Any Upadacitinib Analysis Set are depicted in Figure 42. Mean change from baseline to Week 56 was -0.077 × 10E9/L in the upadacitinib 15 mg group and -0.084 × 10E9/L in the upadacitinib 30 mg group. Grade 2 and 3 decreases were seen in 7.4% and 1.3% of subjects in the upadacitinib 15 mg group, and 9.9% and 2.7% of subjects in the upadacitinib 30 mg group. One subject on 30 mg experienced a Grade 4 decrease at Day 540; study drug was temporarily interrupted with the subject experiencing a nonserious event of upper respiratory tract inflammation and a SAE of bronchitis. This subject was treated with antibiotics, MTX dose was decreased, and the subject's lymphocyte count returned to Grade 2 through data cut-off. Two subjects (0.2%) on upadacitinib 15 mg and 3 subjects (0.4%) on upadacitinib 30 mg discontinued study drug permanently due to TEAEs of lymphopenia. No SAEs of lymphopenia were reported.

<div style=\"page-break-after: always\"></div>

Variable(unit):LYMPHOCYTES(10^9/L)

<!-- image -->

ARMA=Upadacitinib 15mgQD(NoCross-OverfromPlacebo),ARM B=Upadacitinib30mgQD(NoCross-OverfromPlacebo).ARMC=AnyUpadacitinib15mg QD.

Note:Patientscouldbeincluded inmorethanone treatmentgroup.

ARMD=AnyUpadacitinib30mgQD.

Baselinemeanincludessubjectswithnon-missingbaseline andatleastonepost-baselinevalue.

- #LSmeanisbasedonANcoVAmodel with treatmentasamainfactor,andbaseline and studyascovariates.

Figure 42 Plot of Mean Change from Baseline in Lymphocytes Over Time (Any Upadacitinib Analysis Set)

In Study 572, Grade 2 lymphopenias were seen in 7.1% of subjects in the upadacitinib 15 mg group, 8.8% of subjects in the upadacitinib 30 mg group and 0.9% of subjects in the adalimumab group; Grade 3 to 4 lymphopenias were seen in 1.2% of subjects in the upadacitinib 15 mg group, 3.7% of subjects in the upadacitinib 30 mg group and no subjects in the adalimumab group.

## Creatine phosphokinase elevation

In the PBO-controlled Analysis Set, the mean increases in CPK values from baseline to Week 24 were 111.1 U/L in the upadacitinib 15 mg group and 139.5 U/L in the 30 mg group, compared to 7.5 U/L in the placebo group. In line with this, Grade 2 and Grade 3 CPK increases were more frequent in the upadacitinib groups compared to placebo (Table 70); Grade 4 decreases were infrequent but were seen across all groups including placebo. A TEAE of CPK elevation was reported for 6.6% and 8.3% of subjects in the upadacitinib 15 mg and 30 mg groups, respectively, compared to 1.6% of subjects in the placebo group. There were no serious TEAEs of CPK elevation in any group; discontinuation of study drug was reported in 1 subject (0.2%) in the placebo group and 2 subjects (0.3%) in the upadacitinib 30 mg group.

<div style=\"page-break-after: always\"></div>

Table 70 Number and Percentage of Subjects Meeting Criteria for Potentially Clinically Significant Values for CPK (PBO-controlled Analysis Set)

| Variable (U/L)             | Placebo (N= 635)   | Upadacitinib 15 mg QD (N = 640)   | Upadacitinib 30 mg QD (N= 641)   |
|----------------------------|--------------------|-----------------------------------|----------------------------------|
|                            |                    | n/N_0BS (%) [SSA %]               |                                  |
|                            |                    |                                   | 48/638 (7.5)                     |
| Creatine kinase            | [0.6]              | [1.1]                             | [1.9]                            |
|                            | [1.3]              | [5.5] 7/635 (1.1)                 | [7.5] 12/638 (1.9)               |
| Grade 3 (> 5.0-10.0 x ULN) | 4/627 (0.6)        |                                   |                                  |
| Grade 4 (> 10.0 x ULN)     | 3/627 (0.5) [0.5]  | 2/635 (0.3) [0.3]                 | 4/638 (0.6) [0.6]                |
|                            | 7/627 (1.1)        | 9/635 (1.4)                       | 16/638 (2.5)                     |
| ≥Grade 3                   |                    | [1.4]                             |                                  |
|                            |                    |                                   | [2.5]                            |
|                            | [1.1]              |                                   |                                  |

CPK = creatine phosphokinase; CTC = Common Teminology Criteria, NCI = National Cancer Institute;

OBS = observed; PBO = placebo; QD = once daily, SSA = study size adjusted; ULN = upper limit of normal

Note: Toxicity grading scale is based on NCI CTC v4.03. Grade must also be more extreme than the baseline grade. N\\_OBS indicates the number of subjects with both baseline and postbaseline values up to Week 24 for the respective parameter.

In the Any Upadacitinib Analysis Set, mean increases from baseline to Week 56 in CPK values were 82.6 U/L in the upadacitinib 15 mg group and 137.9 U/L in the upadacitinib 30 mg group. The percentage of subjects with Grade 2 increases in CPK levels were 7.7% in the 15 mg group and 11.5% in the 30 mg group. Grade 3 and Grade 4 increases in CPK levels were similar in the upadacitinib 15 mg (1.6% and 0.8%) and 30 mg groups (1.9% and 1.0%). No serious TEAEs of CPK elevations were reported in either group, and the EAERs of discontinuation of study drug due to TEAEs of CPK elevation were similar between the upadacitinib 15 mg and 30 mg groups (0.1 E/100 PY and 0.2 E/100 PY, respectively). No cases of rhabdomyolysis were reported.

In Study 572, Grade 3 increases in CPK values were recorded in 1.9% and 2.0% of subjects in the upadacitinib 15 mg and 30 mg groups, respectively, and 0.5% of subjects in the adalimumab group. Grade 4 increases in CPK values were recorded in 0.7% of subjects in the upadacitinib 15 mg and adalimumab groups, and in 1.5% of subjects in the upadacitinib 30 mg group.

## Renal dysfunction / serum creatinine

In the PBO-controlled Analysis Set, small increases from baseline to Week 24 in mean serum creatinine were observed in all treatment groups. From baseline values of approximately 70 umol/L, the increases were 1.8 μmol/L in the placebo group, 4.7 μmol/L in the upadacitinib 15 mg group and 6.0 μmol/L in the upadacitinib 30 mg group. One Grade 3 increase in creatinine was reported in a subject in the upadacitinib 30 mg group on Day 57, and the increase returned to baseline value on Day 72 without interruption or discontinuation of study drug. No Grade 3 increases in creatinine were reported in the upadacitinib 15 mg or placebo groups and there were no Grade 4 increases in creatinine in any treatment group.

In the PBO-controlled Analysis Set, no TEAE of renal dysfunction was reported in the upadacitinib 15 mg group, 1 subject in the upadacitinib 30 mg group had a TEAE of renal dysfunction (acute kidney injury), and 2 subjects in the placebo group had TEAEs of renal dysfunction (1 subject had acute kidney injury and 1 subject had renal failure and acute kidney injury).

<div style=\"page-break-after: always\"></div>

The event of acute kidney injury reported in the upadacitinib 30 mg group was considered serious. This case occurred in a 54-year old female subject who had been on study drug for about 5 months. The developed acute kidney injury (serum creatinine was approximately 2 x ULN) in the context of a traumatic hand injury, a systemic staphylococcal infection and a lower back epidural abscess. The investigator assessed the events as being not related to study medication.

According to the MAH, no events of renal dysfunction led to discontinuation of study drug; however, the subject with the serious acute kidney injury was permanently discontinued from the study upon event resolution.

In the Any Upadacitinib Analysis Set, the small increase in mean serum creatinine remained stable through the treatment period. Grade 3 increases were only observed in 2 subjects (0.2%) in the upadacitinib 30 mg group. Beyond the serious acute kidney injury described above, another serious acute kidney injury was reported in 52-year old male subject with a preceding history of abnormal kidney function. The subject had been on upadacitinib 15 mg for about 17 months and also developed the acute kidney injury in the context of an infection (post-traumatic leg cellulitis). The investigator assessed the event as being not related to study medication.

In Study 572, there were no Grade 3 increases in serum creatinine. Grade 4 increases were recorded in 1 subject in the upadacitinib 30 mg group and 2 subjects in the adalimumab group.

## Adjudicated MACE and other CV events

MACE are identified as an important potential risk for upadacitinib, although no definite link to an increased risk has been established to date. Subjects with a very high underlying risk of MACE have generally been excluded from studies, but a substantial proportion of the population enrolled in the RA programme as well as the current PsA programme did have pre-existing risk factors such as hypertension, tobacco use, obesity as well as low HDL and/or elevated LDL. The MAH has established an independent external Cardiovascular Adjudication Committee (CAC) to review and adjudicate all potential CV events, including VTEs, as well as all deaths.

In the PBO-controlled Analysis Set, 1 subject each in the upadacitinib 15 mg and placebo groups had a non-fatal MI, and no subjects in the upadacitinib 30 mg group had a treatment-emergent MACE. In the Any Upadacitinib Analysis Set, the EAIR of treatment-emergent MACE was 0.5 n/100 PY (N=4) in the upadacitinib 15 mg group and 0.2 n/100 PY (N=2) in the upadacitinib 30 mg group (Table 71). No fatal events of MACE were reported. According to the MAH, multiple CV risk factors were present in all the subjects who had an event of MACE, including pre-existing CV conditions, hyperlipidaemia, diabetes, smoking, and obesity in addition to the underlying PsA.

<div style=\"page-break-after: always\"></div>

|                  | Upadacitinib                                    | Upadacitinib                                    | Upadacitinib                   | Upadacitinib                   |
|------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------|--------------------------------|
|                  | 15 mg QD (No Cross-Over from Placebo) (N = 640) | 30 mg QD (No Cross-Over from Placebo) (N = 641) | Any 15 mg QD (N = 907)         | Any 30 mg QD (N=920)           |
|                  | n/PY (n/100 PY) [SSA n/100 PY]                  | n/PY (n/100 PY) [SSA n/100 PY]                  | n/PY (n/100 PY) [SSA n/100 PY] | n/PY (n/100 PY) [SSA n/100 PY] |
| MACEa            | 4/649.1 (0.6) [0.6]                             | 1/646.0 (0.2) [0.2]                             | 4/814.2 (0.5) [0.5]            | 2/821.2 (0.2) [0.2]            |
| CV death         | 0/651.8                                         | 0/647.1                                         | 0/816.9                        | 0/822.3                        |
| Non-fatal MI     | 2/650.1 (0.3) [0.3]                             | 1/646.0 (0.2) [0.2]                             | 2/815.2 (0.2) [0.2]            | 1/821.2 (0.1) [0.1]            |
| Non-fatal stroke | 2/650.8 (0.3) [0.3]                             | 0/647.1                                         | 2/815.9 (0.2) [0.2]            | 1/822.3 (0.1) [0.1]            |

Note: Subjects could be included in more than 1 treatment group.

In study 572, there were 3 treatment-emergent adjudicated MACE events in the adalimumab group, 1 event in the upadacitinib 15 mg group and 3 events in the upadacitinib 30 mg group. No fatal events were reported. The long-term rates of adjudicated MACE were comparable across the treatment groups of upadacitinib 15 mg and 30 mg, and adalimumab (0.6, 0.2, and 0.8 n/100 PY, respectively).

Other adjudicated CV events in the Any Upadacitinib Analysis Set are summarised in Table 72. In study 572, 1 subject in the adalimumab group had a TIA and CV procedure, 1 subject in the upadacitinib 15 mg group had a TIA, and 1 subject in the upadacitinib 30 mg group had a CV procedure.

<div style=\"page-break-after: always\"></div>

Table 72 Treatment-Emergent Adjudicated Cardiovascular Events EAIR per 100 PY (Any Upadacitinib Analysis Set)

|                                            | Upadacitinib                                    | Upadacitinib                                    | Upadacitinib                   | Upadacitinib                   |
|--------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------|--------------------------------|
|                                            | 15 mg QD (No Cross-Over from Placebo) (N = 640) | 30 mg QD (No Cross-Over from Placebo) (N = 641) | Any 15 mg QD (N =907)          | Any 30 mg QD (N =920)          |
|                                            | n/PY (n/100 PY) [SSA n/100 PY]                  | n/PY (n/100 PY) [SSA n/100 PY]                  | n/PY (n/100 PY) [SSA n/100 PY] | n/PY (n/100 PY) [SSA n/100 PY] |
| Other CV events (non-fatal)                | 0/651.8                                         | 4/644.9 (0.6) [0.6]                             | 0/816.9                        | 4/820.1 (0.5) [0.5]            |
| CV procedures                              | 0/651.8                                         | 2/645.9 (0.3) [0.3]                             | 0/816.9                        | 2/821.1 (0.2) [0.2]            |
| Unstable angina requiring hospitalization  | 0/651.8                                         | 0/647.1                                         | 0/816.9                        | 0/822.3                        |
| Hospital based treatment for heart failure | 0/651.8                                         | 0/647.1                                         | 0/816.9                        | 0/822.3                        |
| Transient ischemic attack                  | 0/651.8                                         | 2/646.1 (0.3) [0.3]                             | 0/816.9                        | 2/821.2 (0.2) [0.2]            |

Note:

Subjects could be included in more than one treatment column.

## Adjudicated thrombotic events

Cases of venous thromboembolism [VTE, comprising deep vein thrombosis (DVT) and pulmonary embolism (PE)] have been observed with all JAK inhibitors including upadacitinib, and VTE is identified as an important potential risk for upadacitinib. As stated above, all VTE events were reviewed and adjudicated as part of the work of the independent external CAC.

In the PBO-controlled Analysis Set, treatment-emergent adjudicated VTEs were reported in 1 subject (0.2%) each in the upadacitinib 15 mg (PE), upadacitinib 30 mg (PE), and placebo (DVT) groups. All events were serious, and the 2 events of PE led to discontinuation of the study drug.

The EAIR of adjudicated VTEs in the Any Upadacitinib Analysis Set are summarised in Table 73. According to the MAH, all subjects who developed VTE had one or more risk factors for VTE, such as a history of hypertension, hyperlipidaemia, obesity, smoking, or concurrent comorbidities (e.g., atrial fibrillation, infections). No fatal adjudicated VTEs were reported.

<div style=\"page-break-after: always\"></div>

Table 73

|                       | Upadacitinib                               | Upadacitinib                              | Upadacitinib               | Upadacitinib                   |
|-----------------------|--------------------------------------------|-------------------------------------------|----------------------------|--------------------------------|
|                       | 15mgQD (No Cross-Over fromPlacebo) (N=640) | 30mgQD NoCross-Over from Placebo) (N=641) | Any 15mgQD (N=907)         | Any 30mgQD (N=920)             |
|                       | n/PY(n/100PY) [SSAn/100PY]                 | n/PY(n/100PY) [SSAn/100PY]                | n/PY(n/100PY) [SSAn/100PY] | n/PY(n/100PY) [SSAn/100PY]     |
| VTE(fatalandnonfatal) | 4/651.1 (0.6) [0.6]                        | 2/647.1 (0.3) [0.3]                       | [0.5]                      | 4/816.2(0.5)2/822.3(0.2) [0.2] |
| VTE (fatal)           | 0/651.8                                    | 0/647.1                                   | 0/816.9                    | 0/822.3                        |
| PE                    | 0/651.8                                    | 0/647.1                                   | 0/816.9                    | 0/822.3                        |
| Venous thrombosis     | 0/651.8                                    | 0/647.1                                   | 0/816.9                    | 0/822.3                        |
| VTE (nonfatal)        | 4/651.1(0.6) [0.6]                         | 2/647.1 (0.3) [0.3]                       | [0.5]                      | 4/816.2（0.5)2/822.3（0.2) [0.2] |
| DVT                   | 2/651.1 (0.3) [0.3]                        | 0/647.1                                   | 2/816.2(0.2) [0.2]         | 0/822.3                        |
| PE                    | 3/651.8(0.5) [0.5]                         | 2/647.1(0.3) [0.3]                        | [0.4]                      | 3/816.9(0.4)2/822.30.2) [0.2]  |
| DVTandPE(concurrent)  | 1/651.8(0.2) [0.2]                         | 0/647.1                                   | 1/816.9 (0.1) [0.1]        | 0/822.3                        |

In Study 572, there were 2 treatment emergent adjudicated VTE events in the adalimumab group, 3 events in the upadacitinib 15 mg group and 2 events in the upadacitinib 30 mg group. The long-term rates of adjudicated thromboembolic event were comparable across the treatment groups of upadacitinib 15 mg and 30 mg, and adalimumab (0.6, 0.4, and 0.5 n/100 PY).

## Other observations related to safety

Consistent with previous experience, upadacitinib did not demonstrate any significant effects on blood pressure or heart rate. In the PBO-controlled Analysis Set, an increase in body weight of 7% or more from baseline to Week 24 was seen in 5.3% of subjects on placebo, 10.4% of subjects on upadacitinib 15 mg, and 12.2% of subjects on upadacitinib 30 mg.

## Serious adverse events/deaths/other significant events

## Deaths in the PsA programme

All deaths in the PsA clinical development programme were adjudicated by the externally led CAC. A total of 5 deaths were reported within the programme.

In the PBO-controlled Analysis Set, treatment-emergent deaths were reported in 2 subjects who were both in the placebo group.

In the Any Upadacitinib Analysis Set, 3 additional deaths were reported after Week 24. One death in the 30 mg group was treatment-emergent, and the 2 other deaths (1 each in the upadacitinib 15 mg and 30 mg groups) occurred more than 30 days after the last dose of study drug.

<div style=\"page-break-after: always\"></div>

## Deaths in other programmes

According to the MAH, as of 31 December 2019, 3 deaths have reported in other unblinded studies where the subjects were in the upadacitinib treatment group. The 3 deaths included 2 deaths in a Phase 2 Atopic Dermatitis study (Study M16-048) and 1 death in an open-label Phase 2 Crohn's disease (CD) study (Study M14-327).

## Non-fatal serious adverse events

In the PBO-controlled Analysis Set, the numbers and percentages of subjects with SAEs were 26 subjects (4.1%) in the upadacitinib 15 mg group, 44 subjects (6.9%) in the upadacitinib 30 mg group, and 17 subjects (2.7%) in the placebo group. The majority of SAEs were reported in single subjects within a group, except for gastritis erosive, sepsis, psoriatic arthropathy, and nephrolithiasis (2 subjects each in the upadacitinib 15 mg group), atypical pneumonia and bacteraemia (2 subjects each in the upadacitinib 30 mg group), and pneumonia (2 subjects (0.3%) in the upadacitinib 15 mg group, 6 subjects (0.9%) in the upadacitinib 30 mg group, 2 subjects (0.3%) in the placebo group).

In the Any Upadacitinib Analysis Set, the EAERs of SAEs were 10.9 E/100 PY and 14.8 E/100 PY for the upadacitinib 15 mg and 30 mg groups, respectively. The SAE with the highest EAER in the upadacitinib 15 mg and 30 groups was pneumonia (0.5 E/100 PY and 1.0 E/100 PY, respectively). The most frequently reported SAEs (&gt;= 0.2 E/100 PY in any treatment group) are presented in Table 74.

<div style=\"page-break-after: always\"></div>

Table 74 Treatment-Emergent Serious Adverse Events Reported in ≥ 0.2 Events per 100 PY in any Treatment Group by Decreasing Frequency in the Upadacitinib 15 mg Group (Any Upadacitinib Analysis Set)

| System Organ Class MedDRA 22.0 Preferred Term   | 15 mg QD (No Cross- Over from Placebo) (N = 640) (PY = 651.8)   | 30 mg QD (No Cross- Over from Placebo) (N = 641) (PY = 647.1)   | Any 15 mg QD (N = 907) (PY = 816.9)   | Any 30 mg QD (N = 920) (PY =822.3)   |
|-------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------|--------------------------------------|
|                                                 | E (E/100 PY) [SSA E/100 PY]                                     | E (E/100 PY) [SSA E/100 PY]                                     | E (E/100 PY) [SSA E/100 PY]           | E (E/100 PY) [SSA E/100 PY]          |
| Pneumonia                                       | 4 (0.6) [0.6]                                                   | 6 (0.9) [0.9]                                                   | 4 (0.5) [0.5]                         | 8 (1.0) [1.0]                        |
| Pulmonary embolism                              | 3 (0.5) [0.5]                                                   | 2 (0.3) [0.3]                                                   | 3 (0.4) [0.4]                         | 2 (0.2) [0.2]                        |
| Gastritis erosive                               | 2 (0.3) [0.3]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                    |
| Myocardial infarction                           | 2 (0.3) [0.3]                                                   | 1 (0.2) [0.2]                                                   | 2 (0.2) [0.2]                         | 1 (0.1) [0.1]                        |
| Nephrolithiasis                                 | 2 (0.3) [0.3]                                                   | 1 (0.2) [0.2]                                                   | 2 (0.2) [0.2]                         | 2 (0.2) [0.2]                        |
| Psoriatic arthropathy                           | 2 (0.3) [0.3]                                                   | 1 (0.2) [0.2]                                                   | 2 (0.2) [0.2]                         | 1 (0.1) [0.1]                        |
| Sepsis                                          | 2 (0.3) [0.3]                                                   | 1 (0.2) [0.2]                                                   | 2 (0.2) [0.2]                         | 1 (0.1) [0.1]                        |
| Uterine prolapse                                | 2 (0.3) [0.3]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                    |
| Appendicitis                                    | 1 (0.2) [0.2]                                                   | 1 (0.2) [0.2]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                        |
| Bronchitis                                      | 1 (0.2) [0.2]                                                   | 3 (0.5) [0.5]                                                   | 1 (0.1) [0.1]                         | 3 (0.4) [0.4]                        |
| Cellulitis                                      | 1 (0.2) [0.2]                                                   | 1 (0.2) [0.2]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                        |
| Gastroenteritis viral                           | 1 (0.2) [0.2]                                                   | 1 (0.2) [0.2]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                        |
| Herpes zoster                                   | 1 (0.2) [0.2]                                                   | 4 (0.6) [0.6]                                                   | 1 (0.1) [0.1]                         | 5 (0.6) [0.6]                        |
| Osteoarthritis                                  | 1 (0.2) [0.2]                                                   | 1 (0.2) [0.2]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                        |
| Pyrexia                                         | 1 (0.2) [0.2]                                                   | 2 (0.3) [0.3]                                                   | 1 (0.1) [0.1]                         | 3 (0.4) [0.4]                        |
| Atrial fibrillation                             | 0                                                               | 1 (0.2) [0.2]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Atypical pneumonia                              | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Bacteremia                                      | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Chronic obstructive pulmonary disease           | 0                                                               | 1 (0.2) [0.2]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Duodenal ulcer hemorrhage                       | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Gastroenteritis                                 | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Osteonecrosis                                   | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Pneumocystis jirovecii pneumonia                | 0                                                               | 1 (0.2) [0.2]                                                   | 0                                     | 2 (0.2) [0.2]                        |
| Urinary tract infection                         | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                        |

MedDRA =Medical Dictionary for Regulatory Activities; PY = patient-year; QD = once daily; SSA = study size adjusted

In study 572, the EAER of SAEs was 8.6 E/100 PY in the upadacitinib 15 mg group, 10.9 E/100 PY in the adalimumab group and 12.9 E/100 PY in the upadacitinib 30 mg group. In the adalimumab group, cellulitis and cerebrovascular accident were each reported in 2 subjects, whereas other SAE terms were only reported in single subjects.

## Laboratory findings

## Haematology

Consistent with previous experience, upadacitinib had little effect on platelet counts in PsA patients. In the PBO-controlled Analysis Set, mean initial changes from baseline to Week 2 in platelet counts were 2.1 x 10E9/L for placebo, 9.0 x 10E9/L for upadacitinib 15 mg and 14.0 x 10E9/L for upadacitinib 30

<div style=\"page-break-after: always\"></div>

mg. Mean changes from baseline to Week 24 were -2.7 x 10E9/L for placebo, 1.3 x 10E9/L for upadacitinib 15 mg and 10.6 x 10E9/L for upadacitinib 30 mg. Grade 2 decreases were recorded in 2 subjects (0.3%) on both upadacitinib 15 mg and upadacitinib 30 mg, and a Grade 3 decrease was recorded in 1 subject (0.2%) on upadacitinib 30 mg.

Effects on haemoglobin and white cells are summarised in other sections of the AR.

## Clinical chemistry

In the upadacitinib MAA studies in RA patients, upadacitinib was observed to increase both LDL and HDL cholesterol, but with the effect being of similar magnitude for both types, the LDL/HDL ratio remained quite stable.

In the PBO-controlled Analysis Set, the mean changes in lipid parameters from baseline to Week 24 for placebo, upadacitinib 15 mg and 30 groups were: HDL-C: -0.001, 0.215, 0.247 mmol/L; and LDL-C: 0.018, 0.350, 0.449 mmol/L. At Week 24, for placebo, upadacitinib 15 mg, and 30 mg groups, mean change from baseline in LDL-C/HDL-C ratio was: -0.006, -0.078, -0.013 mmol/L (Figure 43).

Variable (unit): LDL/HDL CHOLESTEROL (RATIO) (MMOL/L)

Figure 43 Mean Change from Baseline in LDL/HDL-C Ratio Over Time (PBO-controlled Analysis Set)

<!-- image -->

During the placebo-controlled period in the Phase 3 studies, statin treatment was initiated postbaseline in 9 subjects in the upadacitinib 15 mg group, 21 in the upadacitinib 30 mg group, and 13 in the placebo group. In this limited sample, a trend could be seen for reversal of mean LDL-C and mean HDL-C toward baseline levels.

Effects on hepatic enzymes, creatine phosphokinase and creatinine are summarised in other sections of the AR.

## Safety in special populations

## Intrinsic factors

Subgroup analyses based on age, race, sex, baseline BMI and baseline renal impairment were conducted to evaluate their impact on the safety profile.

<div style=\"page-break-after: always\"></div>

The analysis based on age is affected by relatively small cell sizes in the 65-75 year age stratum (N=83-89 per treatment group in the PBO-controlled Analysis Set). Moreover, there were only 38 subjects over 75 years in total in the PBO-controlled Analysis Set. In general, an increased frequency of most types of adverse events (any TEAE, serious TEAE, severe TEAE) was seen in the 65-75 year age stratum compared to subjects less than 65 years, although the frequencies were increased in all treatment groups including placebo. The numbers of specific AESIs were generally too small for meaningful conclusions. According to the MAH, an increased rate of serious infections was observed among patients 65 years of age or older as compared to patients &lt; 65 years.

In general, the rates of any TEAE and TEAEs with a reasonable possibility of being related to study drug were higher for non-whites than whites. However, with a 90% white population enrolled, the cell sizes for other races limit the possibility for any robust conclusions.

The overall reporting rates for any TEAE were somewhat higher among female than male subjects, but within each sex, the differences between placebo and upadacitinib were quite similar. In the long-term analysis set, the EAER of urinary tract infection was higher in females compared with males in both upadacitinib doses. The rates of most AESIs were generally similar between males and females.

No noteworthy trends were seen in the subgroup analysis based on BMI. The lowest BMI stratum (&lt;18.5 kg/m^2) had a very small sample size (total N=17 in the PBO-controlled Analysis Set).

No concerning trends were seen in the types of TEAEs or AESIs between subjects with normal renal function compared to subjects with mild renal impairment. Patients with a baseline eGFR &lt; 40 ml/min/1.73m^2 were excluded from the studies, and the study population consequently does not include subjects with severe renal impairment. Furthermore, the number of subjects with moderate renal impairment (i.e. &lt; 60 ml/min/1.73m^2) was small (N=24-38 per treatment group (total N=91) in the PBO-controlled Analysis Set), rendering frequency estimates in this subgroup subject to substantial imprecision.

## Extrinsic factors

## Upadacitinib monotherapy vs combination therapy with non-biologic DMARDs

Some 70% of subjects in the studies across the treatment groups were using one or more background non-biologic DMARDs, most commonly MTX. In the PBO-controlled Analysis Set, the frequencies of most unique AESI terms were too small for reliable conclusions. In the long-term Any Upadacitinib Analysis Set, the rates of serious infections, hepatic disorders, CPK elevation, neutropenia, anaemia, and lymphopenia were higher in the combination therapy subgroup compared with the monotherapy subgroup in both upadacitinib 15 mg and 30 mg groups (Table 75).

<div style=\"page-break-after: always\"></div>

Table 75 Treatment-Emergent AESI EAER  per 100 PY by Upadacitinib Monotherapy vs. Upadacitinib Combination Therapy (Any Upadacitinib Analysis Set)

|                                                                      | Upadacitinib Monotherapy -Upadacitinib            | Upadacitinib Monotherapy -Upadacitinib            | Upadacitinib Monotherapy -Upadacitinib            | Upadacitinib Monotherapy -Upadacitinib            |
|----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                      | 15mgQD                                            | 30mgQD (No Cross-Over                             | Any15 mgQD                                        | Any 30 mgQD                                       |
|                                                                      | (No Cross-Over from Placebo)                      |                                                   |                                                   |                                                   |
|                                                                      |                                                   | from Placebo)                                     |                                                   |                                                   |
|                                                                      | (N=189)                                           | (N=197)                                           | (N=255)                                           | (N=276)                                           |
| Exposure-adjusted event rate:                                        | （PYs=192.2) Events （E/100 PYs)                    | （PYs=198.3) Events （E/100 PYs)                    | （PYS=228.5) Events (E/100 PYs)                    | （PYs=253.2） Events （E/100 PYs)                    |
| Any infections                                                       | [SSA E/100 PYs]                                   | [SSA E/100 PYs] 270（136.2）[136.4]                 | [SSA E/100 PYs] 229（100.2)[100.2]                 | [SSA E/100 PYs] 334(131.9)[132.0]                 |
| Any serious infections                                               | 183(95.2)[95.3] 1（0.5）[0.5]                       | 8(4.0) [3.9]                                      | 3(1.3) [1.3]                                      | 11(4.3） [4.2]                                     |
| Any opportunistic infection excluding tuberculosis and herpes zoster | 1(0.5） [0.5]                                      | 4(2.0) [2.1]                                      | 1(0.4) [s0]                                       | 6（2.4）[2.4]                                       |
| Any herpes zoster                                                    | 8(4.2) [4.2]                                      | 17(8.6) [8.4]                                     | 8(3.5) [3.5]                                      | 25(9.9) [9.7]                                     |
| Any active tuberculosis                                              | 0 [8.0]                                           | 0                                                 | 0 18(7.9) [7.6]                                   | 0                                                 |
| Any hepatic disorder Any adjudicated gastrointestinal                | 16(8.3) 0                                         | 26:(13.1) [13.2] 0                                | 0                                                 | 31(12.2) [12.2] 0                                 |
| perforation Any anemia                                               | 4(2.1) [2.1]                                      | 12(6.1) [6.0]                                     | 5(2.2） [2.2]                                      | 15(5.9) [5.9]                                     |
| Any neutropenia                                                      | 2 (1.0) [1.0]                                     | 8(4.0) [4.1]                                      | 2 (0.9) [0.9]                                     | 9(3.6) [3.6]                                      |
| Any lymphopenia                                                      | 3(1.6) [1.6]                                      | 4(2.0) [2.1]                                      | 3(1.3) [1.3]                                      | 4(1.6) [1.7]                                      |
| Any creatine phosphokinase （CPK) elevation                           | 16(8.3) [8.0]                                     | 23(11.6) [11.8]                                   | 18(7.9) [7.6]                                     | 29(11.5) [11.6]                                   |
| Any renal dysfunction                                                | 1(0.5）[0.5]                                       | 0                                                 | 1(0.4) [0.4]                                      | 0                                                 |
|                                                                      | Upadacitinib Combination Therapy --Upadacitinib-- | Upadacitinib Combination Therapy --Upadacitinib-- | Upadacitinib Combination Therapy --Upadacitinib-- | Upadacitinib Combination Therapy --Upadacitinib-- |
|                                                                      | 15mgQD                                            | 30mgQD                                            | Any15                                             | Any30                                             |
|                                                                      | (No Cross-Over                                    | (No Cross-Over                                    |                                                   |                                                   |
|                                                                      | from Placebo)                                     | from Placebo)                                     | mgQD                                              | mgQD                                              |
|                                                                      | (N=451)                                           | (N=444)                                           |                                                   | (N=644)                                           |
|                                                                      |                                                   |                                                   | (N=652)                                           |                                                   |
|                                                                      |                                                   |                                                   |                                                   | 0                                                 |
| Exposure-adjusted event rate:                                        | 479(104.2) [104.4]                                | 598(133.2) [133.0]                                | 598(101.6) [101.8]                                | 713（125.3) [125.1]                                |
| Any infections Any serious infections                                | 14(3.0) [3.0] 2(0.4） [0.4]                        | 31(6.9) [6.9] 3(0.7) [0.7]                        | 16(2.7) [2.7] 3(0.5）[0.5]                         | 38(6.7) [6.7] 3（0.5）[0.5]                         |
| Any opportunistic infection excluding tuberculosis and herpes zoster | 15(3.3) [3.3]                                     | 31(6.9) [7.0]                                     | 21(3.6) [3.6] 0                                   | 40(7.0) [7.1] 0                                   |
| Any active tuberculosis                                              | 0 94(20.4) [20.8]                                 | 0 128 (28.5) [28.4]                               | 115 (19.5) [19.8]                                 | 152(26.7) [26.7]                                  |
| Any hepatic disorder                                                 | 1(0.2） [0.2]                                      | 0                                                 | 1(0.2） [0.2]                                      | 42(7.4) [7.4]                                     |
| Any adjudicated gastrointestinal perforation Any anemia              | 17(3.7)                                           | 38(8.5) [8.5]                                     | 18(3.1) [3.1]                                     |                                                   |
| Any neutropenia                                                      | [3.7] 13 (2.8) [2.9]                              | 34 (7.6) [7.5]                                    | 16 (2.7) [2.7]                                    | 42 (7.4) [7.4]                                    |
| Any lymphopenia Any creatine phosphokinase (CPK) elevation           | 16(3.5) [3.5] 62(13.5) [13.6]                     | 22(4.9) [4.9] 98(21.8) [21.7]                     | 17(2.9) [2.9] 75(12.7) [12.8]                     | 25 (4.4) [4.4] 111(19.5) [19.3]                   |
| Any renal dysfunction                                                | 1(0.2）[0.2]                                       | 1(0.2）[0.2]                                       | 1(0.2）[0.2]                                       | 1(0.2）[0.2]                                       |

Use with MTX vs other non-biologic DMARDs

As seen in Table 75 above, the majority of subjects on combination therapy were receiving MTX, and the very small cell sizes for individual non-MTX agents severely limit a comparative analysis. Within the Any Upadacitinib 15 mg QD group of the integrated Any Upadacitinib Analysis Set, the total numbers of subjects receiving different non-biologic DMARDs in combination with upadacitinib were as follows: MTX only, N=516; non-MTX non-biologic only, N=99; leflunomide without MTX, N=37; sulfasalazine without MTX, N=36; apremilast without MTX, N=23; MTX+another non-MTX agent, N=37.

A comparison of EAER/EAIRs of TEAEs within subgroups with different types of background medication is displayed in Table 76, and a similar comparison of AESI EAER/EAIRs is displayed in Table 77.

<div style=\"page-break-after: always\"></div>

Table 76 TEAE EAER/EAIRs per 100 PY by Concomitant Non-Biologic DMARDs Use at Baseline (Any Upadacitinib Analysis Set, Any 15 mg QD group only)

|                                                                    | Mono Any 15 mgQD （N=255）                          | MTXonly Any15 mgQD (N=516)                     | non-MTXonly MTX+non-MTX Any 15 Any 15 mgQD mgQD (66=N) （N=37）                                |
|--------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------------------------------|
| Exposure-adjusted event rate:                                      | （PYs=228.5） Events (E/100 PYs) [SSA E/100 PYs]    | （PYs=463.3) Events (E/100 PYs) [SSA E/100 PYs] | （PYS =90.4) （PYS=34.7) Events (E/100 PYs) Events (E/100 PYs) [SSA E/100 PYs] [SSA E/100 PYs] |
| Any adverse event (AE) Any serious AE                              | 721（315.5)[315.4]356(292.7)[293.3] 25(10.9)[11.0] | 41(8.9)[8.8]                                   | 305（337.4)[339.1]141（406.1)[407.4] 15 (16.6)[16.3] 8(23.0)[22.6]                             |
| Any AE leading to discontinuation of study drug                    | 23(10.1)[10.3]                                    | 26(5.6)[5.6]                                   | 17(18.8)[18.3] 3(8.6）[9.2]                                                                   |
| Any severe AE                                                      | 32（14.0):[14.2]                                   | 46(9.9)[9.9]                                   | 13（14.4) [14.0] 10(28.8)[28.7]                                                               |
| Any AE with reasonable possibility of being related to study drugs | 185(81.0)[80.1]                                   | 550（118.7)[119.3] 0                            | 108（119.5)[121.0]58（167.0)[173.2] 1(2.9）[3.1]                                                |
| Any AE leading to death                                            | 0                                                 |                                                | 0                                                                                            |
| Exposure-adjusted incidence rate:                                  | n/PYs(n/100 PYs) [SSAn/100 PYs]                   | n/PYs (n/100 PYs) [SSA n/100 PYs]              | n/PYs （n/100 PYs) n/PYs (n/100 PYs) [SSA n/100 PYs] [SSA n/100 PYs]                          |
| Deaths#                                                            | 0/228.5                                           | 0/463.3                                        | 0/90.4 1/34.9(2.9)[3.0]                                                                      |

Table 77 AESI EAER/EAIRs per 100 PY by Concomitant Non-Biologic DMARDs Use at Baseline (Any Upadacitinib Analysis Set, Any 15 mg QD group only); Table prepared by assessor

|                                                                      | Mono Any 15 mgQD （N=255)                       | MTXonly Any 15 mgQD (N=516)                    | non-MTXonly Any 15 mgQD （66=N）                | MTX+non-MTX Any 15 mgQD (N=37)                |
|----------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Exposure-adjusted event rate:                                        | （PYs=228.5） Events (E/100 PYs) [SSA E/100 PYs] | （PYs=463.3) Events (E/100 PYs) [SSA E/100 PYs] | （PY8=90.4) Events （E/100 PYs) [SSA E/100 PYs] | （PY8=34.7） Events (E/100 PYs) [SSA E/100 PYs] |
| Any infections                                                       | 229（100.2)[100.2]                              | 463(99.9) [100.0]                              | 94（104.0) [104.5]                             | 41(118.1) [117.1]                             |
| Any serious infections                                               | 3(1.3) [1.3]                                   | 12(2.6) [2.6]                                  | 2 (2.2) [2.2]                                 | 2(5.8) [5.5]                                  |
| Any opportunistic infection excluding tuberculosis and herpes zoster | 1(0.4) [0.5]                                   | 1(0.2） [0.2]                                   | 1 (1.1) [1.0]                                 | 1(2.9) [3.1]                                  |
| Any herpes zoster                                                    | （3.5) [3.5]                                    | 17(3.7) [3.7] 0                                | 3（3.3) [3.4] 0                                | 1(2.9) [2.4] 0                                |
| Any active tuberculosis Any hepatic disorder                         | 0 18(7.9) [7.6] 0                              | [21.6]                                         | 10(11.1) [11.2]                               | 6 (17.3)                                      |
| Any adjudicated gastrointestinal perforation                         |                                                | 99(21.4) 1(0.2) [0.2]                          | 0                                             | [18.3] 0                                      |
| Any anemia                                                           | 5 (2.2) [2.2]                                  | 17 (3.7) [3.7]                                 | 1 (1.1) [1.0]                                 | 0                                             |
| Any neutropenia                                                      | 2 (0.9) [0.9]                                  | 14 (3.0) [3.0]                                 | 1 (1.1) [1.1]                                 | 1(2.9) [3.1]                                  |
| Any lymphopenia                                                      |                                                | 14(3.0) [3.1]                                  | 2(2.2) [2.3]                                  | 1(2.9) [2.4]                                  |
| Any creatine phosphokinase (CPK) elevation                           | 3(1.3） [1.3] 18(7.9)[7.6]                      | 53（11.4) [11.5]                                | 15(16.6) [16.5] 0                             | 7(20.2) [19.5] 0                              |
| Any renal dysfunction                                                | 1(0.4)[0.4] n/PYs （n/100 PYs)                  | 1（0.2）[0.2] n/PYs （n/100 PYs)                  | n/PYs (n/100 PYs)                             | n/PYs （n/100 PYs) [SSA n/100 PYs]             |
| Exposure-adjusted incidence rate:                                    | [SSA n/100 PYs]                                | [SSA n/100 PYs]                                | [SSAn/100 PYs]                                | 1/34.7(2.9)[3.1]                              |
|                                                                      | 8/227.0(3.5) [3.6]                             | 3/461.7(0.6) [0.7]                             |                                               | 1/34.7(2.9)                                   |
| Any possible malignancy                                              |                                                |                                                | 1/89.1(1.1)[1.1]                              |                                               |
| Any malignancy                                                       | 8/227.0(3.5) [3.6]                             | 1/463.2(0.2) [0.2]                             | 1/89.1(1.1) [1.1] 1/89.1(1.1)[1.1]            | [3.1] 0/34.7                                  |
| Any non-melanoma skin cancer (NMsC) Any malignancy other than NMsC   | 3/227.2(1.3) [1.3] 5/228.3（2.2) [2.2]          | 1/463.3(0.2) [0.2] 1/463.2(0.2)                | 0/90.4 0/90.4                                 | 1/34.7(2.9)[3.1] 0/34.7                       |
| Any lymphoma                                                         | 1/226.7(0.4) [0.5]                             | [0.2] 1/463.1(0.2) [0.2]                       |                                               |                                               |
| Any adjudicated MACE*                                                | 1/228.1(0.4) [0.4]                             | 3/460.9(0.7) [0.6]                             | 0/90.4                                        | 0/34.7                                        |
| Any adjudicated VTE**                                                | 0/228.5                                        | 1/462.5(0.2) [0.2]                             | 2/90.4(2.2)[2.2]                              | 1/34.7(2.9)[3.0]                              |

Use in non-biologic DMARD-IR vs biologic DMARD-IR patients

Summaries of AESI in long-term datasets from studies M15-554 (i.e. biologic DMARD-IR subjects) and M15-572 (non-biologic DMARD-IR subjects) are displayed in Table 78 and Table 79, respectively.

<div style=\"page-break-after: always\"></div>

Table 78 Overview of AESI per 100 PY in biologic DMARD-IR subjects (Study M-15-554 Long-Term Safety Analysis Set)

|                                  | Upadacitinib 15 mg QD (N = 290) (PY = 292.8)   | Upadacitinib 30 mg QD (N =308) (PY = 296.2)   |
|----------------------------------|------------------------------------------------|-----------------------------------------------|
| Exposure-adjusted event rate     | E (E/100 PY)                                   | E (E/100 PY)                                  |
| Any serious infection            | 8 (2.7)                                        | 20 (6.8)                                      |
| Any opportunistic infectiona     | 2 (0.7)                                        | 4 (1.4)                                       |
| Any herpes zoster                | 11 (3.8)                                       | 31 (10.5)                                     |
| Any active TB                    | 0                                              | 0                                             |
| Any hepatic disorder             | 15 (5.1)                                       | 55 (18.6)                                     |
| Any adjudicated GI perforation   | 0                                              | 0                                             |
| Any anemia                       | 8 (2.7)                                        | 19 (6.4)                                      |
| Any neutropenia                  | 4 (1.4)                                        | 12 (4.1)                                      |
| Any lymphopenia                  | 3 (1.0)                                        | 4 (1.4)                                       |
| Any CPK elevation                | 18 (6.1)                                       | 27 (9.1)                                      |
| Any renal dysfunction            | 1 (0.3)                                        | 1 (0.3)                                       |
| Exposure-adjusted incidence rate | n/PY (n/100 PY)                                | n/PY (n/100 PY)                               |
| Any malignancy                   | 7/290.5 (2.4)                                  | 6/294.6 (2.0)                                 |
| Any NMSC                         | 3/290.7 (1.0)                                  | 1/295.2 (0.3)                                 |
| Any malignancy other than NMSC   | 4/292.6 (1.4)                                  | 5/295.6 (1.7)                                 |
| Any lymphoma                     | 2/290.8 (0.7)                                  | 0/296.2                                       |
| Any adjudicated MACEb            | 1/291.5 (0.3)                                  | 1/296.3 (0.3)                                 |
| Any adjudicated VTE              | 1/292.8 (0.3)                                  | 0/296.2                                       |

CPK = creatine phosphokinase; E = events; GI = gastrointestinal; MACE = major adverse cardiovascular event; NMSC = non-melanoma skin cancer; PY = patient-years; QD = once daily: TB = tuberculosis; VTE = venous thromboembolic event

a. Excluding TB and herpes zoster.

b. Defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Cardiovascular death includes PE and venous thrombosis, which are also included in the adjudicated VTEs.

C. Includes DVT and PE.

<div style=\"page-break-after: always\"></div>

Table 79 Overview of AESI per 100 PY in non-biologic DMARD-IR subjects (Study M-15-572 LongTerm Safety Analysis Set)

|                                  | ADA 40mgEOW (N=429) (PY=394.5)   | Upadacitinib 15mgQD (N=617) (PY=524.1)   | Upadacitinib 30mgQD (N=612) (PY=526.0)   |
|----------------------------------|----------------------------------|------------------------------------------|------------------------------------------|
| Exposure-adjusted event rate     |                                  | E(E/100PY)                               |                                          |
| Any serious infection            | 6 (1.5)                          | 11 (2.1)                                 | 29 (5.5)                                 |
| Any opportunistic infection      |                                  | 2(0.4)                                   | 5(1.0)                                   |
| Any herpes zoster                | 2(0.5)                           | 18 (3.4)                                 | 34(6.5)                                  |
| Any active TB                    | 0                                | 0                                        | 0                                        |
| Anyhepatic disorder              | 122 (30.9)                       | 118 (22.5)                               | 128 (24.3)                               |
| Anyadjudicated GIperforation     | 0                                | 1(0.2)                                   | 0                                        |
| Any anemia                       | 6(1.5)                           | 15 (2.9)                                 | 38(7.2)                                  |
| Any neutropelia                  | 23 (5.8)                         | 14(2.7)                                  | 39 (7.4)                                 |
| Any lymphopenia                  | 1(0.3)                           | 17 (3.2)                                 | 25 (4.8)                                 |
| Any CPKelevation                 | 36 (9.1)                         | 75(14.3)                                 | 113 (21.5)                               |
| Anyrenal dysfunction             | 0                                | 1(0.2)                                   | 0                                        |
| Exposure-adjusted incidence rate |                                  | n/PY (n/100 PY)                          |                                          |
| Any malignancy                   | 6/394.0 (1.5)                    | 4/523.5(0.8)                             | 6/524.3(1.1)                             |
| AnyNMSC                          | 2/394.3 (0.5)                    | 2/523.6(0.4)                             | 4/524.4(0.8)                             |
| Anymalignancy other than NMSC    | 4/394.1(1.0)                     | 3/524.0 (0.6)                            | 2/525.8 (0.4)                            |
| Anylymphoma                      | 0/394.5                          | 0/524.1                                  | 0/526.0                                  |
| Any adjudicatedMACEb             | 3/394.3(0.8)                     | 3/522.7 (0.6)                            | 1/524.9 (0.2)                            |
| Any adjudicatedVTEc              | 2/392.9 (0.5)                    | 3/523.4(0.6)                             | 2/526.0 (0.4)                            |

ADA=adalimumab;CPK=creatine phosphokinase;DVT=deep vein thrombosis;E=events;E/100 PY=eventsper 100PY;EOW=every other week;GI=gastrointestinal:MACE=major adversecardiacevent;NMSC=nonmelanoma skin cancer,PE=pulmonary embolismPY=patient-year.QD=once daily,TB=tuberculosis;

VTE=venous thromboembolicevent

a. Excluding TB and herpes zoster.

b. Defined as cardiovascular death,nonfatal myocardialinfarction,and nonfatal stroke.Cardiovascular death includesPE and venous thrombosis,which are also included in the adjudicated VTEs.

C. IncludesDVT andPE

According to the MAH, the higher rates of laboratory related AESI in non-biologic DMARD-IR subjects compared with biologic DMARD-IR subjects are not readily supported by analysis of actual laboratory data (e.g. Grade 3 and/or Grade 4 abnormalities) and may therefore reflect differences in the subjective reporting of laboratory abnormalities as AEs across different countries or investigators in the two studies. Furthermore, the frequency of background DMARD was higher among subjects using 1 or more non-biologic DMARDs in the non-biologic DMARD-IR population as compared with the biologic DMARD-IR population (82.3% versus 48.8%).

A subgroup analysis was also undertaken in study 554 to determine whether the safety profiles differ among subjects with an insufficient response to biologic DMARDs as opposed to intolerance to biologic DMARDs. The number of genuinely biologic DMARD-intolerant subjects is very low (N=25 for Any 15 mg upadacitinib exposure and N=22 for Any 30 mg upadacitinib exposure in the Safety Analysis Set for study M15-554) and mostly results in only single events being reported across most AESI

<div style=\"page-break-after: always\"></div>

categories. Whereas this limitation should be taken into account, there is no direct evidence of an overt safety issue in this small subgroup.

## Use in pregnancy

According to the MAH, as of 15 February 2020, there were a total of 39 pregnancies reported in female subjects conservatively considered to have been exposed to upadacitinib in clinical studies of RA, PsA, atopic dermatitis (AD), ulcerative colitis (UC), and CD. Of the 39 pregnancies, 3 occurred in females participating in PsA clinical studies with pregnancy outcomes of ectopic pregnancy, spontaneous abortion, and pregnancy still ongoing.

Of the 39 pregnancies, 13 were live births in women exposed to upadacitinib during the first 4 to 8 weeks of pregnancy with no congenital anomalies reported. There were 12 spontaneous abortions identified in pregnant females with various risk factors (e.g., age &gt; 35 years of age, MTX exposure during pregnancy) and the resulting rate of spontaneous abortion was consistent with what has been reported in patients with rheumatic diseases on MTX. Four elective terminations did not report any foetal defects. There was 1 ectopic pregnancy, 1 unknown outcome, and 8 pregnancies are ongoing.

In addition to the clinical trial cases described above, there was one post-marketing spontaneous report of a pregnancy in a 34-year-old with a medical history of \"juvenile RA and IBD\"; the pregnancy is ongoing and the timing of exposure to upadacitinib was not reported.

A total of 12 male subject partner pregnancies have been reported through 15 February 2020; all were from clinical trials and in the following indications: 3 RA, 6 CD, 2 PsA, and 1 ankylosing spondylitis. Nine of the 12 subjects are known to have been assigned to upadacitinib at the time of partner pregnancy. Among these 9 subjects, the outcomes are: 4 live births without congenital anomalies, 2 ongoing pregnancies, 1 each of spontaneous abortion, subject lost to follow up and unknown outcome.

Regarding lactation reports, it should be recognised that upadacitinib clinical study protocols exclude breastfeeding women and reference documents provide guidance to avoid breastfeeding while on upadacitinib. In a search of the MAH's safety database, two post-marketing reports from the United States were identified. No neonatal AEs were reported. Both reports contained minimal information.

## Other observations

According to the MAH, there have been no reported cases of overdose, drug abuse or dependence, and there is no evidence for and no anticipation of upadacitinib to affect the ability to drive or operate machinery, or to otherwise impair mental ability.

## Safety related to drug-drug interactions and other interactions

According to the MAH, upadacitinib plasma exposures in Phase 3 PsA studies were similar between subjects who were co-administered apremilast, hydroxychloroquine, sulfasalazine, leflunomide, and MTX and subjects who did not receive these DMARDs, indicating lack of effect of these DMARDs on upadacitinib pharmacokinetics. See Section on PK/PD modelling of the AR for details.

## Discontinuation due to adverse events

In the PBO-controlled Analysis Set, the percentage of subjects with TEAEs leading to discontinuation of study drug was 3.8% in the placebo group, 4.4% in the upadacitinib 15 mg group and 6.4% in the upadacitinib 30 mg group. Most TEAEs leading to discontinuation of study drug were reported in 1-2 subjects in any group; ALT increased was reported in 3 subjects on upadacitinib 30 mg and psoriatic arthropathy was reported in 5 subjects on upadacitinib 15 mg.

<div style=\"page-break-after: always\"></div>

In the Any Upadacitinib Analysis Set, the EAERs of TEAEs leading to discontinuation of study drug were 8.4 E/100 PY and 9.5 E/100 PY for the upadacitinib 15 mg and 30 mg groups, respectively. The TEAE leading to discontinuation of study drug with the highest EAER was psoriatic arthropathy in the upadacitinib 15 mg group (5 events [0.6 E/100 PY]) and pyrexia in the upadacitinib 30 mg group (4 events [0.5 E/100 PY]). The most frequently reported TEAEs leading to discontinuation of study drug (&gt;= 0.2 E/100 PY in any treatment group) are presented in Table 80.

Table 80 Treatment-Emergent Adverse Events Leading to Discontinuation of Study Drug Reported in ≥ 0.2 Events per 100 PY in any Treatment Group by Decreasing Frequency in the Upadacitinib 15 mg Group (Any Upadacitinib Analysis Set)

| System Organ Class MedDRA 22.0 Preferred Term   | 15 mg QD (No Cross- Over from Placebo) (N = 640) (PY = 651.8)   | 30 mg QD (No Cross- Over from Placebo) (N = 641) (PY = 647.1)   | Any 15 mg QD (N = 907) (PY = 816.9)   | Any 30 mg QD (N = 920) (PY = 822.3)   |
|-------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------|---------------------------------------|
|                                                 | E (E/100 PY) [SSA E/100 PY]                                     | E (E/100 PY) [SSA E/100 PY]                                     | E (E/100 PY) [SSA E/100 PY]           | E (E/100 PY) [SSA E/100 PY]           |
| Psoriatic arthropathy                           | 5 (0.8) [0.8]                                                   | 0                                                               | 5 (0.6) [0.6]                         | 0                                     |
| Herpes zoster                                   | 2 (0.3) [0.3]                                                   | 2 (0.3) [0.3]                                                   | 2 (0.2) [0.2]                         | 2 (0.2) [0.2]                         |
| Prostate cancer                                 | 1 (0.2) [0.2]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                     |
| Psoriasis                                       | 1 (0.2) [0.2]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                     |
| Pulmonary embolism                              | 2 (0.3) [0.3]                                                   | 2 (0.3) [0.3]                                                   | 2 (0.2) [0.2]                         | 2 (0.2) [0.2]                         |
| Sepsis                                          | 2 (0.3) [0.3]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                     |
| White blood cell count decreased                | 2 (0.3) [0.3]                                                   | 0                                                               | 2 (0.2) [0.2]                         | 0                                     |
| Blood creatine phosphokinase increased          | 0                                                               | 2 (0.3) [0.3]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                         |
| Bronchitis                                      | 0                                                               | 2 (0.3) [0.3]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                         |
| Lymphopenia                                     | 1 (0.2) [0.2]                                                   | 3 (0.5) [0.5]                                                   | 1 (0.1) [0.1]                         | 3 (0.4) [0.4]                         |
| Pneumonia                                       | 1 (0.2) [0.2]                                                   | 2 (0.3) [0.3]                                                   | 1 (0.1) [0.1]                         | 2 (0.2) [0.2]                         |
| Pyrexia                                         | 1 (0.2) [0.2]                                                   | 3 (0.5) [0.5]                                                   | 1 (0.1) [0.1]                         | 4 (0.5) [0.5]                         |
| Alanine aminotransferase increased              | 0                                                               | 3 (0.5) [0.5]                                                   | 0                                     | 3 (0.4) [0.4]                         |
| Chronic obstructive pulmonary disease           | 0                                                               | 1 (0.2) [0.2]                                                   | 0                                     | 2 (0.2) [0.2]                         |
| Diarrhea                                        | 0                                                               | 3 (0.5) [0.5]                                                   | 0                                     | 3 (0.4) [0.4]                         |
| Folliculitis                                    | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                         |
| Hepatic enzyme increased                        | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                         |
| Urinary tract infection                         | 0                                                               | 2 (0.3) [0.3]                                                   | 0                                     | 2 (0.2) [0.2]                         |

MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year; QD = once daily; SSA = study size adjusted

In long-term data from study 572, the EAER of TEAEs leading to discontinuation of study drug were 5.9 E/100 PY for upadacitinib 15 mg, 7.4 E/100 PY for upadacitinib 30 mg, and 10.1 E/100 PY for adalimumab. TEAEs leading to discontinuation of study drug reported in more than 1 subject in any treatment group are presented in Table 81.

<div style=\"page-break-after: always\"></div>

Table 81 Treatment-Emergent Adverse Events Leading to Discontinuation Reported in ≥ 2 Events in any Treatment Group by Decreasing Frequency in the Upadacitinib 30 mg QD Group - Long Term (Safety Analysis Set; Study M15-572)

| MedDRA 22.0 Preferred Term   | Upadacitinib 15 mg QD (N = 617) (PY = 524.1) E (E/100 PY)   | Upadacitinib 30 mg QD (N = 612) (PY = 526.0) E (E/100 PY)   | ADA 40 mgE0W (N = 429) (PY =394.5) E (E/100 PY)   |
|------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------|
| Any adverse event            | 31 (5.9)                                                    | 39 (7.4)                                                    | 40 (10.1)                                         |
| Lymphopenia                  | 1 (0.2)                                                     | 3 (0.6)                                                     | 0                                                 |
| Pyrexia                      | 1 (0.2)                                                     | 3 (0.6)                                                     | 0                                                 |
| Bronchitis                   | 0                                                           | 2 (0.4)                                                     | 0                                                 |
| Folliculitis                 | 0                                                           | 2 (0.4)                                                     | 0                                                 |
| Pulmonary embolism           | 1 (0.2)                                                     | 2 (0.4)                                                     | 0                                                 |
| ALT increased                | 0                                                           | 1 (0.2)                                                     | 2 (0.5)                                           |
| Alopecia                     | 0                                                           | 0                                                           | 2 (0.5)                                           |
| AST increased                | 0                                                           | 0                                                           | 2 (0.5)                                           |
| Herpes zoster                | 2 (0.4)                                                     | 0                                                           | 0                                                 |
| Psoriasis                    | 0                                                           | 0                                                           | 3 (0.8)                                           |
| Sepsis                       | 2 (0.4)                                                     | 0                                                           | 0                                                 |

ADA = adalimumab; ALT = alanine aminotransferase; AST = aspartate aminotransferase; EOW = every other week; MedDRA = Medical Dictionary for Regulatory Activities; PY = patient-year; QD = once daily

Note: Subjects in upadacitinib 15 mg or 30 mg group included those who started upadacitinib 15 mg or 30 mg at the beginning of the study and those who switched from placebo to upadacitinib 15 mg or 30 mg at Week 24.

## Post marketing experience

Upadacitinib was approved for rheumatoid arthritis in the United States on 16 August 2019 (international birth date) and in the European Union on 18 December 2019. Through 31 January 2020, upadacitinib has been approved in 41 countries with estimated cumulative exposure of 3,138 patient treatment years across 9 countries. The MAH has been continuing to monitor potential new safety signals through its ongoing routine pharmacovigilance that includes weekly review of all postmarketing reports, serious and non-serious, received from all sources (including literature) and SAEs from clinical trials; quarterly review of data mining scores generated from FDA's Adverse Event Reporting System database; periodic reports (Periodic Safety Update Report, development safety update reports, periodic adverse drug experience reports, etc.) with inclusion of sections outlining findings for AEs of interest, per mandated timelines, and post-marketing studies.

The overall safety of upadacitinib 15 mg QD therapy was evaluated through review of post-marketing reports (spontaneous, solicited, literature) received from 16 August 2019 through 15 February 2020. Search of the MAH's global safety database retrieved 1,573 reports. Overall, 90% of the reports were considered non-serious and 95% were from solicited source. The most frequently reported MedDRA SOC was Infections and Infestations, in which nasopharyngitis, sinusitis, and URTI had the greatest number of reports. Among all the reports, the most common AEs reported included headache (7%), nausea (7%), drug ineffective (6%), fatigue (6%), and arthralgia (5%). Most of the post-marketing events were either expected for upadacitinib or commonly seen in the general population or patients with RA. Although drug ineffective is listed as one of the most frequently reported events, it is also not unexpected for a product once reaching market.

<div style=\"page-break-after: always\"></div>

The most commonly reported SAE was pneumonia (1%), and the remaining SAEs were reported in less than 0.5% of the retrieved reports. Generally, the type and pattern of SAEs reported were similar to what has been observed in the RA clinical trials for upadacitinib. Causality could not be assessed for the few reports describing events of hypersensitivity/anaphylactic reactions due to limited information in these reports.

Review of the post-marketing reports did not identify any new safety risks for the marketing of upadacitinib in treating patients with moderate to severe active RA.

## Supportive analyses from clinical studies in RA

To support the current application, the MAH provided an overview of long-term safety data from the RA global clinical studies, with a data cut-off of 31 December 2019. The RA studies included in this analysis are 8 ongoing Phase 3 studies, 2 completed Phase 2 dose-ranging studies, and 1 ongoing Phase 2 open-label extension study.

The population of subjects in the Any upadacitinib analysis set (N=5,579) is about 80% female, and about 79% of subject are white. The number of subjects aged 75 to &lt;85 years is 182, and the number of subjects aged 85 years older is 8. About 34%, 31% and 35% of subjects are in the BMI categories &lt;25 kg/m^2, 25 - &lt;30 kg/m^2 and &gt;=30 kg/m^2, respectively. At baseline, 34% of subjects did not use any concomitant csDMARDs; 52% were on MTX, 6.5% were on MTX + another csDMARD, and 8.1% were on a non-MTX csDMARD only.

In the upadacitinib RA clinical development programme, a total of 5,579 subjects have received at least 1 dose of upadacitinib in the Phase 2 or Phase 3 RA studies, for a mean duration of 733.3 days and 11,201 PY of total exposure including over 6,815 PY of upadacitinib 6 mg BID/15 mg QD exposure and over 2,949 PY of upadacitinib 12 mg BID/30 mg QD exposure. The extent of exposure is summarised in Table 82.

Table 82 Number and Percentage of Subjects Exposed to Study Drug in the RA Development Programme by Duration Intervals

|                       | Any RA Phase 3 Upadacitinib 15 mg Analysis Set Upadacitinib 15 mg QD (N = 3209) (%) I   | Any RA Phase 3 Upadacitinib 15 mg Analysis Set Upadacitinib 15 mg QD (N = 3209) (%) I   | Any RA Phase 3 Upadacitinib 30 mg Analysis Set Upadacitinib 30 mg QD (N =1204) n (%)   | Any RA Phase 3 Upadacitinib 30 mg Analysis Set Upadacitinib 30 mg QD (N =1204) n (%)   | Any RA Upadacitinib Analysis Set Any Upadacitinib (N = 5579) n (%)   | Any RA Upadacitinib Analysis Set Any Upadacitinib (N = 5579) n (%)   |
|-----------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Duration              |                                                                                         |                                                                                         |                                                                                        |                                                                                        |                                                                      |                                                                      |
| ≥4 weeks (28 days)    | 3168                                                                                    | (98.7)                                                                                  | 1182                                                                                   | (98.2)                                                                                 | 5493                                                                 | (98.5)                                                               |
| ≥ 12 weeks (84 days)  | 3081                                                                                    | (96.0)                                                                                  | 1131                                                                                   | (93.9)                                                                                 | 5296                                                                 | (94.9)                                                               |
| ≥24 weeks (168 days)  | 2760                                                                                    | (86.0)                                                                                  | 1058                                                                                   | (87.9)                                                                                 | 4835                                                                 | (86.7)                                                               |
| ≥36 weeks (252 days)  | 2485                                                                                    | (77.4)                                                                                  | 1026                                                                                   | (85.2)                                                                                 | 4458                                                                 | (79.9)                                                               |
| ≥ 48 weeks (336 days) | 2265                                                                                    | (70.6)                                                                                  | 979                                                                                    | (81.3)                                                                                 | 4111                                                                 | (73.7)                                                               |
| ≥ 72 weeks (504 days) | 1986                                                                                    | (61.9)                                                                                  | 926                                                                                    | (76.9)                                                                                 | 3527                                                                 | (63.2)                                                               |
| ≥ 96 weeks (672 days) | 1830                                                                                    | (57.0)                                                                                  | 863                                                                                    | (71.7)                                                                                 | 3272                                                                 | (58.6)                                                               |
| Mean duration (days)  | 676.9                                                                                   | 676.9                                                                                   | 821.5                                                                                  | 821.5                                                                                  | 733.3                                                                | 733.3                                                                |

QD = once a day, RA = rheumatoid arthritis

<div style=\"page-break-after: always\"></div>

An overview of EAERs for TEAEs, providing a side-by-side comparison of data in the initial RA submission and the updated dataset of 31 December 2019, is displayed in Table 83.

Table 83 Overview of Treatment-Emergent Adverse Events Per 100 PY - Long Term All Exposure

|                                                             | AnyRAPhase3 Upadacitinib15mgAnalysisSet   | AnyRAPhase3 Upadacitinib15mgAnalysisSet   | AnyRAPhase3 Upadacitinib30mgAnalysisSet   | AnyRAPhase3 Upadacitinib30mgAnalysisSet   | AnyRA UpadacitinibAnalysisSet   | AnyRA UpadacitinibAnalysisSet   |
|-------------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------|---------------------------------|
|                                                             | Data Cutoffa                              | InitialRA Submission                      | Data Cutoffa                              | Initial RA Submission                     | Data Cutoffa                    | Initial RA Submission           |
|                                                             | (N=3209) (PY=5947.1)                      | (N=2630) (PY=2655.1)                      | (N=1204) (PY=2708.0)                      | (N=1204) (PY=1365.0)                      | (N=5579) (PY=11201.0)           | (N=4443) (PY=5263.5)            |
| Exposure-adjusted eventrate                                 | E(E/100PY)                                | E(E/100PY)                                | E(E/100PY)                                | E(E/100PY)                                | E(E/100PY)                      | E(E/100PY)                      |
| AnyAE                                                       | 14465 (243.2)                             | 7852 (295.7)                              | 8084 (298.5)                              | 5033(368.7)                               | 29380 (262.3)                   | 15598(296.3)                    |
| Any SAE                                                     | 784(13.2)                                 | 399 (15.0)                                | 536(19.8)                                 | 291(21.3)                                 | 1697 (15.2)                     | 827 (15.7)                      |
| AnyAEleadingtodiscontinuationof study drug                  | 368 (6.2)                                 | 224 (8.4)                                 | 255 (9.4)                                 | 182 (13.3)                                | 825 (7.4)                       | 502(9.5)                        |
| Any severe AE                                               | 719 (12.1)                                | 397 (15.0)                                | 440 (16.2)                                | 270 (19.8)                                | 1496(13.4)                      | 759 (14.4)                      |
| AnyAEwithreasonablepossibilityof beingrelated to study drug | 4735 (79.6)                               | 2676 (100.8)                              | 2699 (99.7)                               | 1755 (128.6)                              | 9781 (87.3)                     | 5179 (98.4)                     |
| AnyAE leading to death                                      | 30 (0.5)                                  | 20(0.8)                                   | 26 (1.0)                                  | 18(1.3)                                   | 62(0.6)                         | 43(0.8)                         |
| Exposure-adjusted incidencerate                             | n/PY(n/100PY)                             | n/PY(n/100PY)                             | n/PY(n/100PY)                             | n/PY(n/100PY)                             | n/PY(n/100PY)                   | n/PY(n/100PY)                   |
| Deaths                                                      | 23/5947.6(0.4)                            | 11/2655.1(0.4)                            | 17/2708.4(0.6)                            | 11/1365.0(0.8)                            | 44/11201.9（0.4）                 | 25/5263.5(0.5)                  |

AE=adverse event;PY=patient-year,RA=rheumatoid arthritis;SAE=serious adverse event

a. Datacutoff=31December2019

b. As assessed by investigator.

Most deaths continued to be considered cardiovascular deaths in subjects with known risk factors, followed by malignancies, infectious deaths, and traumatic deaths. Since the initial RA submission, one suicide has been reported in the upadacitinib 15 mg dose group. This was a non-treatment-emergent death by hanging and occurred approximately 15 months after the last dose of upadacitinib (no further information was available). In the initial RA submission, there was one fatal report of meningitis in a subject receiving upadacitinib 30 mg. In the updated dataset, there are 2 additional fatal events of meningitis reported. The first report concerns a listeria meningitis in a 50-year-old male subject on upadacitinib 15 mg QD. The second report concerns a case of recurrent polymicrobial meningitis in the context of an undefined gastrointestinal condition in a 63-year-old male on upadacitinib 15 mg QD.

The MAH also performed a standard mortality ratio (SMR) analysis using World Health Organization country-age-gender specific death data for the general population that yielded an SMR estimate of 0.42 (95% CI: 0.30, 0.56) for the treatment-emergent deaths in the upadacitinib treatment groups. The expected number of deaths on upadacitinib was 105 compared to 44 observed.

Since the initial RA submission, one serious case of severe angioedema has been reported in a 55year-old male who received upadacitinib 15 mg. The investigator and MAH assessed the event of angioedema as possibly related to study drug. According to the MAH, no other cases of serious hypersensitivity reactions have been reported in the upadacitinib clinical development programme that were attributed to upadacitinib treatment.

An overview of EAERs for AESI in the updated dataset of 31 December 2019 is displayed in Table 84. According to the MAH, the event rates across the different AESI have remained constant compared to the initial RA submission, and the analyses did not reveal any new safety risks. Compared to long-term AESI event/incidence rates with upadacitinib 15 mg in RA patients, higher rates with upadacitinib 15 mg among PsA patients were observed for the following categories (values are E/100 PY or N/100 PY): Any opportunistic infection excluding tuberculosis and herpes zoster (0.5 for PsA vs. 0.3 for RA); Any herpes zoster (3.6 vs. 3.5); Any hepatic disorder (16.9 vs. 12.4); Any lymphopenia (2.6 vs. 1.8); Any CPK elevation (11.4 vs. 5.3); Any malignancy (1.5 vs. 1.0); Any NMSC (0.7 vs. 0.3); Any malignancy other than NMSC (0.9 vs. 0.8); Any adjudicated MACE (0.5 vs. 0.4).

<div style=\"page-break-after: always\"></div>

Table 84 Overview of Treatment-Emergent AESI Per 100 PY - Long Term All Exposure

|                                                        | AnyRA Phase3 Upadacitinib 15mg Analysis Set (N=3209) (PY=5947.1)   | AnyRA Phase3 Upadacitinib 30mg AnalysisSet (N=1204)   | AnyRA UpadacitinibAnalysisSet (N=5579)   |
|--------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------|
|                                                        | (PY=2708.0) (PY=11201.0) E(E/100PY)                                | (PY=2708.0) (PY=11201.0) E(E/100PY)                   | (PY=2708.0) (PY=11201.0) E(E/100PY)      |
| Exposure-adjustedeventrate Any seriousinfection        | 188 (3.2)                                                          | 145(5.4)                                              | 449(4.0)                                 |
| Any opportunisticinfection excludingTB andherpeszoster | 18(0.3)                                                            | 6(0.2)                                                | 39(0.3)                                  |
| Any herpes zoster                                      | 208(3.5)                                                           | 169 (6.2)                                             | 546(4.9)                                 |
| Any active TB                                          | 5（<0.1)                                                            | 3(0.1)                                                | 9(<0.1)                                  |
| Any hepatic disorder                                   | 738(12.4)                                                          | 309(11.4)                                             | 1320 (11.8)                              |
| Any adjudicated GIperforation                          | 5（0.1)                                                             | 5(0.2)                                                | 14(0.1)                                  |
| Any anemia                                             | 211(3.5)                                                           | 121(4.5)                                              | 416(3.7)                                 |
| Any neutropenia                                        | 147(2.5)                                                           | 130(4.8)                                              | 347(3.1)                                 |
| Any lymphopenia                                        | 108(1.8)                                                           | 83(3.1)                                               | 276(2.5)                                 |
| Any CPKelevation                                       | 314(5.3)                                                           | 250 (9.2)                                             | 699 (6.2)                                |
| Anyrenaldysfunction                                    | 18(0.3)                                                            | 18(0.7)                                               | 39(0.3)                                  |
| Exposure-adjustedincidencerate                         |                                                                    | n/PY(n/100PY)                                         |                                          |
| Any malignancy                                         | 61/5924.8(1.0)                                                     | 47/2681.0 (1.8)                                       | 135/11136.6 (1.2)                        |
| AnyNMSC                                                | 17/5932.2(0.3)                                                     | 20/2683.8(0.7)                                        | 44/11149.8(0.4)                          |
| Anymalignancy other thanNMSC                           | 47/5938.8(0.8)                                                     | 30/2704.8 (1.1)                                       | 100/11180.2(0.9)                         |
| Anylymphoma                                            | 3/5946.2(<0.1)                                                     | 1/2707.8(<0.1)                                        | 7/11199.6(<0.1)                          |
| Any adjudicatedMACEa                                   | 24/5930.7(0.4)                                                     | 19/2697.3 (0.7)                                       | 55/11166.8(0.5)                          |
| AnyadjudicatedVTEb                                     | 30/5936.7(0.5)                                                     | 9/2701.3(0.3)                                         | 52/11171.9(0.5)                          |

CPK-creatine phosphokinase;CV-cardiovascular,DVT-deep vein thrombosisGI-gastrointestinal;MACE-majoradverse cardiac event,MI-myocardial infarction; NMSC=non-melanoma skin cancer,PE=pulmonary embolism;PY=patient-year,RA=rheumatoid arthritis;TB=fuberculosis;VTE=venous thromboembolism

- a. Definedas CV death,non-MI,andnon-fatal stroke.

b. Includes DVTandPE

## 2.5.1. Discussion on clinical safety

Safety data is presented from two pivotal Phase 3 studies in PsA patients, of which one also included an authorised active control (adalimumab). Safety data was integrated into two datasets, where the short-term (24 week) dataset enables assessment against placebo, and the long-term dataset provides a snapshot of all available safety data. To support the safety assessment, the MAH also provided a summary of cumulative long-term safety data from the RA programme (comprising 11,201.0 PY of exposure among a total of 5,579 subjects) and a summary of post-marketing data (with cumulative exposure of about 3,100 PY).

In the pivotal studies, over 1,800 subjects were exposed to upadacitinib, and 359 subjects were treated for 12 months or longer at the proposed registration dose of 15 mg QD. Total exposure within the PsA programme amounts to 1,639 PY. The exposure is considered sufficient for adequate safety assessment.

The studies enrolled a primarily white population with approximately equal gender distribution. Mean BMI was over 30 kg/m^2, and considerable proportions of subjects had underlying hypertension or a metabolic disorder.

About 70% of subjects were using a background non-biologic DMARD at baseline; use was more frequent among non-biologic DMARD-IR subjects (82% in study 572) than among biologic DMARD-IR subjects (49% in study 554). MTX was clearly the most common background DMARD in both populations, whereas the use patterns of non-MTX DMARDs was slightly different between the two populations. The majority of subjects in both studies were on a concomitant NSAID, and 15-20% of subjects were using a concomitant systemic corticosteroid.

<div style=\"page-break-after: always\"></div>

In the PBO-controlled Analysis Set, SAEs, AEs leading to discontinuation, and severe AEs were more frequent on upadacitinib than placebo, and more frequent on 30 mg than 15 mg. Reporting rates in subjects receiving adalimumab in study 572 were comparable to those in the integrated upadacitinib 15 mg dataset. There were two deaths, both reported in the placebo group.

In the long-term Analysis Set, exposure-adjusted event rates for AEs, SAEs, AEs leading to discontinuation, severe TEAEs and treatment-related AEs were higher for 30 mg than 15 mg. Exposure-adjusted event rates in subjects receiving adalimumab in study 572 were comparable to those in the integrated upadacitinib 15 mg dataset. Three deaths were reported; one death in the 30 mg group was treatment-emergent, and the 2 other deaths (1 each in the upadacitinib 15 mg and 30 mg groups) occurred more than 30 days after the last dose of study drug.

In the PBO-controlled Analysis Set, the pattern of common TEAEs was consistent with the known safety profile for upadacitinib. An increased frequency vs. placebo, and a dose response relationship between the 15 and 30 mg upadacitinib doses, could be seen e.g. for URTI, increased blood CPK, herpes zoster, as well as leukopenia and neutropenia. For anaemia and lymphopenia, an increased frequency compared to placebo was only seen in the 30 mg group. Psoriasis and psoriatic arthropathy were most frequently reported in the placebo group. The pattern of common events remained consistent with long-term exposure.

Based on the MAH's analysis, two new ADRs (bronchitis and acne) are proposed to be included in the Tabulated list of ADRs with a frequency common in Section 4.8 of the SmPC; furthermore, the frequency categories for herpes zoster and herpes simplex are proposed to be changed from uncommon to common. The MAH's proposals were endorsed by the CHMP.

In short-term placebo-controlled analyses, the frequency of serious infections with 15 mg upadacitinib was similar to placebo. However, similar to the original MAA studies with upadacitinib in RA, serious infections were more frequent with the higher 30 mg dose of upadacitinib, and this increased frequency with the 30 mg dose was also observed in long-term data. Most subgroup analyses based on demographic and baseline characteristics were hampered by small sample sizes across several cells, but with this caveat, no obvious clustering was noted. The MAH has proposed a change in Section 4.4 of the SmPC to indicate that there is a higher incidence of infections among patients aged 65 and older (previously 75 and older); this change was acceptable to the CHMP. In general, treatment-emergent serious infections seemed more frequent among subjects on combination therapy than subjects on upadacitinib monotherapy, but small sample sizes for individual non-biologic DMARDs other than MTX prevent any reliable comparison of individual agents.

Opportunistic infections are an important identified risk for upadacitinib. Although they were reported infrequently, some evidence of a dose-related increase in reporting rates can be seen. The SmPC contains adequate information concerning the risk of an atypical infection associated with this class of agents. Consistent with previous experience, the risk of herpes zoster was dose-dependently increased, and higher with upadacitinib than with adalimumab. No cases of active TB were reported in the studies.

In the current dataset, the overall incidence rate of malignancies other than NMSC was consistent with that expected in the general population. Considering the limited follow-up time for a large proportion of subjects, it is recognised that the dataset is not sensitive for detection of rare events with typically long latencies.

Consistent with observations in the RA studies, upadacitinib was associated with a modest increase in transaminase levels; in most cases, these elevations were self-limiting and there is no signal of potential for actual hepatic toxicity.

<div style=\"page-break-after: always\"></div>

GI perforation is identified as an important potential risk for upadacitinib. However, with only one confounded case reported in the PsA programme, no further conclusions can be drawn about this important potential risk.

Inhibition of JAK2 is known to be associated with reduced erythropoietin signalling, and the doserelated decrease in haemoglobin was already previously observed in the RA studies with upadacitinib. The current SmPC includes adequate provisions for management of clinically relevant haemoglobin decreases.

The 10-15% decrease seen in mean neutrophil count is consistent with earlier observations in the RA studies. However, cases of severe Grade 4 neutropenia were not reported in the PsA studies, and the current posology section of the SmPC includes appropriate guidelines for management of low neutrophil counts.

Whereas upadacitinib, in line with previous experience, evoked a transient increase in mean lymphocyte counts, transient decreases were also seen quite frequently, and some dose dependency in decreased count frequency was also seen between the 15 and 30 mg doses. In the long-term analysis of Study 572, lymphopenia was clearly more frequent on upadacitinib than adalimumab. Nevertheless, lymphopenias seem to be mostly transient, and where necessary, have been appropriately manageable with protocol-mandated dose interruptions. Similar guidelines are already included in the current SmPC and they remain appropriate and up to date.

An increase in serum creatinine is a common phenomenon with all JAK inhibitors including upadacitinib and was also seen within the current programme, with mean values almost doubling from baseline during treatment. However, it does not seem to bear particular clinical significance, and the SmPC adequately informs prescribers of the phenomenon.

Consistent with the RA studies, upadacitinib was associated with a small increase in mean creatinine that does not seem to be associated with any clinical consequences. Serious cases of decreased renal function were only reported in conjunction with acute infections and were not attributed to upadacitinib.

The EAIRs of MACE in the PsA programme were consistent with those previously seen in the RA programme; no fatal adjudicated MACE were recorded, and no dose relationship was seen between the 15 mg and 30 mg risk. Given the low incidence of MACE events, it remains warranted to continue following this important potential risk in long-term studies.

Similar to the RA programme, VTE events were reported with a low incidence across all treatment groups including placebo and adalimumab. Similar to MACE, given the low incidence as well as the findings across the class of JAK inhibitors, it remains warranted to continue follow-up regarding this potential risk. Given the absence of any new information from the PsA programme, the SmPC remains up to date with respect to VTE. Consistent with previous experience, upadacitinib was not associated with any significant effects on platelet counts.

Upadacitinib does not have significant effect on vital signs. Consistent with weight increase being an adverse reaction already included in the SmPC, a ≥ 7% increase in body weight was seen in more subjects on upadacitinib than placebo.

The overall number of deaths in the PsA programme was low. A fatal interstitial pneumonitis and dermatomyositis in subject is accounted for as a non-treatment-emergent death, but the sequence of events would also be consistent with a progressively worsening inflammatory cascade that initially started when the subject was exposed to upadacitinib. In light of a potential causative role of upadacitinib and also bearing in mind that interstitial lung disease is considered an important potential risk for another JAK inhibitor, the MAH was requested to provide a more detailed discussion, including

<div style=\"page-break-after: always\"></div>

a summary of any previous cases of similar nature. According to the MAH's analysis, the occurrence of interstitial lung disease -type events is infrequent, confined to patients with an underlying rheumatic disorder, and most cases are confounded by a history of smoking and/or concomitant MTX use. The MAH proposes to continue monitoring reports describing interstitial lung disease and dermatomyositis through standardised surveillance activities; this was considered adequate by the CHMP.

The overall frequency of non-fatal SAEs was low, and most event terms were only reported in 1-2 subjects per treatment group. The most frequently reported non-fatal SAE was pneumonia.

Upadacitinib, similar to other JAK kinase inhibitors, induces an increase in plasma lipids, but with the effect size being similar across both LDL and HDL, there was no significant effect on atherogenic indices in the current studies. The SmPC contains adequate information and management guidelines concerning lipid changes associated with upadacitinib treatment.

Subgroup analyses based on several intrinsic factors (age, race, sex, baseline BMI and baseline renal impairment) did not highlight specific concerns. However, sample sizes for some subgroups were small and results should be interpreted with caution. According to the MAH, an increased rate of serious infections was observed in patients 65 years of age or older, and the MAH has proposed a corresponding change in Sections 4.4 and 4.8 of the SmPC. Although the analysis is based on a small number of subjects, the change was considered acceptable to the CHMP.

Given that non-biologic DMARDs, including MTX, are associated with distinct patterns of adverse effects, it is not unexpected that AEs were reported more often on combination therapy. Hence, section 4.8 of the SmPC includes the following statement ' A higher rate of serious infections (2.6 events per 100 patient years and 1.3 events per 100 patient years, respectively) and hepatic transaminase elevations (ALT elevations Grade 3 and higher rates 1.4% and 0.4%, respectively) was observed in patients treated with upadacitinib in combination with MTX therapy compared to patients treated with monotherapy '.

The majority of subjects on combination therapy were using MTX, and a comparison of MTX vs. nonMTX combinations is consequently limited by the small sample sizes. However, within the Any 15 mg QD group of the long-term Any Upadacitinib Analysis Set, the EAERs of serious adverse events, adverse events leading to discontinuation and severe adverse events were clearly higher among subjects on a non-MTX non-biologic DMARD than subjects on MTX. For serious adverse events and severe adverse events, the EAERs were further increased in the group on both MTX and a non-MTX non-biologic DMARD, although the sample size is very small. In the AESI analysis, the numbers of individual AESI in the non-MTX only and MTX+non-MTX groups are generally too small for a meaningful analysis. Nevertheless, the use of upadacitinib concomitantly with a non-MTX non-biologic DMARD seems to be associated with a higher frequency of adverse events, including serious and severe events, and since the subject numbers are small, there are considerable remaining uncertainties regarding the safety profile when upadacitinib is used concomitantly with non-MTX agents or with a combination of MTX and a non-MTX agent. Furthermore, each individual non-MTX non-biologic DMARD is associated with its unique safety profile, but with the small number of patients for each individual non-MTX non-biologic DMARD, it is not possible to adequately assess the safety profile of each individual combination. Lastly, the findings with non-MTX non-biologic DMARDs bear similarities to those in the RA program, where combination therapy with upadacitinib was ultimately restricted to MTX only. As described in the clinical efficacy section, the proposed indication was not endorsed by the CHMP and the MAH consequently agreed to restrict the concomitant use of upadacitinib to methotrexate only.

Whereas combination therapy was used more frequently in the non-biologic DMARD-IR population, slightly elevated rates of serious infections and herpes zoster were seen among biologic DMARD-IR

<div style=\"page-break-after: always\"></div>

subjects compared to non-biologic DMARD-IR subjects. The higher frequency of combination therapy in the non-biologic DMARD-IR population could account for a higher rate of laboratory changes being reported in the non-biologic DMARD-IR population, although the MAH indicated that these differences are not completely supported by actual laboratory data. Comparison of profiles of common adverse events between the two subgroups did not identify concerning trends. Overall, the safety profiles can be considered to have been adequately characterised in both biologic DMARD-IR and non-biologic DMARD-IR subjects. The very small number of genuinely biologic DMARD-intolerant subjects enrolled into study 554 (total N=47) precludes reliable analysis of potential specificities in the safety profile in this small subgroup. However, in the absence of any overt safety issues and considering that upadacitinib in RA is already authorised for use in patients who are intolerant to one or more DMARDs (i.e., including biologic DMARDs), a similar wording in the indication is supported by the CHMP in PsA from the safety perspective.

Due to findings of teratogenicity in non-clinical studies, upadacitinib is contraindicated in pregnancy. The absence of reports of congenital abnormalities among offspring of female subjects exposed to upadacitinib during pregnancy is reassuring, but the small number of pregnancies prevents reliable conclusions. No changes to the Product Information are therefore currently warranted.

In the PBO-controlled Analysis Set, AEs leading to discontinuation of study medication were reported in less than 5% of subjects in the placebo and upadacitinib 15 mg groups. Events within the Infections and infestations SOC were the most common reason for discontinuation.

Post-marketing data for upadacitinib in its approved RA indication comprises approximately 3,100 PY of exposure. Based on the MAH's analysis of post-marketing data, no new signals or safety risks have been identified. The most commonly reported serious event was pneumonia.

To support and contextualise the safety findings in PsA patients, the MAH presented a summary of long-term data from the ongoing RA clinical development programme. Compared to the original submission, there was no evidence of an increased exposure-adjusted event rate for any category of overall TEAEs or AESI. Similar to the original submission, the event rates for upadacitinib 30 mg were higher than for the 15 mg dose.

Compared to long-term AESI event/incidence rates with upadacitinib 15 mg in RA patients, higher rates with upadacitinib 15 mg were noted among PsA patients for some AESI categories. However, these differences were generally small and can be accounted for by differences between patient populations, the sizes of the respective databases as well as differences in length of exposure. Overall, no new or unexpected safety issues emerged from the updated RA dataset.

## 2.5.2. Conclusions on clinical safety

The safety profile of upadacitinib in PsA patients with an insufficient response to DMARDs was evaluated in two placebo-controlled Phase 3 studies. One study was conducted in a non-biologic DMARD-IR population, and the other one in a biologic DMARD-IR population. The first study also included an active control group receiving adalimumab.

In general, the safety profile was consistent with previous experience in RA patients. Based on an analysis of the safety data, the MAH proposed addition of two new ADRs (bronchitis, acne; frequency common) and a change in the frequency categorisation of herpes zoster and herpes simplex from uncommon to common in Section 4.8 of the SmPC. The proposed changes were acceptable to the CHMP.

The use of upadacitinib as monotherapy or in combination with MTX, as well as its use in both nonbiologic and biologic DMARD-IR patients is supported by the CHMP. However, the use of upadacitinib in

<div style=\"page-break-after: always\"></div>

combination with non-MTX non-biologic DMARDs has been studied in a small number of subjects, precluding adequate assessment of its safety profile with such combinations. Furthermore, within this limited dataset, the use of upadacitinib concomitantly with a non-MTX non-biologic DMARD seemed to be associated with a higher frequency of adverse events, including serious and severe events, than when it was used in combination with MTX. At the CHMP's request, the MAH agreed to restrict the indication to the use as monotherapy or in combination therapy with MTX.

The CHMP considered that the safety of upadacitinib in the following indication is supported by the data submitted by the MAH: ' RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate. '

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.3 is acceptable.

The CHMP endorsed the Risk Management Plan version 2.3 with the following content:

| Safety Concern                                    | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious and opportunistic infections including TB | Routine risk minimization measures: SmPC Section 4.4 summarizes the risk and provides guidance on ways to reduce the risk. The PL warns that patients who have an infection or who have a recurring infection should consult their doctor or pharmacist before and during treatment with Rinvoq and describes the risk of viral reactivation. The PL advises that patients do not take Rinvoq if they have active TB and warns that patients with a history of TB, or who have been in close contact with someone with TB should consult their doctor or pharmacist before and during treatment with Rinvoq. SmPC Section 4.2 outlines lymphocyte and neutrophil counts and when not to initiate upadacitinib dosing. SmPC Section 4.2 outlines interruption guidelines based on ALC and ANC. SmPC Section 4.3 indicates that upadacitinib is contraindicated in patients with active TB or active serious infections. | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaire for serious and opportunistic infections including TB Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Upadacitinib Drug Utilisation Study for aRMM Effectiveness Evaluation Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572) |

<div style=\"page-break-after: always\"></div>

| Safety Concern   | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance Activities   |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
|                  | SmPC Section 4.4 states that patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with upadacitinib and that upadacitinib therapy should be interrupted if a patient develops a serious or opportunistic infection. SmPC Section 4.4 advises to consider the risks and benefits of initiating upadacitinib in patients with active, chronic, or recurrent infections. A patient who develops a new infection during treatment with upadacitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and upadacitinib should be interrupted if the patient is not responding to therapy. Screening for TB prior to initiation is advised, and upadacitinib should not be given if active TB is diagnosed. Anti-TB therapy should be considered prior to initiation of upadacitinib in patients with untreated latent TB or in patients with risk factors for TB infection. Additional risk minimization measures: HCP educational brochure PAC Other routine risk minimization measures: Prescription only medicine. |                                |

<div style=\"page-break-after: always\"></div>

| Safety Concern   | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Herpes zoster    | Routine risk minimization measures: SmPC Section 4.4 describes the risk of viral reactivation such as herpes zoster. SmPC Section 4.8 describes findings from upadacitinib clinical trials. The PL warns that patients who have an infection or who have a recurring infection should consult their doctor or pharmacist before and during treatment with Rinvoq and will describe the risk of viral reactivation. The PL warns that patients who have had a herpes zoster infection (shingles) should tell their doctor if they get a painful skin rash with blisters as these can be signs of shingles. SmPC Section 4.4 advises that if a patient develops herpes zoster, interruption of upadacitinib therapy should be considered until the episode resolves. Additional risk minimization measures: HCP educational brochure PAC Other routine risk minimization measures: Prescription only medicine. | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaire for serious infections Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Upadacitinib Drug Utilisation Study for aRMM Effectiveness Evaluation Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572) |
| Malignancies     | Routine risk minimization measures: SmPC Section 4.4 describes the risk in patients with RA and indicates that upadacitinib clinical data are currently limited and long-term studies are ongoing. The PL warns that patients who have cancer, develop a new lesion or any change in the appearance of an area on the skin, or are at high risk of developing skin cancer should consult their doctor or pharmacist before and during treatment with Rinvoq. SmPC Section 4.4 advises that periodic skin examination is recommended for patients who are at increased risk for skin cancer. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaire for malignancies Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572)                                                                             |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                      | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MACE                                                | Routine risk minimization measures: SmPC Section 4.4 describes the effect of upadacitinib on lipids and describes that impact on CV morbidity and mortality has not been determined. SmPC Section 4.4 contains a section on CV risk including a statement on increased CV risk in RA patients and need for management of CV risk factors as part of usual standard care. SmPC Section 4.2 describes monitoring of lipid parameters following initiation of upadacitinib. The PL warns that patients who have heart problems, high blood pressure, or high cholesterol should consult their doctor or pharmacist before and during treatment with Rinvoq. Additional risk minimization measures: HCP educational brochure PAC Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaire for MACE Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Upadacitinib Drug Utilisation Study for aRMM Effectiveness Evaluation Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572)                                                                        |
| VTEs (deep venous thrombosis and pulmonary embolus) | Routine risk minimization measures: SmPC Section 4.4 indicates that events of deep vein thrombosis and pulmonary embolism have been reported in patients receiving JAK inhibitors including upadacitinib. The PL warns that patients who have had blood clots in the veins of the legs (deep vein thrombosis) or lungs (pulmonary embolism) should consult their doctor or pharmacist before and during treatment with Rinvoq and advises that patients tell their doctor if they get a painful swollen leg, chest pain, or shortness of breath. SmPC Section 4.4 advises that upadacitinib should be used with caution in patients at high risk for deep vein thrombosis/pulmonary embolism. Risk factors that should be considered in determining the patient's risk for deep venous thrombosis/pulmonary embolism include older age, obesity, a medical history of deep venous thrombosis/pulmonary embolism, patients undergoing major surgery, and prolonged immobilisation. SmPC Section 4.4 advises that if clinical features of deep vein thrombosis/pulmonary embolism occur, upadacitinib treatment should be discontinued and patients should | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including: Follow-up questionnaire for VTEs Monitoring of VTE risk and literature review provided within the PSUR Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Upadacitinib Drug Utilisation Study for aRMM Effectiveness Evaluation Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572) |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                  | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | be evaluated promptly, followed by appropriate treatment. Additional risk minimization measures: HCP educational brochure PAC Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| GI perforation                                  | Routine risk minimization measures: None Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and                         |
| DILI                                            | Routine risk minimization measures: SmPC Section 4.4 describes the effect of upadacitinib on transaminases. SmPC Section 4.4 recommends prompt investigation of the cause of liver enzyme elevation to identify potential cases of DILI. SmPC Section 4.4 advises that if increases in ALT or AST are observed during routine patient management and DILI is suspected, upadacitinib should be interrupted until this diagnosis is excluded. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine. | M15-572) Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572)       |
| Foetal malformation following exposure in utero | Routine risk minimization measures: SmPC Section 4.6 describes the teratogenic effects observed in animals receiving upadacitinib and states that there are no or limited data from use of upadacitinib in pregnant women. The PL advises that patients do not take Rinvoq if they are pregnant, that Rinvoq must not be used during pregnancy, and that patients who become pregnant while taking Rinvoq must consult their doctor straight away. SmPC Section 4.3 and Section 4.6 indicate that upadacitinib is contraindicated during pregnancy.            | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaires for pregnancies Additional pharmacovigilance activities: Upadacitinib Drug Utilisation Study for aRMM Effectiveness Evaluation Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572) |

<div style=\"page-break-after: always\"></div>

| Safety Concern                          | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                                 |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                         | SmPC Section 4.6 and PL advise on use of effective contraception. Additional risk minimization measures: HCP educational brochure PAC Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                              |
| Use in very elderly (≥ 75 years of age) | Routine risk minimization measures: SmPC Section 4.2 states that there are limited data in patients aged 75 years and older. SmPC Section 4.8 states that there was a higher rate of serious infections in patients ≥ 75 years of age, although data are limited. SmPC Section 4.4 states that as there is a higher incidence of infections in the elderly ≥ 75 years of age, caution should be used when treating this population. Additional risk minimization measures: None Other routine risk minimization measures:                                                                                                                                                    | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US |
| Effect on vaccination efficacy          | Routine risk minimization measures: SmPC Section 4.4 includes language that no data are available on the response to vaccination with live or inactivated vaccines in patients receiving upadacitinib. SmPC Section 4.4 states that use with live, attenuated vaccines during, or immediately prior to, upadacitinib therapy is not recommended. SmPC Section 4.4 includes language that prior to initiating upadacitinib, it is recommended that patients be brought up to date with all immunisations in agreement with current immunisation guidelines. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine. | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Vaccination substudy                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                               | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with evidence of untreated chronic infection with hepatitis B or hepatitis C | Routine risk minimization measures: SmPC Section 4.4 describes the risk of viral reactivation. The PL warns that patients who have ever had hepatitis B or hepatitis C should consult their doctor or pharmacist before and during treatment with Rinvoq. SmPC Section 4.4 describes the need for screening and consultation with a hepatologist if HBV DNA is detected. Additional risk minimization measures: None Other routine risk minimization measures:                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe |
| Use in patients with moderate hepatic impairment                                             | Prescription only medicine. Routine risk minimization measures: SmPC Section 4.2 describes use in patients with hepatic impairment. SmPC Section 4.2 states that upadacitinib should not be used in patients with severe (Child-Pugh C) hepatic impairment. SmPC Section 4.3 indicates that upadacitinib is contraindicated for use in patients with severe hepatic impairment. The PL advises that patients do not take Rinvoq if they have severe liver problems and warns that patients should consult their doctor or pharmacist before and during treatment with Rinvoq if their liver does not work as well as it should. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine. | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe |
| Use in patients with severe renal impairment                                                 | Routine risk minimization measures: SmPC Section 4.2 describes use in patients with renal impairment. SmPC Section 4 states 2 that upadacitinib should be used with caution in patients with severe renal impairment. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe |

<div style=\"page-break-after: always\"></div>

| Safety Concern   | Risk Minimization Measures                                                                                                                                                                                                                                                                | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Long-term safety | Routine risk minimization measures: SmPC Section 4.4 indicates that upadacitinib clinical data on malignancies are currently limited and long-term studies are ongoing. Additional risk minimization measures: None Other routine risk minimization measures: Prescription only medicine. | Pharmacovigilance activities beyond adverse reaction reporting and signal detection: Routine pharmacovigilance activities including follow-up questionnaire for malignancies Additional pharmacovigilance activities: Long-Term Safety Studies of Upadacitinib Use in RA Patients in Europe Long-Term Safety Study of Upadacitinib Use in RA Patients in the US Long-term extension portion of Phase 3 RA trials (Studies M13-542, M13-549, M14-465, M15-555, and M13-545) Long-term extension portion of Phase 3 PsA trials (Studies M15-554 and M15-572) |

ALC = absolute lymphocyte count; ALT = alanine transaminase; aRMMs = additional risk minimization measures; AST = aspartate transaminase; CV = cardiovascular; DILI = drug-induced liver injury; DNA = deoxyribonucleic acid; GI = gastrointestinal; HBV = hepatitis B virus; HCP = healthcare professional; JAK = Janus kinase; MACE = major adverse cardiovascular event; PAC = patient alert card; PL = package leaflet; PsA = psoriatic arthritis; PSUR = periodic safety update report; RA = rheumatoid arthritis; SmPC = Summary of Product Characteristics; TB = tuberculosis; US = United States; VTE = venous thromboembolic event

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly. Minor updates were made to the Annex II.

## 2.7.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Rinvoq. The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

PsA is a chronic systemic inflammatory disease classified as a sub type of spondyloarthritis and characterized by the association of arthritis and psoriasis. Patients with PsA experience varying combinations of disease manifestations affecting the synovium, tendons, entheses, skin, and bone. Cardiovascular, psychological and metabolic comorbidities associated with PsA add a significant impact on QoL and increased mortality.

Key cytokines involved in SpA pathogenesis like interleukin (IL)-6, IL-7, IL-22, IL-23 and interferon signal through the JAK-STAT pathway. Some of these cytokines activate Th1 and Th17 cells, which in turn release further pro-inflammatory cytokines, including IL-1, IL-17, IL-21, IL-22 and tumour

<div style=\"page-break-after: always\"></div>

necrosis factor (TNF). As JAKs mediate signals of multiple pro-inflammatory cytokines in various immune cell types, targeting these intra-cellular kinases can be an effective approach to reduce inflammatory responses by directly and indirectly inhibiting key cytokines involved in the pathogenesis of PsA.

## 3.1.2. Available therapies and unmet medical need

Treatment of PsA is initiated with NSAIDs and local glucocorticoid injections. Systemic pharmacological treatment is recommended to be started in non-responders. Systemic medications for PsA include corticosteroids - used with caution at the lowest effective dose for a short time  - csDMARDs, such as MTX , sulfasalazine, leflunomide, or cyclosporin; targeted synthetic DMARDs, such as phosphodiesterase-4 inhibitors like apremilast; and biologic DMARDs, such as TNF inhibitors, interleukin-12/23 inhibitors, and interleukin-17 inhibitors.

Tofacitinib was the first JAKi approved for use in PsA.  The current recommendation is to consider starting a JAKi in patients with peripheral arthritis and an inadequate response to at least one csDMARD and at least one bDMARD, or when a bDMARD is not appropriate.

Despite the beneficial results achieved with the available biologic agents, a marked proportion of PsA patients do not achieve clinical remission after 1 year of treatment or sustained remission for at least 1 year. Polyarticular disease, increased inflammatory marker levels, progressive radiographical changes and concomitant diabetes and cardiovascular diseases indicate poor prognosis. Hence, there remains a medical need for additional therapeutic options in PsA for patients with inadequate response to or intolerance to currently available therapies.

## 3.1.3. Main clinical studies

Efficacy data are available from 2 controlled clinical studies, both of which are pivotal randomized, double-blind, Phase 3 studies. Study M15-572 is conducted in subjects who have been inadequate responders or were intolerant to non-biologic DMARDs (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs] and/or targeted synthetic disease-modifying anti-rheumatic drugs [tsDMARDs]) or had a contraindication for non-biologic DMARDs. Study M15-554 includes subjects who have been inadequate responders or were intolerant to biologic disease-modifying anti-rheumatic drugs (bDMARDs).

Both of these ongoing Phase 3 studies evaluate upadacitinib 15 mg QD and 30 mg QD in combination with non-biologic DMARDs or as monotherapy. Study M15-572 includes also comparison to adalimumab 40 mg EOW. This study also evaluates progression of erosive joint disease, which is not included in study M15-554. Both studies include Period 1, a 56-week blinded controlled period and Period 2, a long-term extension. The submission initially included data up to 24 weeks of the Period 1 of both studies; complete efficacy data up to 56 weeks on endpoints proposed to be included in the SmPC was submitted during the review.

## 3.2. Favourable effects

In both study populations, patients with inadequate response (IR) or intolerance to non-biologic DMARDs (study M15-572) and bDMARDs (study M15-554), upadacitinib 15 mg was statistically significantly more effective than placebo in reaching the primary endpoint, ACR20 response rate at Week 12. In the upadacitinib 15 mg vs. placebo arm, the proportion of ACR20 responders in study M15-572 at Week 12 was 70.6 vs. 36.2 % in the upadacitinib 15 mg and placebo arms, respectively.

<div style=\"page-break-after: always\"></div>

The 12-week ACR20 response rates for study M15-544 are 56.9 % vs. 24.1 % in the upadacitinib 15 mg and placebo arms, respectively. Furthermore, the ARC20 response rate for upadacitinib was noninferior to adalimumab 40 mg EOW (response rate 65.0 %) in study M15-572 (non-biologic DMARD-IR subjects). These results were adjusted for multiplicity and supported by sensitivity analyses.

The ACR20 results of both studies were independent of the number of previously used DMARDs.

Difference between upadacitinib 15 mg and placebo arms in the proportion of the ACR20 response rate at Week 12 was 34.4 % in patients with intolerance to prior bDMARDs and 32.7 % in patients with inadequate response to prior bDMARDs (study M15-554). However, the overall response to upadacitinib 15 mg was better in intolerant subjects (73.3 %) than in bDMARD-IR subjects (55.4 %).

Structural joint changes were evaluated in study M15-572 at week 24. The change from baseline in SHS (equivalent to modified Total Sharp Score [mTSS]), Joint Erosion Score, and JSN Score at Week 24 all showed improvement by upadacitinib 15 mg compared with placebo. The difference in SHS is small, but statistically significant, in the comparison of upadacitinib 15 mg with placebo (LS mean, 95% CI): -0.29 (-0.44, -0.14).  No difference was seen in the comparison of upadacitinib 15 mg and adalimumab.

During the phase 3 studies, methotrexate (MTX) was used concomitantly with study medication by 69 % of subjects in study M15-572 and 39.3 % of subjects in study M15-554. For the upadacitinib 15 mg arms, there were 56 subjects in study M15-572 and 23 subjects in study M15-554 who used a combination of upadacitinib 15 mg and other non-biologic DMARD than MTX by Week 24; these figures include also triple combinations with MTX, since in the integrated data set, the number of subjects on dual combination of upadacitinib 15 mg and non-MTX-non-biologic DMARDs was only 45.

Upadacitinib 15 mg was similarly effective when used as monotherapy or in combination with DMARDs. In the upadacitinib 15 mg group of the placebo-controlled integrated data set, the 12-week ACR20 responder rate was 70.4 % in combination with MTX (n=379), 61.5 % in combination with MTX + other non-biologic DMARDs (n=16) and 62.5 % in combination with non-biologic DMARDs other than MTX (n=45). Other endpoints analysed for monotherapy in the integrated upadacitinib 15 mg database (ACR20/50/70 and change in HAQ-DI at week 12, sIGA response rate and PASI 75/90/100 response at Week 16, proportion of subjects achieving MDA at weeks 16 and 24, proportion of subjects achieving resolution of dactylitis, and proportion of subjects achieving resolution of enthesitis at Week 24) were consistent with the primary endpoint. Additional analyses comparing treatment effect with monotherapy vs. combination of upadacitinib with confirmed overall similar efficacy of the two treatment modalities.

Upadacitinib 15 mg was more effective in improving physical function in PsA as demonstrated by a statistically significantly greater improvement in HAQ-DI and a greater proportion of subjects achieving a clinically meaningful improvement in HAQ-DI (change from baseline in HAQ-DI ≥ 0.35) at Week 12 vs. placebo in both target populations. Also FACIT-F and 36-Item Short Form Health Survey (SF-36) and SF-36 Physical Component Summary (PCS) scores improved statistically significantly more with upadacitinib 15 mg than placebo. Other measures of quality of life and patient reported outcomes evaluated as additional secondary outcomes in both studies (e.g. Mental Component Summary (MCS), and individual domains, EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L), Work Productivity and Activity Impairment (WPAI), and morning stiffness (overall, duration, and severity) at Week 12 improved numerically more by upadacitinib 15 mg vs. placebo; however, these comparisons were not adjusted for multiplicity.

Measures of dactylitis, enthesitis and activity of spondyloarthritis (BASDAI, ASDAS) were evaluated in the subgroups with these symptoms at baseline and showed improvement with upadacitinib 15 mg vs. placebo. However, only the comparisons on dactylitis and enthesitis in study M15-572 were multiplicity

<div style=\"page-break-after: always\"></div>

controlled and the results significantly in favour of upadacitinib 15 mg, whereas the other comparisons were numerical. Patients with psoriatic spondylitis treated with upadacitinib 15 mg showed improvements from baseline in BASDAI scores compared to placebo at week 24. Improvements from baseline were maintained through week 56 in both studies.

Activity of skin manifestations was statistically significantly reduced with upadacitinib 15 compared with placebo as assessed by Psoriasis Area and Severity Index (PASI75) and static Investigator Global Assessment of Psoriasis (sIGA). A measure developed by the MAH, Self-Assessment of Psoriasis Symptoms (SAPS) improved numerically with upadacitinib; however, the difference in SAPS compared to placebo was not significant after adjustment for multiplicity.

Available efficacy data are presented through Week 56 for patients having completed the 56-week Period 1 of the studies by the data cut-off dates for the submission (39.7% of subjects in study M15572 and 49.2% of subjects in study M15-554). The mean ACR20 response appears to be maintained in this subset, up to Week 56.

Overall, the totality of evidence from the clinical studies demonstrates superiority of upadacitinib over placebo, and non-inferiority in comparison with adalimumab, up to 56 weeks.

## 3.3. Uncertainties and limitations about favourable effects

The difference between placebo and upadacitinib in structural joint changes is small since a great majority of patients in both placebo and active treatment arms experienced no radiographic progression. This may reflect the importance of longer-term radiographic data in showing benefit in radiographic measures. Nevertheless, the CHMP concluded that the completed 56-week efficacy data supports the inclusion of the radiographic results in the SmPC.

The effect of upadacitinib on mental health was considered very modest in comparison with that on physical health based on the SF-36 MCS and PCS.

The MAH originally proposed to include in the SmPC nominal superiority vs. adalimumab in some individual measures. Since comparison of upadacitinib 15 mg with adalimumab in the primary endpoint (ACR20) did not show superiority and the other comparisons were not statistically significant, the MAH removed this information from Section 5.1 of the SmPC at the CHMP's request.

The complete efficacy results for the 56-week period confirmed the sustained efficacy of upadacitinib up to 56 weeks. The data are deemed sufficient for inclusion of these results in the SmPC. However, long-term effects on maintenance of effect will be further assessed when the ongoing trials are completed.

Data are scarce regarding efficacy in combination of upadacitinib 15 mg with other non-biologic DMARDs without MTX due to the overall low number of subjects in this group (n=45 in the integrated placebo-controlled upadacitinib 15 mg data set). Furthermore, several different DMARDs were combined with upadacitinib, with small numbers of combinations of individual other DMARDs with upadacitinib 15 mg. Data on other combinations of upadacitinib with DMARDs expect with MTX was considered insufficient for confirmation of efficacy. A major objection was raised on this issue during the review and the MAH agreed to restrict the indication for use of upadacitinib in PsA to monotherapy or in combination with MTX.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Overall, SAEs, AEs leading to discontinuation and severe AEs were more frequent on upadacitinib 15 mg than placebo (SAEs, 4.1% upadacitinib vs. 2.7% placebo; AEs leading to discontinuation, 4.4% upadacitinib vs. 3.8% placebo; severe AEs, 5.3% upadacitinib vs. 3.8% placebo). Corresponding frequencies for adalimumab in study 572 were 3.7% for SAEs, 5.1% for AEs leading to discontinuation, and 6.5% for severe AEs.

In the PBO-controlled Analysis Set, the most common AEs with upadacitinib 15 mg included upper respiratory tract infections (8.9%), blood CPK increased (6.5%), nasopharyngitis (4.8%), urinary tract infection (4.2%), bronchitis (3.6%), diarrhoea (3.6%), ALT increased (3.3%), headache (3.3%), hypertension (3.1%) and influenza (3.0%). When 15 mg and 30 mg doses were compared, a doserelated increase in frequency was seen for most of these AEs.

In the PBO-controlled Analysis Set, the frequency of serious infections, most commonly pneumonia, was 0.8% for placebo, 0.9% for 15 mg and 2.7% for 30 mg. Long-term EAERs were 2.3 E / 100 PY for 15 mg and 6.0 E / 100 PY for 30 mg. Serious infections were more frequent among subjects on combination therapy than subjects on monotherapy; long-term EAERs were 2.7 E / 100 PY vs. 1.3 E / 100 PY, respectively, for 15 mg.

The frequency of herpes zoster was also increased in a dose-related manner. In the PBO-controlled Analysis Set, the frequencies of herpes zoster were 0.8% for placebo, 1.0% for 15 mg and 2.0% for 30 mg. Long-term EAERs for herpes zoster were 3.6 E/100 PY for 15 mg and 7.9 E/100 PY for 30 mg. Most events involved a single dermatome.

The safety profile of upadacitinib 15 mg in PsA patients was generally consistent with previous experience gained in the development programme in RA. Based on an analysis of the safety data, the MAH has proposed addition of two new ADRs (bronchitis, acne; frequency common) and a change in the frequency categorisation of herpes zoster and herpes simplex from uncommon to common in Section 4.8 of the SmPC. The proposed changes are considered acceptable to the CHMP.

## 3.5. Uncertainties and limitations about unfavourable effects

No new information was gained concerning several important potential risks, including malignancies, MACE, VTE and GI perforation. The size of the safety database as well as the limited amount of longterm exposure limits possibilities to detect low-frequency events with sometimes long latencies. However, those risks are adequately addressed in the product information and the RMP.

The small number of subjects on non-MTX non-biologic DMARDs precludes a detailed analysis of the safety profile of these other combinations. However, within the limited dataset, there is some evidence of a potentially less favourable safety profile when upadacitinib was used in combination with non-MTX non-biologic DMARDs as opposed to use in combination with MTX. It should also be borne in mind that combination treatment with upadacitinib in RA is restricted to MTX only. At the CHMP's request, the MAH agreed to restrict the indication to the use as a monotherapy or combination therapy with MTX.

## 3.6. Effects Table

## Table 85

Effects Table for upadacitinib 15 mg QD

(data cut-off: M15-554: 09 Oct 2019), M15-572:13 Dec 2019)

<div style=\"page-break-after: always\"></div>

| Effect             | Short description                                  | Unit                                    | Treatment                 | Control                   | Control                   | Between- group difference                                               | Uncertainties / Strength of evidence                            | References         |
|--------------------|----------------------------------------------------|-----------------------------------------|---------------------------|---------------------------|---------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects                                 | Favourable Effects                      | Favourable Effects        | Favourable Effects        | Favourable Effects        | Favourable Effects                                                      | Favourable Effects                                              | Favourable Effects |
|                    |                                                    | N, within- group point estimate, 95% CI | UPA 15 mg QD              | ADA 40 mg EOW             | PBO                       | UPA vs. placebo LS mean treatment difference (95% CI) Adjusted P- value |                                                                 |                    |
| ACR20              | Proportion (%) ≥ 20% improvement at W12            | N, % (95% CI)                           | 429 70.6 (66.3, 74.9)     | 429 65.0 (60.5, 69.5)     | 423 36.2 (31.6, 40.7)     | 34.5 (28.2, 40.7) p<0.0001                                              | Superiority to PBO and non- inferiority to ADA in both studies. | M15-572            |
|                    |                                                    | N, % (95% CI)                           | 211 56.9 (50.2, 63.6)     | N.A.                      | 212 24.1 (18.3, 29.8)     | 32.8 (24.0, 41.6) p<0.0001                                              | Superiority not shown for upadacitinib 15 mg vs. ADA.           | M15-554            |
| Δ HAQ- DI          | Change from BL at W 12                             | N, LS mean (95% CI)                     | 404 -0.42 (-0.47, -0.37)  | 406 -0.34 (-0.38, - 0.29) | 392 -0.14 (-0.18, -0.09)  | -0.28 (-0.35, - 0.22) p<0.0001                                          | Superiority to PBO in both studies.                             | M15-572            |
|                    |                                                    |                                         | 199 -0.30 (-0.37, - 0.24) | N.A.                      | 180 -0.10 (-0.16, - 0.03) | 0.21 (-0.30, - 0.12) p<0.0001                                           | Superiority to PBO in both studies.                             | M15-554            |
| sIGA               | Proportion 0 or 1 or >2 improvement from BL at W16 | N % LS mean (95% CI)                    | 322 41.9 (36.5, 47.3)     | 330 38.5 (33.2, 43.7)     | 313 10.9 (7.4, 14.3)      | 31.1 (24.7, 37.5) p<0.0001                                              | Superiority to PBO in both studies.                             | M15-572            |
|                    |                                                    |                                         | 171 36.8 (29.6, 44.1)     | N.A.                      | 163 9.2 (4.8, 13.6)       | 27.6 (19.2, 36.1) p<0.0001                                              | Superiority to PBO in both studies.                             | M15-554            |

| Effect               | Short description                    | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence   | References                    |
|----------------------|--------------------------------------|----------------------|----------------------|----------------------|----------------------------------------|-------------------------------|
| Unfavourable Effects | Unfavourable Effects                 | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects          |
| AEs                  | All AEs, 24 weeks vs. PBO            | N (%)                | 422 (65.9)           | 391 (61.6)           |                                        | PBO- controlled Analysis Set  |
| AEs                  | All AEs, 24 weeks vs. ADA            | N (%)                | 287 (66.9)           | 278 (64.8)           |                                        | M15-572                       |
| SAEs                 | All SAEs, 24 weeks vs. PBO           | N (%)                | 26 (4.1)             | 17 (2.7)             |                                        | PBO- controlled Analysis Set  |
| SAEs                 | All SAEs, 24 weeks vs. ADA           | N (%)                | 14 (3.3)             | 16 (3.7)             |                                        | M15-572                       |
| SAEs                 | Long-term event rate                 | E/PY (E/100 PY)      | 89/816.9 (10.9)      | --                   |                                        | Any Upadacitinib Analysis Set |
| Serious infections   | Serious infections, 24 weeks vs. PBO | N (%)                | 6 (0.9)              | 5 (0.8)              |                                        | PBO- controlled Analysis Set  |

<div style=\"page-break-after: always\"></div>

| Effect             | Short description                    | Unit            | Treatment      | Control   | Uncertainties / Strength of evidence   | References                    |
|--------------------|--------------------------------------|-----------------|----------------|-----------|----------------------------------------|-------------------------------|
| Serious infections | Serious infections, 24 weeks vs. ADA | N (%)           | 5 (1.2)        | 3 (0.7)   |                                        | M15-572                       |
| Serious infections | Long-term event rate                 | E/PY (E/100 PY) | 19/816.9 (2.3) |           |                                        | Any Upadacitinib Analysis Set |
| Herpes zoster      | Herpes zoster, 24 weeks vs. PBO      | N (%)           | 7 (1.1)        | 5 (0.8)   |                                        | PBO- controlled Analysis Set  |
| Herpes zoster      | Herpes zoster, 24 weeks vs. ADA      | N (%)           | 4 (0.9)        | 0 (0)     |                                        | M15-572                       |
| Deaths             | Long-term incidence rate             | N/PY (N/100 PY) | 1/817.1 (0.1)  |           |                                        | Any Upadacitinib Analysis Set |

Abbreviations: ADA=adalimumab; AE=adverse event; E=number of events; N=number of subjects; PBO=placebo; PY=patientyears;  SAE  =serious  adverse  event;  CI=confidence  interval;  BL=baseline;  NI=non-inferiority;  QD=once  daily,  EOW=every  other week; ACR20=American College of Rheumatology 20% (ACR20) response: ≥ 20% or greater improvement in TJC and SJC and ≥ 3 of the 5 measures of Patient's Assessment of Pain NRS, PtGA-Disease Activity NRS, PGA-Disease Activity NRS, HAQ-DI, or hs-CRP; Δ HAQ-DI=change from baseline in Health Assessment Questionnaire - Disability Index; sIGA=Static Investigator Global Assessment of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Upadacitinib 15 mg QD was statistically and clinically significantly more effective than placebo in patients with inadequate response (IR) or intolerance to non-biologic DMARDs (study M15-572) and bDMARDs (study M15-554). Efficacy was demonstrated in relevant outcomes measuring treatment response on all main manifestations of psoriasis and psoriatic arthritis, including polyarthritis, axial disease, enthesitis, dactylitis, extent of skin involvement, physical function, and quality of life. The effect was demonstrated in patients at two different stages in the treatment algorithm of psoriatic arthritis: firstly, in patients who had failed both the phase I of EULAR 2019 algorithm (pharmacological treatment with NSAIDs and local glucocorticoid injections) and treatment with one of more nonbiologic DMARDs (phase II of EULAR algorithm), and, secondly, in subjects who had additionally been treated with one or more biologic DMRADs but experienced either IR or intolerance (phase III of EULAR algorithm). The submitted results were completed up to 56 weeks in both of the ongoing phase 3 studies. However, the results for long-term efficacy from the ongoing extensions of the phase 3 trials will be important for assessment of benefit and optimal duration of treatment over years in this chronic condition.

Treatment with upadacitinib 15 mg was non-inferior to adalimumab in subjects with intolerance or IR to non-biologic DMARDs in study M15-572. This study also evaluated radiographic changes in structural joint involvement. Even though the radiographic progression in joint disease was statistically significantly decreased in subjects administered upadacitinib or adalimumab compared with placebo, the difference between active treatment and placebo is clinically small, dominated by no change in a great majority of subjects in all study arms. However, a small but statistically significant difference between upadacitinib and placebo was demonstrated up to 56 weeks of therapy. Final evaluation of effects on joint disease will require longer-term experience that will be obtained with the finalisation of the ongoing studies. The submission of the results for the long term extension for both studies is included in the RMP.

The demonstration of efficacy was robust for upadacitinib 15 mg QD as monotherapy and as combined with MTX. However, the numbers of subjects using other non-biologic DMARDs than MTX in

<div style=\"page-break-after: always\"></div>

combination were relatively small and divided in subgroups with different DMARDs with various modes of action and individual efficacy and safety profiles. The small number of subjects on non-MTX nonbiologic DMARDs precludes a detailed analysis of the efficacy and safety profile of these other combinations. However, within the limited dataset, there is some evidence of a potentially less favourable safety profile when upadacitinib was used in combination with non-MTX non-biologic DMARDs as opposed to use in combination with MTX. It should also be borne in mind that combination treatment with upadacitinib in RA is restricted to MTX only. A major objection was raised on the therapeutic indication during the review and the MAH agreed to modify the indication to monotherapy or combination with MTX.

While there are a number of important identified and potential risks associated with upadacitinib, the current dataset in PsA patients is generally consistent with the previously known safety profile in RA and a number of post-authorisation measures are in place for further characterisation of important identified and potential risks. The Product Information has been adequately updated with new information on PsA and includes adequate warnings and precautions regarding the management of these risks.

## 3.7.2. Balance of benefits and risks

The proposed indication does not include any statement on the degree of severity of PsA. However, no universally agreed definition for mild, moderate or severe PsA exists. Further, the patients had clearly active disease according to the inclusion criteria and final baseline characteristics (incl. &gt;3 tender and swollen joints). Hence, the wording 'active disease' is deemed acceptable to the CHMP without stating mild/moderate/severe disease in the indication, in line with other products for the same indication.

There is robust evidence to allow use of upadacitinib when patients have been intolerant or with inadequate response to both non-biologic and biologic DMARD(s), including patients who have received not only one but also more than one previous DMARD(s). Consequently, the part of indication stating 'inadequate response/intolerance to one or more DMARDs' is acceptable to the CHMP. The inclusion criteria of study M15-572 allowed also patients who had contraindication to non-biologic DMARDs to be entered in the study. There is no biological reason to assume differential efficacy of upadacitinib in patients with contraindication to prior DMARDs vs. intolerance to prior DMARDs; hence, the CHMP considered that it would be appropriate that this small group is not specifically mentioned in the wording of the indication.

Finally, the results on upadacitinib monotherapy and combination therapy with MTX show robust efficacy of upadacitinib 15 mg compared to placebo up to 56-weeks. Hence, both the indication for monotherapy and combination therapy with MTX are considered acceptable to the CHMP.

## 3.8. Conclusions

The overall B/R of Rinvoq is positive in the following indication:

## ' Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.'

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include the treatment of active psoriatic arthritis in adult patients for Rinvoq; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates were made to the Annex II. Version 2.3 of the RMP has been adopted.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

Prior to launch of RINVOQ in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

<div style=\"page-break-after: always\"></div>

The objective of the programme is to increase awareness of HCPs and patients on the risks of serious and opportunistic infections including TB, herpes zoster, foetal malformation (pregnancy risk), MACE, and VTEs and how to manage these risks.

The MAH shall ensure that in each Member State where RINVOQ is marketed, all healthcare professionals and patients/carers who are expected to prescribe, dispense or use RINVOQ have access to/are provided with the following educational package:

## The physician educational material should contain:

- The Summary of Product Characteristics
- Guide for healthcare professionals
- Patient Alert Card (PAC)

## The Guide for healthcare professionals shall contain the following key elements:

- General introductory language that the HCP measure contains important information to assist the discussion with patients when prescribing upadacitinib. The brochure also informs on steps which can be taken to reduce a patient's risk for key safety aspects of upadacitinib.
- Language for HCPs to inform patients of the importance of the PAC
- Risk of serious and opportunistic infections including TB
- o Language on the risk of infections during treatment with upadacitinib
- o Details on how to reduce the risk of infection with specific clinical measures (what laboratory parameters should be used to initiate upadacitinib, screening for TB, and getting patients immunised as per local guidelines, and interruption of upadacitinib if an infection develops)
- o Language on avoidance of live vaccines (i.e., Zostavax) prior to and during upadacitinib treatment
- o Details to advise patients on signs/symptoms of infection to be aware of, so that patients can seek medical attention quickly.
- Risk of herpes zoster
- o Language on the risk of herpes zoster during treatment with upadacitinib
- o Details to advise patients on signs/symptoms of infection to be aware of, so that patients can seek medical attention quickly.
- Risk of foetal malformation
- o Language on teratogenicity of upadacitinib in animals
- o Details on how to reduce the risk of exposure during pregnancy for women of childbearing potential based on the following: upadacitinib is contraindicated during pregnancy, women of childbearing potential should be advised to use effective contraception both during treatment and for 4 weeks after the final dose of upadacitinib treatment, and to advise patients to inform their HCP immediately if they think they could be pregnant or if pregnancy is confirmed.
- Risk of MACE

<div style=\"page-break-after: always\"></div>

- o Language on the increased risk of MACE in patients with immune-related inflammatory diseases and the need to consider typical CV risk factors (e.g., hypertension, hyperlipidaemia) when treating patients
- o Language on the risk of MACE during treatment with upadacitinib
- o Language on the risk of hyperlipidaemia during upadacitinib therapy
- o Details on monitoring of lipid levels and management of elevated lipid levels per clinical guidelines
- Risk of VTE
- o Examples of the risk factors which may put a patient at higher risk for VTE and in whom caution is needed when using upadacitinib.
- o Language on the risk of VTE during treatment with upadacitinib
- o Language on need for discontinuation of upadacitinib, evaluation, and appropriate treatment for VTE if clinical features of deep venous thrombosis or pulmonary embolism develop
- o Instructions for how to access digital HCP information
- o Instructions on where to report AEs

The patient information pack should contain:

- Patient information leaflet
- A patient alert card
- The patient alert card shall contain the following key messages:
- o Contact details of the upadacitinib prescriber
- o Language that the PAC should be carried by the patient at any time and to share it with HCPs involved in their care (i.e., non-upadacitinib prescribers, emergency room HCPs, etc.)
- o Description of signs/symptoms of infections the patient needs to be aware of, so that they can seek attention from their HCP:
-  Language to advise patients and their HCPs about the risk of live vaccinations when given during upadacitinib therapy
- o Description of targeted risks for awareness by the patient and for HCPs involved in their care including:
-  Elevations in plasma lipids and the need for monitoring and lipid lowering treatment
-  A reminder to use contraception, that upadacitinib is contraindicated during pregnancy, and to notify their HCPs if they become pregnant while taking upadacitinib

<div style=\"page-break-after: always\"></div>

- o Description of signs/symptoms of deep venous thrombosis or pulmonary embolism which the patient needs to be aware of, so that they can seek attention from an HCP.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to the Scientific Discussion: Rinvoq EMEA/H/C/4760/II/0004

## Attachments

1. SmPC, Annex II, Package Leaflet (changes highlighted) as adopted by the CHMP on 10 December 2020